

ADEONA PHARMACEUTICALS, INC.
Form 10-Q
November 14, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2008

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 333-139354

ADEONA PHARMACEUTICALS, INC.
(Name of small business issuer in its charter)

Delaware

(State or other jurisdiction of incorporation or
organization)

13-3808303

(IRS Employer Identification Number)

3930 Varsity Drive
Ann Arbor, MI

(Address of principal executive offices)

48108

(Zip Code)

Registrant's telephone number, including area code:
(734) 332-7800

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

State registrant's revenues for its most recent fiscal year: \$0

As of November 1, 2008, the registrant had 20,838,528 shares of common stock outstanding.

Transitional Small Business Disclosure Format (Check one): Yes No

1

ADEONA PHARMACEUTICALS, INC.

FORM 10-Q
TABLE OF CONTENTS

	Page
	PART I.—FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets (Unaudited) 3
	Consolidated Statements of Operations (Unaudited) 4
	Consolidated Statements of Cash Flows (Unaudited) 5
	Notes to Consolidated Financial Statements (Unaudited) 6
Item 2.	Management’s Discussion and Analysis of Financial Information and Results of Operations 22
Item 3.	Controls and Procedures 28
	PART II—OTHER INFORMATION
Item 1.	Legal Proceedings 29
Item 1A.	Risk Factors 29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds 47
Item 3.	Defaults Upon Senior Securities 47
Item 4.	Submission of Matters to a Vote of Security Holders 47
Item 5.	Other Information 47
Item 6.	Exhibits 48
SIGNATURE	49

PART I.—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Consolidated Balance Sheets

Assets	September 30, 2008 (Unaudited)	December 31, 2007 (Audited)
Current Assets		
Cash	\$ 6,435,607	\$ 11,492,802
Prepaid expenses	10,583	63,636
Other receivable	48,617	-
Total Current Assets	6,494,807	11,556,438
Property and Equipment, net of accumulated depreciation of \$521,518 and \$232,564	1,699,301	2,063,233
Deposits and other assets	11,989	13,381
Total Assets	\$ 8,206,097	\$ 13,633,052
Liabilities and Stockholders' Equity		
Current Liabilities:		
Accounts payable	\$ 500,648	\$ 728,119
Accrued liabilities	176,388	59,409
Notes payable	-	900,000
Total Current Liabilities	677,036	1,687,528
Stockholders' Equity		
Preferred stock, \$0.001 par value; 10,000,000 shares authorized, none issued and outstanding	-	-
Common stock, \$0.001 par value; 100,000,000 shares authorized, 20,838,528 and 20,433,467 shares issued and outstanding	20,839	20,433
Additional paid-in capital	44,874,712	43,001,609
Deficit accumulated during the development stage	(37,366,490)	(31,076,518)
Total Stockholders' Equity	7,529,061	11,945,524
Total Liabilities and Stockholders' Equity	\$ 8,206,097	\$ 13,633,052

See accompanying notes to unaudited consolidated financial statements

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Consolidated Statements of Operations
(Unaudited)

	For the three months ended September 30,		For the nine months ended September 30,		For the Period from January 8, 2001
	2008	2007	2008	2007	(Inception) to September 30, 2008
Operating Expenses:					
Research and development	\$ 863,272	\$ 1,573,610	\$ 4,156,255	\$ 4,069,782	\$ 15,317,050
General and administrative	606,685	599,388	2,242,855	2,852,126	9,088,066
Total Operating Expenses	1,469,957	2,172,998	6,399,110	6,921,908	24,405,116
Loss from Operations	(1,469,957)	(2,172,998)	(6,399,110)	(6,921,908)	(24,405,116)
Other Income (Expense):					
Interest income	26,688	66,041	108,503	218,298	451,892
Gain on sale of equipment	14,430	-	14,430	-	14,430
Interest expense	-	(13,985)	(13,831)	(29,270)	(66,760)
Total Other Income, net	41,118	52,056	109,102	189,028	399,562
Net Loss	\$ (1,428,839)	\$ (2,120,942)	\$ (6,290,008)	\$ (6,732,880)	\$ (24,005,554)
Less: Preferred stock dividend - subsidiary	-	-	-	-	(951,250)
Less: Merger dividend	-	-	-	(12,409,722)	(12,409,722)
Net Loss Applicable to Common Shareholders	\$ (1,428,839)	\$ (2,120,942)	\$ (6,290,008)	\$ (19,142,602)	\$ (37,366,526)
Net Loss Per Share - Basic and Diluted	\$ (0.07)	\$ (0.12)	\$ (0.31)	\$ (1.12)	\$ (6.49)
Weighted average number of shares outstanding during the period - basic and	20,715,966	17,110,581	20,587,746	17,042,690	5,759,615

diluted

See accompanying notes to unaudited consolidated financial statements

4

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Consolidated Statements of Cash Flows
(Unaudited)

	For the nine months ended September 30,		For the Period from January 8, 2001 (Inception) to September 30, 2008
	2008	2007	
Cash Flows From Operating Activities:			
Net loss	\$ (6,290,008)	\$ (6,732,880)	\$ (24,005,554)
Adjustments to reconcile net loss to net cash used in operating activities:			
Stock-based compensation	1,110,771	703,386	3,047,417
Stock-based consulting	344,169	641,926	1,505,156
Stock issued as compensation	55,385	-	55,385
Stock issued as compensation in acquisition of subsidiary	-	601,712	601,712
Contributed services - related party	73,750	275,124	349,395
Stock issued for license fee	145,000	-	533,691
Stock issued for milestone payment	50,000	-	75,000
Stock issued for consulting fee	90,042	-	90,042
Depreciation	307,466	108,642	540,030
Gain on sale of equipment	(14,430)	-	(14,430)
Changes in operating assets and liabilities:			
Prepaid expenses and other	4,436	9,372	(59,200)
Deposits and other assets	1,392	(17,534)	(11,989)
Accounts payable	(135,177)	189,525	592,942
Accrued liabilities	116,979	(158,899)	179,406
Net Cash Used In Operating Activities	(4,140,225)	(4,379,626)	(16,500,997)
Cash Flows From Investing Activities:			
Purchases of property and equipment	(21,398)	(1,743,313)	(2,032,805)
Cash paid to acquire shell in reverse acquisition	-	-	(665,000)
Net Cash Used In Investing Activities	(21,398)	(1,743,313)	(2,697,805)
Cash Flows From Financing Activities:			
Proceeds from loans payable - related party	-		3,210,338
Repayments of loans payable - related party	-		(220,000)
Proceeds from notes payable	-	1,100,000	1,100,000
Repayments of notes payable	(900,000)	(100,000)	(1,100,000)
Net proceeds from issuance of common stock for stock options exercised	4,428	-	4,428

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Proceeds from issuance of preferred and common stock	-	-	1,150,590
Proceeds from sale of common stock and warrants in private placements	-	-	13,926,362
Proceeds from sale of common stock in connection with warrants exercise	-	282,841	7,552,378
Cash paid as direct offering costs in private placements and warrant call	-	-	(1,739,987)
Proceeds from issuance of Series B, convertible preferred stock - subsidiary	-	-	1,902,500
Direct offering costs in connection with issuance of series B, convertible preferred stock - subsidiary	-	-	(152,200)
Net Cash Provided By (Used In) Financing Activities	(895,572)	1,282,841	25,634,409
Net increase (decrease) in cash and cash equivalents	(5,057,195)	(4,840,098)	6,435,607
Cash and cash equivalents at beginning of period	11,492,802	12,192,426	-
Cash and cash equivalents at end of period	\$ 6,435,607	\$ 7,352,328	\$ 6,435,607
Supplemental disclosures of cash flow information:			
Cash paid for interest	\$ 13,831	\$ 29,270	\$ 66,760
Cash paid for taxes	\$ -	\$ -	\$ -
Supplemental disclosure of non-cash investing and financing activities:			
Sale of equipment in exchange for accounts payable	\$ 92,294	\$ -	\$ 92,294
Exchange of EPI preferred stock into Adeona common stock in acquisition	\$ -	\$ 12,409,722	\$ 12,409,722
Adeona acquired equipment in exchange for a loan with a related party	\$ -	\$ -	\$ 284,390
EPI declared a 10% and 30% in-kind dividend on its Series B, convertible preferred stock.	\$ -	\$ -	\$ 951,250
The Company issued shares and warrants in connection with the conversion of certain related party debt.	\$ -	\$ -	\$ 3,274,728
Conversion of accrued liabilities to contributed capital - former related party	\$ -	\$ -	\$ 3,017

See accompanying notes to unaudited consolidated financial statements

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

Note 1 Organization and Nature of Operations and Basis of Presentation

(A) Description of the Business

Adeona Pharmaceuticals, Inc. (“Adeona”) is a development-stage pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.

(B) Corporate Name Change

On October 16, 2008, the Company completed a corporate name change to Adeona Pharmaceuticals, Inc. from Pipex Pharmaceuticals, Inc.

(C) Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly they do not include all of the information and footnotes necessary for a fair presentation of financial condition, results of operations and cash flows in conformity with generally accepted accounting principles. In the opinion of management of Adeona, the interim consolidated financial statements included herewith contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for their fair presentation.

The unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-KSB, which contains the audited financial statements and notes thereto, together with the Management’s Discussion and Analysis, for the year ended December 31, 2007. The interim results for the period ended September 30, 2008 are not necessarily indicative of results for the full fiscal year.

(D) Corporate Structure, Basis of Presentation and Non-Controlling Interest

The Company has seven subsidiaries, Pipex Therapeutics, Inc. (“Pipex Therapeutics”), Effective Pharmaceuticals, Inc. (“EPI”), Solovax, Inc. (“Solovax”), CD4 Biosciences, Inc. (“CD4”), Epitope Pharmaceuticals, Inc. (“Epitope”), Healthmine Inc. (“Healthmine”) and Putney Drug Corp. (“Putney”) which were previously under common control. As of September 30, 2008, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority owned. The combinations of these entities prior to 2006 were accounted for in a manner similar to a pooling of interests.

For financial reporting purposes, the outstanding preferred stock and common stock of the Company is that of Adeona, the legal registrant. All statements of operations, stockholders’ equity (deficit) and cash flows for each of the entities are presented as consolidated since January 8, 2001 (inception) due to the existence of common control since that date. All subsidiaries were incorporated on January 8, 2001, except for EPI, which was incorporated on December 12, 2000, Epitope which was incorporated in January of 2002, Putney which was incorporated in November of 2006 and Healthmine which was incorporated in December 2007. All of the subsidiaries were incorporated under the laws of the State of Delaware.

For financial accounting purposes, the Company's inception is deemed January 8, 2001. The activity of EPI for the period from December 12, 2000 to January 7, 2001 was nominal. Therefore, there is no financial information presented for this period.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

The Company's ownership in its subsidiaries requires the Company to account for the related non-controlling interest. Under generally accepted accounting principles, when losses applicable to the minority interest in a subsidiary exceed the minority interest in the equity capital of the subsidiary, the excess is not charged to the minority interest since there is no obligation of the minority interest to make good on such losses. The Company, therefore, has included losses applicable to the minority interest against its interest. Since the Company's subsidiaries have never been profitable and present negative equity, there has been no establishment of a positive non-controlling interest. This value is not presented as a deficit balance in the accompanying consolidated balance sheet.

(E) Reverse Stock Split

In January 2007, and effective on April 25, 2007, the Company's Board of Directors approved a 3 for 1 reverse stock split of all outstanding common stock, stock options and stock warrants of Adeona. All share and per share amounts have been retroactively restated to reflect this reverse stock split.

(F) Reverse Acquisition and Recapitalization

On October 31, 2006, Sheffield Pharmaceuticals, Inc. ("Sheffield"), a then shell corporation, entered into a Merger Agreement ("Merger") with Pipex Therapeutics, a privately owned company, whereby Pipex Therapeutics was the surviving corporation. This transaction was accounted for as a reverse acquisition. Sheffield did not have any operations at the time of the merger, and this was treated as a recapitalization of Pipex Therapeutics. Since Pipex Therapeutics acquired a controlling voting interest in a public shell corporation, it was deemed the accounting acquirer, while Sheffield was deemed the legal acquirer. The historical financial statements of the Company are those of Pipex Therapeutics, EPI, Solovax and CD4 since inception, and of the consolidated entities from the date of Merger and subsequent. On December 11, 2006, Sheffield changed its name to Pipex Pharmaceuticals, Inc.

Since the transaction is considered a reverse acquisition and recapitalization, the guidance in SFAS No. 141 does not apply for purposes of presenting pro-forma financial information.

Pursuant to the agreement, Sheffield issued 34,000,000 shares of common stock for all of the outstanding Series A, convertible preferred and common stock of Pipex Therapeutics, and Sheffield assumed all of Pipex Therapeutics' outstanding options and warrants, but did not assume the options and warrants outstanding within any of Pipex Therapeutics' subsidiaries (EPI, CD4 and Solovax). On October 31, 2006, concurrent with the Merger, Pipex Therapeutics executed a private stock purchase agreement to purchase an additional 2,426,300 shares of common stock held by Sheffield's sole officer and director; these shares were immediately cancelled and retired. Aggregate consideration paid for Sheffield was \$665,000. Upon the closing of the reverse acquisition, shareholders of Sheffield retained an aggregate 245,824 shares of common stock. As a result of these two stock purchase transactions, Pipex Therapeutics acquired approximately 99% ownership of the issued and outstanding common shares of Sheffield.

See Note 2(H) as it pertains to the retroactive effect of the share and per share amounts pursuant to the reverse acquisition and recapitalization discussed in this Note 1(F).

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

(G) Contribution Agreements — Consolidation of Entities under Common Control

1. EPI's Acquisition of CD4

On December 31, 2004, EPI acquired 91.61% of the issued and outstanding common stock of CD4 in exchange for 825,000 shares of common stock having a fair value of \$825. EPI assumed certain outstanding accounts payable and loans of CD4 of approximately \$664,000. The fair value of the exchange was equivalent to the par value of the common stock issued. CD4 shareholders retained 119,000 shares (8.39%) of the issued and outstanding common stock of CD4; these shareholders comprise the non-controlling shareholder base of CD4.

2. Pipex Therapeutics' Acquisition of Solovax

On July 31, 2005, Pipex Therapeutics acquired 96.9% of the aggregate voting preferred and common stock of Solovax. Pipex Therapeutics assumed all outstanding liabilities of approximately \$310,000, the transfer of 1,000,000 shares of Series A Convertible Preferred Stock owned by Solovax's president and 250,000 shares of common stock owned by Solovax's COO. The fair value of the exchange was equivalent to the par value of the common stock received pursuant to the terms of the contribution.

3. Pipex Therapeutics' Acquisition of EPI/CD4

On December 31, 2005, Pipex Therapeutics acquired 65.47% of the aggregate voting preferred and common stock of EPI and EPI's majority owned subsidiary CD4. In addition, Pipex Therapeutics assumed \$583,500 of outstanding liabilities of EPI. The fair value of the exchange was equivalent to the par value of the common stock received pursuant to the terms of the contribution.

In the consolidated financial statements, each of these transactions described in Note 1F, was analogous to a recapitalization with no net change to equity since the entities were under common control at the date of the transaction.

4. Adeona's Acquisition of EPI, Share Issuances and Paid-in Kind Merger Dividend

On January 5, 2007, EPI merged with and into a wholly owned subsidiary of Adeona, Effective Acquisition Corp. In the transaction, Adeona issued an aggregate 795,248 shares of common stock having a fair value of \$15,865,198 based upon the quoted closing trading price of \$19.95 per share. As consideration for the share issuance, EPI exchanged 1,902,501 shares of Series B Convertible Preferred stock and 75,000 shares of common stock into 765,087 and 30,161, shares of Adeona common stock, respectively.

See additional discussion below for the issuance of the 765,087 shares, the Company recorded a paid-in kind/merger dividend.

In connection with the issuance of the 30,161 shares, the Company recorded additional compensation expense of \$601,712 as the stock was issued to an officer and director of the Company.

During 2006, EPI declared a 10% and 30% preferred stock dividend, respectively, on its outstanding Series B, convertible preferred stock. During 2005, EPI declared a 10% preferred stock dividend on its outstanding Series B, convertible preferred stock. In total, 951,250 shares of additional Series B, convertible preferred stock were issued to the holders of record at the declaration date. These 951,250 shares of outstanding Series B preferred stock dividend were cancelled and retired and were not contemplated in the exchange with Adeona. EPI also cancelled and retired all of the issued and outstanding 3,000,000 shares of Series A Convertible Preferred stock as well as 750,000 shares of common stock

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

In connection with this exchange and pursuant to Securities and Exchange Commission Regulation S-X, Rule 11-01(d) and EITF 98-3, "Determining whether a Non-Monetary Transaction involves the receipt of Productive Assets or of a Business" EPI was classified as a development stage company and thus was not considered a business. As a result, SFAS No. 141 purchase accounting rules did not apply. Additionally, the Company applied the provisions of EITF 86-32, "Early Extinguishment of a Subsidiary's Mandatorily Redeemable Preferred Stock" and has determined that even though the preferred stock of EPI was not mandatorily redeemable, this transaction is analogous to a capital transaction, and there would be no resulting gain or loss.

Finally, in connection with EITF Topic D-42, "The Effect on the Calculation of Earnings Per Share for the Redemption or Induced Conversion of Preferred Stock", The Company has determined that the fair value of the consideration transferred to the holders of EPI Series B, convertible preferred stock over the carrying amount of the preferred stock represents a return to the preferred stockholders. The difference is \$12,409,722, which is included as a component of paid in-kind dividends. This amount is included as an additional reduction in net loss applicable to common shareholders for purposes of computing loss per share in the accompanying financial statements for the period from January 8, 2001 (inception) to June 30, 2008.

As part of the acquisition of EPI, the Company granted an aggregate 68,858 warrants and 34,685 options for the outstanding warrants and options held by the EPI warrant and option holders. These new warrants and options will continue to vest according to their original terms. Pursuant to SFAS No. 123R and fair value accounting, the Company treated the exchange as a modification of an award of equity instruments. As such, incremental compensation cost was measured as the excess of the fair value of the replacement award over the fair value of the cancelled award at the cancellation date. In substance, Adeona repurchased the EPI instruments by issuing a new instrument of greater value.

The Company used the following weighted average assumptions for the fair value of the replacement award: expected dividend yield of 0%; expected volatility of 196.10%; risk-free interest rate of 4.65%, an expected life ranging from seven to eight years and exercise prices ranging from \$0.09 - \$3.30.

The Company has the following weighted average assumptions for the fair value of the cancelled award at the cancellation date: expected dividend yield of 0%; expected volatility of 200%; risk-free interest rate of 4.65%, an expected life ranging from seven to eight years and exercise prices ranging from \$0.09 - \$3.30.

The fair value of the replacement award required an increase in compensation expense of approximately \$352,734.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

Note 2 Summary of Significant Accounting Policies

(A) Principles of Consolidation

All significant inter-company accounts and transactions have been eliminated in consolidation.

(B) Development Stage

The Company's consolidated financial statements are presented as statements of a development stage enterprise. For the period from inception (January 8, 2001) to date, the Company has been a development stage enterprise, and accordingly, the Company's operations have been directed primarily toward the acquisition and creation of intellectual properties and certain research and development activities to improve current technological concepts. As the Company is devoting its efforts to research and development, there have been no sales, license fees or royalties earned. Additionally, the Company continually seeks sources of debt or equity based funding to further its intended research and development activities. The Company has experienced net losses since its inception, and had an accumulated deficit of \$37,366,490 at September 30, 2008.

(C) Use of Estimates

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the periods presented. Actual results may differ from these estimates.

Significant estimates during 2008 and 2007 include depreciable lives of property, valuation of warrants and stock options granted for services or compensation pursuant to EITF No. 96-18 and SFAS No. 123R, respectively, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing operating losses.

(D) Cash and Cash Equivalents

The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. At September 30, 2008, the balance exceeded the federally insured limit by \$6,271,207.

(E) Property and Equipment

Property and equipment is stated at cost, less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred. Items of property and equipment with costs greater than \$1,000 are capitalized and depreciated on a straight-line basis over the estimated useful lives, as follows:

Description	Estimated Useful Life
Office equipment and furniture	5 years

Laboratory equipment	10 years
Manufacturing equipment	10 years
Leasehold improvements and fixtures	Lesser of estimated useful life or life of lease

On September 19, 2008, the Company transferred certain manufacturing equipment with a net book value of \$77,710 and \$30,000 in cash to settle an account payable totaling \$122,140. This transaction resulted in a gain on the sale in the amount of \$14,430 that is included in the accompanying Consolidated Statements of Operations.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

(F) Long Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. There were no impairment charges taken during the three and nine month periods ended September 30, 2008 and September 30, 2007 and for the period from January 8, 2001 (inception) to September 30, 2008.

(G) Derivative Liabilities

In connection with the reverse acquisition, all outstanding convertible preferred stock of Adeona was cancelled and retired, as such, the provisions of EITF No. 00-19, "Accounting for Derivative Financial Instruments Issued in, and Potentially Settled in, a Company's Own Stock" do not apply. The Company's majority owned subsidiaries also contain issued convertible preferred stock; however, none of these instruments currently contains any provisions that require the recording of a derivative liability. In connection with the acquisition of EPI on January 5, 2007 (See Note 1(G)(4)), all issued and outstanding shares of Series A and B, convertible preferred stock were cancelled and retired. As such, no potential derivative liabilities will exist pertaining to these instruments.

(H) Net Loss per Share

Basic earnings (loss) per share is computed by dividing the net income (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of share equivalents. Since the Company reported a net loss for the three and nine month periods ended September 30, 2008 and September 30, 2007 and for the period from January 8, 2001 (inception) to September 30, 2008, respectively, all common stock equivalents would be anti-dilutive; as such there is no separate computation for diluted earnings per share.

The Company's net loss per share for the three and nine month periods ended September 30, 2008 and 2007 and for the period from January 8, 2001 (inception) to September 30, 2008 was computed assuming the recapitalization associated with the reverse acquisition, as such, all share and per share amounts have been retroactively restated. Additionally, the numerator for computing net loss per share was adjusted for preferred stock dividends recorded during the three and nine month periods ended September 30, 2008 and 2007 and the period from January 8, 2001 (inception) to September 30, 2008, in connection with the acquisition of EPI (See Note 1(G)(4)) as well as and certain provisions relating to the sale of EPI's Series B, convertible preferred stock.

(I) Research and Development Costs

The Company expenses all research and development costs as incurred for which there is no alternative future use. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock based

compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company's product candidates, as well as an allocation of overhead expenses incurred by the Company.

(J) Fair Value of Financial Instruments

The carrying amounts of the Company's short-term financial instruments, including other receivable, prepaid expenses, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

(K) Stock Based Compensation

All share-based payments to employees since inception have been recorded and expensed in the statements of operations as applicable under SFAS No. 123R "Share-Based Payment".

(L) Reclassifications

Certain amounts in the year 2007 financial statements have been reclassified to conform to the year 2008 presentation. The results of these reclassifications did not materially affect the Company's consolidated financial position, results of operations or cash flows.

(M) Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements", which clarifies the principle that fair value should be based on the assumptions that market participants would use when pricing an asset or liability. It also defines fair value and established a hierarchy that prioritizes the information used to develop assumptions. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007. The adoption of SFAS No. 157 is not expected to have a material effect on our financial position, results of operations or cash flows.

On February 15, 2007, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities — Including an Amendment of FASB Statement No. 115" ("SFAS 159"). This standard permits an entity to measure financial instruments and certain other items at estimated fair value. Most of the provisions of SFAS No. 159 are elective; however, the amendment to FASB No. 115, "Accounting for Certain Investments in Debt and Equity Securities," applies to all entities that own trading and available-for-sale securities. The fair value option created by SFAS 159 permits an entity to measure eligible items at fair value as of specified election dates. The fair value option (a) may generally be applied instrument by instrument, (b) is irrevocable unless a new election date occurs, and (c) must be applied to the entire instrument and not to only a portion of the instrument. SFAS 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of the previous fiscal year provided that the entity (i) makes that choice in the first 120 days of that year, (ii) has not yet issued financial statements for any interim period of such year, and (iii) elects to apply the provisions of FASB 157. The adoption of SFAS No. 159 is not expected to have a material effect on its financial position, results of operations or cash flows.

In June 2007, the Emerging Issues Task Force ("EITF") issued EITF No. 07-01, Accounting for Collaborative Arrangements, ("EITF 07-1"). EITF 07-1 provides guidance for companies in the biotechnology or pharmaceutical industries that may enter into agreements with other companies to collaboratively develop, manufacture, and market a drug candidate (Collaboration Agreements) and is effective for fiscal years beginning after December 15, 2007. The adoption of EITF 07-1 is not expected to have a material effect on the Company's financial position, results of operations or cash flows.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

In June 2007, the EITF issued EITF No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities, (“EITF 07-3”). EITF 07-3 provides guidance for upfront payments related to goods and services of research and development costs and is effective for fiscal years beginning after December 15, 2007. The adoption of EITF 07-3 is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements, an amendment of Accounting Research Bulletin No 51” (“SFAS 160”). SFAS 160 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, changes in a parent’s ownership of a noncontrolling interest, calculation and disclosure of the consolidated net income attributable to the parent and the noncontrolling interest, changes in a parent’s ownership interest while the parent retains its controlling financial interest and fair value measurement of any retained noncontrolling equity investment. SFAS 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. Early adoption is prohibited. The adoption of SFAS No. 160 is not expected to have a material effect on its financial position, results of operations or cash flows.

In December 2007, the FASB issued SFAS 141R, Business Combinations (“SFAS 141R”), which replaces FASB SFAS 141, Business Combinations. This Statement retains the fundamental requirements in SFAS 141 that the acquisition method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141R defines the acquirer as the entity that obtains control of one or more businesses in the business combination and establishes the acquisition date as the date that the acquirer achieves control. SFAS 141R will require an entity to record separately from the business combination the direct costs, where previously these costs were included in the total allocated cost of the acquisition. SFAS 141R will require an entity to recognize the assets acquired, liabilities assumed, and any non-controlling interest in the acquired at the acquisition date, at their fair values as of that date. This compares to the cost allocation method previously required by SFAS No. 141. SFAS 141R will require an entity to recognize as an asset or liability at fair value for certain contingencies, either contractual or non-contractual, if certain criteria are met. Finally, SFAS 141R will require an entity to recognize contingent consideration at the date of acquisition, based on the fair value at that date. This Statement will be effective for business combinations completed on or after the first annual reporting period beginning on or after December 15, 2008. Early adoption of this standard is not permitted and the standards are to be applied prospectively only. Upon adoption of this standard, there would be no impact to the Company’s results of operations and financial condition for acquisitions previously completed. The adoption of SFAS No. 141R is not expected to have a material effect on its financial position, results of operations or cash flows.

In March 2008, the FASB issued SFAS No. 161 “Disclosures about Derivative Instruments and Hedging Activities—An Amendment of FASB Statement No. 133.” (“SFAS 161”). SFAS 161 establishes the disclosure requirements for derivative instruments and for hedging activities with the intent to provide financial statement users with an enhanced understanding of the entity’s use of derivative instruments, the accounting of derivative instruments and related hedged items under Statement 133 and its related interpretations, and the effects of these instruments on the entity’s financial position, financial performance, and cash flows. This statement is effective for financial statements issued for fiscal years beginning after November 15, 2008. The Company does not expect its adoption of SFAS 161 to have a material impact on its financial position, results of operations or cash flows.

In April 2008, the FASB issued FASB Staff Position (“FSP”) SFAS No. 142-3, “Determination of the Useful Life of Intangible Assets”. This FSP amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under FASB Statement No. 142, “Goodwill and Other Intangible Assets” (“SFAS 142”). The intent of this FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS 141R, and other GAAP. This FSP is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. Early adoption is prohibited. The Company is currently evaluating the impact of SFAS FSP 142-3, but does not expect the adoption of this pronouncement will have a material impact on its financial position, results of operations or cash flows.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

In May 2008, the FASB issued FSP Accounting Principles Board (“APB”) 14-1 “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)” (“FSP APB 14-1”). FSP APB 14-1 requires the issuer of certain convertible debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer’s non-convertible debt borrowing rate. FSP APB 14-1 is effective for fiscal years beginning after December 15, 2008 on a retroactive basis. The Company does not believe the adoption of FSP APB 14-1 will have a significant effect on its financial position, results of operations or cash flows.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date and are not expected to have a material impact on the financial statements upon adoption.

Note 3 Notes Payable

During 2007, the Company borrowed \$1,100,000 and repaid \$200,000 under notes payable. These notes were secured by all assets of the Company as well as the stock certificates of Pipex Therapeutics, EPI, Solovax and CD4; the notes bore interest of prime plus 2% and were due March 30, 2010. On March 6, 2008, all of the outstanding principal and accrued interest was repaid.

Note 4 Stockholders’ Equity and Non-Controlling Interest

(A) Preferred Stock Issuances

1. For the Year Ended December 31, 2001

On January 8, 2001, EPI issued 3,000,000 shares of Series A Convertible Preferred Stock to the Founder serving as the CEO and Chairman of the Board of EPI in exchange for \$250,000 (\$0.08 per share). On January 5, 2007, pursuant to the acquisition of EPI, these shares were cancelled and retired.

On January 15, 2001, Pipex Therapeutics issued 5,421,554 shares of Series A Convertible Preferred Stock to a founder serving as Chairman of the Board of Pipex in exchange for \$300,000 (\$0.055 per share). On October 31, 2006, pursuant to the reverse acquisition with Sheffield, these shares were cancelled and retired.

On January 31, 2001, Solovax issued 1,000,000 shares of Series A Convertible Preferred Stock to the Founder of Solovax in exchange for \$300,000 (\$0.30 per share).

On February 7, 2001, CD4 issued 1,000,000 shares of Series A Convertible Preferred Stock, to an affiliate of a founder in exchange for \$300,000 (\$0.30 per share).

2. For the Year Ended December 31, 2005

On March 10, 2005, EPI's board of directors and stockholders voted to authorize the designation of a Series B Convertible Preferred Stock. From March through June 2005, EPI issued 1,902,500 shares of Series B Convertible Preferred Stock, at \$1 per share, for proceeds of \$1,902,500. In connection with this offering, EPI paid \$152,200 of offering costs that were charged against additional paid in capital. The Company also granted 171,225 warrants as compensation in connection with this equity raise.

On January 5, 2007, pursuant to the acquisition of EPI, the shares of Series B Convertible Preferred Stock were converted into 765,087 shares of Adeona common stock and the warrants were converted into 68,858 warrants of Adeona. (See Note 1(E)(4))

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

(B) Common Stock Issuances of Issuer

For the Year Ended 2006

During October 2006, the Company issued 422,314 shares of common stock to an unrelated third party in connection with the terms of a license agreement. The fair value was \$388,691 based upon the recent cash offering price at that time and was charged to research and development expense.

During October 2006, the Company converted all of its 5,421,554 shares of Series A, convertible preferred stock in exchange for equivalent common shares. The fair value of the exchange was based upon par value with a net effect of \$0 to the statement of equity.

On October 31, 2006, the loans payable to the Company's founder, President and CEO were converted into 1,665,211 shares of common stock and 832,606 warrants. There were no gain or loss on this transaction since it was with a related party.

During October and November of 2006, the Company completed private placements of its stock, which resulted in the issuance of 6,900,931 shares of common stock and 3,451,524 warrants. The net proceeds from the private placements were \$12,765,945, which included cash paid as direct offering costs of \$1,160,418.

For the Year Ended 2007

During 2007, the Company issued 3,401,972 shares of common stock in connection with the exercise of warrants for net proceeds of \$6,972,809 (\$2.22 per share).

In September and December of 2007, the Company issued an aggregate 2,920 shares of common stock having a fair value of \$20,000 (\$6.85 per share) based on the quoted closing trading price for license fees.

In December 2007, the Company issued 5,102 shares of common stock having a fair value of \$25,000 (\$4.90 per share) based on the quoted closing trading price for a milestone payment.

For the Year Ended 2008

In January, April and August of 2008, the Company issued 37,948 shares of common stock in connection with the exercise of stock options for net proceeds of \$4,428. The related exercise prices were \$0.09 and \$0.18 per share.

In March and April of 2008, the Company issued 61,392 shares of common stock having a fair value of \$55,385 (\$0.90 per share) based on the quoted closing trading prices for payment of salaries to employees.

In April and September 2008, the Company issued 127,845 shares of common stock having a fair value of \$90,042 (\$0.70 per share) based on the quoted closing trading price for consulting fees.

In May, June, August and September of 2008, the Company issued an aggregate 138,505 shares of common stock having a fair value of \$145,000 (\$1.05 per share) based on the quoted closing trading prices for license fees.

In June 2008, the Company issued 39,370 shares of common stock having a fair value of \$50,000 (\$1.27 per share) based on the quoted closing trading price for a milestone payment.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

(C) Common Stock Issuances of Subsidiaries

During the period from January 8, 2001 (inception) to September 30, 2008, the Company's majority owned subsidiaries; CD4, Solovax, EPI and Epitepe issued 419,000, 419,000, 825,000 and 125,000 shares of common stock, respectively, for an aggregate \$1,788. Of the 825,000 shares of common stock issued by EPI, 75,000 were converted into 30,161 common shares of Adeona and the remaining 750,000 shares were cancelled and retired for no additional consideration in the acquisition of EPI on January 5, 2007.

(D) Stock Incentive Plan

During 2001, Pipex Therapeutics' Board and stockholders adopted the 2001 Stock Incentive Plan (the "2001 Stock Plan"). This plan was assumed by Pipex in the merger, in October 2006. As of the date of the merger, there were 1,489,353 options issued and outstanding. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period shall not exceed 1,250,000. All awards pursuant to the Plan shall terminate upon the termination of the grantee's employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the "Awards"). The Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the Plan. The Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of September 30, 2008, there are 1,229,987 options issued and outstanding under the 2001 Stock Plan.

On March 20, 2007, the Company's Board of Directors approved the Company's 2007 Stock Incentive Plan (the "2007 Stock Plan") for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company's common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. This plan was approved by stockholders on November 2, 2007. As of September 30, 2008, there are 1,459,108 options issued and outstanding under the 2007 Stock Plan.

Pursuant to the provisions of SFAS No. 123R, in the event of termination, the Company will cease to recognize compensation expense. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the share-based payment is recognized ratably over the stated vesting period.

The Company has followed fair value accounting and the related provisions of SFAS No. 123R for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the three and nine months ended September 30, 2008 and 2007 are as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	2008	2007	2008	2007
Exercise price	\$0.72	\$4.64 - \$6.80	\$0.72 - \$5.10	\$0.09 - \$22.50
Expected dividends	0%	0%	0%	0%
Expected volatility	225%	196.06% - 197.04%	201.11% - 225%	103.29% - 200%
Risk free interest rate	3.95%	4.79% - 5.16%	3.52% - 4.02%	4.18% - 5.16%
Expected life of option	10 years	5 - 10 years	10 years	5 - 10 years

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

All option grants are expensed in the appropriate period based upon vesting terms, in each case with an offsetting credit to additional paid in capital. The stock-based compensation expense recorded by the Company for the three and nine months ended September 30, 2008 and 2007 and the period from inception to September 30, 2008 with respect to stock option awards is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,		Inception to September 30, 2008
	2008	2007	2008	2007	
Research and development:					
employees	\$ 102,556	\$ 13,797	\$ 768,846	\$ 255,846	\$ 2,234,728
non-employees	21,071	-	313,319	145,783	519,062
General and administrative:					
employees	137,902	44,098	341,926	172,431	1,396,079
non-employees	-	-	30,850	293,599	969,625
Total	\$ 261,529	\$ 57,895	\$ 1,454,941	\$ 867,659	\$ 5,119,494

Pursuant to FAS 123R, the Company records stock based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows: immediate vesting, half vesting immediately and the remainder over three years, quarterly over three years, annually over three years, one-third immediate vesting and remaining annually over two years, one half immediate vesting with remaining vesting over six months and one quarter immediate vesting with the remaining over three years.

A summary of stock option activity for Adeona for the nine months ended September 30, 2008 (unaudited) and for the year ended December 31, 2007 is as follows:

	Number of Shares	Weighted Average Exercise Price
Balance at December 31, 2006	1,613,855	\$ 1.45
Granted	700,176	\$ 6.21
Exercised	—	\$ —
Forfeited	(16,667)	\$ 15.75
Balance at December 31, 2007	2,297,364	\$ 2.72
Granted	1,105,667	\$ 1.03
Exercised	(37,948)	\$ 0.12
Forfeited	(675,988)	\$ 5.01
Balance at September 30, 2008 (unaudited)	2,689,095	\$ 1.49

The weighted average remaining contractual term for options outstanding at September 30, 2008 was 7.93 years. At September 30, 2008, the Company had 550,780 stock options outstanding that had an exercise price less than the market price on that date for an aggregate intrinsic value of \$267,490. Of the total options granted, 1,835,607 are fully vested, exercisable and non-forfeitable and have a weighted average exercise price of \$1.61.

Of the total 2,689,095 options outstanding, 1,374,830 options are held by related parties of which 665,413 are fully vested, exercisable and non-forfeitable.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

(E) Stock Warrants

On October 31, 2006, the loans payable to the Company's founder, President and CEO were converted into 1,665,211 shares of common stock and 832,606 warrants to purchase common stock. The warrants have an exercise price of \$2.22 and a life of 5 years.

In October and November 2006, the Company issued warrants to purchase 3,451,524 shares of common stock as part of the private placement offering. The warrants have an exercise price of \$2.22 and each warrant has a life of 5 years.

In addition, as part of the private placements, the Company issued warrants to purchase 958,277 shares of common stock to the placement agent, which is a company that is controlled by the Company's Chairman and CEO. The warrants have an exercise price of \$2.22. Since these warrants were granted as compensation in connection with an equity raise, the Company has treated these warrants as a direct offering cost. The result of the transaction has a \$0 net effect to equity. The warrants are fully vested and non-forfeitable.

On January 5, 2007, the Company issued warrants to purchase 68,858 shares of common stock as part of the acquisition of EPI. (See Note (1)(F)(4))

On February 15, 2007, the Company executed an agreement with a third party to provide certain consulting services. Pursuant to the terms of the agreement, the Company will issue warrants to purchase 100,000 shares of common stock upon the achievement of various milestones as well as over the life of the contract. The warrants have an exercise price of \$3.75. The fair value of the warrants totals \$374,760 and was determined by using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 187.22%; risk-free interest rate of 4.68% and an expected life of five years. As of June 30, 2008, 50,000 warrants have been issued for which the Company has recognized stock based consulting expense for \$187,500.

During May through August 2007, the Company issued 127,406 shares of common stock in exchange for common stock warrants for \$2.22/share. The net proceeds totaled \$282,841.

During October and November 2007, the Company issued 3,274,566 shares of common stock in connection with the exercise of common stock warrants, pursuant to a warrant call for \$2.22/share. The warrant call had occurred due to the terms by which the Company sold its common stock and warrants in private placement offerings. The net proceeds from the warrant call were \$6,972,809, which included cash paid as direct offering costs of \$579,569.

In connection with this warrant call, the Company entered into a warrant solicitation agreement with Noble International Investments, Inc. ("Noble"). As compensation for Noble's services, the Company paid Noble a cash fee of \$579,569 which totals 8% of the gross proceeds from the Holder's exercise of warrants. In addition, the Company issued Noble 327,456 common stock warrants. The warrants have a term of five years, will contain customary anti-dilution provisions, piggyback registration rights, and will be exercisable at a purchase price of \$6.36 per share. The Company may, at its option, call the warrants if the average daily trading price of the Company's common stock exceeds, for at least 20 of 30 consecutive trading days, a price per share that is equal to or greater than 250% of the warrant's exercise price of \$6.36 per share, and there is an effective registration statement registering the shares of the Company's common stock underlying the warrant. Noble will have the right at any time during the five-year term

of the warrants to exercise the warrants at its option on a “cashless” basis, only if the Company fails to maintain an effective registration statement registering the shares of the Company’s common stock underlying the warrants. Since these warrants were granted as compensation in connection with an equity raise, the Company has treated these warrants as a direct offering cost. The result of the warrant grant has a \$0 net effect to equity. These warrants are fully vested and non-forfeitable.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

A summary of warrant activity for Adeona for the nine months ended September 30, 2008 (unaudited) and for the year ended December 31, 2007 is as follows:

	Number of Shares	Weighted Average Exercise Price
Balance as December 31, 2006	5,242,407	\$2.22
Granted	437,981	\$5.63
Exercised	(3,401,972)	\$2.22
Forfeited	—	
Balance at December 31, 2007	2,278,416	\$2.22
Granted	8,333	\$3.75
Exercised	—	
Forfeited	—	
Balance as September 30, 2008 (unaudited)	2,286,749	\$2.88

All outstanding warrants are fully vested and exercisable.

Warrants Outstanding and Exercisable

Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life
\$ 2.22	1,840,435	4.07 Years
\$ 3.30	68,858	6.67 Years
\$ 3.75	50,000	7.38 Years
\$ 6.36	327,456	4.11 Years
	2,286,749	5.49 Years

(F) Options of Subsidiary

CD4 has 30,000 options outstanding and exercisable, with an exercise price of \$0.20 and a remaining contractual life of 2.23 years as of September 30, 2008.

Epitope has 50,000 options outstanding and none exercisable, with an exercise price of \$.001 and a remaining contractual life of 9.75 years as of September 30, 2008. These options vest annually over 5 years and have a fair value of \$50 which was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47% and an expected life of 10 years.

(G) Non-Controlling Interest

Since the Company's majority owned subsidiaries have never been profitable and present negative equity, there has been no establishment of a positive non-controlling interest. Since this value cannot be presented as a deficit balance, the accompanying consolidated balance sheet does not reflect any notation.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

Note 5 Commitments

(A) License Agreements

Since inception, the Company has entered into various option and license agreements for the use of patents and their corresponding applications. These agreements have been entered into with various educational institutions and hospitals. These agreements contain payment schedules or stated amounts due for (a) option and license fees, (b) expense reimbursements, and (c) achievement of success milestones. All expenses related to these agreements have been recorded as research and development.

In connection with these agreements, the Company may be obligated to make future milestone payments up to an amount of \$19,425,000. Some of these payments may be fulfilled through the issuance of the Company's common stock, at the Company's option. As of September 30, 2008, the Company has achieved two milestones which the Company fulfilled by issuing common stock having a fair value of \$75,000. See Note (4(B)). The Company can give no assurances that any other milestones will be achieved. In addition to the milestone payments, the Company may be obligated to make royalty payments on future sales pursuant to the agreements.

(B) Research Agreement

In September 2005, the Company entered into a three-year sponsored research agreement with a University. Pursuant to that agreement, the Company sponsors approximately \$460,000 per year, payable in monthly installments. This agreement can be extended for an additional two-year period. The Company can terminate the agreement by giving 90 days prior written notice. On March 20, 2008, the Company provided the University with written notice of termination of the agreement.

(C) Consulting Agreement

In August 2005, Adeona entered into an agreement with an individual to provide consulting services for the Company's research and development. The consultant was paid \$25,000 upon the execution of the agreement. The consultant will receive annual consulting fees of \$120,000 for each of the next three years. The consultant also received 216,847 options having a fair value \$59,960 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%, expected volatility of 200%, risk free interest rate of 1.81% and an expected life of 10 years. On March 24, 2008, the Company granted the individual an additional 216,667 options having a fair value of \$437,667 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 221%, risk free interest rate of 3.56% and an expected life of 10 years. On September 16, 2008 this agreement was amended whereby the consultant will receive an hourly consulting rate of \$300 per hour for a minimum of 10 hours per month, payable in either cash or restricted common stock rather than a quarterly fee of \$30,000 effective October 1, 2008.

On February 15, 2007, the Company executed an agreement with a third party to provide certain services. Pursuant to the terms of the agreement, the Company will pay \$9,000 per month for a period of twelve months and grant 100,000 stock warrants with a cashless exercise provision. These warrants vest upon various milestones as well as over the life of the contract.

(D) Employment Agreements

In January 2005, the Company entered into a four-year employment agreement with the Company's Chairman and Chief Executive Officer. Pursuant to this agreement, Adeona will pay an annual base salary of \$297,000, an annual bonus equal to 30% of base salary and a ten-year option to acquire 271,058 shares of common stock at the completion of the Company's private placement that occurred on October 31, 2006. As of June 30, 2008, 180,705 options have vested, with the remainder vesting on October 31, 2008. The fair value of the options totaled \$544,827 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%, expected volatility of 200%, risk free interest rate of 4.61% and an expected life of 10 years. On July 20, 2007, the Board of Directors approved an amended and restated employment agreement with the Chief Executive Officer. The amended employment agreement provides that the Chief Executive Officer is to be paid a base salary of \$195,000 per year plus a guaranteed bonus of \$100,000. The Chief Executive Officer may also be entitled to discretionary transactional bonuses. In addition, the amended agreement provides that the Chief Executive Officer has waived the receipt of any salary and bonus payable under the original agreement, which amounts to \$275,645, for no additional consideration. This amount was treated as a capital contribution to the Company in September 2007. On July 1, 2008, the Chief Executive Officer resigned his position with the Company but remains as Chairman and will continue to receive compensation under this employment agreement.

Adeona Pharmaceuticals, Inc. and Subsidiaries
(A Development Stage Company)

Notes to Consolidated Financial Statements
(Unaudited)

The Company entered into an employment agreement with its President on May 24, 2006. Pursuant to this agreement, Adeona will pay an annual base salary of \$295,000 and a guaranteed bonus of one-third of base salary. Adeona has also granted a ten-year option to purchase 664,252 shares of common stock, of which 332,126 have vested as of December 31, 2007. The remainder of these options will vest quarterly over a three-year period. In the event of a termination, the Company will provide six-month severance, payable over a six-month period. On March 5, 2008, the Company's President has agreed to work for no cash compensation until May 17, 2008 at which time his compensation will be at the discretion of the compensation committee. The President will be eligible to receive a contingent bonus in the event that the Company is acquired or the stock price retraces or exceeds to the level of the share price on January 28, 2008. Additionally, the President agreed to eliminate severance provisions of his agreement. The Company has recorded contributed services from a related party totaling \$73,750 during 2008. On July 1, 2008 the President resigned his position with the Company.

On October 10, 2007, the Company entered into a three-year employment agreement with its Chief Scientific Officer. The Company paid the Chief Scientific Officer a \$7,500 signing bonus and a base salary of \$205,000 per year. The agreement also provided that the Chief Scientific Officer was eligible for cash and non-cash bonuses at the end of each of the Company's fiscal years during the term of the agreement at the discretion of the Company's compensation committee as well as additional commission-based cash and stock bonuses during each fiscal year based on significant revenue-generating, out-licensing and merger and acquisition transactions initiated and completed by the Chief Scientific Officer, again at the discretion of the compensation committee. Pursuant to the agreement, the Company granted a ten-year option to purchase 150,000 shares of the Company's common stock of which none are outstanding as of September 30, 2008. This agreement was terminated on March 7, 2008.

On July 1, 2008, the Company's Board of Directors approved a compensation package with its Vice Chairman as a result of his appointment as Chief Executive Officer. Under the terms of arrangement, the Chief Executive Officer will receive an annual salary of \$195,000. The Chief Executive Officer is also eligible for a bonus at the discretion of the Board of Directors. In the event of termination, the Company will provide six-month severance, payable over the Company's ordinary pay periods. The Company has also granted a ten year option to purchase 800,000 shares of the Company's common stock, exercisable at \$0.72 per share, with one-quarter of the options vesting immediately, and the remainder vesting quarterly in equal increments over three years. These options shall vest in full should the Company be acquired. The fair value of the options totaled \$576,000 and was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%, expected volatility of 225.79%, risk free interest rate of 3.95% and an expected life of 10 years.

Note 6 Corporate Restructuring

On March 11, 2008, the Company announced that it has implemented cost reduction measures in order to substantially reduce operating expenses given the delay in refiling its New Drug Application for oral tetrathiomolybdate (oral TTM) for the treatment of initially presenting neurologic Wilson's disease. As part of the corporate restructuring, the Company eliminated positions in the areas of manufacturing, analytical, quality control, quality assurance, clinical, regulatory, diagnostic product development, principally relating to the development of oral TTM and diagnostics division.

On July 8, 2008, the Company announced changes in senior management. See Note (5)(D).

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL INFORMATION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the attached unaudited consolidated financial statements and notes thereto, and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2007, found in our Annual Report on Form 10-KSB. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as "anticipate," "believe," "intends," or similar expressions. Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under "Risk Factors" in Part II, Item 1A of this Report.

Overview

Since our inception during January 2001, our efforts and resources have been focused primarily on acquiring and developing our pharmaceutical products, raising capital and recruiting personnel. We are a development stage company and have had no product sales to date and we will not have any product sales until and unless we receive approval from the FDA or receive approval from equivalent foreign regulatory bodies to begin selling our pharmaceutical candidates. Our major sources of working capital have been proceeds from equity financings from our Chairman and various private financings, primarily involving private sales of our common stock and other equity securities.

Our company's current corporate structure resulted from the October 2006 merger of a newly-created wholly owned subsidiary of Sheffield Pharmaceuticals, Inc. ("Sheffield"), a Delaware corporation incorporated in September 1993, and Pipex Therapeutics, Inc., a Delaware corporation ("Pipex Therapeutics"). In connection with that transaction, a wholly owned subsidiary of Sheffield merged with and into Pipex Therapeutics, with Pipex Therapeutics remaining as the surviving corporation and a wholly-owned subsidiary of Sheffield. On December 11, 2006, Sheffield changed its name to Pipex Pharmaceuticals, Inc. ("Pipex") and on October 16, 2008 the Company changed its name to Adeona Pharmaceuticals, Inc. ("Adeona"). In exchange for their shares of capital stock in Pipex Therapeutics, the former stockholders of Pipex Therapeutics received shares of capital stock of Sheffield representing approximately 98 percent of the outstanding equity of Sheffield on a primary diluted basis after giving effect to the transaction, with Sheffield assuming Pipex's outstanding options and warrants. In addition, the board of directors of Sheffield was reconstituted shortly following the effective time of the transaction such that the directors of Sheffield were replaced by our current directors, all of whom were previously directors of Pipex Therapeutics. Further, upon the effective time of the merger, the business of Sheffield was abandoned and the business plan of Pipex Therapeutics was adopted. The transaction was therefore accounted for as a reverse acquisition with Pipex Therapeutics as the acquiring party and Sheffield as the acquired party. Accordingly, when we refer to our business and financial information relating to periods prior to the merger, we are referring to the business and financial information of Pipex Therapeutics, unless the context indicates otherwise.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants discuss their most "critical accounting policies" in management's discussion and analysis of financial condition and results of operations. The SEC indicated that a "critical accounting policy" is one which is both important to the portrayal of the company's financial condition and results and requires management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We believe that the following discussion regarding research and development expenses, general and administrative expenses and non-cash compensation expense involve our most critical accounting policies.

Research and development expenses consist primarily of manufacturing costs, license fees, salaries and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and organizational affairs and other expenses relating to the design, development, testing, and enhancement of our product candidates, as well as an allocation of overhead expenses incurred by the Company. We expense our research and development costs as they are incurred.

General and administrative expenses consist primarily of salaries and related expenses for executive, finance and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including business development and general legal activities, as well as an allocation of overhead expenses incurred by the Company. We expense our general and administrative expenses as they are incurred.

Our results include non-cash compensation expense as a result of the issuance of stock and stock option grants. Compensation expense for options granted to employees represents the fair value of the award at the date of grant. All share-based payments to employees since inception have been recorded and expensed in the statements of operations as applicable under SFAS No. 123R "Share-Based Payment".

This amount is being recorded over the respective vesting periods of the individual stock options. The expense is included in the respective categories of expense in the statement of operations. We expect to record additional non-cash compensation expense in the future, which may be significant. However, because some of the options are milestone-based, the total expense is uncertain.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Results of Operations

388,702

Verizon Communications, Inc. (a)

29,200 1,364,516

	Shares	Value
2,921,203		
Common Stocks		
Electric Utilities 3.2%		
Duke Energy Corp. (a)	5,200	\$ 387,348
NextEra Energy, Inc. (a)	15,400	1,537,690
SSE PLC	35,000	902,523
		2,827,561
Electrical Equipment 2.0%		
Emerson Electric Co. (a)	26,800	1,827,224
Food & Staples Retailing 0.8%		
Wal-Mart Stores, Inc. (a)	8,714	694,593
Food Products 4.4%		
General Mills, Inc. (a)	35,200	1,866,304
Kraft Foods Group, Inc. (a)	9,933	564,790
Mondelez International, Inc., Class A (a)	29,200	1,040,980
Nestle SA	5,700	440,520
		3,912,594
Health Care Equipment & Supplies 0.5%		
Abbott Laboratories (a)	11,100	430,014
Hotels, Restaurants & Leisure 1.5%		
McDonald's Corp. (a)	12,900	1,307,802
Household Products 1.4%		
The Procter & Gamble Co. (a)	15,600	1,287,780
Industrial Conglomerates 4.7%		
3M Co. (a)	11,200	1,557,808
General Electric Co. (a)	53,800	1,446,682
Hopewell Holdings Ltd.	85,684	295,499

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Keppel Corp. Ltd.	53,800	452,675
Siemens AG ADR (a)	3,700	487,771
		4,240,435
Insurance 5.0%		
Aflac, Inc. (a)	7,100	445,312
Allianz SE	3,600	626,507
The Chubb Corp.	8,500	782,680
Cincinnati Financial Corp. (a)	11,400	555,636
MetLife, Inc. (a)	6,600	345,510
Prudential Financial, Inc. (a)	18,100	1,460,308
Zurich Insurance Group AG	976	279,876
		4,495,829
IT Services 1.2%		
Automatic Data Processing, Inc. (a)	13,400	1,044,664
Leisure Products 0.5%		
Mattel, Inc.	11,800	462,737
Machinery 1.2%		
Scania AB, B Shares	35,800	1,090,696
Media 2.3%		
The Walt Disney Co. (a)	25,500	2,023,170

Portfolio Abbreviations

ADR American Depositary Receipt	GBP British Pound	PEN Peruvian Nuevo Sol
AUD Australian Dollar	GDR Global Depositary Receipts	REIT Real Estate Investment Trust
BRL Brazil Real	HKD Hong Kong Dollar	SEK Swedish Krona
CAD Canadian Dollar	ILS Israeli Shekel	SGD Singapore Dollar
CHF Swiss Franc	JPY Japanese Yen	TWD Taiwan Dollar
CLP Chilean Peso	KRW Korean Won	USD U.S. Dollar
DKK Danish Krone	MXN Mexican New Peso	ZAR South African Rand
EUR Euro	NOK Norwegian Krone	

See Notes to Financial Statements.

Table of Contents**BlackRock Dividend Income Trust (BQY)****Schedule of Investments (continued)**

(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Metals & Mining 1.2%		
BHP Billiton Ltd. ADR (a)	8,012	\$ 565,166
BHP Billiton PLC	14,150	459,368
		1,024,534
Multi-Utilities 3.9%		
Ameren Corp. (a)	22,300	921,213
Dominion Resources, Inc. (a)	23,500	1,704,690
Sempra Energy	4,800	473,328
Wisconsin Energy Corp.	8,300	402,384
		3,501,615
Oil, Gas & Consumable Fuels 11.2%		
Chevron Corp. (a)	16,300	2,045,976
Enbridge, Inc. (a)	24,400	1,177,424
Exxon Mobil Corp. (a)	27,000	2,765,070
Royal Dutch Shell PLC ADR	6,850	539,369
Santos Ltd.	66,600	853,900
Suncor Energy, Inc. (a)	3,450	133,083
Total SA ADR	28,000	1,994,720
TransCanada Corp. (a)	10,700	498,660
		10,008,202
Pharmaceuticals 10.7%		
AbbVie, Inc. (a)	10,287	535,747
AstraZeneca PLC	17,700	1,397,136
Bristol-Myers Squibb Co. (a)	34,300	1,718,087
GlaxoSmithKline PLC	32,425	895,916
Johnson & Johnson (a)	15,700	1,590,253
Merck & Co., Inc. (a)	17,500	1,024,800
Pfizer, Inc. (a)	50,200	1,570,256
Sanofi	3,400	366,927
Takeda Pharmaceutical Co. Ltd.	10,800	485,785
		9,584,907
Real Estate Investment Trusts (REITs) 3.2%		
Equity Residential	10,800	641,952
HCP, Inc.	12,000	502,320
Health Care REIT, Inc.	10,700	675,063
Keppel REIT Management Ltd.	15,824	15,295
Liberty Property Trust	7,200	270,000
Ventas, Inc. (a)	11,213	740,955
		2,845,585
Road & Rail 0.3%		
CSX Corp. (a)	10,600	299,132
Semiconductors & Semiconductor Equipment 2.3%		
Intel Corp. (a)	41,900	1,118,311
Microchip Technology, Inc. (a)	19,500	927,030
		2,045,341
Common Stocks	Shares	Value
Software 2.8%		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Microsoft Corp. (a)	41,500	\$ 1,676,600
Oracle Corp. Japan	8,900	410,162
SAP AG ADR (a)	5,450	441,396
		2,528,158
Specialty Retail 2.7%		
Hennes & Mauritz AB, B Shares	21,500	880,058
The Home Depot, Inc. (a)	19,500	1,550,445
		2,430,503
Technology Hardware, Storage & Peripherals 0.5%		
Canon, Inc. ADR (a)	3,700	115,736
Ricoh Co. Ltd.	32,000	368,738
		484,474
Thrifts & Mortgage Finance 0.3%		
Hudson City Bancorp, Inc.	25,800	256,968
Tobacco 4.7%		
Altria Group, Inc. (a)	40,700	1,632,477
British American Tobacco PLC	17,300	998,983
Philip Morris International, Inc.	10,400	888,472
Reynolds American, Inc. (a)	12,800	722,304
		4,242,236
Total Long-Term Investments		
(Cost \$78,114,427) 97.6%		87,280,306
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (b)(c)	3,038,407	3,038,407
Total Short-Term Securities		
(Cost \$3,038,407) 3.4%		3,038,407
Total Investments Before Options Written		
(Cost \$81,152,834) 101.0%		90,318,713
Options Written		
(Premiums Received \$529,380) (1.0)%		(875,586)
Total Investments Net of Options Written 100.0%		89,443,127
Liabilities in Excess of Other Assets 0.0%		(579)
Net Assets 100.0%		\$ 89,442,548

Notes to Schedule of Investments

(a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(b) Represents the current yield as of report date.

(c) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Affiliate	Shares Held at October 31, 2013	Net Activity	Shares Held at April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	3,708,345	(669,938)	3,038,407	\$ 856

See Notes to Financial Statements.

30

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock Dividend Income Trust (BQY)**

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Altria Group, Inc.	Call	USD	38.00	5/02/14	55	\$ (11,440)
Bank of America Corp.	Call	USD	18.00	5/02/14	34	(34)
The Goldman Sachs Group, Inc.	Call	USD	167.50	5/02/14	10	(10)
Microsoft Corp.	Call	USD	40.50	5/02/14	42	(840)
U.S. Bancorp.	Call	USD	41.50	5/02/14	23	(115)
The Walt Disney Co.	Call	USD	81.00	5/02/14	102	(459)
Cincinnati Financial Corp.	Call	USD	48.50	5/05/14	23	(1,073)
The Home Depot, Inc.	Call	USD	80.00	5/05/14	18	(495)
Johnson & Johnson	Call	USD	98.00	5/05/14	31	(9,765)
McDonald's Corp.	Call	USD	98.00	5/05/14	26	(8,450)
Pfizer, Inc.	Call	USD	31.00	5/05/14	44	(1,672)
Pfizer, Inc.	Call	USD	33.00	5/05/14	43	(43)
United Technologies Corp.	Call	USD	116.00	5/05/14	37	(8,510)
Ventas, Inc.	Call	USD	61.45	5/05/14	22	(10,188)
M&T Bank Corp.	Call	USD	119.35	5/07/14	18	(5,060)
3M Co.	Call	USD	136.00	5/09/14	22	(7,425)
Altria Group, Inc.	Call	USD	38.00	5/09/14	55	(11,605)
Chevron Corp.	Call	USD	118.00	5/09/14	24	(18,720)
The Coca-Cola Co.	Call	USD	38.50	5/09/14	44	(10,032)
The Home Depot, Inc.	Call	USD	78.00	5/09/14	42	(7,980)
McDonald's Corp.	Call	USD	99.00	5/09/14	25	(6,325)
Merck & Co., Inc.	Call	USD	57.00	5/09/14	18	(3,276)
QUALCOMM, Inc.	Call	USD	80.00	5/09/14	17	(502)
Mondelez International, Inc., Class A	Call	USD	34.75	5/13/14	58	(6,448)
3M Co.	Call	USD	135.00	5/19/14	22	(9,900)
Abbott Laboratories	Call	USD	39.00	5/19/14	22	(803)
Abbott Laboratories	Call	USD	40.00	5/19/14	22	(198)
AbbVie, Inc.	Call	USD	55.00	5/19/14	10	(150)
Aflac, Inc.	Call	USD	65.00	5/19/14	28	(308)
Altria Group, Inc.	Call	USD	38.00	5/19/14	55	(11,853)
Automatic Data Processing, Inc.	Call	USD	75.00	5/19/14	53	(16,960)
Bank of Nova Scotia	Call	CAD	65.00	5/19/14	46	(7,198)
BHP Billiton Ltd. ADR	Call	USD	67.50	5/19/14	16	(5,360)
BHP Billiton Ltd. ADR	Call	USD	72.50	5/19/14	16	(592)
The Coca-Cola Co.	Call	USD	39.00	5/19/14	44	(8,052)
CSX Corp.	Call	USD	30.00	5/19/14	21	(52)
Duke Energy Corp.	Call	USD	72.50	5/19/14	20	(4,350)
Emerson Electric Co.	Call	USD	70.00	5/19/14	107	(3,745)
Exxon Mobil Corp.	Call	USD	100.00	5/19/14	108	(29,538)
General Electric Co.	Call	USD	26.00	5/19/14	107	(9,897)
General Mills, Inc.	Call	USD	51.75	5/19/14	140	(20,092)
Genuine Parts Co.	Call	USD	90.00	5/19/14	24	(600)
HSBC Holdings PLC ADR	Call	USD	52.50	5/19/14	96	(2,304)
Intel Corp.	Call	USD	27.00	5/19/14	83	(1,120)
Kraft Foods Group, Inc.	Call	USD	57.50	5/19/14	39	(2,145)
Merck & Co., Inc.	Call	USD	57.50	5/19/14	18	(3,150)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

MetLife, Inc.	Call	USD	55.00	5/19/14	13	(292)
Microchip Technology, Inc.	Call	USD	48.00	5/19/14	78	(6,435)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

31

Table of Contents

Schedule of Investments (continued)

BlackRock Dividend Income Trust (BQY)

Exchange-traded options written as of April 30, 2014 were as follows: (continued)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Microsoft Corp.	Call	USD	40.00	5/19/14	27	\$ (2,133)
Mondelez International, Inc., Class A	Call	USD	35.00	5/19/14	29	(2,929)
Morgan Stanley	Call	USD	31.00	5/19/14	42	(2,121)
Morgan Stanley	Call	USD	32.00	5/19/14	42	(651)
PepsiCo, Inc.	Call	USD	85.00	5/19/14	30	(4,500)
Pfizer, Inc.	Call	USD	31.00	5/19/14	34	(2,091)
PPG Industries, Inc.	Call	USD	195.00	5/19/14	23	(4,600)
The Procter & Gamble Co.	Call	USD	82.50	5/19/14	38	(3,325)
Prudential Financial, Inc.	Call	USD	88.00	5/19/14	36	(505)
Reynolds American, Inc.	Call	USD	55.00	5/19/14	51	(9,945)
SAP AG ADR	Call	USD	80.00	5/19/14	21	(3,675)
Siemens AG ADR	Call	USD	135.00	5/19/14	15	(1,762)
Suncor Energy, Inc.	Call	CAD	40.00	5/19/14	13	(2,853)
T Rowe Price Group, Inc.	Call	USD	80.00	5/19/14	22	(5,720)
TransCanada Corp.	Call	CAD	52.00	5/19/14	42	(709)
Verizon Communications, Inc.	Call	USD	48.00	5/19/14	33	(347)
Wells Fargo & Co.	Call	USD	49.00	5/19/14	31	(2,465)
Cincinnati Financial Corp.	Call	USD	48.50	5/22/14	23	(1,621)
The Home Depot, Inc.	Call	USD	78.00	5/23/14	18	(4,653)
Intel Corp.	Call	USD	27.00	5/23/14	1	(20)
Microsoft Corp.	Call	USD	41.00	5/23/14	15	(622)
Pfizer, Inc.	Call	USD	31.00	5/23/14	35	(2,503)
U.S. Bancorp.	Call	USD	41.50	5/23/14	23	(598)
Verizon Communications, Inc.	Call	USD	48.00	5/23/14	33	(594)
Wells Fargo & Co.	Call	USD	49.00	5/23/14	30	(2,595)
Wells Fargo & Co.	Call	USD	50.00	5/23/14	20	(700)
Prudential Financial, Inc.	Call	USD	85.00	5/28/14	36	(2,576)
American Express Co.	Call	USD	87.00	5/30/14	26	(5,018)
General Electric Co.	Call	USD	26.00	5/30/14	108	(10,854)
Merck & Co., Inc.	Call	USD	58.50	5/30/14	34	(5,151)
Microsoft Corp.	Call	USD	41.00	5/30/14	82	(4,018)
Pfizer, Inc.	Call	USD	31.50	5/30/14	44	(2,486)
The Procter & Gamble Co.	Call	USD	82.00	5/30/14	24	(3,432)
Verizon Communications, Inc.	Call	USD	48.50	5/30/14	20	(280)
Canon, Inc. ADR	Call	USD	31.70	6/04/14	14	(714)
Chevron Corp.	Call	USD	125.00	6/06/14	20	(4,500)
Intel Corp.	Call	USD	26.50	6/06/14	83	(4,233)
Johnson & Johnson	Call	USD	101.00	6/06/14	31	(5,224)
U.S. Bancorp.	Call	USD	40.50	6/06/14	44	(3,894)
Wal-Mart Stores, Inc.	Call	USD	79.00	6/06/14	17	(2,780)
Wells Fargo & Co.	Call	USD	50.00	6/06/14	41	(2,030)
AbbVie, Inc.	Call	USD	50.00	6/23/14	31	(9,610)
Ameren Corp.	Call	USD	40.00	6/23/14	89	(16,020)
Bristol-Myers Squibb Co.	Call	USD	55.00	6/23/14	137	(6,233)
Chevron Corp.	Call	USD	125.00	6/23/14	21	(5,260)
Dominion Resources, Inc.	Call	USD	72.50	6/23/14	47	(6,345)
Honeywell International, Inc.	Call	USD	95.00	6/23/14	23	(2,242)
Lockheed Martin Corp.	Call	USD	165.00	6/23/14	17	(5,525)
MetLife, Inc.	Call	USD	52.50	6/23/14	13	(1,970)
NextEra Energy, Inc.	Call	USD	97.50	6/23/14	22	(8,250)
QUALCOMM, Inc.	Call	USD	80.00	6/23/14	17	(1,955)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

32

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock Dividend Income Trust (BQY)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Verizon Communications, Inc.	Call	USD	47.00	6/23/14	30	\$ (2,535)
Wal-Mart Stores, Inc.	Call	USD	80.00	6/23/14	17	(2,218)
Total						\$ (465,151)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Sempra Energy	Goldman Sachs International	Call	USD	97.72	5/02/14	1,900	\$ (1,823)
The Chubb Corp.	Credit Suisse International	Call	USD	87.37	5/05/14	1,700	(8,008)
Honeywell International, Inc.	Deutsche Bank AG	Call	USD	94.27	5/05/14	2,300	(353)
Mattel, Inc.	Credit Suisse International	Call	USD	38.29	5/05/14	4,700	(4,618)
Mondelez International, Inc., Class A	Credit Suisse International	Call	USD	35.00	5/05/14	2,900	(2,212)
Total SA ADR	Morgan Stanley & Co. International PLC	Call	USD	64.50	5/05/14	5,600	(37,746)
Ventas, Inc.	Citibank N.A.	Call	USD	61.50	5/05/14	2,200	(10,077)
Wisconsin Energy Corp.	Credit Suisse International	Call	USD	44.10	5/05/14	1,650	(7,228)
Health Care REIT, Inc.	Bank of America N.A.	Call	USD	61.07	5/06/14	4,200	(8,492)
TeliaSonera AB	Credit Suisse International	Call	SEK	48.83	5/07/14	21,300	(80)
BHP Billiton PLC	Morgan Stanley & Co. International PLC	Call	GBP	19.45	5/08/14	2,800	(678)
GlaxoSmithKline PLC	Credit Suisse International	Call	GBP	16.72	5/08/14	13,000	(367)
Keppel Corp. Ltd.	Deutsche Bank AG	Call	SGD	10.81	5/08/14	21,000	(315)
Ricoh Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	1,167.27	5/08/14	12,800	(3,151)
Takeda Pharmaceutical Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	4,989.44	5/08/14	4,300	(15)
Frontier Communications Corp.	JPMorgan Chase Bank N.A.	Call	USD	5.71	5/12/14	39,200	(12,498)
NextEra Energy, Inc.	Morgan Stanley & Co. International PLC	Call	USD	94.50	5/12/14	3,900	(21,776)
Zurich Insurance Group AG	Deutsche Bank AG	Call	CHF	259.67	5/13/14	390	(371)
Hang Seng Bank Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	124.33	5/14/14	7,000	(2,456)
Hopewell Holdings Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	26.61	5/14/14	34,000	(1,414)
Oracle Corp. Japan	Citibank N.A.	Call	JPY	4,411.50	5/14/14	3,500	(10,464)
Santos Ltd.	Morgan Stanley & Co. International PLC	Call	AUD	13.43	5/14/14	26,600	(11,108)
Allianz SE	UBS AG	Call	EUR	120.73	5/15/14	1,400	(9,144)
AstraZeneca PLC	Morgan Stanley & Co. International PLC	Call	GBP	38.07	5/15/14	7,000	(102,972)
Hudson City Bancorp, Inc.	Morgan Stanley & Co. International PLC	Call	USD	9.82	5/15/14	10,300	(2,189)
Solvay SA	Morgan Stanley & Co. International PLC	Call	EUR	114.53	5/15/14	900	(2,915)
Philip Morris International, Inc.	Citibank N.A.	Call	USD	83.21	5/20/14	2,050	(5,287)
Nestle SA	Morgan Stanley & Co. International PLC	Call	CHF	69.08	5/21/14	2,200	(932)
The Chubb Corp.	Credit Suisse International	Call	USD	92.36	5/28/14	1,700	(1,922)
Equity Residential	Morgan Stanley & Co. International PLC	Call	USD	58.00	5/28/14	4,300	(8,028)
Frontier Communications Corp.	JPMorgan Chase Bank N.A.	Call	USD	5.71	5/28/14	39,200	(15,538)
HCP, Inc.	Citibank N.A.	Call	USD	41.47	5/28/14	4,800	(3,543)
Liberty Property Trust	Goldman Sachs International	Call	USD	38.28	5/28/14	2,800	(1,041)
Philip Morris International, Inc.	Citibank N.A.	Call	USD	84.04	5/28/14	2,050	(4,186)
Dominion Resources, Inc.	Credit Suisse International	Call	USD	73.10	6/02/14	4,700	(4,644)
BHP Billiton PLC	Morgan Stanley & Co. International PLC	Call	GBP	19.39	6/03/14	2,800	(1,892)
Vinci SA	Deutsche Bank AG	Call	EUR	54.54	6/03/14	4,800	(8,597)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Sanofi	Morgan Stanley & Co. International PLC	Call	EUR	75.13	6/04/14	1,400	(5,166)
Enbridge, Inc.	Citibank N.A.	Call	CAD	51.10	6/05/14	4,800	(8,550)
Royal Dutch Shell PLC	Citibank N.A.	Call	USD	76.24	6/05/14	1,400	(4,357)
Total SA	Morgan Stanley & Co. International PLC	Call	USD	66.83	6/05/14	5,600	(24,886)
SSE PLC	Deutsche Bank AG	Call	GBP	15.17	6/10/14	14,000	(11,400)
British American Tobacco PLC	Bank of America N.A.	Call	GBP	34.51	6/11/14	7,000	(7,226)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

33

Table of Contents**Schedule of Investments (continued)****BlackRock Dividend Income Trust (BQY)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
				Price			
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/12/14	600	\$ (1,785)
National Australia Bank Ltd.	UBS AG	Call	AUD	35.53	6/13/14	12,800	(3,543)
Wisconsin Energy Corp.	Credit Suisse International	Call	USD	48.97	6/13/14	1,700	(818)
CSX Corp.	Morgan Stanley & Co. International PLC	Call	USD	28.52	6/17/14	2,100	(1,164)
United Overseas Bank Ltd. Australia & New Zealand Banking Group Ltd.	UBS AG	Call	SGD	22.32	6/17/14	7,000	(1,855)
BASF SE	Deutsche Bank AG	Call	AUD	33.99	6/18/14	7,200	(4,916)
Hennes & Mauritz AB, B Shares	Deutsche Bank AG	Call	EUR	83.64	6/18/14	3,800	(7,855)
Royal Dutch Shell PLC ADR	Deutsche Bank AG	Call	SEK	278.62	6/18/14	8,600	(2,644)
Enbridge, Inc.	Citibank N.A.	Call	USD	76.62	6/18/14	700	(2,153)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	6/21/14	2,500	(1,779)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	7/09/14	2,500	(2,258)
Total							\$ (410,435)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Long-Term Investments:

Common Stocks:

Aerospace & Defense	\$ 2,900,668		\$ 2,900,668
Banks	5,191,334	\$ 2,236,905	7,428,239
Beverages	1,549,713	126,662	1,676,375
Capital Markets	1,536,296		1,536,296
Chemicals	1,122,996	1,486,380	2,609,376
Communications Equipment	676,906		676,906
Construction & Engineering		913,626	913,626
Consumer Finance	577,038		577,038
Distributors	531,432		531,432
Diversified Financial Services	612,393		612,393
Diversified Telecommunication Services	2,532,501	388,702	2,921,203
Electric Utilities	1,925,038	902,523	2,827,561

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (concluded)****BlackRock Dividend Income Trust (BQY)**

	Level 1	Level 2	Level 3	Total
Assets: (concluded)				
Investments: (concluded)				
Long-Term Investments: (concluded)				
Common Stocks: (concluded)				
Electrical Equipment	\$ 1,827,224			\$ 1,827,224
Food & Staples Retailing	694,593			694,593
Food Products	3,472,074	\$ 440,520		3,912,594
Health Care Equipment & Supplies	430,014			430,014
Hotels, Restaurants & Leisure	1,307,802			1,307,802
Household Products	1,287,780			1,287,780
Industrial Conglomerates	3,492,261	748,174		4,240,435
Insurance	3,589,446	906,383		4,495,829
IT Services	1,044,664			1,044,664
Leisure Products	462,737			462,737
Machinery		1,090,696		1,090,696
Media	2,023,170			2,023,170
Metals & Mining	565,166	459,368		1,024,534
Multi-Utilities	3,501,615			3,501,615
Oil, Gas & Consumable Fuels	9,154,302	853,900		10,008,202
Pharmaceuticals	6,439,143	3,145,764		9,584,907
Real Estate Investment Trusts (REITs)	2,830,290	15,295		2,845,585
Road & Rail	299,132			299,132
Semiconductors & Semiconductor Equipment	2,045,341			2,045,341
Software	2,117,996	410,162		2,528,158
Specialty Retail	1,550,445	880,058		2,430,503
Technology Hardware, Storage & Peripherals	115,736	368,738		484,474
Thrifts & Mortgage Finance	256,968			256,968
Tobacco	3,243,253	998,983		4,242,236
Short-Term Securities	3,038,407			3,038,407
Total	\$ 73,945,874	\$ 16,372,839		\$ 90,318,713

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (416,874)	\$ (458,712)		\$ (875,586)

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets approximates fair value for financial statement purposes. As of April 30, 2014, such assets are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 23,966			\$ 23,966
Foreign currency at value	26,460			26,460
Total	\$ 50,426			\$ 50,426

There were no transfers between levels during the six months ended April 30, 2014.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock EcoSolutions Investment Trust (BQR)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Auto Components 0.9%		
Johnson Controls, Inc. (a)(b)	23,200	\$ 1,047,248
Biotechnology 0.3%		
Genus PLC	18,000	307,820
Building Products 0.5%		
Kingspan Group PLC (c)	31,800	598,456
Chemicals 16.7%		
Agrium, Inc.	28,500	2,737,995
Air Liquide SA	4,300	615,190
CF Industries Holdings, Inc. (a)	3,000	735,510
FMC Corp. (a)	2,800	215,600
Incitec Pivot Ltd.	261,700	702,471
Israel Chemicals Ltd.	50,000	443,763
Johnson Matthey PLC	17,304	957,252
Linde AG	2,900	602,285
Monsanto Co. (a)	36,700	4,062,690
The Mosaic Co. (a)	30,000	1,501,200
Novozymes A/S, B Shares	27,900	1,337,668
Nufarm Ltd.	57,460	222,283
Potash Corp. of Saskatchewan, Inc. (a)	34,000	1,229,440
Sinofert Holdings Ltd.	2,165,500	268,810
Syngenta AG	6,000	2,375,950
Umicore SA	5,400	264,701
Uralkali OJSC GDR	20,000	443,608
Wacker Chemie AG	5,600	658,282
		19,374,698
Commercial Services & Supplies 2.7%		
Covanta Holding Corp. (a)	9,900	182,655
Tetra Tech, Inc. (c)	63,500	1,820,545
Tianjin Capital Environmental Protection Group Co. Ltd., Class H	2,007,000	1,065,479
		3,068,679
Construction & Engineering 1.1%		
Aegion Corp. (a)(c)	11,400	290,586
KBR, Inc.	14,600	370,402
Layne Christensen Co. (a)(c)	10,100	175,942
Quanta Services, Inc. (a)(c)	11,200	395,136
		1,232,066
Electric Utilities 2.4%		
Fortum OYJ	16,900	381,806
ITC Holdings Corp.	32,900	1,216,313
NextEra Energy, Inc. (a)(b)	11,300	1,128,305
		2,726,424
Electrical Equipment 5.0%		
ABB Ltd.	25,400	611,533
Eaton Corp. PLC (a)	8,700	631,968
Regal-Beloit Corp. (a)	11,300	844,449
Roper Industries, Inc. (a)	12,840	1,784,118
Schneider Electric SA	10,700	1,004,418
Vestas Wind Systems A/S (c)	21,833	969,628
		5,846,114
Electronic Equipment, Instruments & Components 1.5%		
Azbil Corp.	9,800	222,389

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Itron, Inc. (a)(c)	6,800	258,400
Trimble Navigation Ltd. (a)(c)	33,000	1,268,190
		1,748,979
Food & Staples Retailing 1.2%		
The Andersons, Inc. (a)	15,000	934,350
Common Stocks	Shares	Value
Food & Staples Retailing (concluded)		
Total Produce PLC (c)	330,000	\$ 476,595
		1,410,945
Food Products 17.9%		
Archer-Daniels-Midland Co. (a)	97,200	4,250,556
BrasilAgro Co. Brasileira de Propriedades Agricolas	400,000	1,612,737
BRF SA ADR	104,000	2,350,400
Bunge Ltd. (a)	36,600	2,915,190
Illovo Sugar Ltd.	200,000	551,305
Ingredion, Inc. (a)	6,000	422,700
IOI Corp. Bhd	533,333	816,086
Origin Enterprises PLC (c)	30,000	324,639
Sao Martinho SA	100,000	1,475,950
Select Harvests Ltd.	54,633	320,418
SLC Agricola SA	150,000	1,155,062
SunOpta, Inc. (a)(c)	43,600	508,812
Tyson Foods, Inc., Class A (a)	66,000	2,770,020
Wilmar International Ltd.	378,000	1,027,334
Wynnstay Group PLC	24,600	250,660
		20,751,869
Independent Power and Renewable Electricity Producers 2.2%		
China Longyuan Power Group Corp., Series H	488,000	502,639
EDP Renovaveis SA (c)	146,500	1,004,643
Enel Green Power SpA (a)	223,400	639,371
Greenko Group PLC (c)	59,000	160,380
Ormat Technologies, Inc. (a)	11,000	293,480
		2,600,513
Industrial Conglomerates 1.1%		
Danaher Corp. (a)	16,800	1,232,784
Machinery 8.7%		
Deere & Co. (a)	10,000	933,400
IDEX Corp. (a)	9,150	682,316
Kubota Corp.	80,000	1,031,082
Kurita Water Industries Ltd.	56,500	1,189,895
Pall Corp. (a)	9,300	782,595
Pentair Ltd. (a)	23,960	1,779,988
Watts Water Technologies, Inc., Class A (a)	27,300	1,452,360
Xylem, Inc.	59,500	2,236,605
		10,088,241
Multi-Utilities 3.5%		
Hera SpA	361,600	1,064,533
National Grid PLC	33,700	478,984
Suez Environnement Co.	9,925	195,021
Veolia Environnement SA	126,000	2,350,639
		4,089,177
Oil, Gas & Consumable Fuels 2.1%		
AltaGas Ltd. (a)	15,500	660,417
Oil Search Ltd.	47,900	396,851
Sasol Ltd.	10,100	566,048
TransCanada Corp. (a)	13,000	605,848
Veresen, Inc.	12,000	177,474
		2,406,638
Paper & Forest Products 1.0%		
Canfor Corp. (a)(c)	25,000	567,036

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

International Forest Products Ltd., Class A (c)	35,000	530,724
Precious Woods Holding AG	20,000	45,449
		1,143,209

See Notes to Financial Statements.

Table of Contents**BlackRock EcoSolutions Investment Trust (BQR)****Schedule of Investments (continued)**

(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Real Estate Investment Trusts (REITs) 2.0%		
Plum Creek Timber Co., Inc.	20,000	\$ 872,000
Rayonier, Inc.	12,000	541,200
Weyerhaeuser Co. (a)	31,000	925,350
		2,338,550
Real Estate Management & Development 0.2%		
Cresud SACIF y A ADR	20,000	241,400
Semiconductors & Semiconductor Equipment 1.1%		
Aixtron SE (c)	7,600	121,005
SMA Solar Technology AG	2,600	108,871
Trina Solar Ltd. ADR (a)(c)	54,100	604,838
Veeco Instruments, Inc. (a)(c)	11,200	414,064
		1,248,778
Water Utilities 25.1%		
American States Water Co.	75,800	2,301,288
American Water Works Co., Inc.	51,600	2,349,348
Aqua America, Inc.	116,525	2,923,612
Artesian Resources Corp., Class A	37,200	819,144
California Water Service Group	86,200	1,939,500
China Water Affairs Group Ltd.	4,556,000	1,535,998
Cia de Saneamento Basico do Estado de Sao Paulo	105,000	995,964
Cia de Saneamento de Minas Gerais COPASA	43,100	673,441
Guangdong Investment Ltd.	563,000	612,098
Hyflux Ltd.	749,000	717,151
Inversiones Aguas Metropolitanas SA	1,500,000	2,482,893
Manila Water Co., Inc.	5,610,000	3,358,060
Common Stocks	Shares	Value
Water Utilities (concluded)		
Pennon Group PLC	215,200	\$ 2,754,905
Severn Trent PLC	113,500	3,535,617
United Utilities Group PLC	158,381	2,130,375
		29,129,394
Total Long-Term Investments		
(Cost \$98,187,781) 97.2%		112,631,982
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (d)(e)	4,186,554	4,186,554
Total Short-Term Securities		
(Cost \$4,186,554) 3.6%		4,186,554
Total Investments Before Options Written		
(Cost \$102,374,335) 100.8%		116,818,536
Options Written		
(Premiums Received \$982,018) (1.0)%		(1,174,848)
Total Investments Net of Options Written 99.8%		115,643,688
Other Assets Less Liabilities 0.2%		246,567
Net Assets 100.0%		\$ 115,890,255

Notes to Schedule of Investments

- (a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.
- (b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- (c) Non-income producing security.
- (d) Represents the current yield as of report date.
- (e) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares Held at October 31, 2013	Net Activity	Shares Held at April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	7,688,865	(3,502,311)	4,186,554	\$ 1,326
BlackRock Liquidity Series, LLC Money Market Series				\$ 1,261

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price	Price			
The Andersons, Inc.	Call	USD	57.00	5/05/14	68	\$ (35,991)
Covanta Holding Corp.	Call	USD	18.45	5/05/14	44	(1,084)
Deere & Co.	Call	USD	89.00	5/05/14	45	(19,682)
Archer-Daniels-Midland Co.	Call	USD	43.50	5/09/14	4	(248)
CF Industries Holdings, Inc.	Call	USD	260.00	5/09/14	14	(1,470)
The Mosaic Co.	Call	USD	50.00	5/09/14	17	(1,556)
Potash Corp. of Saskatchewan, Inc.	Call	USD	35.50	5/09/14	39	(3,334)
NextEra Energy, Inc.	Call	USD	94.75	5/12/14	26	(13,935)
Aegion Corp.	Call	USD	25.00	5/19/14	51	(4,208)

See Notes to Financial Statements.

Table of Contents

Schedule of Investments (continued)

BlackRock EcoSolutions Investment Trust (BQR)

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
AltaGas Ltd.	Call	CAD	46.00	5/19/14	69	\$ (5,981)
Archer-Daniels-Midland Co.	Call	USD	44.00	5/19/14	32	(1,472)
Bunge Ltd.	Call	USD	82.50	5/19/14	170	(18,700)
Canfor Corp.	Call	CAD	28.00	5/19/14	112	(613)
Danaher Corp.	Call	USD	75.00	5/19/14	76	(3,420)
FMC Corp.	Call	USD	80.00	5/19/14	12	(630)
IDEX Corp.	Call	USD	75.00	5/19/14	41	(16,400)
Ingredion, Inc.	Call	USD	70.00	5/19/14	27	(3,578)
Layne Christensen Co.	Call	USD	17.50	5/19/14	45	(6,188)
The Mosaic Co.	Call	USD	47.50	5/19/14	118	(32,745)
Pall Corp.	Call	USD	90.00	5/19/14	41	(1,025)
Pentair Ltd.	Call	USD	80.00	5/19/14	110	(825)
Potash Corp. of Saskatchewan, Inc.	Call	USD	36.00	5/19/14	114	(7,752)
Quanta Services, Inc.	Call	USD	36.00	5/19/14	26	(1,820)
Quanta Services, Inc.	Call	USD	38.00	5/19/14	26	(520)
Regal-Beloit Corp.	Call	USD	75.00	5/19/14	50	(8,875)
Roper Industries, Inc.	Call	USD	135.00	5/19/14	29	(13,920)
TransCanada Corp.	Call	CAD	52.00	5/19/14	34	(574)
Trimble Navigation Ltd.	Call	USD	40.00	5/19/14	149	(12,665)
Tyson Foods, Inc., Class A	Call	USD	43.00	5/19/14	148	(9,990)
Tyson Foods, Inc., Class A	Call	USD	44.00	5/19/14	149	(5,215)
Veeco Instruments, Inc.	Call	USD	41.00	5/19/14	50	(1,750)
Watts Water Technologies, Inc., Class A	Call	USD	60.00	5/19/14	61	(1,525)
Itron, Inc.	Call	USD	36.00	5/22/14	30	(7,436)
Monsanto Co.	Call	USD	112.00	5/22/14	82	(11,054)
Ormat Technologies, Inc.	Call	USD	28.15	5/22/14	45	(1,453)
SunOpta, Inc.	Call	USD	12.00	5/22/14	125	(3,963)
Wisconsin Energy Corp.	Call	USD	28.75	5/22/14	286	(23,197)
Archer-Daniels-Midland Co.	Call	USD	44.00	5/23/14	32	(1,872)
Eaton Corp. PLC	Call	USD	76.00	5/23/14	39	(780)
Archer-Daniels-Midland Co.	Call	USD	45.00	5/30/14	368	(11,592)
SunOpta, Inc.	Call	USD	11.55	5/30/14	72	(4,275)
Monsanto Co.	Call	USD	115.00	6/10/14	83	(8,214)
Enel Green Power SpA	Call	EUR	2.10	6/20/14	100	(10,377)
Johnson Controls, Inc.	Call	USD	48.00	6/23/14	104	(3,900)
NextEra Energy, Inc.	Call	USD	97.50	6/23/14	24	(9,000)
Trina Solar Ltd. ADR	Call	USD	14.00	6/23/14	121	(4,537)
Watts Water Technologies, Inc., Class A	Call	USD	60.00	6/23/14	61	(1,830)
Weyerhaeuser Co.	Call	USD	30.00	6/23/14	48	(2,640)
Total						\$ (343,811)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

TransCanada Corp.	Deutsche Bank AG	Call	CAD	51.08	5/02/14	2,400	\$	(276)
American Water Works Co., Inc.	Citibank N.A.	Call	USD	45.54	5/05/14	5,700		(3,274)
BRF SA ADR	UBS AG	Call	USD	19.33	5/05/14	49,500		(161,880)
California Water Service Group	Goldman Sachs International	Call	USD	22.95	5/05/14	14,600		(671)
ITC Holdings Corp.	Morgan Stanley & Co. International PLC	Call	USD	36.59	5/05/14	7,500		(4,160)
ABB Ltd.	Goldman Sachs International	Call	CHF	23.38	5/06/14	11,500		(4)
Illovo Sugar Ltd.	UBS AG	Call	ZAR	28.55	5/06/14	26,000		(1,670)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock EcoSolutions Investment Trust (BQR)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Uralkali OJSC GDR	Morgan Stanley & Co. International PLC	Call	USD	23.39	5/06/14	9,000	\$ (466)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	45.94	5/07/14	5,800	(2,957)
Total Produce PLC	Goldman Sachs International	Call	EUR	1.03	5/07/14	90,000	(2,853)
Air Liquide SA	Morgan Stanley & Co. International PLC	Call	EUR	99.73	5/08/14	1,900	(9,188)
Guangdong Investment Ltd.	Goldman Sachs International	Call	HKD	8.20	5/08/14	124,000	(4,530)
Incitec Pivot Ltd.	UBS AG	Call	AUD	3.23	5/08/14	117,700	(729)
Linde AG	Goldman Sachs International	Call	EUR	146.80	5/08/14	1,300	(6,467)
Select Harvests Ltd.	Morgan Stanley & Co. International PLC	Call	AUD	6.78	5/08/14	24,300	(390)
Tianjin Capital Environmental Protection Group Co. Ltd., Class H	Deutsche Bank AG	Call	HKD	3.94	5/08/14	300,000	(10,282)
ITC Holdings Corp.	Citibank N.A.	Call	USD	37.48	5/09/14	7,200	(1,717)
Agrium, Inc.	Credit Suisse International	Call	USD	97.00	5/13/14	6,400	(7,148)
Cia de Saneamento de Minas Gerais COPASA	Goldman Sachs International	Call	BRL	35.33	5/13/14	3,300	(1,285)
Illovo Sugar Ltd.	UBS AG	Call	ZAR	28.55	5/13/14	27,000	(2,209)
Kingspan Group PLC	Goldman Sachs International	Call	EUR	14.04	5/13/14	3,000	(366)
Syngenta AG	Goldman Sachs International	Call	CHF	340.78	5/13/14	2,700	(25,338)
Xylem, Inc.	Morgan Stanley & Co. International PLC	Call	USD	39.00	5/13/14	26,700	(10,065)
China Longyuan Power Group Corp., Series H	Deutsche Bank AG	Call	HKD	8.16	5/14/14	219,000	(6,251)
Guangdong Investment Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	7.36	5/14/14	130,000	(17,954)
Israel Chemicals Ltd.	Goldman Sachs International	Call	ILS	31.24	5/14/14	22,500	(2,528)
Severn Trent PLC	Deutsche Bank AG	Call	GBP	18.13	5/14/14	25,500	(20,923)
Tianjin Capital Environmental Protection Group Co. Ltd., Class H	Deutsche Bank AG	Call	HKD	3.94	5/14/14	300,000	(11,943)
Veresen, Inc.	Deutsche Bank AG	Call	CAD	16.61	5/14/14	5,400	(519)
Weyerhaeuser Co.	Citibank N.A.	Call	USD	29.77	5/14/14	4,400	(1,282)
Wilmar International Ltd.	Deutsche Bank AG	Call	SGD	3.50	5/14/14	85,000	(395)
American States Water Co.	Bank of America N.A.	Call	USD	31.10	5/15/14	17,050	(4,245)
Aqua America, Inc.	Morgan Stanley & Co. International PLC	Call	USD	25.60	5/15/14	18,000	(2,776)
California Water Service Group	Citibank N.A.	Call	USD	22.87	5/20/14	24,000	(5,100)
Cia de Saneamento de Minas Gerais COPASA	Goldman Sachs International	Call	BRL	35.33	5/20/14	3,300	(1,703)
Inversiones Aguas Metropolitanas SA	Deutsche Bank AG	Call	CLP	919.59	5/20/14	225,000	(10,130)
SLC Agricola SA	Credit Suisse International	Call	BRL	18.70	5/20/14	25,000	(576)
Tianjin Capital Environmental Protection Group Co. Ltd., Class H	Deutsche Bank AG	Call	HKD	3.94	5/20/14	300,000	(13,473)
Kingspan Group PLC	Goldman Sachs International	Call	EUR	13.80	5/21/14	2,600	(801)
Novozymes A/S, B Shares	Morgan Stanley & Co. International PLC	Call	DKK	240.69	5/21/14	13,400	(44,788)
SMA Solar Technology AG	Morgan Stanley & Co. International PLC	Call	EUR	45.79	5/21/14	1,100	(1)
Wacker Chemie AG	Morgan Stanley & Co. International PLC	Call	EUR	88.25	5/21/14	2,500	(6,398)
Aixtron SE	Morgan Stanley & Co. International PLC	Call	EUR	12.26	5/22/14	1,700	(265)
Total Produce PLC	Goldman Sachs International	Call	EUR	1.06	5/22/14	58,500	(1,978)
International Forest Products Ltd., Class A	Goldman Sachs International	Call	CAD	15.80	5/23/14	13,600	(13,915)
Agrium, Inc.	Credit Suisse International	Call	USD	97.00	5/27/14	6,400	(11,435)
American States Water Co.	Bank of America N.A.	Call	USD	31.10	5/27/14	17,050	(7,260)
Azbil Corp.	Morgan Stanley & Co. International PLC	Call	JPY	2,569.02	5/27/14	4,400	(207)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock EcoSolutions Investment Trust (BQR)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
				Price			
Cia de Saneamento de Minas Gerais							
COPASA	Citibank N.A.	Call	BRL	35.86	5/28/14	9,700	\$ (5,228)
Cresud SACIF y A ADR	Goldman Sachs International	Call	USD	11.52	5/28/14	9,000	(7,348)
Sao Martinho SA	UBS AG	Call	BRL	32.44	5/28/14	24,000	(16,630)
SLC Agricola SA	Deutsche Bank AG	Call	BRL	18.87	5/28/14	25,000	(876)
Wilmar International Ltd.	Deutsche Bank AG	Call	SGD	3.50	5/28/14	85,000	(1,000)
Johnson Matthey PLC	Morgan Stanley & Co. International PLC	Call	GBP	31.11	5/29/14	7,800	(24,295)
Aqua America, Inc.	Goldman Sachs International	Call	USD	25.95	5/30/14	34,400	(6,923)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	46.66	6/02/14	5,700	(5,062)
Illovo Sugar Ltd.	Deutsche Bank AG	Call	ZAR	29.73	6/03/14	37,000	(2,408)
National Grid PLC	Morgan Stanley & Co. International PLC	Call	GBP	8.31	6/03/14	15,000	(5,377)
Suez Environnement Co.	Morgan Stanley & Co. International PLC	Call	EUR	13.95	6/04/14	4,500	(1,358)
China Water Affairs Group Ltd.	Bank of America N.A.	Call	HKD	2.94	6/05/14	500,000	(1,811)
Schneider Electric SA	Bank of America N.A.	Call	EUR	68.36	6/05/14	4,800	(6,078)
Sao Martinho SA	UBS AG	Call	BRL	26.89	6/06/14	24,200	(73,838)
Veolia Environnement SA	Deutsche Bank AG	Call	EUR	13.99	6/06/14	56,700	(17,003)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	45.75	6/09/14	6,000	(4,453)
Kubota Corp.	UBS AG	Call	JPY	1,365.00	6/10/14	36,000	(12,589)
Cia de Saneamento de Minas Gerais							
COPASA	Goldman Sachs International	Call	BRL	35.67	6/11/14	3,300	(2,276)
Fortum OYJ	Credit Suisse International	Call	EUR	16.81	6/11/14	7,700	(2,756)
Inversiones Aguas Metropolitanas SA	UBS AG	Call	CLP	943.33	6/11/14	225,000	(6,322)
Kurita Water Industries Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	2,164.44	6/11/14	25,400	(13,477)
Pennon Group PLC	Goldman Sachs International	Call	GBP	7.44	6/11/14	96,900	(38,879)
SLC Agricola SA	Deutsche Bank AG	Call	BRL	17.34	6/11/14	17,000	(4,600)
Vestas Wind Systems A/S	Goldman Sachs International	Call	DKK	244.77	6/11/14	9,800	(19,705)
Oil Search Ltd.	UBS AG	Call	AUD	8.73	6/12/14	21,500	(7,207)
Severn Trent PLC	Bank of America N.A.	Call	GBP	18.42	6/13/14	25,500	(22,801)
Roper Industries, Inc.	Goldman Sachs International	Call	USD	135.00	6/16/14	2,900	(16,524)
Aixtron SE	Morgan Stanley & Co. International PLC	Call	EUR	12.26	6/17/14	1,700	(575)
Hyflux Ltd.	Bank of America N.A.	Call	SGD	1.23	6/17/14	169,000	(3,562)
Umicore SA	Morgan Stanley & Co. International PLC	Call	EUR	37.78	6/25/14	2,400	(566)
China Water Affairs Group Ltd.	Bank of America N.A.	Call	HKD	2.68	6/26/14	500,000	(7,689)
United Utilities Group PLC	Bank of America N.A.	Call	GBP	7.85	7/01/14	71,300	(21,190)
EDP Renovaveis SA	UBS AG	Call	EUR	4.84	7/02/14	33,400	(10,548)
EDP Renovaveis SA	UBS AG	Call	EUR	4.69	7/16/14	32,500	(15,312)
Total							\$ (831,037)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

See Notes to Financial Statements.

40

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock EcoSolutions Investment Trust (BQR)**

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Auto Components	\$ 1,047,248			\$ 1,047,248
Biotechnology		\$ 307,820		307,820
Building Products	598,456			598,456
Chemicals	10,482,435	8,892,263		19,374,698
Commercial Services & Supplies	2,003,200	1,065,479		3,068,679
Construction & Engineering	1,232,066			1,232,066
Electric Utilities	2,344,618	381,806		2,726,424
Electrical Equipment	3,260,535	2,585,579		5,846,114
Electronic Equipment, Instruments & Components	1,526,590	222,389		1,748,979
Food & Staples Retailing	1,410,945			1,410,945
Food Products	18,588,031	2,163,838		20,751,869
Independent Power and Renewable Electricity Producers	453,860	2,146,653		2,600,513
Industrial Conglomerates	1,232,784			1,232,784
Machinery	7,867,264	2,220,977		10,088,241
Multi-Utilities	1,064,533	3,024,644		4,089,177
Oil, Gas & Consumable Fuels	1,443,739	962,899		2,406,638
Paper & Forest Products	1,097,760	45,449		1,143,209
Real Estate Investment Trusts (REITs)	2,338,550			2,338,550
Real Estate Management & Development	241,400			241,400
Semiconductors & Semiconductor Equipment	1,018,902	229,876		1,248,778
Water Utilities	18,020,807	11,108,587		29,129,394
Short-Term Securities	4,186,554			4,186,554
Total	\$ 81,460,277	\$ 35,358,259		\$ 116,818,536

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (203,149)	\$ (971,699)		\$ (1,174,848)

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets approximates fair value for financial statement purposes. As of April 30, 2014, such assets are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Foreign currency at value.	\$ 16,164	\$ 16,164
Cash pledged as collateral for OTC derivatives	100,000	100,000
Total	\$ 116,164	\$ 116,164

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

41

Table of Contents

Schedule of Investments (concluded)

BlackRock EcoSolutions Investment Trust (BQR)

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013, securities with a value of \$4,116,506 were systematically fair valued due to significant market movements, but were not valued using systematic fair values as of April 30, 2014. Therefore, these securities were transferred from Level 2 to Level 1 during the period October 31, 2013 to April 30, 2014.

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013 the Trust did not utilize the external pricing service model adjustments as significant market movements did not occur. As of April 30, 2014, securities with a value of \$1,002,701 were systematically fair valued due to significant market movements. Therefore, these securities were transferred from Level 1 to Level 2 during the period October 31, 2013 to April 30, 2014.

See Notes to Financial Statements.

Table of Contents**BlackRock Energy and Resources Trust (BGR)****Schedule of Investments** April 30, 2014 (Unaudited)

(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Energy Equipment & Services 9.4%		
Cameron International Corp. (a)(b)	203,260	\$ 13,203,770
Halliburton Co. (b)	446,900	28,185,983
Schlumberger Ltd. (b)	372,224	37,799,347
		79,189,100
Oil, Gas & Consumable Fuels 88.4%		
Anadarko Petroleum Corp. (b)(c)	371,833	36,818,904
BG Group PLC	1,218,500	24,649,310
BP PLC ADR (b)	802,700	40,632,674
Cairn Energy PLC (a)	1,856,000	5,780,994
Canadian Natural Resources Ltd. (b)	414,000	16,868,975
Canadian Oil Sands Ltd. (b)	316,013	6,850,480
Caracal Energy, Inc. (a)	1,061,900	9,735,458
Chevron Corp. (b)(c)	664,828	83,449,211
Cimarex Energy Co. (b)	139,900	16,664,888
ConocoPhillips (b)	600,000	44,586,000
CONSOL Energy, Inc. (b)	218,021	9,704,115
Devon Energy Corp. (b)	160,500	11,235,000
Enbridge, Inc. (b)	223,800	10,799,491
Encana Corp. (b)	739,000	17,118,936
EOG Resources, Inc. (b)	259,200	25,401,600
Exxon Mobil Corp. (b)(c)	792,100	81,118,961
Imperial Oil Ltd. (b)	196,000	9,570,658
Kosmos Energy Ltd. (a)	881,407	9,624,964
Murphy Oil Corp.	128,500	8,150,755
Noble Energy, Inc. (b)	407,492	29,249,776
Oil Search Ltd.	2,232,863	18,499,240
Phillips 66 (b)	186,300	15,503,886
Pioneer Natural Resources Co. (b)	109,500	21,163,065
Common Stocks	Shares	Value
Oil, Gas & Consumable Fuels (concluded)		
Range Resources Corp. (b)	138,400	\$ 12,518,280
Royal Dutch Shell PLC ADR	1,216,800	95,810,832
Southwestern Energy Co. (a)(b)	261,300	12,511,044
Statoil ASA	763,526	23,276,405
Total SA	366,000	26,185,133
TransCanada Corp. (b)	445,000	20,738,652
		744,217,687
Total Long-Term Investments		
(Cost \$694,491,167) 97.8%		823,406,787
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (d)(e)	31,463,547	31,463,547
Total Short-Term Securities		
(Cost \$31,463,547) 3.7%		31,463,547
Total Investments Before Options Written		
(Cost \$725,954,714) 101.5%		854,870,334

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Options Written		
(Premiums Received \$5,396,719) (1.3)%		(11,333,766)
Total Investments Net of Options Written 100.2%		843,536,568
Liabilities in Excess of Other Assets (0.2)%		(1,362,834)
Net Assets 100.0%		\$ 842,173,734

Notes to Schedule of Investments

(a) Non-income producing security.

(b) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(c) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(d) Represents the current yield as of report date.

(e) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares Held at October 31, 2013	Net Activity	Shares Held at April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	60,810,523	(29,346,976)	31,463,547	\$ 10,556

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
BP PLC ADR	Call	USD 49.50	5/02/14	845	\$ (100,978)
EOG Resources, Inc.	Call	USD 100.00	5/02/14	408	(9,384)
Exxon Mobil Corp.	Call	USD 94.00	5/02/14	1,235	(1,000,350)
Schlumberger Ltd.	Call	USD 91.00	5/02/14	151	(153,642)
Chevron Corp.	Call	USD 120.00	5/05/14	261	(149,423)
ConocoPhillips	Call	USD 68.50	5/05/14	1,252	(757,460)
Schlumberger Ltd.	Call	USD 93.00	5/05/14	502	(425,445)
EOG Resources, Inc.	Call	USD 100.00	5/09/14	406	(75,719)
EOG Resources, Inc.	Call	USD 102.00	5/09/14	104	(12,532)

See Notes to Financial Statements.

Table of Contents

Schedule of Investments (continued)

BlackRock Energy and Resources Trust (BGR)

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
BP PLC ADR	Call	USD	48.00	5/19/14	844	\$ (217,752)
Cameron International Corp.	Call	USD	65.00	5/19/14	712	(80,100)
Canadian Natural Resources Ltd.	Call	CAD	46.00	5/19/14	735	(24,141)
Canadian Oil Sands Ltd.	Call	CAD	23.00	5/19/14	930	(75,092)
Cimarex Energy Co.	Call	USD	125.00	5/19/14	201	(30,652)
ConocoPhillips	Call	USD	75.00	5/19/14	1,254	(83,391)
CONSOL Energy, Inc.	Call	USD	43.00	5/19/14	381	(71,628)
Devon Energy Corp.	Call	USD	72.50	5/19/14	561	(33,660)
Encana Corp.	Call	CAD	26.00	5/19/14	1,293	(47,777)
Halliburton Co.	Call	USD	62.50	5/19/14	551	(83,201)
Imperial Oil Ltd.	Call	CAD	50.00	5/19/14	343	(111,877)
Imperial Oil Ltd.	Call	CAD	52.00	5/19/14	343	(54,765)
Noble Energy, Inc.	Call	USD	75.00	5/19/14	555	(16,650)
Phillips 66	Call	USD	80.00	5/19/14	652	(237,980)
Pioneer Natural Resources Co.	Call	USD	195.00	5/19/14	191	(96,455)
Range Resources Corp.	Call	USD	92.50	5/19/14	242	(25,410)
Range Resources Corp.	Call	USD	95.00	5/19/14	242	(10,890)
Schlumberger Ltd.	Call	USD	92.50	5/19/14	649	(592,212)
Southwestern Energy Co.	Call	USD	47.00	5/19/14	642	(112,992)
TransCanada Corp.	Call	CAD	52.00	5/19/14	608	(10,262)
BP PLC ADR	Call	USD	48.50	5/23/14	1,120	(233,520)
Chevron Corp.	Call	USD	123.00	5/23/14	525	(174,563)
Chevron Corp.	Call	USD	123.00	5/30/14	525	(181,125)
Exxon Mobil Corp.	Call	USD	101.00	5/30/14	769	(163,797)
Anadarko Petroleum Corp.	Call	USD	100.00	6/04/14	590	(156,735)
Chevron Corp.	Call	USD	125.00	6/06/14	507	(114,075)
Exxon Mobil Corp.	Call	USD	101.00	6/06/14	769	(171,103)
Halliburton Co.	Call	USD	64.50	6/06/14	553	(61,383)
Anadarko Petroleum Corp.	Call	USD	100.00	6/23/14	712	(233,180)
Chevron Corp.	Call	USD	125.00	6/23/14	508	(127,254)
Cimarex Energy Co.	Call	USD	120.00	6/23/14	289	(157,505)
Encana Corp.	Call	CAD	26.00	6/23/14	1,294	(79,691)
Halliburton Co.	Call	USD	67.50	6/23/14	460	(25,760)
Pioneer Natural Resources Co.	Call	USD	205.00	6/23/14	192	(84,480)
CONSOL Energy, Inc.	Call	USD	44.00	7/21/14	381	(91,059)
Total						\$ (6,757,050)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	73.90	5/02/14	124,700	\$ (603,479)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	74.28	5/02/14	64,400	(287,060)
TransCanada Corp.	Deutsche Bank AG	Call	CAD	51.08	5/02/14	95,000	(10,922)
Kosmos Energy Ltd.	Morgan Stanley & Co. International PLC	Call	USD	11.15	5/05/14	95,600	(3,645)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

BG Group PLC	Credit Suisse International	Call	GBP	11.22	5/06/14	200,000	(260,046)
Kosmos Energy Ltd.	Morgan Stanley & Co. International PLC	Call	USD	11.09	5/07/14	45,200	(6,761)
Noble Energy, Inc.	Citibank N.A.	Call	USD	70.00	5/07/14	87,200	(168,222)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/07/14	60,150	(146,718)
Total SA	Goldman Sachs International	Call	EUR	48.11	5/07/14	64,000	(308,732)
Caracal Energy, Inc.	Credit Suisse International	Call	GBP	3.74	5/08/14	60,000	(170,872)
Oil Search Ltd.	Goldman Sachs International	Call	AUD	8.41	5/08/14	394,000	(189,978)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/13/14	60,150	(150,252)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Energy and Resources Trust (BGR)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Total SA	Goldman Sachs International	Call	EUR	48.11	5/13/14	64,000	\$ (313,774)
Murphy Oil Corp.	Citibank N.A.	Call	USD	63.35	5/15/14	22,500	(26,086)
Canadian Natural Resources Ltd.	Citibank N.A.	Call	CAD	44.53	5/28/14	35,700	(39,707)
Statoil ASA	UBS AG	Call	NOK	169.92	5/28/14	155,500	(297,598)
Kosmos Energy Ltd.	Citibank N.A.	Call	USD	10.93	5/29/14	59,000	(26,385)
Murphy Oil Corp.	Citibank N.A.	Call	USD	63.35	5/29/14	22,500	(37,178)
Statoil ASA	UBS AG	Call	NOK	169.92	6/03/14	155,500	(298,772)
Southwestern Energy Co.	Goldman Sachs International	Call	USD	49.38	6/04/14	27,300	(24,287)
Oil Search Ltd.	UBS AG	Call	AUD	8.73	6/12/14	388,400	(130,192)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/12/14	118,400	(352,294)
BG Group PLC	Goldman Sachs International	Call	GBP	11.92	6/17/14	226,000	(189,037)
Canadian Natural Resources Ltd.	Citibank N.A.	Call	CAD	44.53	6/17/14	35,700	(48,644)
Kosmos Energy Ltd.	Morgan Stanley & Co. International PLC	Call	USD	11.00	6/18/14	108,300	(59,047)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/18/14	118,300	(363,886)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	6/21/14	39,100	(27,825)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	7/09/14	39,100	(35,317)
Total							\$ (4,576,716)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Energy Equipment & Services	\$ 79,189,100			\$ 79,189,100
Oil, Gas & Consumable Fuels	645,826,605	\$ 98,391,082		744,217,687
Short-Term Securities	31,463,547			31,463,547
Total	\$ 756,479,252	\$ 98,391,082		\$ 854,870,334

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

45

Table of Contents

Schedule of Investments (concluded)

BlackRock Energy and Resources Trust (BGR)

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (6,600,315)	\$ (4,733,451)		\$ (11,333,766)

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets approximates fair value for financial statement purposes. As of April 30, 2014, such assets are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 6,930			\$ 6,930
Foreign currency at value	184,978			184,978
Total	\$ 191,908			\$ 191,908

There were no transfers between levels during the six months ended April 30, 2014.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock Enhanced Capital and Income Fund, Inc. (CII)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Air Freight & Logistics 0.0%		
Royal Mail PLC (a)	11,200	\$ 100,347
Airlines 5.4%		
Japan Airlines Co. Ltd.	580,800	30,067,685
United Continental Holdings, Inc. (a)(b)	169,100	6,911,117
		36,978,802
Automobiles 6.3%		
Bayerische Motoren Werke AG	53,800	5,291,926
General Motors Co. (b)(c)	961,700	33,159,416
Renault SA	48,400	4,732,055
		43,183,397
Banks 3.9%		
Citigroup, Inc. (b)(c)	221,930	10,632,666
JPMorgan Chase & Co. (b)	282,400	15,808,752
		26,441,418
Beverages 0.5%		
PepsiCo, Inc. (b)	36,800	3,160,752
Biotechnology 0.4%		
Gilead Sciences, Inc. (a)(b)	33,300	2,613,717
Building Products 2.3%		
Owens Corning (b)	392,300	16,025,455
Capital Markets 0.7%		
Atlas Mara Co-Nvest Ltd. (a)	200,000	2,280,000
Legg Mason, Inc.	60,200	2,822,778
		5,102,778
Chemicals 3.6%		
CF Industries Holdings, Inc. (b)	100,300	24,590,551
Communications Equipment 2.6%		
QUALCOMM, Inc. (b)	228,100	17,953,751
Consumer Finance 3.5%		
Ally Financial, Inc. (a)(b)	492,300	11,889,045
Discover Financial Services (b)(c)	161,700	9,039,030
Springleaf Holdings, Inc. (a)(b)	134,300	3,086,214
		24,014,289
Diversified Financial Services 1.4%		
Berkshire Hathaway, Inc., Class B (a)(b)	74,200	9,560,670
Diversified Telecommunication Services 1.1%		
Verizon Communications, Inc. (b)	163,110	7,622,130
Energy Equipment & Services 0.5%		
Noble Corp. PLC (b)	108,800	3,352,128
Food & Staples Retailing 2.9%		
Metro AG (a)	356,800	14,294,724
Wal-Mart Stores, Inc. (b)	71,200	5,675,352
		19,970,076
Health Care Providers & Services 4.5%		
Express Scripts Holding Co. (a)(b)	79,000	5,259,820
UnitedHealth Group, Inc. (b)	337,800	25,348,512

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

			30,608,332
Industrial Conglomerates 0.3%			
3M Co. (b)	13,100		1,822,078
Insurance 9.6%			
The Allstate Corp. (b)	121,700		6,930,815
American International Group, Inc. (b)(c)	682,200		36,245,286
Fidelity National Financial, Inc., Class A (b)	698,300		22,471,294
			65,647,395
Common Stocks	Shares		Value
Internet & Catalog Retail 2.2%			
Expedia, Inc. (b)	215,300	\$	15,284,147
Internet Software & Services 5.7%			
eBay, Inc. (a)(b)	312,400		16,191,692
Google, Inc., Class A (a)(b)	15,001		8,023,735
Google, Inc., Class C (a)	15,001		7,900,427
Yahoo!, Inc. (a)(b)	187,200		6,729,840
			38,845,694
IT Services 4.0%			
Leidos Holdings, Inc.	383,500		14,281,540
Science Applications International Corp. (b)	223,692		8,723,988
Visa, Inc., Class A (b)	22,700		4,599,247
			27,604,775
Leisure Products 0.3%			
Brunswick Corp. (b)	52,700		2,118,013
Media 6.6%			
Comcast Corp., Special Class A (b)	353,400		18,034,002
News Corp. Class A (a)	134,100		2,282,382
Nexstar Broadcasting Group, Inc., Class A (b)	112,500		4,483,125
Sinclair Broadcast Group, Inc., Class A (b)	628,800		16,807,824
The Walt Disney Co. (b)	45,600		3,617,904
			45,225,237
Metals & Mining 0.8%			
Freeport-McMoRan Copper & Gold, Inc. (b)	166,300		5,715,731
Oil, Gas & Consumable Fuels 7.4%			
HollyFrontier Corp. (b)	214,660		11,288,969
Linn Energy LLC (b)	105,700		3,014,564
Marathon Petroleum Corp. (b)	68,000		6,320,600
PBF Energy, Inc., Class A (b)	103,100		3,173,418
Suncor Energy, Inc.	691,500		26,691,900
			50,489,451
Pharmaceuticals 8.9%			
Eli Lilly & Co. (b)	125,300		7,405,230
Johnson & Johnson (b)	138,900		14,069,181
Merck & Co., Inc. (b)	237,600		13,913,856
Novartis AG ADR (b)	43,300		3,764,502
Pfizer, Inc. (b)	697,800		21,827,184
			60,979,953
Real Estate Investment Trusts (REITs) 1.5%			
American Capital Agency Corp. (b)	226,000		5,132,460
American Realty Capital Properties, Inc.	152,840		2,000,676
Annaly Capital Management, Inc. (b)	302,400		3,492,720
			10,625,856
Semiconductors & Semiconductor Equipment 3.0%			
Samsung Electronics Co. Ltd.	20,200		20,312,706
Software 2.3%			
Activision Blizzard, Inc. (b)(c)	432,800		8,660,328
Oracle Corp. (b)	169,100		6,912,808

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Technology Hardware, Storage & Peripherals	3.6%		15,573,136
Apple Inc. (b)		42,300	24,960,807
Wireless Telecommunication Services	2.7%		
Vodafone Group PLC ADR (b)		490,308	18,612,092
Total Common Stocks	98.5%		675,095,664

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

47

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Capital and Income Fund, Inc. (CII)**
(Percentages shown are based on Net Assets)

	Shares	Value
Warrants (d)		
Capital Markets 0.0%		
Atlas Mara Co-Nvest Ltd., Expires 12/17/17 (a)	200,000	\$ 300,000
Total Long-Term Investments		
(Cost \$602,097,260) 98.5%		675,395,664
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (e)(f)	3,204,081	3,204,081
Total Short-Term Securities		
(Cost \$3,204,081) 0.5%		3,204,081
		Value
Total Investments Before Options Written		
(Cost \$605,301,341) 99.0%		\$ 678,599,745
Options Written		
(Premiums Received \$9,033,294) (1.4)%		(9,841,545)
Total Investments Net of Options Written 97.6%		668,758,200
Other Assets Less Liabilities 2.4%		16,642,052
Net Assets 100.0%		\$ 685,400,252

Notes to Schedule of Investments

(a) Non-income producing security.

(b) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(c) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(d) Warrants entitle the Trust to purchase a predetermined number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any.

(e) Represents the current yield as of report date.

(f) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	Shares Held at	Net	Shares Held at	
Affiliate	October 31, 2013	Activity	April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	20,482,532	(17,278,451)	3,204,081	\$ 3,966

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
eBay, Inc.	Call	USD 58.00	5/02/14	656	\$ (656)
Expedia, Inc.	Call	USD 80.00	5/02/14	300	(33,000)
General Motors Co.	Call	USD 33.00	5/02/14	520	(73,060)
JPMorgan Chase & Co.	Call	USD 60.00	5/02/14	106	(212)
Oracle Corp.	Call	USD 39.00	5/02/14	179	(32,310)
The Walt Disney Co.	Call	USD 81.00	5/02/14	250	(1,125)
American International Group, Inc.	Call	USD 50.50	5/05/14	500	(132,750)
Apple Inc.	Call	USD 545.00	5/05/14	106	(484,155)
Citigroup, Inc.	Call	USD 48.50	5/05/14	325	(2,600)
HollyFrontier Corp.	Call	USD 49.00	5/05/14	590	(218,300)
Johnson & Johnson	Call	USD 98.00	5/05/14	479	(150,885)
Pfizer, Inc.	Call	USD 31.00	5/05/14	500	(19,000)
Pfizer, Inc.	Call	USD 33.00	5/05/14	361	(361)
QUALCOMM, Inc.	Call	USD 80.00	5/05/14	621	(3,416)
Activision Blizzard, Inc.	Call	USD 21.00	5/09/14	470	(12,925)
American International Group, Inc.	Call	USD 52.00	5/09/14	922	(161,811)
Apple Inc.	Call	USD 535.00	5/09/14	53	(295,210)
CF Industries Holdings, Inc.	Call	USD 260.00	5/09/14	552	(57,960)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Capital and Income Fund, Inc. (CII)**

Exchange-traded options written as of April 30, 2014 were as follows: (continued)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		USD	Price			
Citigroup, Inc.	Call	USD	50.00	5/09/14	450	\$ (2,700)
General Motors Co.	Call	USD	35.50	5/09/14	550	(9,900)
Google, Inc., Class A	Call	USD	565.00	5/09/14	68	(2,210)
HollyFrontier Corp.	Call	USD	49.50	5/09/14	590	(199,125)
Merck & Co., Inc.	Call	USD	57.00	5/09/14	407	(74,074)
Noble Corp. PLC	Call	USD	34.00	5/09/14	463	(5,093)
Pfizer, Inc.	Call	USD	32.00	5/09/14	629	(9,120)
QUALCOMM, Inc.	Call	USD	80.00	5/09/14	633	(18,674)
UnitedHealth Group, Inc.	Call	USD	83.00	5/09/14	450	(1,800)
Visa, Inc., Class A	Call	USD	210.00	5/09/14	55	(2,200)
Yahoo!, Inc.	Call	USD	37.00	5/09/14	500	(24,500)
3M Co.	Call	USD	135.00	5/19/14	72	(32,400)
Activision Blizzard, Inc.	Call	USD	20.00	5/19/14	956	(65,964)
The Allstate Corp.	Call	USD	56.00	5/19/14	497	(79,212)
The Allstate Corp.	Call	USD	57.50	5/19/14	173	(12,110)
American International Group, Inc.	Call	USD	50.00	5/19/14	1,330	(448,875)
Apple Inc.	Call	USD	575.00	5/19/14	20	(36,100)
Brunswick Corp.	Call	USD	46.00	5/19/14	145	(2,175)
Citigroup, Inc.	Call	USD	48.00	5/19/14	120	(8,040)
Comcast Corp., Special Class A	Call	USD	49.00	5/19/14	571	(127,048)
eBay, Inc.	Call	USD	52.50	5/19/14	250	(17,375)
Eli Lilly & Co.	Call	USD	60.00	5/19/14	690	(35,535)
Fidelity National Financial, Inc., Class A	Call	USD	32.00	5/19/14	1,020	(79,050)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD	34.00	5/19/14	343	(29,498)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD	35.00	5/19/14	340	(12,750)
Google, Inc., Class A	Call	USD	560.00	5/19/14	14	(2,415)
Marathon Petroleum Corp.	Call	USD	87.50	5/19/14	123	(79,335)
Merck & Co., Inc.	Call	USD	57.50	5/19/14	397	(69,475)
Nexstar Broadcasting Group, Inc., Class A	Call	USD	45.00	5/19/14	225	(12,375)
Novartis AG ADR	Call	USD	85.00	5/19/14	238	(49,385)
Owens Corning	Call	USD	45.00	5/19/14	990	(7,425)
PepsiCo, Inc.	Call	USD	85.00	5/19/14	203	(30,450)
Pfizer, Inc.	Call	USD	31.00	5/19/14	748	(46,002)
Science Applications International Corp.	Call	USD	40.00	5/19/14	1,230	(55,350)
Sinclair Broadcast Group, Inc., Class A	Call	USD	30.00	5/19/14	986	(34,510)
United Continental Holdings, Inc.	Call	USD	46.00	5/19/14	230	(4,715)
United Continental Holdings, Inc.	Call	USD	47.00	5/19/14	470	(6,345)
United Continental Holdings, Inc.	Call	USD	55.00	5/19/14	170	(595)
Vodafone Group PLC ADR	Call	USD	38.00	5/19/14	675	(48,938)
Yahoo!, Inc.	Call	USD	36.00	5/19/14	400	(45,800)
Berkshire Hathaway, Inc., Class B	Call	USD	127.00	5/22/14	482	(143,060)
American Capital Agency Corp.	Call	USD	22.50	5/23/14	628	(28,260)
Annaly Capital Management, Inc.	Call	USD	11.50	5/23/14	1,663	(45,733)
eBay, Inc.	Call	USD	54.50	5/23/14	161	(4,588)
General Motors Co.	Call	USD	35.00	5/23/14	640	(38,080)
Gilead Sciences, Inc.	Call	USD	74.00	5/23/14	46	(24,840)
Pfizer, Inc.	Call	USD	31.00	5/23/14	747	(53,410)
Visa, Inc., Class A	Call	USD	215.00	5/23/14	65	(3,380)
Yahoo!, Inc.	Call	USD	38.00	5/23/14	140	(9,450)
Activision Blizzard, Inc.	Call	USD	20.50	5/30/14	956	(51,624)
American Capital Agency Corp.	Call	USD	23.00	5/30/14	615	(14,452)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Capital and Income Fund, Inc. (CII)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
Apple Inc.	Call	USD 535.00	5/30/14	53	\$ (295,872)
Citigroup, Inc.	Call	USD 48.50	5/30/14	325	(23,075)
Express Scripts Holding Co.	Call	USD 72.00	5/30/14	217	(1,844)
Gilead Sciences, Inc.	Call	USD 76.00	5/30/14	91	(38,220)
JPMorgan Chase & Co.	Call	USD 56.50	5/30/14	482	(39,283)
Marathon Petroleum Corp.	Call	USD 91.00	5/30/14	125	(50,625)
Merck & Co., Inc.	Call	USD 58.50	5/30/14	502	(76,053)
Noble Corp. PLC	Call	USD 32.00	5/30/14	250	(7,500)
Oracle Corp.	Call	USD 40.00	5/30/14	600	(84,300)
Pfizer, Inc.	Call	USD 31.50	5/30/14	361	(20,396)
Verizon Communications, Inc.	Call	USD 48.50	5/30/14	800	(11,200)
American International Group, Inc.	Call	USD 52.50	6/06/14	1,000	(185,000)
eBay, Inc.	Call	USD 55.50	6/06/14	656	(18,696)
Johnson & Johnson	Call	USD 101.00	6/06/14	285	(48,022)
Marathon Petroleum Corp.	Call	USD 91.00	6/06/14	126	(54,810)
UnitedHealth Group, Inc.	Call	USD 78.00	6/06/14	1,405	(76,573)
Wal-Mart Stores, Inc.	Call	USD 79.00	6/06/14	241	(39,404)
Ally Financial, Inc.	Call	USD 25.00	6/23/14	500	(18,750)
Brunswick Corp.	Call	USD 46.00	6/23/14	145	(4,350)
Discover Financial Services	Call	USD 57.50	6/23/14	445	(34,488)
Fidelity National Financial, Inc., Class A	Call	USD 32.00	6/23/14	500	(57,500)
Fidelity National Financial, Inc., Class A	Call	USD 33.00	6/23/14	634	(42,795)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD 34.00	6/23/14	230	(31,855)
Gilead Sciences, Inc.	Call	USD 75.00	6/23/14	46	(25,990)
Linn Energy LLC	Call	USD 30.00	6/23/14	250	(8,750)
Nexstar Broadcasting Group, Inc., Class A	Call	USD 45.00	6/23/14	125	(14,062)
Oracle Corp.	Call	USD 42.00	6/23/14	150	(12,900)
Owens Corning	Call	USD 46.00	6/23/14	580	(10,150)
PBF Energy, Inc., Class A	Call	USD 30.00	6/23/14	568	(97,980)
Pfizer, Inc.	Call	USD 32.00	6/23/14	491	(31,424)
Sinclair Broadcast Group, Inc., Class A	Call	USD 30.00	6/23/14	902	(74,415)
Springleaf Holdings, Inc.	Call	USD 25.00	6/23/14	244	(20,130)
United Continental Holdings, Inc.	Call	USD 48.00	6/23/14	235	(13,865)
Verizon Communications, Inc.	Call	USD 47.00	6/23/14	500	(42,250)
Vodafone Group PLC ADR	Call	USD 40.00	6/23/14	1,011	(63,188)
Wal-Mart Stores, Inc.	Call	USD 80.00	6/23/14	242	(31,581)
Discover Financial Services	Call	USD 57.50	7/21/14	445	(52,288)
Total					\$ (5,684,840)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
American Realty Capital Properties, Inc.	Citibank N.A.	Call	USD 14.09	5/05/14	84,000	\$ (8)
Fidelity National Financial, Inc., Class A	Morgan Stanley & Co. International PLC	Call	USD 32.79	5/06/14	168,600	(21,628)
Sinclair Broadcast Group, Inc., Class A	Morgan Stanley & Co. International PLC	Call	USD 26.74	5/06/14	77,100	(67,412)
Sinclair Broadcast Group, Inc., Class A	Morgan Stanley & Co. International PLC	Call	USD 27.28	5/06/14	79,800	(52,002)
Metro AG	Morgan Stanley & Co. International PLC	Call	EUR 30.31	5/07/14	196,200	(29,859)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Comcast Corp., Special Class A	Deutsche Bank AG	Call	USD	50.25	5/08/14	34,300	(33,642)
--------------------------------	------------------	------	-----	-------	---------	--------	----------

See Notes to Financial Statements.

50 SEMI-ANNUAL REPORT APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Capital and Income Fund, Inc. (CII)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
Samsung Electronics Co. Ltd.	Bank of America N.A.	Call	KRW 1,075,900.00	5/08/14	4,500	\$ (16,147)
Suncor Energy, Inc.	Morgan Stanley & Co. International PLC	Call	USD 34.13	5/09/14	177,800	(794,951)
Comcast Corp., Special Class A	Citibank N.A.	Call	USD 50.75	5/13/14	34,300	(26,867)
Bayerische Motoren Werke AG	Morgan Stanley & Co. International PLC	Call	EUR 69.37	5/14/14	15,000	(43,929)
Japan Airlines Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY 4,798.73	5/14/14	160,100	(778,956)
Samsung Electronics Co. Ltd.	UBS AG	Call	KRW 1,019,606.38	5/14/14	5,100	(152,935)
Expedia, Inc.	Morgan Stanley & Co. International PLC	Call	USD 73.81	5/22/14	75,000	(317,042)
Comcast Corp., Special Class A	Deutsche Bank AG	Call	USD 50.25	5/27/14	34,300	(45,922)
Bayerische Motoren Werke AG	Morgan Stanley & Co. International PLC	Call	EUR 69.02	5/28/14	15,000	(55,986)
Owens Corning	Citibank N.A.	Call	USD 44.63	5/28/14	58,000	(14,167)
Springleaf Holdings, Inc.	Credit Suisse International	Call	USD 25.00	5/28/14	25,000	(14,712)
Japan Airlines Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY 5,160.00	5/29/14	79,700	(183,652)
Renault SA	Goldman Sachs International	Call	EUR 76.12	6/03/14	26,600	(21,390)
Vodafone Group PLC ADR	Deutsche Bank AG	Call	USD 37.31	6/03/14	101,100	(139,373)
Expedia, Inc.	Morgan Stanley & Co. International PLC	Call	USD 73.81	6/04/14	75,000	(254,618)
Legg Mason, Inc.	UBS AG	Call	USD 46.42	6/04/14	33,100	(54,171)
Suncor Energy, Inc.	Citibank N.A.	Call	USD 36.56	6/05/14	202,500	(423,393)
Comcast Corp., Special Class A	Citibank N.A.	Call	USD 51.59	6/09/14	34,300	(27,097)
Samsung Electronics Co. Ltd.	Morgan Stanley & Co. International PLC	Call	KRW 1,110,410.00	6/10/14	2,600	(29,698)
Japan Airlines Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY 5,160.00	6/12/14	79,700	(208,852)
Samsung Electronics Co. Ltd.	UBS AG	Call	KRW 1,091,461.39	6/17/14	2,600	(47,718)
News Corp. Class A	Morgan Stanley & Co. International PLC	Call	USD 17.37	6/26/14	73,700	(32,575)
Annaly Capital Management, Inc.	Morgan Stanley & Co. International PLC	Put	USD 11.55	5/12/14	497,000	(112,908)
Noble Corp. PLC	Morgan Stanley & Co. International PLC	Put	USD 32.50	5/12/14	59,700	(127,231)
PBF Energy, Inc., Class A	Citibank N.A.	Put	USD 28.10	5/12/14	285,900	(27,864)
Total						\$ (4,156,705)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

51

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Capital and Income Fund, Inc. (CII)**

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Air Freight & Logistics		\$ 100,347		\$ 100,347
Airlines	\$ 6,911,117	30,067,685		36,978,802
Automobiles	38,451,342	4,732,055		43,183,397
Banks	26,441,418			26,441,418
Beverages	3,160,752			3,160,752
Biotechnology	2,613,717			2,613,717
Building Products	16,025,455			16,025,455
Capital Markets	2,822,778	2,280,000		5,102,778
Chemicals	24,590,551			24,590,551
Communications Equipment	17,953,751			17,953,751
Consumer Finance	24,014,289			24,014,289
Diversified Financial Services	9,560,670			9,560,670
Diversified Telecommunication Services	7,622,130			7,622,130
Energy Equipment & Services	3,352,128			3,352,128
Food & Staples Retailing	5,675,352	14,294,724		19,970,076
Health Care Providers & Services	30,608,332			30,608,332
Industrial Conglomerates	1,822,078			1,822,078
Insurance	65,647,395			65,647,395
Internet & Catalog Retail	15,284,147			15,284,147
Internet Software & Services	38,845,694			38,845,694
IT Services	27,604,775			27,604,775
Leisure Products	2,118,013			2,118,013
Media	45,225,237			45,225,237
Metals & Mining	5,715,731			5,715,731
Oil, Gas & Consumable Fuels	50,489,451			50,489,451
Pharmaceuticals	60,979,953			60,979,953
Real Estate Investment Trusts (REITs)	10,625,856			10,625,856
Semiconductors & Semiconductor Equipment		20,312,706		20,312,706
Software	15,573,136			15,573,136
Technology Hardware, Storage & Peripherals	24,960,807			24,960,807
Wireless Telecommunication Services	18,612,092			18,612,092
Warrants		300,000		300,000
Short-Term Securities	3,204,081			3,204,081
Total	\$ 606,512,228	\$ 72,087,517		\$ 678,599,745
	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (5,462,567)	\$ (4,378,978)		\$ (9,841,545)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets approximates fair value for financial statement purposes. As of April 30, 2014, such assets are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 2,113			\$ 2,113
Foreign currency at value	3,608			3,608
Cash pledged as collateral for OTC derivatives	200,000			200,000
Total	\$ 205,721			\$ 205,721

See Notes to Financial Statements.

Table of Contents

Schedule of Investments (concluded)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013 the Trust did not utilize the external pricing service model adjustments as significant market movements did not occur. As of April 30, 2014, securities with a value of \$50,480,738 were systematically fair valued due to significant market movements. Therefore, these securities were transferred from Level 1 to Level 2 during the period October 31, 2013 to April 30, 2014.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

53

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock Enhanced Equity Dividend Trust (BDJ)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Aerospace & Defense 7.1%		
Honeywell International, Inc. (a)	217,600	\$ 20,215,040
Lockheed Martin Corp. (a)	81,000	13,295,340
Northrop Grumman Corp. (a)	179,200	21,774,592
Raytheon Co.	343,100	32,759,188
United Technologies Corp. (a)	241,400	28,564,862
		116,609,022
Air Freight & Logistics 1.1%		
United Parcel Service, Inc., Class B	183,000	18,025,500
Auto Components 0.5%		
Johnson Controls, Inc.	172,300	7,777,622
Banks 13.7%		
Bank of America Corp. (a)	329,800	4,993,172
Citigroup, Inc. (a)	386,700	18,526,797
Fifth Third Bancorp.	867,700	17,883,297
JPMorgan Chase & Co. (a)(b)	958,499	53,656,774
M&T Bank Corp. (a)	33,800	4,123,938
SunTrust Banks, Inc. (a)	672,340	25,723,728
The Toronto-Dominion Bank (a)	355,800	17,110,422
U.S. Bancorp. (a)	637,100	25,980,938
Wells Fargo & Co. (a)(b)	1,157,300	57,448,372
		225,447,438
Beverages 2.2%		
The Coca-Cola Co. (a)	398,400	16,250,736
Diageo PLC ADR (a)(b)	155,200	19,055,456
		35,306,192
Capital Markets 0.7%		
Morgan Stanley (a)	394,700	12,208,071
Chemicals 3.4%		
The Dow Chemical Co.	230,200	11,486,980
El du Pont de Nemours & Co. (a)	408,500	27,500,220
Olin Corp.	192,100	5,398,010
Praxair, Inc. (a)	91,600	11,958,380
		56,343,590
Communications Equipment 1.5%		
Motorola Solutions, Inc. (a)	190,800	12,131,064
QUALCOMM, Inc. (a)	161,500	12,711,665
		24,842,729
Consumer Finance 1.5%		
American Express Co. (a)	276,300	24,156,909
Containers & Packaging 0.7%		
MeadWestvaco Corp.	292,300	11,420,161
Diversified Financial Services 0.7%		
CME Group, Inc.	162,700	11,452,453
Diversified Telecommunication Services 2.0%		
BCE, Inc.	115,700	5,153,278
Verizon Communications, Inc. (a)	598,500	27,967,905
		33,121,183
Electric Utilities 2.3%		
Duke Energy Corp. (a)	97,200	7,240,428
ITC Holdings Corp.	134,000	4,953,980

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

NextEra Energy, Inc. (a)	186,200	18,592,070
Northeast Utilities (a)	155,220	7,335,697
		38,122,175
Electrical Equipment 0.4%		
Rockwell Automation, Inc.	53,400	6,364,212
Energy Equipment & Services 0.6%		
Schlumberger Ltd. (a)	98,500	10,002,675
Common Stocks	Shares	Value
Food & Staples Retailing 0.6%		
Wal-Mart Stores, Inc. (a)	121,300	\$ 9,668,823
Food Products 2.7%		
General Mills, Inc. (a)	230,600	12,226,412
Kraft Foods Group, Inc. (a)	149,195	8,483,228
Mondelez International, Inc., Class A (a)	445,085	15,867,280
Unilever NV	191,200	8,187,184
		44,764,104
Health Care Equipment & Supplies 0.4%		
Abbott Laboratories (a)	145,700	5,644,418
Health Care Providers & Services 0.4%		
Quest Diagnostics, Inc. (a)	124,800	6,980,064
Hotels, Restaurants & Leisure 1.5%		
McDonald's Corp. (a)	249,700	25,314,586
Household Products 2.0%		
Kimberly-Clark Corp. (a)	112,850	12,667,412
The Procter & Gamble Co. (a)	250,400	20,670,520
		33,337,932
Industrial Conglomerates 4.1%		
3M Co. (a)	121,700	16,927,253
General Electric Co. (a)	1,877,200	50,477,908
		67,405,161
Insurance 5.2%		
ACE Ltd.	171,000	17,496,720
The Chubb Corp.	153,800	14,161,904
MetLife, Inc. (a)	139,550	7,305,444
Prudential Financial, Inc. (a)	343,200	27,689,376
The Travelers Cos., Inc. (a)	212,300	19,230,134
		85,883,578
IT Services 2.0%		
Automatic Data Processing, Inc. (a)	63,560	4,955,138
International Business Machines Corp. (a)	145,200	28,527,444
		33,482,582
Leisure Products 0.3%		
Mattel, Inc.	104,300	4,090,124
Media 3.3%		
Comcast Corp., Special Class A (a)	859,000	43,834,770
The Walt Disney Co. (a)	123,500	9,798,490
		53,633,260
Metals & Mining 1.6%		
BHP Billiton Ltd. ADR (a)(b)	302,700	21,352,458
Southern Copper Corp.	157,077	4,734,301
		26,086,759
Multi-Utilities 2.1%		
Dominion Resources, Inc. (a)	254,300	18,446,922
Sempra Energy	88,700	8,746,707
Wisconsin Energy Corp.	151,800	7,359,264
		34,552,893
Oil, Gas & Consumable Fuels 13.6%		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Chevron Corp. (a)(b)	416,600	52,291,632
ConocoPhillips (a)	119,860	8,906,797
Enbridge, Inc. (a)	492,200	23,751,159
Exxon Mobil Corp. (a)	359,600	36,826,636
Kinder Morgan, Inc.	266,178	8,693,373
Marathon Oil Corp. (a)	381,300	13,783,995
Marathon Petroleum Corp. (a)	169,600	15,764,320
Occidental Petroleum Corp. (a)	170,200	16,296,650
Phillips 66 (a)	80,350	6,686,727

See Notes to Financial Statements.

Table of Contents

Schedule of Investments (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Oil, Gas & Consumable Fuels (concluded)		
Royal Dutch Shell PLC ADR	61,900	\$ 4,874,006
Spectra Energy Corp. (a)	204,000	8,100,840
Total SA ADR (a)	380,400	27,099,696
		223,075,831
Paper & Forest Products 0.7%		
International Paper Co. (a)	247,150	11,529,547
Pharmaceuticals 8.7%		
AbbVie, Inc. (a)	143,127	7,454,054
Bristol-Myers Squibb Co. (a)	558,100	27,955,229
Johnson & Johnson (a)	295,500	29,931,195
Merck & Co., Inc. (a)	648,200	37,958,592
Pfizer, Inc. (a)	1,258,700	39,372,136
		142,671,206
Professional Services 0.2%		
Nielsen Holdings NV	74,100	3,478,995
Real Estate Investment Trusts (REITs) 0.8%		
American Tower Corp. (a)	72,500	6,055,200
Weyerhaeuser Co. (a)	236,300	7,053,555
		13,108,755
Road & Rail 1.4%		
CSX Corp. (a)	198,300	5,596,026
Union Pacific Corp. (a)	90,700	17,272,001
		22,868,027
Semiconductors & Semiconductor Equipment 1.3%		
Intel Corp. (a)	815,900	21,776,371
Software 1.9%		
Microsoft Corp. (a)	752,700	30,409,080
Specialty Retail 2.3%		
The Home Depot, Inc. (a)	476,900	37,918,319
Textiles, Apparel & Luxury Goods 1.1%		
VF Corp. (a)	301,600	18,424,744
Common Stocks	Shares	Value
Tobacco 1.5%		
Altria Group, Inc. (a)	203,800	\$ 8,174,418
Philip Morris International, Inc.	195,100	16,667,393
		24,841,811
Water Utilities 0.7%		
American Water Works Co., Inc.	258,600	11,774,058
Total Long-Term Investments		
(Cost \$1,349,384,408) 98.8%		1,623,920,960
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (c)(d)	38,251,313	38,251,313
Total Short-Term Securities		
(Cost \$38,251,313) 2.3%		38,251,313

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Options Purchased	
(Cost \$7,273) 0.0%	4,329
Total Investments Before Options Written	
(Cost \$1,387,642,994) 101.1%	1,662,176,602
Options Written	
(Premiums Received \$13,752,252) (1.1)%	(18,043,340)
Total Investments Net of Options Written	1,644,133,262
Liabilities in Excess of Other Assets	(106,755)
Net Assets	\$ 1,644,026,507

Notes to Schedule of Investments

(a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(c) Represents the current yield as of report date.

(d) Investments in companies considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares Held at	Net	Shares Held at	
Affiliate	October 31, 2013	Activity	April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	48,920,346	(10,669,033)	38,251,313	\$ 9,059

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options purchased as of April 30, 2014 were as follows:

Description	Put/	Strike	Expiration	Contracts	Market Value
	Call	Price	Date		
JPMorgan Chase & Co.	Call	USD 59.50	5/09/14	1,443	\$ 4,329

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Equity Dividend Trust (BDJ)**

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		USD	Price			
Altria Group, Inc.	Call	USD	38.00	5/02/14	373	\$ (77,584)
Bank of America Corp.	Call	USD	18.00	5/02/14	907	(907)
EI du Pont de Nemours & Co.	Call	USD	67.00	5/02/14	571	(29,406)
Exxon Mobil Corp.	Call	USD	94.00	5/02/14	184	(149,040)
JPMorgan Chase & Co.	Call	USD	60.00	5/02/14	1,000	(2,000)
Microsoft Corp.	Call	USD	40.50	5/02/14	1,300	(26,000)
Occidental Petroleum Corp.	Call	USD	97.00	5/02/14	350	(5,775)
Schlumberger Ltd.	Call	USD	91.00	5/02/14	135	(137,362)
U.S. Bancorp.	Call	USD	41.50	5/02/14	1,176	(5,880)
The Walt Disney Co.	Call	USD	81.00	5/02/14	679	(3,056)
Chevron Corp.	Call	USD	120.00	5/05/14	488	(279,380)
Citigroup, Inc.	Call	USD	48.50	5/05/14	512	(4,096)
ConocoPhillips	Call	USD	68.50	5/05/14	330	(199,650)
The Home Depot, Inc.	Call	USD	80.00	5/05/14	921	(25,328)
International Business Machines Corp.	Call	USD	192.50	5/05/14	350	(140,000)
Johnson & Johnson	Call	USD	98.00	5/05/14	809	(254,835)
Marathon Oil Corp.	Call	USD	35.00	5/05/14	1,052	(140,442)
McDonald's Corp.	Call	USD	98.00	5/05/14	686	(222,950)
Pfizer, Inc.	Call	USD	33.00	5/05/14	1,622	(1,622)
Schlumberger Ltd.	Call	USD	93.00	5/05/14	136	(115,260)
Union Pacific Corp.	Call	USD	190.00	5/05/14	250	(31,125)
United Technologies Corp.	Call	USD	116.00	5/05/14	1,327	(305,210)
M&T Bank Corp.	Call	USD	119.35	5/07/14	185	(52,001)
3M Co.	Call	USD	136.00	5/09/14	334	(112,725)
Altria Group, Inc.	Call	USD	38.00	5/09/14	373	(78,703)
Citigroup, Inc.	Call	USD	50.00	5/09/14	500	(3,000)
The Coca-Cola Co.	Call	USD	38.50	5/09/14	1,095	(249,660)
EI du Pont de Nemours & Co.	Call	USD	67.00	5/09/14	571	(45,109)
Exxon Mobil Corp.	Call	USD	98.00	5/09/14	825	(377,438)
General Electric Co.	Call	USD	26.50	5/09/14	1,000	(47,000)
The Home Depot, Inc.	Call	USD	78.00	5/09/14	780	(148,200)
JPMorgan Chase & Co.	Call	USD	60.50	5/09/14	1,443	(4,329)
McDonald's Corp.	Call	USD	99.00	5/09/14	687	(173,811)
Merck & Co., Inc.	Call	USD	57.00	5/09/14	1,130	(205,660)
QUALCOMM, Inc.	Call	USD	80.00	5/09/14	444	(13,098)
Schlumberger Ltd.	Call	USD	100.00	5/09/14	135	(28,418)
U.S. Bancorp.	Call	USD	42.00	5/09/14	1,152	(4,032)
Union Pacific Corp.	Call	USD	192.50	5/09/14	250	(24,375)
Mondelez International, Inc., Class A	Call	USD	34.75	5/13/14	1,338	(148,751)
The Toronto-Dominion Bank	Call	USD	46.25	5/13/14	956	(177,358)
The Toronto-Dominion Bank	Call	USD	47.00	5/14/14	937	(106,333)
3M Co.	Call	USD	135.00	5/19/14	335	(150,750)
Abbott Laboratories	Call	USD	39.00	5/19/14	400	(14,600)
AbbVie, Inc.	Call	USD	55.00	5/19/14	197	(2,955)
Altria Group, Inc.	Call	USD	38.00	5/19/14	373	(80,382)
American Tower Corp.	Call	USD	82.50	5/19/14	198	(36,630)
Automatic Data Processing, Inc.	Call	USD	75.00	5/19/14	349	(111,680)
BHP Billiton Ltd. ADR	Call	USD	67.50	5/19/14	650	(217,750)
BHP Billiton Ltd. ADR	Call	USD	70.00	5/19/14	260	(36,010)
BHP Billiton Ltd. ADR	Call	USD	72.50	5/19/14	754	(27,898)
Bristol-Myers Squibb Co.	Call	USD	52.50	5/19/14	860	(31,390)
Citigroup, Inc.	Call	USD	48.00	5/19/14	600	(40,200)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

56

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Equity Dividend Trust (BDJ)**

Exchange-traded options written as of April 30, 2014 were as follows: (continued)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
The Coca-Cola Co.	Call	USD	39.00	5/19/14	1,096	\$ (200,568)
Comcast Corp., Special Class A	Call	USD	49.00	5/19/14	1,302	(289,695)
ConocoPhillips	Call	USD	75.00	5/19/14	329	(21,877)
CSX Corp.	Call	USD	30.00	5/19/14	545	(1,361)
Diageo PLC ADR	Call	USD	125.00	5/19/14	428	(33,170)
Duke Energy Corp.	Call	USD	72.50	5/19/14	460	(100,050)
El du Pont de Nemours & Co.	Call	USD	70.00	5/19/14	570	(3,420)
Enbridge, Inc.	Call	CAD	52.00	5/19/14	400	(42,151)
Exxon Mobil Corp.	Call	USD	100.00	5/19/14	723	(197,740)
General Electric Co.	Call	USD	26.00	5/19/14	3,912	(361,860)
General Mills, Inc.	Call	USD	51.75	5/19/14	1,268	(181,976)
Intel Corp.	Call	USD	27.00	5/19/14	1,769	(23,882)
International Paper Co.	Call	USD	46.00	5/19/14	348	(36,366)
Kimberly-Clark Corp.	Call	USD	112.50	5/19/14	620	(81,550)
Kraft Foods Group, Inc.	Call	USD	57.50	5/19/14	820	(45,100)
Marathon Petroleum Corp.	Call	USD	87.50	5/19/14	308	(198,660)
Merck & Co., Inc.	Call	USD	57.50	5/19/14	1,101	(192,675)
MetLife, Inc.	Call	USD	55.00	5/19/14	384	(8,640)
Microsoft Corp.	Call	USD	40.00	5/19/14	851	(67,229)
Mondelez International, Inc., Class A	Call	USD	35.00	5/19/14	555	(56,055)
Morgan Stanley	Call	USD	31.00	5/19/14	551	(27,826)
Morgan Stanley	Call	USD	32.00	5/19/14	549	(8,510)
Motorola Solutions, Inc.	Call	USD	65.00	5/19/14	525	(35,438)
Northeast Utilities	Call	USD	45.00	5/19/14	468	(106,470)
Northrop Grumman Corp.	Call	USD	125.00	5/19/14	530	(33,125)
Occidental Petroleum Corp.	Call	USD	95.00	5/19/14	236	(51,094)
Occidental Petroleum Corp.	Call	USD	97.50	5/19/14	350	(36,050)
Pfizer, Inc.	Call	USD	31.00	5/19/14	1,030	(63,345)
Phillips 66	Call	USD	80.00	5/19/14	441	(160,965)
Praxair, Inc.	Call	USD	132.00	5/19/14	503	(47,825)
The Procter & Gamble Co.	Call	USD	82.50	5/19/14	1,006	(88,025)
Prudential Financial, Inc.	Call	USD	88.00	5/19/14	944	(13,230)
Quest Diagnostics, Inc.	Call	USD	55.00	5/19/14	345	(54,337)
Schlumberger Ltd.	Call	USD	92.50	5/19/14	135	(123,187)
Spectra Energy Corp.	Call	USD	37.00	5/19/14	280	(78,400)
Spectra Energy Corp.	Call	USD	39.00	5/19/14	700	(59,500)
SunTrust Banks, Inc.	Call	USD	38.00	5/19/14	1,230	(92,250)
SunTrust Banks, Inc.	Call	USD	39.00	5/19/14	1,230	(37,515)
The Travelers Cos., Inc.	Call	USD	87.50	5/19/14	1,168	(379,600)
Verizon Communications, Inc.	Call	USD	48.00	5/19/14	1,423	(14,942)
VF Corp.	Call	USD	62.50	5/19/14	825	(37,125)
Wells Fargo & Co.	Call	USD	49.00	5/19/14	1,590	(126,405)
Chevron Corp.	Call	USD	123.00	5/23/14	368	(122,360)
El du Pont de Nemours & Co.	Call	USD	68.50	5/23/14	150	(4,875)
General Electric Co.	Call	USD	26.50	5/23/14	1,500	(90,000)
The Home Depot, Inc.	Call	USD	78.00	5/23/14	921	(238,079)
Intel Corp.	Call	USD	27.00	5/23/14	950	(19,000)
Microsoft Corp.	Call	USD	41.00	5/23/14	492	(20,418)
Pfizer, Inc.	Call	USD	31.00	5/23/14	1,029	(73,574)
U.S. Bancorp.	Call	USD	41.50	5/23/14	1,176	(30,576)
Verizon Communications, Inc.	Call	USD	48.00	5/23/14	1,423	(25,614)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Equity Dividend Trust (BDJ)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Wells Fargo & Co.	Call	USD	49.00	5/23/14	1,591	\$ (137,622)
Wells Fargo & Co.	Call	USD	50.00	5/23/14	1,715	(60,025)
Northrop Grumman Corp.	Call	USD	125.00	5/27/14	456	(39,511)
American Express Co.	Call	USD	88.00	5/30/14	760	(107,540)
Chevron Corp.	Call	USD	123.00	5/30/14	367	(126,615)
Citigroup, Inc.	Call	USD	48.50	5/30/14	514	(36,494)
El du Pont de Nemours & Co.	Call	USD	68.00	5/30/14	385	(22,330)
Exxon Mobil Corp.	Call	USD	101.00	5/30/14	123	(26,199)
General Electric Co.	Call	USD	26.00	5/30/14	3,912	(393,156)
JPMorgan Chase & Co.	Call	USD	56.50	5/30/14	1,422	(115,893)
Marathon Oil Corp.	Call	USD	37.00	5/30/14	522	(22,707)
Marathon Oil Corp.	Call	USD	37.50	5/30/14	522	(14,877)
Marathon Petroleum Corp.	Call	USD	91.00	5/30/14	311	(125,955)
Merck & Co., Inc.	Call	USD	58.50	5/30/14	1,334	(202,101)
Microsoft Corp.	Call	USD	41.00	5/30/14	1,496	(73,304)
Pfizer, Inc.	Call	USD	31.50	5/30/14	1,621	(91,587)
The Procter & Gamble Co.	Call	USD	82.00	5/30/14	371	(53,053)
American Tower Corp.	Call	USD	84.00	6/06/14	200	(29,500)
Chevron Corp.	Call	USD	125.00	6/06/14	535	(120,375)
Exxon Mobil Corp.	Call	USD	101.00	6/06/14	123	(27,368)
Intel Corp.	Call	USD	26.50	6/06/14	1,769	(90,219)
Johnson & Johnson	Call	USD	101.00	6/06/14	816	(137,496)
Marathon Petroleum Corp.	Call	USD	91.00	6/06/14	311	(135,285)
Wal-Mart Stores, Inc.	Call	USD	79.00	6/06/14	334	(54,609)
Wells Fargo & Co.	Call	USD	50.00	6/06/14	1,469	(72,716)
Total SA ADR	Call	USD	68.75	6/13/14	645	(176,389)
AbbVie, Inc.	Call	USD	50.00	6/23/14	590	(182,900)
American Express Co.	Call	USD	90.00	6/23/14	760	(91,200)
Bristol-Myers Squibb Co.	Call	USD	55.00	6/23/14	917	(41,723)
Chevron Corp.	Call	USD	125.00	6/23/14	533	(133,516)
Dominion Resources, Inc.	Call	USD	72.50	6/23/14	700	(94,500)
Honeywell International, Inc.	Call	USD	95.00	6/23/14	600	(58,500)
International Business Machines Corp.	Call	USD	195.00	6/23/14	448	(197,120)
Lockheed Martin Corp.	Call	USD	165.00	6/23/14	445	(144,625)
MetLife, Inc.	Call	USD	52.50	6/23/14	383	(58,024)
Morgan Stanley	Call	USD	32.00	6/23/14	1,070	(56,175)
NextEra Energy, Inc.	Call	USD	97.50	6/23/14	265	(99,375)
Pfizer, Inc.	Call	USD	32.00	6/23/14	1,620	(103,680)
QUALCOMM, Inc.	Call	USD	80.00	6/23/14	444	(51,060)
Verizon Communications, Inc.	Call	USD	47.00	6/23/14	445	(37,602)
Wal-Mart Stores, Inc.	Call	USD	80.00	6/23/14	333	(43,456)
Weyerhaeuser Co.	Call	USD	30.00	6/23/14	325	(17,875)
Total						\$ (13,255,096)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Sempra Energy	Goldman Sachs International	Call	USD	97.72	5/02/14	13,100	\$ (12,571)
American Water Works Co., Inc.	Citibank N.A.	Call	USD	45.54	5/05/14	55,500	(31,881)
The Chubb Corp.	Credit Suisse International	Call	USD	87.37	5/05/14	42,250	(199,014)
The Dow Chemical Co.	UBS AG	Call	USD	50.73	5/05/14	126,600	(21,130)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Equity Dividend Trust (BDJ)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Honeywell International, Inc.	Deutsche Bank AG	Call	USD	94.27	5/05/14	59,500	\$ (9,143)
ITC Holdings Corp.	Morgan Stanley & Co. International PLC	Call	USD	36.59	5/05/14	37,100	(20,579)
Mattel, Inc.	Credit Suisse International	Call	USD	38.29	5/05/14	104,000	(102,190)
MeadWestvaco Corp.	Citibank N.A.	Call	USD	36.42	5/05/14	43,200	(114,317)
Mondelez International, Inc., Class A	Credit Suisse International	Call	USD	35.00	5/05/14	55,000	(41,947)
Northeast Utilities	Deutsche Bank AG	Call	USD	43.95	5/05/14	38,500	(127,654)
Total SA ADR	Morgan Stanley & Co. International PLC	Call	USD	64.50	5/05/14	62,400	(420,600)
Wisconsin Energy Corp.	Credit Suisse International	Call	USD	44.10	5/05/14	41,700	(182,675)
SunTrust Banks, Inc.	Citibank N.A.	Call	USD	41.00	5/06/14	123,700	(85)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	45.94	5/07/14	15,400	(7,852)
Comcast Corp., Special Class A	Deutsche Bank AG	Call	USD	50.25	5/08/14	86,100	(84,448)
Sempra Energy	UBS AG	Call	USD	97.00	5/08/14	35,600	(71,239)
ITC Holdings Corp.	Citibank N.A.	Call	USD	37.48	5/09/14	36,600	(8,729)
United Parcel Service, Inc., Class B	UBS AG	Call	USD	98.43	5/09/14	100,700	(47,917)
International Paper Co.	Credit Suisse International	Call	USD	45.73	5/12/14	101,100	(115,143)
NextEra Energy, Inc.	Morgan Stanley & Co. International PLC	Call	USD	94.50	5/12/14	75,900	(423,802)
Comcast Corp., Special Class A	Citibank N.A.	Call	USD	50.75	5/13/14	85,000	(66,579)
MeadWestvaco Corp.	Citibank N.A.	Call	USD	36.42	5/14/14	43,200	(114,307)
Total SA ADR	Deutsche Bank AG	Call	USD	64.85	5/14/14	19,900	(128,418)
Weyerhaeuser Co.	Citibank N.A.	Call	USD	29.77	5/14/14	64,900	(18,905)
BCE, Inc.	Morgan Stanley & Co. International PLC	Call	USD	44.43	5/15/14	63,600	(30,116)
Olin Corp.	Credit Suisse International	Call	USD	27.93	5/15/14	53,600	(29,639)
Philip Morris International, Inc.	Citibank N.A.	Call	USD	83.21	5/20/14	53,750	(138,614)
ACE Ltd.	Credit Suisse International	Call	USD	98.59	5/27/14	43,100	(176,410)
Comcast Corp., Special Class A	Deutsche Bank AG	Call	USD	50.25	5/27/14	86,100	(115,273)
The Chubb Corp.	Credit Suisse International	Call	USD	92.36	5/28/14	42,250	(47,757)
Philip Morris International, Inc.	Citibank N.A.	Call	USD	84.04	5/28/14	53,750	(109,758)
Rockwell Automation, Inc.	Morgan Stanley & Co. International PLC	Call	USD	128.27	5/28/14	30,000	(7,002)
VF Corp.	UBS AG	Call	USD	63.00	5/28/14	82,500	(45,626)
Quest Diagnostics, Inc.	Morgan Stanley & Co. International PLC	Call	USD	61.15	5/30/14	34,100	(5,397)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	46.66	6/02/14	55,500	(49,292)
Dominion Resources, Inc.	Credit Suisse International	Call	USD	73.10	6/02/14	69,900	(69,072)
Raytheon Co.	Morgan Stanley & Co. International PLC	Call	USD	98.00	6/03/14	94,300	(103,237)
ACE Ltd.	Deutsche Bank AG	Call	USD	102.15	6/04/14	50,900	(96,573)
MeadWestvaco Corp.	Goldman Sachs International	Call	USD	38.50	6/04/14	74,300	(74,255)
Enbridge, Inc.	Citibank N.A.	Call	CAD	51.10	6/05/14	114,300	(203,604)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.24	6/05/14	17,000	(52,909)
Total SA ADR	Morgan Stanley & Co. International PLC	Call	USD	66.83	6/05/14	62,400	(277,306)
Unilever NV	Citibank N.A.	Call	USD	42.73	6/06/14	47,500	(39,869)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	45.75	6/09/14	15,800	(11,726)
Fifth Third Bancorp.	Citibank N.A.	Call	USD	20.76	6/09/14	238,600	(97,702)
Olin Corp.	Citibank N.A.	Call	USD	28.10	6/09/14	52,000	(43,858)
Bristol-Myers Squibb Co.	Morgan Stanley & Co. International PLC	Call	USD	52.05	6/11/14	129,200	(133,619)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/12/14	8,500	(25,291)
Unilever NV	Morgan Stanley & Co. International PLC	Call	USD	42.79	6/12/14	57,600	(54,064)
Wisconsin Energy Corp.	Credit Suisse International	Call	USD	48.97	6/13/14	41,700	(20,061)
CSX Corp.	Morgan Stanley & Co. International PLC	Call	USD	28.52	6/17/14	54,500	(30,212)
Raytheon Co.	Morgan Stanley & Co. International PLC	Call	USD	98.00	6/17/14	94,300	(135,928)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/18/14	8,500	(26,146)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	6/21/14	58,200	(41,418)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Enhanced Equity Dividend Trust (BDJ)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	7/09/14	58,200	\$ (52,569)
Mattel, Inc.	Credit Suisse International	Put	USD	38.50	5/27/14	121,300	(72,816)
Total							\$ (4,788,244)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks ¹	\$ 1,623,920,960			\$ 1,623,920,960
Short-Term Securities	38,251,313			38,251,313
Options Purchased	4,329			4,329
Total	\$ 1,662,176,602			\$ 1,662,176,602

¹ See above Schedule of Investments for values in each industry

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ²				
Liabilities:				
Equity contracts	\$ (12,230,172)	\$ (5,813,168)		\$ (18,043,340)

² Derivative financial instruments are options written, which are shown at value.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (concluded)****BlackRock Enhanced Equity Dividend Trust (BDJ)**

The carrying amount for certain of the Trust's assets approximates fair value for financial statement purposes. As of April 30, 2014, such assets are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 74,629			\$ 74,629
Foreign currency at value	1,778			1,778
Cash pledged as collateral for OTC derivatives	100,000			100,000
Total	\$ 176,407			\$ 176,407

There were no transfers between levels during the six months ended April 30, 2014.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

61

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock Global Opportunities Equity Trust (BOE)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Austria 0.8%		
Erste Group Bank AG	269,586	\$ 9,064,646
Belgium 1.5%		
Anheuser-Busch InBev NV	154,859	16,878,963
Canada 1.6%		
MEG Energy Corp. (a)(b)	351,700	12,661,906
Suncor Energy, Inc.	152,600	5,886,527
		18,548,433
China 2.6%		
Anhui Conch Cement Co. Ltd., Class H (c)	2,585,560	9,653,839
Baidu, Inc. ADR (a)(b)	34,700	5,338,595
Beijing Enterprises Water Group Ltd.	10,224,000	6,497,864
China Cinda Asset Management Co. Ltd., Class H (a)(c)	7,085,000	3,573,094
Ping An Insurance Group Co. of China Ltd., Class H	609,500	4,523,787
		29,587,179
Denmark 1.2%		
ISS A/S (a)	107,959	3,758,498
Novo Nordisk A/S, Class B	223,500	10,143,775
		13,902,273
France 4.0%		
Rexel SA	268,200	6,771,976
Schneider Electric SA	69,900	6,561,573
Societe Generale SA	305,120	19,002,001
Vivendi SA	510,650	13,719,491
		46,055,041
Germany 4.2%		
Bayer AG	63,500	8,829,137
Daimler AG	146,200	13,611,073
Henkel AG & Co KGaA	87,200	9,727,165
OSRAM Licht AG (a)	189,900	9,969,615
Telefonica Deutschland Holding AG	693,500	5,769,525
		47,906,515
Greece 0.9%		
Alpha Bank AE (a)(c)	10,384,721	10,059,147
Hong Kong 1.9%		
AIA Group Ltd.	1,731,500	8,421,314
Melco Crown Entertainment Ltd. ADR (b)	146,000	4,990,280
Samsonite International SA	2,582,600	8,205,959
		21,617,553
Indonesia 1.3%		
Global Mediacom Tbk PT	33,195,500	6,301,278
Matahari Department Store Tbk PT (a)	6,580,271	8,550,022
		14,851,300
Ireland 2.7%		
CRH PLC	421,000	12,273,285
Green REIT PLC (a)	10,891,189	18,131,835
		30,405,120
Italy 1.7%		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Assicurazioni Generali SpA (b)	259,000	6,055,748
Banca Generali SpA	293,690	9,244,552
Moncler SpA (a)	224,200	3,947,870
		19,248,170
Japan 5.3%		
Calbee, Inc.	241,800	5,922,308
Kenedix Office Investment Corp. REIT	990	4,945,514
Nabtesco Corp.	368,600	7,957,465
Common Stocks	Shares	Value
Japan (concluded)		
Shinsei Bank Ltd.	5,174,000	\$ 10,087,350
SMC Corp.	22,600	5,380,061
SoftBank Corp.	147,100	10,955,716
Sumitomo Mitsui Financial Group, Inc.	199,300	7,878,391
Tokyo Tatemono Co. Ltd.	946,300	7,546,552
		60,673,357
Mexico 0.5%		
Cemex SAB de CV ADR (a)	457,392	5,781,435
Netherlands 0.5%		
ING Groep NV (a)	400,300	5,722,224
New Zealand 0.8%		
Xero Ltd. (Acquired 10/15/13, Cost \$5,317,368) (a)(d)	350,000	9,074,516
Norway 0.3%		
Statoil ASA	125,700	3,832,016
Panama 0.5%		
Copa Holdings SA, Class A	39,900	5,397,672
Peru 0.5%		
Credicorp Ltd.	40,700	6,074,475
South Africa 0.5%		
Naspers Ltd., N Shares	64,000	6,047,954
South Korea 0.6%		
Hyundai Development Co.	44,570	1,274,599
NAVER Corp.	7,620	5,487,290
		6,761,889
Spain 2.3%		
NH Hoteles SA (a)	2,334,549	14,915,070
Sacyr SA (a)	1,818,142	11,975,008
		26,890,078
Sweden 2.7%		
Nordea Bank AB	792,658	11,453,080
Skanska AB, B Shares	282,000	6,474,523
Svenska Cellulosa AB SCA, Class B	453,727	12,755,648
		30,683,251
Switzerland 4.3%		
Adecco SA	186,700	15,673,847
Novartis AG	140,800	12,240,107
Roche Holding AG	39,170	11,490,374
UBS AG	462,749	9,677,877
		49,082,205
Taiwan 0.3%		
Hermes Microvision Inc. GDR (a)	77,642	3,215,155
United Kingdom 7.5%		
AO World PLC (a)	1,033,800	4,119,281
APR Energy PLC	675,318	9,053,193
AstraZeneca PLC	144,000	11,366,534
Crest Nicholson Holdings PLC	2,205,219	12,956,983
Foxtons Group PLC	1,678,587	9,026,843
Metro Bank PLC, (Acquired 1/16/14, (Cost \$5,768,771) (a)(d)	271,008	5,948,376
Nomad Holdings Ltd. (a)	556,597	5,705,119

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Perform Group PLC (a)	1,345,898	4,897,025
Polypipe Group PLC (a)	3,105,291	13,893,802
Poundland Group PLC (a)	382,700	2,245,361
Vodafone Group PLC ADR (b)	173,840	6,598,966
		85,811,483

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**
(Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
United States 47.0%		
AbbVie, Inc. (b)(e)	234,823	\$ 12,229,582
Actavis PLC (a)(b)	28,000	5,721,240
Acuity Brands, Inc. (b)	44,133	5,497,648
Adobe Systems, Inc. (a)(b)	99,600	6,144,324
Alkermes PLC (a)(b)	173,500	8,026,110
Altria Group, Inc. (b)	296,200	11,880,582
American Airlines Group, Inc. (a)(b)	156,800	5,498,976
Apple Inc. (b)(e)	34,284	20,230,646
ARAMARK Holdings Corp.	291,700	8,223,023
Autodesk, Inc. (a)(b)	143,600	6,895,672
BankUnited, Inc.	452,683	14,934,012
Biogen Idec, Inc. (a)(b)	17,300	4,967,176
BioMarin Pharmaceutical, Inc. (a)	113,600	6,614,928
Bristol-Myers Squibb Co. (b)	159,700	7,999,373
Cabot Oil & Gas Corp. (b)(e)	251,809	9,891,058
CBS Corp., Class B (b)	146,100	8,438,736
Charles River Laboratories International, Inc. (a)	151,700	8,149,324
Citigroup, Inc. (b)(e)	380,961	18,251,842
Comcast Corp., Class A (b)	287,600	14,886,176
Concho Resources, Inc. (a)(b)	100,800	13,149,360
Continental Building Products, Inc. (a)	186,795	3,175,515
Covidien PLC (b)	201,800	14,378,250
Crown Holdings, Inc. (a)(b)	155,000	7,311,350
Eastman Chemical Co. (b)	116,700	10,172,739
Eaton Corp. PLC (b)	79,300	5,760,352
Facebook, Inc., Class A (a)(b)	94,600	5,655,188
Flowerserve Corp.	116,900	8,539,545
General Motors Co. (e)	215,300	7,423,544
Genworth Financial, Inc., Class A (a)(b)	369,900	6,602,715
Google, Inc., Class A (a)(b)	24,139	12,911,468
Google, Inc., Class C (a)	24,439	12,871,044
The Hain Celestial Group, Inc. (a)(b)	118,141	10,162,489
Hertz Global Holdings, Inc. (a)(b)	350,900	9,990,123
JPMorgan Chase & Co. (b)	281,115	15,736,818
Kennedy-Wilson Holdings, Inc. (b)	698,600	15,257,424
Las Vegas Sands Corp. (b)	77,900	6,164,227
Lowe's Cos., Inc.	147,200	6,757,952
Merck & Co., Inc. (b)	155,300	9,094,368
Mondelez International, Inc., Class A (b)	345,500	12,317,075
National Oilwell Varco, Inc. (b)	78,400	6,156,752
Oasis Petroleum, Inc. (a)(b)	139,722	6,498,470
Pfizer, Inc. (b)	372,300	11,645,544
Platform Specialty Products Corp. (a)	572,033	11,177,525
Public Service Enterprise Group, Inc.	227,900	9,337,063
Ralph Lauren Corp. (b)	53,400	8,083,158
Roper Industries, Inc. (b)	110,900	15,409,555
Schlumberger Ltd. (b)	91,560	9,297,918
St. Jude Medical, Inc. (b)	137,800	8,746,166
Strategic Growth Bancorp. (Acquired \$3/13/14, Cost \$5,461,690) (a)(d)	438,690	5,461,690
SunPower Corp. (a)(b)(e)	124,645	4,165,636
Textron, Inc. (b)	170,800	6,985,720
United Parcel Service, Inc., Class B (b)	119,800	11,800,300
United Rentals, Inc. (a)(b)	131,128	12,303,740
US Silica Holdings, Inc. (b)	128,700	5,813,379
Varian Medical Systems, Inc. (a)(b)	103,600	8,241,380
Whole Foods Market, Inc. (b)	149,200	7,415,240
WisdomTree Investments, Inc. (a)(b)	932,393	10,526,717

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)****Notes to Schedule of Investments**

- (a) Non-income producing security.
- (b) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.
- (c) Security, or a portion of security, is on loan.
- (d) Restricted securities as to resale. As of April 30, 2014 the Trust held 4.2% of its net assets, with current market value of \$47,584,010 and original cost of \$43,647,257, in these securities.
- (e) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- (f) Convertible security.
- (g) Warrants entitle the Trust to purchase a predetermined number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any.
- (h) Represents the current yield as of report date.
- (i) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares/Beneficial Interest Held at	Net Activity	Shares/Beneficial Interest Held at	Income
Affiliate	October 31, 2013	Activity	April 30, 2014	
BlackRock Liquidity Funds, TempFund, Institutional Class	36,387,584	(27,320,018)	9,067,566	\$ 5,179
BlackRock Liquidity Series, LLC Money Market Series		\$ 9,198,761	\$ 9,198,761	\$ 63,183

- (j) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series, LLC Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

Exchange-traded options purchased as of April 30, 2014 were as follows:

Description	Put/ Strike	Expiration Date	Contracts	Market Value
-------------	----------------	--------------------	-----------	-----------------

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	Call	Price			
Kennedy-Wilson Holdings, Inc.	Call	USD 25.00	5/19/14	368	\$ 9,200

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Bristol-Myers Squibb Co.	Call	USD	56.00	5/02/14	444	\$ (1,332)
Genworth Financial, Inc., Class A	Call	USD	17.50	5/02/14	1,110	(47,175)
JPMorgan Chase & Co.	Call	USD	60.00	5/02/14	236	(472)
Apple Inc.	Call	USD	545.00	5/05/14	1	(4,567)
Citigroup, Inc.	Call	USD	48.50	5/05/14	159	(1,272)
Eaton Corp. PLC	Call	USD	73.00	5/05/14	130	(2,600)
Schlumberger Ltd.	Call	USD	96.00	5/05/14	345	(189,750)
United Rentals, Inc.	Call	USD	95.00	5/05/14	265	(20,861)
American Airlines Group, Inc.	Call	USD	36.50	5/09/14	600	(21,000)
Apple Inc.	Call	USD	535.00	5/09/14	116	(646,120)
Biogen Idec, Inc.	Call	USD	315.00	5/09/14	48	(2,640)
CBS Corp., Class B	Call	USD	59.00	5/09/14	300	(39,750)
Citigroup, Inc.	Call	USD	50.00	5/09/14	500	(3,000)
Genworth Financial, Inc., Class A	Call	USD	18.50	5/09/14	1,110	(10,545)
Schlumberger Ltd.	Call	USD	100.00	5/09/14	200	(42,100)
SunPower Corp.	Call	USD	34.50	5/09/14	230	(14,260)
Whole Foods Market, Inc.	Call	USD	53.00	5/09/14	579	(30,687)
Assicurazioni Generali SpA	Call	EUR	16.50	5/16/14	720	(49,620)
AbbVie, Inc.	Call	USD	55.00	5/19/14	327	(4,905)
Acuity Brands, Inc.	Call	USD	130.00	5/19/14	240	(21,000)
Adobe Systems, Inc.	Call	USD	65.00	5/19/14	548	(31,510)
Alkermes PLC	Call	USD	47.00	5/19/14	630	(64,575)
Altria Group, Inc.	Call	USD	39.00	5/19/14	550	(69,025)
Autodesk, Inc.	Call	USD	50.00	5/19/14	324	(40,986)
Biogen Idec, Inc.	Call	USD	315.00	5/19/14	48	(6,480)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**

Exchange-traded options written as of April 30, 2014 were as follows: (continued)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Bristol-Myers Squibb Co.	Call	USD	57.50	5/19/14	444	\$ (2,442)
Cabot Oil & Gas Corp.	Call	USD	38.75	5/19/14	870	(104,779)
CBS Corp., Class B	Call	USD	65.00	5/19/14	100	(3,000)
Citigroup, Inc.	Call	USD	48.00	5/19/14	700	(46,900)
Concho Resources, Inc.	Call	USD	135.00	5/19/14	289	(55,632)
Covidien PLC	Call	USD	75.00	5/19/14	680	(6,800)
Crown Holdings, Inc.	Call	USD	46.00	5/19/14	440	(64,900)
Eastman Chemical Co.	Call	USD	90.00	5/19/14	642	(22,470)
Google, Inc., Class A	Call	USD	560.00	5/19/14	134	(23,115)
Hertz Global Holdings, Inc.	Call	USD	29.00	5/19/14	975	(68,250)
Hertz Global Holdings, Inc.	Call	USD	30.00	5/19/14	975	(34,125)
Las Vegas Sands Corp.	Call	USD	80.00	5/19/14	217	(34,612)
Las Vegas Sands Corp.	Call	USD	82.50	5/19/14	106	(7,844)
MEG Energy Corp.	Call	CAD	38.00	5/19/14	461	(68,348)
Melco Crown Entertainment Ltd. ADR	Call	USD	38.66	5/19/14	299	(8,222)
Merck & Co., Inc.	Call	USD	57.50	5/19/14	432	(75,600)
Mondelez International, Inc., Class A	Call	USD	35.00	5/19/14	961	(97,061)
Oasis Petroleum, Inc.	Call	USD	45.00	5/19/14	250	(60,000)
Oasis Petroleum, Inc.	Call	USD	48.00	5/19/14	528	(48,840)
Pfizer, Inc.	Call	USD	31.00	5/19/14	517	(31,795)
Ralph Lauren Corp.	Call	USD	160.00	5/19/14	149	(33,152)
Roper Industries, Inc.	Call	USD	135.00	5/19/14	309	(148,320)
St. Jude Medical, Inc.	Call	USD	65.00	5/19/14	383	(31,597)
SunPower Corp.	Call	USD	31.00	5/19/14	233	(66,753)
Textron, Inc.	Call	USD	40.25	5/19/14	215	(33,336)
Textron, Inc.	Call	USD	42.00	5/19/14	110	(7,700)
United Parcel Service, Inc., Class B	Call	USD	97.50	5/19/14	659	(100,827)
United Rentals, Inc.	Call	USD	95.00	5/19/14	235	(44,062)
US Silica Holdings, Inc.	Call	USD	37.00	5/19/14	716	(540,580)
Varian Medical Systems, Inc.	Call	USD	85.00	5/19/14	576	(10,080)
Vodafone Group PLC ADR	Call	USD	38.00	5/19/14	239	(17,328)
WisdomTree Investments, Inc.	Call	USD	15.00	5/19/14	810	(8,100)
Altria Group, Inc.	Call	USD	38.50	5/23/14	550	(96,250)
American Airlines Group, Inc.	Call	USD	37.50	5/23/14	500	(27,500)
Citigroup, Inc.	Call	USD	49.00	5/23/14	579	(24,028)
Comcast Corp., Class A	Call	USD	50.00	5/23/14	942	(194,052)
Eaton Corp. PLC	Call	USD	76.00	5/23/14	307	(6,140)
Pfizer, Inc.	Call	USD	31.00	5/23/14	518	(37,037)
Altria Group, Inc.	Call	USD	38.50	5/30/14	550	(97,350)
Apple Inc.	Call	USD	535.00	5/30/14	116	(647,570)
Baidu, Inc. ADR	Call	USD	170.00	5/30/14	94	(15,181)
Citigroup, Inc.	Call	USD	48.50	5/30/14	157	(11,147)
Comcast Corp., Class A	Call	USD	52.00	5/30/14	640	(50,560)
Facebook, Inc., Class A	Call	USD	63.00	5/30/14	257	(38,550)
JPMorgan Chase & Co.	Call	USD	56.50	5/30/14	436	(35,534)
Merck & Co., Inc.	Call	USD	58.50	5/30/14	432	(65,448)
National Oilwell Varco, Inc.	Call	USD	82.00	5/30/14	432	(19,872)
Pfizer, Inc.	Call	USD	31.50	5/30/14	1,030	(58,195)
St. Jude Medical, Inc.	Call	USD	65.00	6/02/14	383	(52,559)
CBS Corp., Class B	Call	USD	61.00	6/06/14	400	(49,000)
Facebook, Inc., Class A	Call	USD	61.50	6/06/14	263	(61,148)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
SunPower Corp.	Call	USD	35.50	6/06/14	222	\$ (27,417)
Assicurazioni Generali SpA	Call	EUR	17.00	6/20/14	720	(25,588)
AbbVie, Inc.	Call	USD	50.00	6/23/14	964	(298,840)
Baidu, Inc. ADR	Call	USD	175.00	6/23/14	97	(20,952)
The Hain Celestial Group, Inc.	Call	USD	90.00	6/23/14	320	(60,000)
Las Vegas Sands Corp.	Call	USD	80.00	6/23/14	105	(32,025)
Melco Crown Entertainment Ltd. ADR	Call	USD	41.00	6/23/14	290	(14,500)
Ralph Lauren Corp.	Call	USD	165.00	6/23/14	149	(27,938)
Textron, Inc.	Call	USD	40.00	6/23/14	612	(130,356)
United Rentals, Inc.	Call	USD	97.50	6/23/14	235	(65,800)
Vodafone Group PLC ADR	Call	USD	40.00	6/23/14	359	(22,438)
WisdomTree Investments, Inc.	Call	USD	12.50	6/23/14	1,570	(62,800)
Actavis PLC	Call	USD	210.00	8/18/14	154	(172,480)
Total						\$ (5,821,057)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Crest Nicholson Holdings PLC	Morgan Stanley & Co. International PLC	Call	GBP	4.21	5/02/14	223,000	\$ (4)
MEG Energy Corp.	Deutsche Bank AG	Call	CAD	32.50	5/02/14	79,200	(502,999)
BioMarin Pharmaceutical, Inc.	Morgan Stanley & Co. International PLC	Call	USD	80.00	5/05/14	31,600	
Covidien PLC	Bank of America N.A.	Call	USD	70.75	5/05/14	70,800	(59,462)
Mondelez International, Inc., Class A	Credit Suisse International	Call	USD	35.00	5/05/14	94,000	(71,691)
Telefonica Deutschland Holding AG	Deutsche Bank AG	Call	EUR	5.87	5/05/14	136,200	(25,327)
Autodesk, Inc.	Morgan Stanley & Co. International PLC	Call	USD	52.30	5/06/14	46,500	(6,612)
Bayer AG	Credit Suisse International	Call	EUR	97.23	5/06/14	35,000	(164,647)
Roxel SA	Morgan Stanley & Co. International PLC	Call	EUR	18.99	5/06/14	21,000	(452)
Roche Holding AG	Morgan Stanley & Co. International PLC	Call	CHF	267.51	5/06/14	22,000	(4,845)
Societe Generale SA	Credit Suisse International	Call	EUR	48.48	5/06/14	34,000	(1,571)
Societe Generale SA	Goldman Sachs International	Call	EUR	48.34	5/06/14	58,000	(2,807)
ARAMARK Holdings Corp.	UBS AG	Call	USD	29.07	5/07/14	44,300	(5,372)
BankUnited, Inc.	Credit Suisse International	Call	USD	34.78	5/07/14	47,000	(486)
Daimler AG	Morgan Stanley & Co. International PLC	Call	EUR	67.78	5/07/14	21,600	(28,709)
Novartis AG	Deutsche Bank AG	Call	CHF	73.00	5/07/14	35,100	(141,055)
Svenska Cellulosa AB SCA, Class B	Goldman Sachs International	Call	SEK	187.58	5/07/14	70,500	(4,906)
Cemex SAB de CV ADR	Deutsche Bank AG	Call	USD	12.65	5/08/14	126,880	(25,428)
Henkel AG & Co KGaA	Credit Suisse International	Call	EUR	79.58	5/08/14	48,500	(100,193)
Kenedix Office Investment Corp.							
REIT	Morgan Stanley & Co. International PLC	Call	JPY	508,049.83	5/08/14	140	(14,545)
Kennedy-Wilson Holdings, Inc.	Morgan Stanley & Co. International PLC	Call	USD	25.18	5/08/14	36,800	(11)
MEG Energy Corp.	Morgan Stanley & Co. International PLC	Call	CAD	34.88	5/08/14	68,200	(285,435)
NAVER Corp.	UBS AG	Call	KRW	820,910.00	5/08/14	2,600	(3,199)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.93	5/08/14	133,000	(3,632)
SMC Corp.	UBS AG	Call	JPY	25,944.83	5/08/14	6,300	(3,019)
SoftBank Corp.	Morgan Stanley & Co. International PLC	Call	JPY	8,017.98	5/08/14	81,800	(32,863)
Concho Resources, Inc.	Deutsche Bank AG	Call	USD	124.28	5/09/14	26,500	(183,168)
	Goldman Sachs International	Call	USD	42.06	5/09/14	21,400	(23)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Melco Crown Entertainment Ltd.
ADR
Charles River Laboratories
International, Inc.

Citibank N.A.

Call

USD

63.50

5/12/14

42,200

(3)

See Notes to Financial Statements.

66

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Daimler AG	Credit Suisse International	Call	EUR	70.98	5/13/14	42,200	\$ (15,053)
ING Groep NV	Goldman Sachs International	Call	EUR	10.95	5/13/14	142,700	(9,901)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	47.83	5/13/14	29,300	(13)
AIA Group Ltd.	Deutsche Bank AG	Call	HKD	36.88	5/14/14	963,200	(113,272)
Anhui Conch Cement Co. Ltd., Class H	Citibank N.A.	Call	HKD	32.62	5/14/14	540,000	(3,334)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	5/14/14	40	(2,405)
Nabtesco Corp.	Goldman Sachs International	Call	JPY	2,442.35	5/14/14	72,600	(1,229)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.15	5/14/14	297,900	(37,879)
Shinsei Bank Ltd.	Goldman Sachs International	Call	JPY	183.68	5/14/14	1,071,000	(175,682)
Skanska AB, B Shares	Goldman Sachs International	Call	SEK	147.85	5/14/14	78,400	(40,891)
AstraZeneca PLC	Morgan Stanley & Co. International PLC	Call	GBP	38.07	5/15/14	80,000	(1,176,825)
CRH PLC	Morgan Stanley & Co. International PLC	Call	GBP	17.07	5/15/14	57,000	(46,055)
The Hain Celestial Group, Inc.	Citibank N.A.	Call	USD	86.91	5/15/14	32,900	(72,324)
Kennedy-Wilson Holdings, Inc.	Morgan Stanley & Co. International PLC	Call	USD	25.18	5/15/14	36,800	(223)
Naspers Ltd., N Shares	Deutsche Bank AG	Call	ZAR	1,216.95	5/15/14	16,000	(893)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.90	5/15/14	50,000	(3,545)
Svenska Cellulosa AB SCA, Class B	Goldman Sachs International	Call	SEK	187.58	5/15/14	70,500	(10,656)
Telefonica Deutschland Holding AG	Deutsche Bank AG	Call	EUR	5.84	5/15/14	135,000	(35,720)
Telefonica Deutschland Holding AG	Goldman Sachs International	Call	EUR	5.89	5/15/14	113,400	(23,738)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.15	5/20/14	297,900	(42,957)
Anheuser-Busch InBev NV	Morgan Stanley & Co. International PLC	Call	EUR	77.64	5/21/14	32,400	(83,718)
ING Groep NV	Credit Suisse International	Call	EUR	10.32	5/21/14	79,900	(32,256)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	5/21/14	40	(3,399)
Rexel SA	Morgan Stanley & Co. International PLC	Call	EUR	18.70	5/21/14	21,000	(5,304)
Schneider Electric SA	Deutsche Bank AG	Call	EUR	65.15	5/21/14	21,000	(73,158)
ARAMARK Holdings Corp.	Deutsche Bank AG	Call	USD	28.25	5/22/14	59,000	(41,530)
BankUnited, Inc.	Deutsche Bank AG	Call	USD	34.60	5/22/14	66,000	(10,186)
BioMarin Pharmaceutical, Inc.	Morgan Stanley & Co. International PLC	Call	USD	80.00	5/22/14	31,600	(142)
Copa Holdings SA, Class A	Bank of America N.A.	Call	USD	150.39	5/22/14	11,100	(7,852)
Lowe's Cos., Inc.	Morgan Stanley & Co. International PLC	Call	USD	47.17	5/22/14	40,500	(15,317)
Nordea Bank AB	Goldman Sachs International	Call	SEK	94.50	5/22/14	115,000	(22,890)
Vivendi SA	JPMorgan Chase Bank N.A.	Call	EUR	20.24	5/22/14	153,000	(20,568)
Calbee, Inc.	Morgan Stanley & Co. International PLC	Call	JPY	2,505.28	5/27/14	66,000	(45,172)
Cemex SAB de CV ADR	Deutsche Bank AG	Call	USD	12.65	5/27/14	126,880	(47,251)
Charles River Laboratories International, Inc.	Citibank N.A.	Call	USD	63.50	5/27/14	42,200	(444)
China Cinda Asset Management Co. Ltd., Class H	Deutsche Bank AG	Call	HKD	4.33	5/27/14	710,000	(5,784)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.15	5/27/14	297,900	(48,076)
Tokyo Tatemono Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	908.40	5/27/14	284,000	(26,577)
Adecco SA	Morgan Stanley & Co. International PLC	Call	CHF	73.64	5/28/14	32,000	(93,377)
Beijing Enterprises Water Group Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	5.43	5/28/14	2,800,000	(29,476)
Crown Holdings, Inc.	Deutsche Bank AG	Call	USD	46.85	5/28/14	43,000	(45,276)
Foxtons Group PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.75	5/28/14	25,000	(295)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	5/28/14	40	(4,331)
NH Hoteles SA	UBS AG	Call	EUR	5.30	5/28/14	50,000	(1,458)
Sacyr SA	Goldman Sachs International	Call	EUR	5.12	5/28/14	441,000	(55,966)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

67

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Schneider Electric SA	Morgan Stanley & Co. International PLC	Call	EUR	67.37	5/28/14	17,400	\$ (25,176)
Skanska AB, B Shares	Morgan Stanley & Co. International PLC	Call	SEK	152.70	5/28/14	78,500	(27,447)
Statoil ASA	UBS AG	Call	NOK	169.92	5/28/14	34,550	(66,122)
Crest Nicholson Holdings PLC	Credit Suisse International	Call	GBP	3.71	5/29/14	50,000	(2,845)
Kennedy-Wilson Holdings, Inc.	Deutsche Bank AG	Call	USD	25.41	5/29/14	34,000	(1,176)
Nabtesco Corp.	Citibank N.A.	Call	JPY	2,385.00	5/29/14	66,200	(10,267)
Public Service Enterprise Group, Inc.	UBS AG	Call	USD	39.03	5/29/14	63,400	(140,820)
Crest Nicholson Holdings PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.72	6/03/14	36,000	(2,336)
CRH PLC	Morgan Stanley & Co. International PLC	Call	GBP	16.73	6/03/14	46,100	(66,083)
Erste Group Bank AG	Goldman Sachs International	Call	EUR	25.09	6/03/14	55,000	(36,406)
Naspers Ltd., N Shares	Morgan Stanley & Co. International PLC	Call	ZAR	1,180.22	6/03/14	35,400	(27,158)
NH Hoteles SA	Morgan Stanley & Co. International PLC	Call	EUR	5.23	6/03/14	120,000	(4,697)
Rexel SA	Goldman Sachs International	Call	EUR	18.91	6/03/14	64,800	(18,863)
Sacyr SA	Credit Suisse International	Call	EUR	4.84	6/03/14	376,000	(104,722)
Statoil ASA	UBS AG	Call	NOK	169.92	6/03/14	34,550	(66,383)
Vodafone Group PLC ADR	Deutsche Bank AG	Call	USD	37.31	6/03/14	35,900	(49,491)
Adecco SA	Morgan Stanley & Co. International PLC	Call	CHF	71.19	6/04/14	35,500	(155,569)
Beijing Enterprises Water Group Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	5.51	6/04/14	2,800,000	(33,201)
Cabot Oil & Gas Corp.	UBS AG	Call	USD	35.91	6/04/14	51,500	(177,010)
Calbee, Inc.	Morgan Stanley & Co. International PLC	Call	JPY	2,517.56	6/04/14	66,000	(47,726)
Daimler AG	UBS AG	Call	EUR	67.85	6/04/14	16,700	(41,129)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	6/04/14	40	(5,107)
Lowe's Cos., Inc.	Morgan Stanley & Co. International PLC	Call	USD	47.17	6/04/14	40,500	(29,128)
Novo Nordisk A/S, Class B	Deutsche Bank AG	Call	DKK	243.60	6/04/14	62,200	(79,882)
Samsonite International SA	Deutsche Bank AG	Call	HKD	25.31	6/04/14	269,400	(28,769)
Anhui Conch Cement Co. Ltd., Class H	Morgan Stanley & Co. International PLC	Call	HKD	31.76	6/05/14	449,000	(20,522)
Copa Holdings SA, Class A	Bank of America N.A.	Call	USD	150.39	6/05/14	11,100	(10,868)
Nordea Bank AB	Goldman Sachs International	Call	SEK	94.50	6/05/14	115,000	(29,536)
Nordea Bank AB	UBS AG	Call	SEK	92.47	6/05/14	88,800	(37,319)
SMC Corp.	UBS AG	Call	JPY	26,297.43	6/05/14	6,300	(20,442)
Vivendi SA	Goldman Sachs International	Call	EUR	20.15	6/05/14	81,400	(25,532)
Novartis AG	Goldman Sachs International	Call	CHF	74.65	6/06/14	43,200	(124,433)
BankUnited, Inc.	Goldman Sachs International	Call	USD	32.98	6/09/14	66,800	(59,038)
Flowserve Corp.	UBS AG	Call	USD	73.28	6/09/14	32,100	(59,723)
Erste Group Bank AG	Goldman Sachs International	Call	EUR	25.15	6/10/14	67,000	(49,116)
Kennedy-Wilson Holdings, Inc.	Deutsche Bank AG	Call	USD	24.22	6/10/14	48,600	(9,597)
NAVER Corp.	Morgan Stanley & Co. International PLC	Call	KRW	780,000.00	6/10/14	1,646	(45,217)
NH Hoteles SA	Goldman Sachs International	Call	EUR	5.07	6/10/14	133,000	(12,684)
Nordea Bank AB	Bank of America N.A.	Call	SEK	95.60	6/10/14	117,000	(20,622)
Svenska Cellulosa AB SCA, Class B	Deutsche Bank AG	Call	SEK	185.88	6/10/14	111,400	(55,762)
ARAMARK Holdings Corp.	Deutsche Bank AG	Call	USD	28.00	6/11/14	57,200	(62,995)
Kenedix Office Investment Corp. REIT	Bank of America N.A.	Call	JPY	534,220.08	6/11/14	120	(14,541)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	42.78	6/11/14	25,000	(5,917)
Rexel SA	Goldman Sachs International	Call	EUR	18.49	6/11/14	40,000	(21,517)
Societe Generale SA	Goldman Sachs International	Call	EUR	45.26	6/11/14	76,000	(97,784)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Sumitomo Mitsui Financial Group, Inc.	Morgan Stanley & Co. International PLC	Call	JPY	4,284.50	6/11/14	110,800	\$ (60,884)
Tokyo Tatemono Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	849.74	6/11/14	121,000	(38,772)
Nabtesco Corp.	Citibank N.A.	Call	JPY	2,385.00	6/12/14	66,200	(17,153)
Ping An Insurance Group Co. of China Ltd., Class H	UBS AG	Call	HKD	61.76	6/12/14	339,000	(20,871)
Public Service Enterprise Group, Inc.	UBS AG	Call	USD	39.03	6/12/14	63,400	(122,996)
Shinsei Bank Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	207.00	6/12/14	1,092,000	(89,096)
Novo Nordisk A/S, Class B	Goldman Sachs International	Call	DKK	246.64	6/13/14	60,800	(57,040)
UBS AG	Bank of America N.A.	Call	CHF	18.63	6/13/14	254,500	(95,635)
Roper Industries, Inc.	Goldman Sachs International	Call	USD	135.00	6/16/14	30,100	(171,511)
Crest Nicholson Holdings PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.56	6/17/14	50,000	(8,823)
CRH PLC	Goldman Sachs International	Call	GBP	17.45	6/17/14	131,000	(121,978)
Foxtons Group PLC	Bank of America N.A.	Call	GBP	3.25	6/17/14	25,000	(5,188)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.76	6/17/14	100,000	(32,209)
NH Hoteles SA	Morgan Stanley & Co. International PLC	Call	EUR	5.23	6/17/14	120,000	(9,205)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.82	6/17/14	136,800	(21,512)
Suncor Energy, Inc.	UBS AG	Call	CAD	41.78	6/17/14	42,000	(45,568)
Anheuser-Busch InBev NV	Morgan Stanley & Co. International PLC	Call	EUR	79.13	6/18/14	53,800	(120,797)
Anhui Conch Cement Co. Ltd., Class H	UBS AG	Call	HKD	33.07	6/18/14	449,000	(16,452)
Kenedix Office Investment Corp. REIT	Bank of America N.A.	Call	JPY	534,220.08	6/18/14	120	(16,428)
Kennedy-Wilson Holdings, Inc.	Deutsche Bank AG	Call	USD	24.22	6/18/14	48,600	(12,258)
Credicorp Ltd.	Morgan Stanley & Co. International PLC	Call	USD	145.42	6/19/14	22,400	(148,141)
Vivendi SA	Morgan Stanley & Co. International PLC	Call	EUR	19.79	6/24/14	46,500	(23,618)
Tokyo Tatemono Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	849.68	6/25/14	121,000	(47,271)
BankUnited, Inc.	Deutsche Bank AG	Call	USD	33.53	6/26/14	70,000	(57,836)
Shinsei Bank Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	205.92	6/26/14	357,000	(36,622)
Adecco SA	Deutsche Bank AG	Call	CHF	74.44	6/27/14	35,500	(107,245)
Kennedy-Wilson Holdings, Inc.	Deutsche Bank AG	Call	USD	24.22	6/30/14	48,600	(16,160)
Suncor Energy, Inc.	UBS AG	Call	CAD	41.78	6/30/14	42,000	(50,817)
Kennedy-Wilson Holdings, Inc.	Morgan Stanley & Co. International PLC	Call	USD	22.97	7/08/14	32,100	(22,642)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.55	7/08/14	80,000	(37,953)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.00	7/08/14	136,800	(32,652)
Shinsei Bank Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	203.27	7/10/14	357,000	(45,750)
Kennedy-Wilson Holdings, Inc.	Morgan Stanley & Co. International PLC	Call	USD	23.66	7/17/14	33,500	(19,147)
Total							\$ (7,965,770)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets and liabilities or the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

69

Table of Contents**Schedule of Investments (continued)****BlackRock Global Opportunities Equity Trust (BOE)**

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Austria		\$ 9,064,646		\$ 9,064,646
Belgium		16,878,963		16,878,963
Canada	\$ 18,548,433			18,548,433
China	5,338,595	24,248,584		29,587,179
Denmark	3,758,498	10,143,775		13,902,273
France	6,771,976	39,283,065		46,055,041
Germany		47,906,515		47,906,515
Greece		10,059,147		10,059,147
Hong Kong	4,990,280	16,627,273		21,617,553
Indonesia		14,851,300		14,851,300
Ireland	18,131,835	12,273,285		30,405,120
Italy		19,248,170		19,248,170
Japan	5,922,308	54,751,049		60,673,357
Mexico	5,781,435			5,781,435
Netherlands		5,722,224		5,722,224
New Zealand		9,074,516		9,074,516
Norway		3,832,016		3,832,016
Panama	5,397,672			5,397,672
Peru	6,074,475			6,074,475
South Africa		6,047,954		6,047,954
South Korea	1,274,599	5,487,290		6,761,889
Spain		26,890,078		26,890,078
Sweden	11,453,080	19,230,171		30,683,251
Switzerland		49,082,205		49,082,205
Taiwan	3,215,155			3,215,155
United Kingdom	59,469,730	20,393,377	\$ 5,948,376	85,811,483
United States	531,516,237		5,461,690	536,977,927
Investment Companies	5,209,099			5,209,099
Preferred Stocks			27,099,428	27,099,428
Warrants	251,860			251,860
Short-Term Securities	9,067,566	9,198,761		18,266,327
Options Purchased	9,200			9,200
Total	\$ 702,182,033	\$ 430,294,364	\$ 38,509,494	\$ 1,170,985,891

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (5,534,317)	\$ (8,252,510)		\$ (13,786,827)

¹ Derivative financial instruments are options written, which are shown at value.

See Notes to Financial Statements.

70

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (concluded)****BlackRock Global Opportunities Equity Trust (BOE)**

The carrying amount for certain of the Trust's assets and/or liabilities approximates fair value for financial statement purposes. As of April 30, 2014, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 24,330			\$ 24,330
Foreign currency at value	10,988,841			10,988,841
Liabilities:				
Collateral on securities loaned at value		\$ (9,198,761)		(9,198,761)
Total	\$ 11,013,171	\$ (9,198,761)		\$ 1,814,410

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013 the Trust did not utilize the external pricing service model adjustments as significant market movements did not occur. As of April 30, 2014, securities with a value of \$71,210,163 were systematically fair valued due to significant market movements. Therefore, these securities were transferred from Level 1 to Level 2 during the period October 31, 2013 to April 30, 2014.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks	Preferred Stocks	Rights	Total
Assets:				
Opening Balance, as of October 31, 2013				
Transfers into Level 3				
Transfers out of Level 3				
Accrued discounts/premiums				
Net realized gain (loss)				
Net change in unrealized appreciation/depreciation ¹	\$ 179,605			\$ 179,605
Purchases	11,230,461	\$ 23,253,628	\$ 3,845,800	38,329,889
Sales				
Closing Balance, as of April 30, 2014	\$ 11,410,066	\$ 23,253,628	\$ 3,845,800	\$ 38,509,494
Net change in unrealized appreciation/depreciation on investments still held at April 30, 2014	\$ 179,605			\$ 179,605

¹ Included in the related net change in unrealized appreciation/depreciation in the Statement of Operations.

The Trust's investments that are categorized as Level 3 were valued utilizing third party pricing information without adjustment. Such valuations are based on unobservable inputs. A significant change in third party information could result in a significantly lower or higher value of such Level 3 investments.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock Health Sciences Trust (BME)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Biotechnology 24.7%		
ACADIA Pharmaceuticals, Inc. (a)(b)	32,095	\$ 646,072
Accelaron Pharma, Inc. (a)(b)	12,100	415,635
Acorda Therapeutics, Inc. (a)(b)	40,900	1,449,905
Actelion Ltd. (a)	19,300	1,900,156
Adamas Pharmaceuticals, Inc. (a)	6,500	119,925
Aegerion Pharmaceuticals, Inc. (a)(c)	9,000	398,340
Agios Pharmaceuticals, Inc. (a)(b)	8,500	357,510
Akebia Therapeutics, Inc. (a)	5,400	131,598
Alexion Pharmaceuticals, Inc. (a)(b)	50,460	7,982,772
Alkermes PLC (a)(b)	80,300	3,714,678
Amgen, Inc. (b)	47,100	5,263,425
Aquinox Pharmaceuticals, Inc. (a)	6,800	62,084
Array BioPharma, Inc. (a)	88,100	350,638
Biogen Idec, Inc. (a)(b)	34,400	9,876,928
BioMarin Pharmaceutical, Inc. (a)	41,200	2,399,076
Biota Pharmaceuticals, Inc. (a)	38,100	140,589
Bluebird Bio, Inc. (a)	9,300	184,140
Celgene Corp. (a)(b)	50,943	7,489,131
Conatus Pharmaceuticals, Inc. (a)	8,700	53,505
Concert Pharmaceuticals, Inc. (a)	12,400	110,856
Dyax Corp. (a)(b)	55,727	368,356
Epizyme, Inc. (a)	23,300	508,406
Exelixis, Inc. (a)	34,600	122,484
Genomic Health, Inc. (a)	10,700	280,768
Gilead Sciences, Inc. (a)(b)	48,121	3,777,017
Incyte Corp. Ltd. (a)(b)	16,500	801,240
Infinity Pharmaceuticals, Inc. (a)	52,700	514,879
InterMune, Inc. (a)(b)	33,700	1,081,096
Isis Pharmaceuticals, Inc. (a)(b)	32,300	859,503
Karyopharm Therapeutics, Inc. (a)	26,953	723,149
MacroGenics, Inc. (a)	5,300	105,682
Medivation, Inc. (a)	17,900	1,077,759
Neurocrine Biosciences, Inc. (a)(b)	60,062	842,069
Protalix BioTherapeutics, Inc. (a)(c)	122,100	494,505
PTC Therapeutics, Inc. (a)	4,800	93,792
Puma Biotechnology, Inc. (a)(b)	15,300	1,155,762
Regeneron Pharmaceuticals, Inc. (a)(b)	12,758	3,787,723
Seattle Genetics, Inc. (a)(b)	74,867	2,880,882
Tekmira Pharmaceuticals Corp. (a)	25,200	334,908
Ultragenyx Pharmaceutical, Inc. (Acquired 1/31/2014, cost \$384,111) (a)(d)	44,249	1,630,178
uniQure BV (a)	7,000	71,890
Verastem, Inc. (a)	21,800	182,030
Vertex Pharmaceuticals, Inc. (a)	37,005	2,505,240
		67,246,281
Chemicals 0.5%		
Sigma-Aldrich Corp. (b)	14,500	1,395,045
Health Care Equipment & Supplies 16.8%		
Abbott Laboratories (b)	111,500	4,319,510
Alere, Inc. (a)(b)	35,400	1,182,360
AtriCure, Inc. (a)	25,462	392,115
Baxter International, Inc. (b)	18,900	1,375,731
Becton Dickinson and Co. (b)	27,300	3,085,719
Boston Scientific Corp. (a)(b)	331,000	4,173,910
CareFusion Corp. (a)(b)	54,900	2,144,394
Coloplast A/S, Class B	24,800	2,083,027
The Cooper Cos., Inc. (b)	9,200	1,213,572

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Covidien PLC (b)	83,100	5,920,875
DENTSPLY International, Inc. (b)	12,800	571,264
Edwards Lifesciences Corp. (a)(b)	27,500	2,240,425
Medtronic, Inc. (b)	58,800	3,458,616
PW Medtech Group Ltd. (a)	928,400	434,542

Common Stocks	Shares	Value
Health Care Equipment & Supplies (concluded)		
St. Jude Medical, Inc. (b)	65,500	\$ 4,157,285
Stryker Corp. (b)	67,600	5,255,900
Varian Medical Systems, Inc. (a)(b)	28,800	2,291,040
Zimmer Holdings, Inc. (b)	13,300	1,287,440
		45,587,725
Health Care Providers & Services 12.1%		
Aetna, Inc.	32,211	2,301,476
AmerisourceBergen Corp. (b)	10,000	651,800
Cardinal Health, Inc. (b)	58,830	4,089,273
Cigna Corp.	29,100	2,329,164
Envision Healthcare Holdings, Inc. (a)(b)	38,100	1,287,399
Express Scripts Holding Co. (a)(b)	20,776	1,383,266
HCA Holdings, Inc. (a)(b)	75,400	3,920,800
McKesson Corp. (b)	23,600	3,992,884
Premier, Inc., Class A (a)(b)	30,800	924,000
Team Health Holdings, Inc. (a)(b)	28,800	1,396,224
UnitedHealth Group, Inc. (b)	78,734	5,908,199
Universal Health Services, Inc., Class B (b)	39,600	3,238,884
WellPoint, Inc. (b)	16,300	1,641,084
		33,064,453
Health Care Technology 0.7%		
Cerner Corp. (a)	35,300	1,810,890
Life Sciences Tools & Services 5.0%		
Agilent Technologies, Inc. (b)	56,700	3,064,068
Charles River Laboratories International, Inc. (a)(b)	46,500	2,497,980
ICON PLC (a)(b)	23,200	899,464
Illumina, Inc. (a)(b)	28,400	3,858,140
Thermo Fisher Scientific, Inc. (b)	29,900	3,408,600
		13,728,252
Pharmaceuticals 36.5%		
AbbVie, Inc. (b)(e)	164,284	8,555,911
Achaogen, Inc. (a)	16,300	228,526
Actavis PLC (a)(b)	15,500	3,167,115
Allergan, Inc. (b)	26,700	4,427,928
AstraZeneca PLC	38,100	3,007,395
Bayer AG	55,500	7,716,805
Bristol-Myers Squibb Co. (b)	91,100	4,563,199
Chugai Pharmaceutical Co. Ltd.	55,200	1,393,186
Eli Lilly & Co. (b)	81,500	4,816,650
Forest Laboratories, Inc. (a)(b)	39,500	3,630,445
Intra-Cellular Therapies, Inc. (a)	66,181	1,105,223
Johnson & Johnson (b)	115,570	11,706,083
Mallinckrodt PLC (a)(b)	29,500	2,101,285
Merck & Co., Inc. (b)	152,800	8,947,968
Mylan, Inc. (a)(b)	58,700	2,980,786
Novartis AG	88,500	7,693,533
Perrigo Co. PLC (b)	26,500	3,838,790
Pfizer, Inc. (b)	242,200	7,576,016
Phibro Animal Health Corp., Class A (a)	21,000	370,860
Roche Holding AG	14,200	4,165,517
Shire PLC ADR (b)	16,200	2,782,350
Valeant Pharmaceuticals International, Inc. (a)(b)	28,300	3,783,993
Zoetis, Inc. (b)	27,100	820,046
		99,379,610
Total Common Stocks 96.3%		262,212,256

See Notes to Financial Statements.

72

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents

Schedule of Investments (continued)

BlackRock Health Sciences Trust (BME)
(Percentages shown are based on Net Assets)

	Par (000)	Value
Corporate Bonds		
Biotechnology 0.1%		
Kite Pharma, Inc. (Acquired 4/23/2014, cost \$222,000), 6.00%, 10/24/16 (a)(d)	\$ 222	\$ 222,000
Preferred Stocks		
Biotechnology 0.3%		
ProNAi Therapeutics, Inc., Series D (Acquired 4/15/14, cost \$270,735) (a)(d)	386,764	270,735
SAGE Therapeutics, Series C (Acquired 3/10/14, cost \$631,483) (a)(d)	149,128	631,483
		902,218
Total Preferred Stocks 0.3%		902,218
Total Long-Term Investments		
(Cost \$193,466,167) 96.7%		263,336,474
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (f)(g)	Shares	Value
	8,880,290	\$ 8,880,290
	Beneficial	
	Interest	
	(000)	
BlackRock Liquidity Series, LLC Money Market Series, 0.18% (f)(g)(h)	\$ 287	287,000
Total Short-Term Securities		
(Cost \$9,167,290) 3.4%		9,167,290
Total Investments Before Options Written		
(Cost \$202,633,457) 100.1%		272,503,764
Options Written		
(Premiums Received \$2,086,319) (0.7)%		(2,030,854)
Total Investments Net of Options Written 99.4%		270,472,910
Other Assets Less Liabilities 0.6%		1,710,550
Net Assets 100.0%		\$ 272,183,460

Notes to Schedule of Investments

(a) Non-income producing security.

(b) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

(c) Security, or a portion of security, is on loan.

(d) Restricted securities as to resale. As of April 30, 2014 the Trust held 1.0% of its net assets, with current market value of \$2,754,396 and the original cost of \$1,508,329, in these securities.

(e) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(f) Represents the current yield as of report date.

(g) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares/Beneficial Interest Held at October 31, 2013	Net Activity	Shares/Beneficial Interest Held at April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	1,144,662	7,735,628	8,880,290	\$ 1,515
BlackRock Liquidity Series, LLC Money Market Series		\$ 287,000	\$ 287,000	\$ 359

(h) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series, LLC Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
Alexion Pharmaceuticals, Inc.	Call	USD 170.00	5/02/14	160	\$ (3,600)
Johnson & Johnson	Call	USD 98.00	5/05/14	30	(9,450)
Medtronic, Inc.	Call	USD 60.00	5/05/14	55	(220)
Pfizer, Inc.	Call	USD 31.00	5/05/14	250	(9,500)
Pfizer, Inc.	Call	USD 33.00	5/05/14	197	(197)
Zoetis, Inc.	Call	USD 31.50	5/05/14	94	(940)
Biogen Idec, Inc.	Call	USD 315.00	5/09/14	60	(3,300)
Celgene Corp.	Call	USD 147.00	5/09/14	178	(46,458)
Medtronic, Inc.	Call	USD 61.50	5/09/14	75	(525)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Health Sciences Trust (BME)**

Exchange-traded options written as of April 30, 2014 were as follows: (continued)

Description	Put/	Strike	Expiration	Contracts	Market
	Call	Price	Date		
Merck & Co., Inc.	Call	USD 57.00	5/09/14	166	\$ (30,212)
UnitedHealth Group, Inc.	Call	USD 83.00	5/09/14	120	(480)
Abbott Laboratories	Call	USD 39.00	5/19/14	195	(7,118)
Abbott Laboratories	Call	USD 40.00	5/19/14	195	(1,755)
AbbVie, Inc.	Call	USD 55.00	5/19/14	18	(270)
ACADIA Pharmaceuticals, Inc.	Call	USD 30.00	5/19/14	100	(2,500)
ACADIA Pharmaceuticals, Inc.	Call	USD 32.00	5/19/14	20	(300)
Acceleron Pharma, Inc.	Call	USD 45.00	5/19/14	40	(4,600)
Agilent Technologies, Inc.	Call	USD 62.50	5/19/14	196	(1,078)
Agios Pharmaceuticals, Inc.	Call	USD 50.00	5/19/14	18	(1,215)
Alere, Inc.	Call	USD 38.00	5/19/14	123	(3,075)
Alkermes PLC	Call	USD 47.00	5/19/14	200	(20,500)
Allergan, Inc.	Call	USD 140.00	5/19/14	94	(237,348)
AmerisourceBergen Corp.	Call	USD 67.50	5/19/14	35	(875)
Amgen, Inc.	Call	USD 125.00	5/19/14	65	(195)
Baxter International, Inc.	Call	USD 72.50	5/19/14	66	(7,095)
Becton Dickinson and Co.	Call	USD 115.00	5/19/14	21	(2,100)
Becton Dickinson and Co.	Call	USD 120.00	5/19/14	30	(375)
Biogen Idec, Inc.	Call	USD 315.00	5/19/14	56	(7,560)
Boston Scientific Corp.	Call	USD 14.00	5/19/14	459	(1,377)
Bristol-Myers Squibb Co.	Call	USD 52.50	5/19/14	319	(11,644)
Cardinal Health, Inc.	Call	USD 70.00	5/19/14	205	(25,112)
CareFusion Corp.	Call	USD 43.00	5/19/14	100	(2,500)
Charles River Laboratories International, Inc.	Call	USD 60.00	5/19/14	85	(850)
The Cooper Cos., Inc.	Call	USD 130.00	5/19/14	32	(11,520)
Covidien PLC	Call	USD 72.50	5/19/14	138	(6,210)
DENTSPLY International, Inc.	Call	USD 45.00	5/19/14	45	(3,712)
Dyax Corp.	Call	USD 10.00	5/19/14	100	(1,000)
Edwards Lifesciences Corp.	Call	USD 80.00	5/19/14	48	(13,200)
Edwards Lifesciences Corp.	Call	USD 82.50	5/19/14	60	(8,400)
Eli Lilly & Co.	Call	USD 60.00	5/19/14	285	(14,678)
Forest Laboratories, Inc.	Call	USD 95.00	5/19/14	138	(9,315)
Gilead Sciences, Inc.	Call	USD 82.50	5/19/14	84	(5,586)
HCA Holdings, Inc.	Call	USD 52.50	5/19/14	129	(12,578)
ICON PLC	Call	USD 50.00	5/19/14	80	(2,000)
Illumina, Inc.	Call	USD 170.00	5/19/14	120	(2,400)
Incyte Corp. Ltd.	Call	USD 60.00	5/19/14	57	(3,705)
InterMune, Inc.	Call	USD 33.00	5/19/14	59	(12,360)
Isis Pharmaceuticals, Inc.	Call	USD 50.00	5/19/14	75	(750)
Johnson & Johnson	Call	USD 100.00	5/19/14	300	(58,350)
McKesson Corp.	Call	USD 175.00	5/19/14	82	(11,070)
Merck & Co., Inc.	Call	USD 57.50	5/19/14	64	(11,200)
Mylan, Inc.	Call	USD 55.00	5/19/14	120	(6,780)
Mylan, Inc.	Call	USD 57.50	5/19/14	110	(2,860)
Neurocrine Biosciences, Inc.	Call	USD 19.00	5/19/14	210	(5,250)
Pfizer, Inc.	Call	USD 31.00	5/19/14	212	(13,038)
Premier, Inc., Class A	Call	USD 35.00	5/19/14	55	(825)
Puma Biotechnology, Inc.	Call	USD 135.00	5/19/14	26	(11,960)
Seattle Genetics, Inc.	Call	USD 55.00	5/19/14	130	(2,275)
St. Jude Medical, Inc.	Call	USD 65.00	5/19/14	115	(9,488)
Stryker Corp.	Call	USD 80.00	5/19/14	118	(4,130)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Health Sciences Trust (BME)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/	Strike	Expiration	Contracts	Market Value
	Call	Price	Date		
Universal Health Services, Inc., Class B	Call	USD 80.00	5/19/14	135	\$ (43,875)
Varian Medical Systems, Inc.	Call	USD 85.00	5/19/14	100	(1,750)
WellPoint, Inc.	Call	USD 97.50	5/19/14	55	(20,625)
Zimmer Holdings, Inc.	Call	USD 95.00	5/19/14	32	(8,800)
Pfizer, Inc.	Call	USD 31.00	5/23/14	212	(15,158)
Regeneron Pharmaceuticals, Inc.	Call	USD 312.50	5/23/14	40	(22,800)
Regeneron Pharmaceuticals, Inc.	Call	USD 325.00	5/23/14	4	(1,140)
Express Scripts Holding Co.	Call	USD 72.00	5/30/14	36	(306)
HCA Holdings, Inc.	Call	USD 53.50	5/30/14	135	(11,475)
Mallinckrodt PLC	Call	USD 72.00	5/30/14	104	(41,080)
Medtronic, Inc.	Call	USD 59.00	5/30/14	75	(8,550)
Merck & Co., Inc.	Call	USD 58.50	5/30/14	304	(46,056)
St. Jude Medical, Inc.	Call	USD 65.00	6/02/14	115	(15,781)
Sigma-Aldrich Corp.	Call	USD 97.15	6/04/14	50	(5,391)
Gilead Sciences, Inc.	Call	USD 77.00	6/06/14	85	(32,938)
Johnson & Johnson	Call	USD 101.00	6/06/14	75	(12,638)
UnitedHealth Group, Inc.	Call	USD 78.00	6/06/14	155	(8,448)
AbbVie, Inc.	Call	USD 50.00	6/23/14	556	(172,360)
Acorda Therapeutics, Inc.	Call	USD 38.00	6/23/14	150	(18,750)
Becton Dickinson and Co.	Call	USD 115.00	6/23/14	45	(7,762)
CareFusion Corp.	Call	USD 41.00	6/23/14	93	(5,580)
Envision Healthcare Holdings, Inc.	Call	USD 35.00	6/23/14	130	(15,275)
InterMune, Inc.	Call	USD 35.00	6/23/14	59	(16,078)
Perrigo Co. PLC	Call	USD 165.00	6/23/14	95	(13,775)
Premier, Inc., Class A	Call	USD 35.00	6/23/14	54	(1,350)
Puma Biotechnology, Inc.	Call	USD 125.00	6/23/14	30	(7,425)
Seattle Genetics, Inc.	Call	USD 45.00	6/23/14	132	(14,850)
Shire PLC ADR	Call	USD 165.00	6/23/14	45	(63,675)
Stryker Corp.	Call	USD 85.00	6/23/14	119	(2,380)
Team Health Holdings, Inc.	Call	USD 50.00	6/23/14	100	(13,500)
Thermo Fisher Scientific, Inc.	Call	USD 120.00	6/23/14	104	(17,940)
Valeant Pharmaceuticals International, Inc.	Call	USD 145.00	6/23/14	110	(33,550)
Zimmer Holdings, Inc.	Call	USD 95.00	6/23/14	32	(12,160)
Actavis PLC	Call	USD 210.00	8/18/14	54	(60,480)
Total					\$ (1,462,665)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/	Strike	Expiration	Contracts	Market Value
		Call	Price	Date		
BioMarin Pharmaceutical, Inc.	Morgan Stanley & Co. International PLC	Call	USD 80.00	5/05/14	9,100	\$
Covidien PLC	Bank of America N.A.	Call	USD 70.75	5/05/14	15,200	(12,766)
Bayer AG	Credit Suisse International	Call	EUR 98.50	5/06/14	900	(3,151)
Roche Holding AG	Morgan Stanley & Co. International PLC	Call	CHF 267.51	5/06/14	5,000	(1,100)
Chugai Pharmaceutical Co. Ltd.	Citibank N.A.	Call	JPY 2,621.40	5/08/14	19,100	(4,317)
PW Medtech Group Ltd.	Bank of America N.A.	Call	HKD 3.83	5/08/14	162,500	(565)
Charles River Laboratories International, Inc.	Citibank N.A.	Call	USD 63.50	5/12/14	3,900	

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

AstraZeneca PLC	Credit Suisse International	Call	GBP	42.04	5/15/14	6,300	(50,714)
AstraZeneca PLC	Morgan Stanley & Co. International PLC	Call	GBP	38.07	5/15/14	7,000	(102,972)
Novartis AG	Credit Suisse International	Call	CHF	74.44	5/21/14	15,550	(42,782)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

75

Table of Contents**Schedule of Investments (continued)****BlackRock Health Sciences Trust (BME)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/	Strike	Expiration		Contracts	Market Value
		Call	Price	Date			
BioMarin Pharmaceutical, Inc.	Morgan Stanley & Co. International PLC	Call	USD 80.00	5/22/14		9,100	\$ (41)
Intra-Cellular Therapies, Inc.	UBS AG	Call	USD 16.91	5/23/14		23,100	(19,259)
Karyopharm Therapeutics, Inc.	UBS AG	Call	USD 34.25	5/23/14		9,400	(3,415)
Charles River Laboratories International, Inc.	Citibank N.A.	Call	USD 63.50	5/27/14		3,900	(41)
Boston Scientific Corp.	Morgan Stanley & Co. International PLC	Call	USD 13.79	5/28/14		25,000	(2,753)
Boston Scientific Corp.	Barclays Bank PLC	Call	USD 13.83	6/04/14		45,000	(2,980)
Bayer AG	Credit Suisse International	Call	EUR 93.80	6/06/14		19,400	(203,659)
Novartis AG	Goldman Sachs International	Call	CHF 74.65	6/06/14		15,500	(44,646)
Actelion Ltd.	UBS AG	Call	CHF 89.37	6/11/14		3,300	(9,435)
Coloplast A/S, Class B	Goldman Sachs International	Call	DKK 424.57	6/12/14		8,600	(52,130)
Actelion Ltd.	UBS AG	Call	CHF 89.37	6/25/14		3,300	(11,463)
Total							\$ (568,189)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Long-Term Investments:

Common Stocks:

Biotechnology	\$ 63,715,947	\$ 3,530,334		\$ 67,246,281
Chemicals	1,395,045			1,395,045
Health Care Equipment & Supplies	43,070,156	2,517,569		45,587,725
Health Care Providers & Services	33,064,453			33,064,453
Health Care Technology	1,810,890			1,810,890
Life Sciences Tools & Services	13,728,252			13,728,252
Pharmaceuticals	75,403,174	23,976,436		99,379,610
Corporate Bonds			\$ 222,000	222,000
Preferred Stocks			902,218	902,218
Short-Term Securities	8,880,290	287,000		9,167,290
Total	\$ 241,068,207	\$ 30,311,339	\$ 1,124,218	\$ 272,503,764

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (concluded)****BlackRock Health Sciences Trust (BME)**

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (1,441,492)	\$ (589,362)		\$ (2,030,854)

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets and/or liabilities approximates fair value for financial statement purposes. As of April 30, 2014, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 22,182			\$ 22,182
Foreign currency at value	120,537			120,537
Cash collateral on exchange-traded options written	1,892,100			1,892,100
Liabilities:				
Collateral on securities loaned at value		\$ (287,000)		(287,000)
Total	\$ 2,034,819	\$ (287,000)		\$ 1,747,819

The Trust's investments that are categorized as Level 3 were valued utilizing third party pricing information without adjustment. Such valuations are based on unobservable inputs. A significant change in third party information inputs could result in a significantly lower or higher value of such Level 3 investments.

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013, securities with a value of \$3,620,423 were systematically fair valued due to significant market movements, but were not valued using systematic fair values as of April 30, 2014. Therefore, these securities were transferred from Level 2 to Level 1 during the period October 31, 2013 to April 30, 2014.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments** April 30, 2014

(Unaudited)

BlackRock International Growth and Income Trust (BGY)
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Austria 1.0%		
Erste Group Bank AG	304,601	\$ 10,242,001
Belgium 1.7%		
Anheuser-Busch InBev NV	154,646	16,855,747
Brazil 0.8%		
Banco Bradesco SA ADR	180,800	2,688,496
Petroleo Brasileiro SA ADR (a)	376,000	5,218,880
		7,907,376
Canada 3.3%		
Gildan Activewear, Inc. (a)	108,700	5,556,736
MEG Energy Corp. (a)(b)	299,500	10,782,601
Suncor Energy, Inc.	129,600	4,999,305
Tourmaline Oil Corp. (a)(b)	218,472	11,311,789
		32,650,431
China 4.1%		
Anhui Conch Cement Co. Ltd., Class H (c)	2,802,940	10,465,482
Baidu, Inc. ADR (a)(b)	45,720	7,034,022
Beijing Enterprises Water Group Ltd.	5,846,000	3,715,426
China Cinda Asset Management Co. Ltd., Class H (b)	10,010,000	5,048,224
Great Wall Motor Co. Ltd., Class H	994,000	4,500,145
Ping An Insurance Group Co. of China Ltd., Class H	1,281,000	9,507,746
		40,271,045
Denmark 3.0%		
Chr Hansen Holding A/S	217,809	9,819,874
ISS A/S (b)	143,007	4,978,664
Novo Nordisk A/S, Class B	319,500	14,500,833
		29,299,371
Finland 1.5%		
Nokia OYJ (b)	1,296,070	9,704,410
Sanitec Corp. (b)	438,669	5,056,589
		14,760,999
France 7.4%		
BNP Paribas SA	112,199	8,431,125
Publicis Groupe SA	123,200	10,539,658
Rexel SA	440,176	11,114,322
Schneider Electric SA	106,600	10,006,633
Societe Generale SA	216,300	13,470,546
Vivendi SA	699,870	18,803,212
		72,365,496
Germany 7.5%		
Aixtron SE (b)	402,776	6,412,871
Bayer AG	135,600	18,854,032
Daimler AG	181,600	16,906,778
DMG MORI SEIKI AG	129,154	4,069,826
OSRAM Licht AG (b)	227,496	11,943,378
ProSiebenSat.1 Media AG	219,800	9,620,163
Telefonica Deutschland Holding AG	587,200	4,885,169
		72,692,217
Greece 0.8%		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Alpha Bank AE (b)	7,649,311	7,409,495
Hong Kong 2.0%		
AIA Group Ltd.	2,101,552	10,221,097
ASM Pacific Technology Ltd.	172,400	1,916,803
Samsonite International SA	2,411,100	7,661,035
		19,798,935
India 1.0%		
Tata Motors Ltd. ADR (a)	252,400	9,444,808
Common Stocks	Shares	Value
Indonesia 1.2%		
Global Mediacom Tbk PT	23,331,202	\$ 4,428,805
Matahari Department Store Tbk PT (b)	5,498,413	7,144,318
		11,573,123
Ireland 5.8%		
CRH PLC	487,600	14,214,854
Dalata Hotel Group PLC (b)	1,128,668	4,556,637
Green REIT PLC (b)	9,321,118	15,517,955
Kingspan Group PLC	311,013	5,846,596
Ryanair Holdings PLC ADR (a)(b)	167,500	8,957,900
Shire PLC	132,700	7,589,335
		56,683,277
Italy 3.0%		
Banca Generali SpA	229,700	7,230,323
Intesa Sanpaolo SpA (a)	2,514,800	8,605,710
Moncler SpA (b)	276,500	4,868,806
UniCredit SpA (a)	912,951	8,156,776
		28,861,615
Japan 12.6%		
Calbee, Inc.	313,400	7,675,978
Kenedix Office Investment Corp. REIT	2,144	10,710,284
LIXIL Group Corp.	277,400	7,334,203
Makita Corp.	177,900	9,431,388
Mitsui Osk Lines Ltd.	1,254,000	4,183,430
Nabtesco Corp.	617,300	13,326,488
Shinsei Bank Ltd.	5,111,000	9,964,523
SMC Corp.	53,300	12,688,374
SoftBank Corp.	201,700	15,022,216
Sumitomo Mitsui Financial Group, Inc.	393,600	15,559,131
Tokyo Tatemono Co. Ltd.	1,057,500	8,433,350
Yaskawa Electric Corp.	712,200	8,030,525
		122,359,890
Malaysia 0.2%		
Genting Malaysia Bhd	1,334,100	1,724,055
Mexico 1.0%		
Cemex SAB de CV ADR (a)(b)	774,348	9,787,759
Netherlands 2.7%		
Aalberts Industries NV	215,052	7,163,757
ING Groep NV (b)	588,500	8,412,513
Randstad Holding NV	192,565	11,253,426
		26,829,696
New Zealand 0.8%		
Xero Ltd. (Acquired 10/15/13, cost \$4,566,935) (b)(d)	300,605	7,793,842
Norway 1.4%		
Statoil ASA	460,300	14,032,435
Panama 0.5%		
Copa Holdings SA, Class A	34,300	4,640,104
Peru 0.3%		
Credicorp Ltd.	17,400	2,596,950
South Africa 0.5%		
Naspers Ltd., N Shares	49,700	4,696,614
South Korea 0.9%		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Hyundai Development Co.	129,200	3,694,822
NAVER Corp.	7,100	5,112,829
		8,807,651
Spain 2.6%		
NH Hoteles SA (b)	2,166,978	13,844,485

See Notes to Financial Statements.

Table of Contents

Schedule of Investments (continued)

BlackRock International Growth and Income Trust (BGY)
(Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
Spain (concluded)		
Sacyr SA (b)(c)	1,766,550	\$ 11,635,202
		25,479,687
Sweden 3.2%		
Nordea Bank AB	481,636	6,959,137
Seamless Distribution AB (b)(c)	392,670	1,977,344
Skanska AB, B Shares	335,240	7,696,876
Svenska Cellulosa AB SCA, Class B	509,150	14,313,757
		30,947,114
Switzerland 10.0%		
Actelion Ltd. (b)	115,715	11,392,567
Adecco SA	146,200	12,273,789
Novartis AG	384,000	33,382,109
Roche Holding AG	105,023	30,808,108
UBS AG	480,753	10,054,411
		97,910,984
Taiwan 1.1%		
Epistar Corp.	3,636,000	7,956,861
Hermes Microvision Inc. GDR (b)	67,534	2,796,583
		10,753,444
Turkey 0.6%		
Turkiye Halk Bankasi AS	836,059	5,582,833
United Kingdom 15.2%		
AO World PLC (b)	1,058,900	4,219,295
APR Energy PLC (c)	860,234	11,532,144
AstraZeneca PLC	250,100	19,741,459
Babcock International Group PLC	521,300	10,521,854
Crest Nicholson Holdings PLC	2,055,019	12,074,468
DS Smith PLC	1,918,749	10,225,065
Foxtons Group PLC	2,068,184	11,121,957
Halma PLC	782,300	7,432,413
Hargreaves Lansdown PLC	213,277	4,221,948
Imperial Tobacco Group PLC	239,300	10,341,157
Metro Bank PLC, (Acquired 1/15/14, cost \$4,917,700) (b)(d)	231,026	5,070,808
Monitise PLC (b)	6,767,500	7,657,097
Nomad Holdings Ltd. (b)	475,571	4,874,603
Perform Group PLC (b)	1,499,974	5,457,628
Polypipe Group PLC (b)	2,626,409	11,751,171
Poundland Group PLC (b)	334,400	1,961,977
Rio Tinto PLC	176,600	9,601,292
		147,806,336
Common Stocks	Shares	Value
United States 1.1%		
Euronet Worldwide, Inc. (a)(b)(e)	115,207	\$ 5,298,370
Schlumberger Ltd. (a)	49,480	5,024,694
		10,323,064
Total Common Stocks 98.8%		962,888,394
Investment Companies 0.8%		
United Kingdom 0.8%		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Kennedy Wilson Europe Real Estate PLC (b)	429,439	7,395,620
Rights		
United Kingdom 0.2%		
Babcock International Group PLC, Expires 6/06/14 (b)	204,307	1,379,800
Warrants (f)		
United Kingdom 0.0%		
Nomad Holdings Ltd., Expires 4/10/17 (b)	475,571	215,196
Total Long-Term Investments		
(Cost \$876,743,346) 99.8%		971,879,010
	Beneficial Interest (000)	
Short-Term Securities		
BlackRock Liquidity Series, LLC Money Market Series, 0.18% (g)(h)(i)	\$ 10,178	10,177,930
Total Short-Term Securities		
(Cost \$10,177,930) 1.0%		10,177,930
Total Investments Before Options Written		
(Cost \$886,921,276) 100.8%		982,056,940
Options Written		
(Premiums Received \$12,221,364) (1.3)%		(12,305,555)
Total Investments Net of Options Written 99.5%		969,751,385
Other Assets Less Liabilities 0.5%		4,685,181
Net Assets 100.0%		\$ 974,436,566

Notes to Schedule of Investments

(a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(b) Non-income producing security.

(c) Security, or a portion of security, is on loan.

(d) Restricted securities as to resale. As of April 30, 2014 the Trust held 1.3% of its net assets, with a current market value of \$12,864,650 and its original cost of \$9,484,635, in the security,.

(e) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(f) Warrants entitle the Trust to purchase a predetermined number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

(g) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares/Beneficial		Shares/Beneficial		Income
	Interest Held at	Net	Interest Held at		
Affiliate	October 31, 2013	Activity	April 30, 2014		
BlackRock Liquidity Funds, TempFund, Institutional Class	22,346,730	(22,346,730)			\$ 4,500
BlackRock Liquidity Series, LLC, Money Market Series		\$ 10,177,930	\$ 10,177,930		\$ 48,630

(h) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series, LLC Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

(i) Represents the current yield as of report date.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration		Contracts	Market Value
		Price		Date			
Baidu, Inc. ADR	Call	USD	170.00	5/02/14		85	\$ (340)
Schlumberger Ltd.	Call	USD	97.00	5/05/14		100	(45,000)
Schlumberger Ltd.	Call	USD	100.00	5/09/14		70	(14,735)
Intesa Sanpaolo SpA	Call	EUR	2.40	5/16/14		705	(94,507)
UniCredit SpA	Call	EUR	6.60	5/16/14		155	(26,356)
UniCredit SpA	Call	EUR	6.80	5/16/14		155	(12,950)
UniCredit SpA	Call	EUR	7.00	5/16/14		79	(4,669)
Cemex SAB de CV ADR	Call	USD	12.50	5/19/14		1,650	(68,640)
Euronet Worldwide, Inc.	Call	USD	45.00	5/19/14		465	(80,213)
Gildan Activewear, Inc.	Call	CAD	56.00	5/19/14		305	(46,889)
MEG Energy Corp.	Call	CAD	38.00	5/19/14		397	(58,859)
Petroleo Brasileiro SA ADR	Call	USD	15.00	5/19/14		1,035	(17,078)
Ryanair Holdings PLC ADR	Call	USD	60.00	5/19/14		280	(19,600)
Schlumberger Ltd.	Call	USD	97.50	5/19/14		100	(43,500)
Tata Motors Ltd. ADR	Call	USD	35.00	5/19/14		250	(67,500)
Tata Motors Ltd. ADR	Call	USD	36.00	5/19/14		260	(52,650)
Tata Motors Ltd. ADR	Call	USD	37.00	5/19/14		385	(52,938)
Tourmaline Oil Corp.	Call	CAD	52.00	5/19/14		616	(272,579)
Baidu, Inc. ADR	Call	USD	170.00	5/30/14		89	(14,375)
Intesa Sanpaolo SpA	Call	EUR	2.50	6/20/14		705	(69,926)
UniCredit SpA	Call	EUR	6.80	6/20/14		56	(10,292)
UniCredit SpA	Call	EUR	7.00	6/20/14		56	(6,979)
Baidu, Inc. ADR	Call	USD	175.00	6/23/14		82	(17,712)
Cemex SAB de CV ADR	Call	USD	13.00	6/23/14		1,500	(57,750)
Euronet Worldwide, Inc.	Call	USD	45.00	6/23/14		180	(46,350)
Gildan Activewear, Inc.	Call	CAD	58.00	6/23/14		305	(32,001)
Petroleo Brasileiro SA ADR	Call	USD	15.00	6/23/14		1,035	(43,470)
Tata Motors Ltd. ADR	Call	USD	38.00	6/23/14		269	(46,403)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Tata Motors Ltd. ADR	Call	USD	38.00	7/21/14	250	(53,125)
Tourmaline Oil Corp.	Call	CAD	54.00	7/21/14	610	(214,269)
Total						\$ (1,591,655)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
Crest Nicholson Holdings PLC	Morgan Stanley & Co. International PLC	Call	GBP 4.21	5/02/14	200,000	\$ (3)
MEG Energy Corp.	Deutsche Bank AG	Call	CAD 32.50	5/02/14	68,800	(436,949)
Ryanair Holdings PLC ADR	Morgan Stanley & Co. International PLC	Call	USD 58.55	5/02/14	25,400	
AstraZeneca PLC	Credit Suisse International	Call	GBP 40.19	5/05/14	46,800	(518,594)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
AstraZeneca PLC	Goldman Sachs International	Call	GBP	40.28	5/05/14	12,600	\$ (137,688)
AstraZeneca PLC	Goldman Sachs International	Call	GBP	41.33	5/05/14	25,000	(228,648)
DMG MORI SEIKI AG	Goldman Sachs International	Call	EUR	22.51	5/05/14	72,600	(45,652)
DS Smith PLC	Société Générale	Call	GBP	3.20	5/05/14	180,000	(5,738)
Telefonica Deutschland Holding AG	Deutsche Bank AG	Call	EUR	5.87	5/05/14	116,200	(21,608)
UBS AG	Morgan Stanley & Co. International PLC	Call	CHF	18.83	5/05/14	132,200	(11,689)
Aalberts Industries NV	Goldman Sachs International	Call	EUR	24.41	5/06/14	23,900	(2,827)
Adecco SA	Morgan Stanley & Co. International PLC	Call	CHF	74.08	5/06/14	20,400	(25,236)
Bayer AG	Credit Suisse International	Call	EUR	98.50	5/06/14	6,500	(22,758)
Bayer AG	Goldman Sachs International	Call	EUR	96.56	5/06/14	6,200	(34,741)
ProSiebenSat.1 Media AG	Morgan Stanley & Co. International PLC	Call	EUR	33.59	5/06/14	50,000	(2,281)
Rexel SA	Morgan Stanley & Co. International PLC	Call	EUR	18.99	5/06/14	46,000	(989)
Rio Tinto PLC	Credit Suisse International	Call	GBP	33.24	5/06/14	35,700	(5,809)
Roche Holding AG	Morgan Stanley & Co. International PLC	Call	CHF	267.51	5/06/14	59,000	(12,997)
Societe Generale SA	Goldman Sachs International	Call	EUR	48.34	5/06/14	43,800	(2,120)
Chr Hansen Holding A/S	Morgan Stanley & Co. International PLC	Call	DKK	221.00	5/07/14	31,000	(124,251)
Daimler AG	Morgan Stanley & Co. International PLC	Call	EUR	67.78	5/07/14	35,500	(47,183)
Halma PLC	Deutsche Bank AG	Call	GBP	6.28	5/07/14	40,000	(1)
Hargreaves Lansdown PLC	Morgan Stanley & Co. International PLC	Call	GBP	13.91	5/07/14	59,000	(1)
Kingspan Group PLC	Credit Suisse International	Call	EUR	14.76	5/07/14	13,000	(30)
Novartis AG	Deutsche Bank AG	Call	CHF	73.00	5/07/14	38,400	(154,316)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	48.27	5/07/14	13,000	(1)
Randstad Holding NV	Goldman Sachs International	Call	EUR	44.48	5/07/14	29,300	(5,772)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/07/14	64,750	(157,939)
Svenska Cellulosa AB SCA, Class B	Goldman Sachs International	Call	SEK	187.58	5/07/14	74,500	(5,184)
Cemex SAB de CV ADR	Deutsche Bank AG	Call	USD	12.65	5/08/14	52,000	(10,421)
Epistar Corp.	Citibank N.A.	Call	TWD	72.81	5/08/14	853,000	(1,314)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	508,049.83	5/08/14	130	(13,506)
Makita Corp.	Bank of America N.A.	Call	JPY	5,865.00	5/08/14	97,800	(9,213)
MEG Energy Corp.	Morgan Stanley & Co. International PLC	Call	CAD	34.88	5/08/14	56,200	(235,212)
Nabtesco Corp.	Citibank N.A.	Call	JPY	2,552.70	5/08/14	111,600	(8)
NAVER Corp.	UBS AG	Call	KRW	820,910.00	5/08/14	2,500	(3,076)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.93	5/08/14	114,000	(3,114)
Ping An Insurance Group Co. of China Ltd., Class H	Morgan Stanley & Co. International PLC	Call	HKD	63.73	5/08/14	92,000	(25)
Randstad Holding NV	Morgan Stanley & Co. International PLC	Call	EUR	44.01	5/08/14	27,800	(9,603)
Samsonite International SA	Deutsche Bank AG	Call	HKD	21.36	5/08/14	477,000	(202,658)
SMC Corp.	Bank of America N.A.	Call	JPY	26,101.80	5/08/14	3,800	(1,389)
SMC Corp.	Bank of America N.A.	Call	JPY	28,747.30	5/08/14	5,300	(5)
SMC Corp.	UBS AG	Call	JPY	25,944.83	5/08/14	10,600	(5,079)
SoftBank Corp.	Citibank N.A.	Call	JPY	7,749.93	5/08/14	38,000	(44,219)
SoftBank Corp.	Morgan Stanley & Co. International PLC	Call	JPY	8,017.98	5/08/14	136,600	(54,878)
UBS AG	Goldman Sachs International	Call	CHF	18.92	5/08/14	132,200	(14,617)
Ryanair Holdings PLC ADR	Morgan Stanley & Co. International PLC	Call	USD	56.45	5/12/14	14,700	(2,523)
Aalberts Industries NV	Morgan Stanley & Co. International PLC	Call	EUR	25.68	5/13/14	24,600	(573)
Daimler AG	Credit Suisse International	Call	EUR	70.98	5/13/14	51,200	(18,263)
DS Smith PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.21	5/13/14	270,000	(20,517)
ING Groep NV	Goldman Sachs International	Call	EUR	10.95	5/13/14	123,600	(8,576)
Monitise PLC	Goldman Sachs International	Call	GBP	0.82	5/13/14	1,060,000	(665)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	47.83	5/13/14	11,100	(5)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/13/14	64,750	\$ (161,743)
AIA Group Ltd.	Deutsche Bank AG	Call	HKD	36.88	5/14/14	1,177,800	(138,509)
Aixtron SE	Deutsche Bank AG	Call	EUR	11.99	5/14/14	59,000	(9,348)
Anhui Conch Cement Co. Ltd., Class H	Citibank N.A.	Call	HKD	32.62	5/14/14	796,000	(4,915)
ASM Pacific Technology Ltd.	Goldman Sachs International	Call	HKD	81.20	5/14/14	94,800	(66,038)
Babcock International Group PLC	Morgan Stanley & Co. International PLC	Call	GBP	12.56	5/14/14	79,392	(7,938)
Epistar Corp.	Morgan Stanley & Co. International PLC	Call	TWD	76.36	5/14/14	1,185,000	(1,541)
Halma PLC	Morgan Stanley & Co. International PLC	Call	GBP	6.16	5/14/14	40,000	(246)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	5/14/14	80	(4,811)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	539,472.50	5/14/14	130	(4,142)
Kingspan Group PLC	Credit Suisse International	Call	EUR	14.76	5/14/14	13,000	(265)
Nabtesco Corp.	Goldman Sachs International	Call	JPY	2,442.35	5/14/14	126,600	(2,144)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC	Call	DKK	246.54	5/14/14	29,700	(19,399)
Ping An Insurance Group Co. of China Ltd., Class H	Goldman Sachs International	Call	HKD	66.73	5/14/14	182,000	(32)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.15	5/14/14	200,100	(25,443)
Shinsei Bank Ltd.	Goldman Sachs International	Call	JPY	183.68	5/14/14	540,000	(88,579)
Skanska AB, B Shares	Goldman Sachs International	Call	SEK	147.85	5/14/14	121,000	(63,110)
Sumitomo Mitsui Financial Group, Inc.	Bank of America N.A.	Call	JPY	4,544.24	5/14/14	58,300	(1,204)
Tokyo Tatemono Co. Ltd.	Bank of America N.A.	Call	JPY	905.37	5/14/14	191,600	(6,846)
AstraZeneca PLC	Morgan Stanley & Co. International PLC	Call	GBP	38.07	5/15/14	44,000	(647,254)
Banco Bradesco SA ADR	Bank of America N.A.	Call	USD	13.91	5/15/14	50,000	(50,011)
Chr Hansen Holding A/S	Morgan Stanley & Co. International PLC	Call	DKK	216.88	5/15/14	35,900	(171,644)
CRH PLC	Morgan Stanley & Co. International PLC	Call	GBP	17.07	5/15/14	77,000	(62,215)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.90	5/15/14	50,000	(3,545)
Svenska Cellulosa AB SCA, Class B	Goldman Sachs International	Call	SEK	187.58	5/15/14	74,500	(11,261)
Telefonica Deutschland Holding AG	Deutsche Bank AG	Call	EUR	5.84	5/15/14	116,000	(30,693)
Telefonica Deutschland Holding AG	Goldman Sachs International	Call	EUR	5.89	5/15/14	96,700	(20,242)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	539,472.50	5/20/14	130	(6,407)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.15	5/20/14	200,100	(28,854)
Aalberts Industries NV	Morgan Stanley & Co. International PLC	Call	EUR	25.04	5/21/14	21,700	(2,434)
Anheuser-Busch InBev NV	Morgan Stanley & Co. International PLC	Call	EUR	77.64	5/21/14	39,300	(101,549)
Erste Group Bank AG	Morgan Stanley & Co. International PLC	Call	EUR	25.50	5/21/14	83,500	(40,464)
Halma PLC	Deutsche Bank AG	Call	GBP	5.87	5/21/14	40,000	(1,612)
ING Groep NV	Credit Suisse International	Call	EUR	10.32	5/21/14	206,300	(83,283)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	5/21/14	80	(6,798)
Kingspan Group PLC	Goldman Sachs International	Call	EUR	14.72	5/21/14	10,000	(397)
Nokia OYJ	Goldman Sachs International	Call	EUR	5.67	5/21/14	260,000	(30,312)
Novartis AG	Credit Suisse International	Call	CHF	74.44	5/21/14	88,350	(243,072)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	46.70	5/21/14	26,000	(23)
Randstad Holding NV	Deutsche Bank AG	Call	EUR	41.76	5/21/14	56,000	(127,809)
Rexel SA	Morgan Stanley & Co. International PLC	Call	EUR	18.70	5/21/14	46,000	(11,618)
Rio Tinto PLC	Credit Suisse International	Call	GBP	34.14	5/21/14	27,500	(7,679)
Schneider Electric SA	Deutsche Bank AG	Call	EUR	65.15	5/21/14	18,000	(62,707)
Yaskawa Electric Corp.	Goldman Sachs International	Call	JPY	1,471.60	5/21/14	200,000	(228)
Aixtron SE	Morgan Stanley & Co. International PLC	Call	EUR	12.26	5/22/14	24,300	(3,788)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

82

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Copa Holdings SA, Class A	Bank of America N.A.	Call	USD	150.39	5/22/14	9,400	\$ (6,649)
Nordea Bank AB	Morgan Stanley & Co. International PLC	Call	SEK	90.98	5/22/14	97,000	(53,378)
ProSiebenSat.1 Media AG	Morgan Stanley & Co. International PLC	Call	EUR	32.43	5/22/14	73,000	(57,524)
Vivendi SA	JPMorgan Chase Bank N.A.	Call	EUR	20.24	5/22/14	147,000	(19,762)
Calbee, Inc.	Morgan Stanley & Co. International PLC	Call	JPY	2,505.28	5/27/14	86,000	(58,860)
Cemex SAB de CV ADR	Deutsche Bank AG	Call	USD	12.65	5/27/14	52,000	(19,365)
China Cinda Asset Management Co. Ltd., Class H	Deutsche Bank AG	Call	HKD	4.33	5/27/14	1,010,000	(8,227)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	539,472.50	5/27/14	130	(9,061)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.15	5/27/14	200,100	(32,292)
Beijing Enterprises Water Group Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	5.43	5/28/14	1,625,000	(17,107)
Foxtons Group PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.75	5/28/14	25,000	(295)
Hyundai Development Co.	Morgan Stanley & Co. International PLC	Call	KRW	29,423.29	5/28/14	25,000	(32,333)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	5/28/14	80	(8,662)
Kingspan Group PLC	Goldman Sachs International	Call	EUR	14.72	5/28/14	10,000	(687)
NH Hoteles SA	UBS AG	Call	EUR	5.30	5/28/14	50,000	(1,458)
Publicis Groupe SA	Credit Suisse International	Call	EUR	64.07	5/28/14	9,300	(9,890)
Sacyr SA	Goldman Sachs International	Call	EUR	5.12	5/28/14	378,000	(47,971)
Schneider Electric SA	Morgan Stanley & Co. International PLC	Call	EUR	67.37	5/28/14	15,600	(22,573)
Shinsei Bank Ltd.	Bank of America N.A.	Call	JPY	205.64	5/28/14	683,600	(44,387)
Skanska AB, B Shares	Morgan Stanley & Co. International PLC	Call	SEK	152.70	5/28/14	67,000	(23,426)
Svenska Cellulosa AB SCA, Class B	Deutsche Bank AG	Call	SEK	193.29	5/28/14	93,000	(13,956)
Crest Nicholson Holdings PLC	Credit Suisse International	Call	GBP	3.71	5/29/14	50,000	(2,845)
Nabtesco Corp.	Citibank N.A.	Call	JPY	2,385.00	5/29/14	53,800	(8,344)
Nokia OYJ	Credit Suisse International	Call	EUR	5.69	6/02/14	170,000	(28,101)
Babcock International Group PLC	Goldman Sachs International	Call	GBP	12.09	6/03/14	135,000	(45,982)
Crest Nicholson Holdings PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.72	6/03/14	36,000	(2,336)
CRH PLC	Morgan Stanley & Co. International PLC	Call	GBP	16.73	6/03/14	35,200	(50,458)
Great Wall Motor Co. Ltd., Class H	Goldman Sachs International	Call	HKD	42.58	6/03/14	273,000	(3,193)
Halma PLC	Morgan Stanley & Co. International PLC	Call	GBP	6.13	6/03/14	70,000	(1,155)
Imperial Tobacco Group PLC	Goldman Sachs International	Call	GBP	25.36	6/03/14	65,800	(84,166)
Mitsui Osk Lines Ltd.	Goldman Sachs International	Call	JPY	390.06	6/03/14	690,000	(15,021)
Naspers Ltd., N Shares	Deutsche Bank AG	Call	ZAR	1,066.56	6/03/14	11,600	(32,111)
Naspers Ltd., N Shares	Morgan Stanley & Co. International PLC	Call	ZAR	1,180.22	6/03/14	16,200	(12,428)
NH Hoteles SA	Morgan Stanley & Co. International PLC	Call	EUR	5.23	6/03/14	100,000	(3,914)
Rexel SA	Goldman Sachs International	Call	EUR	18.91	6/03/14	123,200	(35,863)
Sacyr SA	Credit Suisse International	Call	EUR	4.84	6/03/14	434,000	(120,876)
Adecco SA	Morgan Stanley & Co. International PLC	Call	CHF	71.19	6/04/14	30,000	(131,467)
Banco Bradesco SA ADR	Bank of America N.A.	Call	USD	13.91	6/04/14	50,000	(57,144)
Beijing Enterprises Water Group Ltd.	Morgan Stanley & Co. International PLC	Call	HKD	5.51	6/04/14	1,625,000	(19,269)
Calbee, Inc.	Morgan Stanley & Co. International PLC	Call	JPY	2,517.56	6/04/14	86,000	(62,189)
Daimler AG	UBS AG	Call	EUR	67.85	6/04/14	15,100	(37,188)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	526,802.87	6/04/14	80	(10,214)
Kenedix Office Investment Corp. REIT	Morgan Stanley & Co. International PLC	Call	JPY	539,472.50	6/04/14	130	(11,673)
Novo Nordisk A/S, Class B	Deutsche Bank AG	Call	DKK	243.60	6/04/14	53,500	(68,708)
Novo Nordisk A/S, Class B	Goldman Sachs International	Call	DKK	248.78	6/04/14	30,600	(26,910)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Samsonite International SA	Deutsche Bank AG	Call	HKD	25.31	6/04/14	115,200	\$ (12,302)
UBS AG	Goldman Sachs International	Call	CHF	18.34	6/04/14	185,200	(91,841)
Yaskawa Electric Corp.	Goldman Sachs International	Call	JPY	1,471.60	6/04/14	200,000	(1,861)
Aalberts Industries NV	Morgan Stanley & Co. International PLC	Call	EUR	25.53	6/05/14	24,300	(4,001)
Anhui Conch Cement Co. Ltd., Class H	Morgan Stanley & Co. International PLC	Call	HKD	31.76	6/05/14	387,000	(17,688)
Babcock International Group PLC	Goldman Sachs International	Call	GBP	12.26	6/05/14	39,696	(17,152)
Babcock International Group PLC	Morgan Stanley & Co. International PLC	Call	GBP	12.41	6/05/14	76,443	(26,555)
Copa Holdings SA, Class A	Bank of America N.A.	Call	USD	150.39	6/05/14	9,400	(9,203)
Hyundai Development Co.	Morgan Stanley & Co. International PLC	Call	KRW	29,708.95	6/05/14	25,000	(33,240)
Nordea Bank AB	Morgan Stanley & Co. International PLC	Call	SEK	90.98	6/05/14	97,000	(57,754)
Nordea Bank AB	UBS AG	Call	SEK	92.47	6/05/14	75,900	(31,898)
Ryanair Holdings PLC ADR	Deutsche Bank AG	Call	USD	60.50	6/05/14	28,300	(8,909)
Schneider Electric SA	UBS AG	Call	EUR	66.46	6/05/14	26,000	(62,421)
SMC Corp.	UBS AG	Call	JPY	26,297.43	6/05/14	10,100	(32,772)
Vivendi SA	Goldman Sachs International	Call	EUR	20.15	6/05/14	112,600	(35,318)
Bayer AG	Credit Suisse International	Call	EUR	93.80	6/06/14	53,200	(558,488)
Bayer AG	Credit Suisse International	Call	EUR	99.52	6/06/14	10,000	(31,679)
Novartis AG	Goldman Sachs International	Call	CHF	74.65	6/06/14	88,400	(254,627)
Rio Tinto PLC	Deutsche Bank AG	Call	GBP	33.85	6/06/14	35,700	(22,574)
Aixtron SE	Deutsche Bank AG	Call	EUR	12.05	6/10/14	59,000	(22,495)
Chr Hansen Holding A/S	Goldman Sachs International	Call	DKK	236.23	6/10/14	36,000	(74,444)
DS Smith PLC	UBS AG	Call	GBP	3.10	6/10/14	270,000	(67,898)
Halma PLC	Goldman Sachs International	Call	GBP	5.97	6/10/14	70,000	(3,536)
Kingspan Group PLC	Morgan Stanley & Co. International PLC	Call	EUR	13.97	6/10/14	10,000	(4,495)
NAVER Corp.	Morgan Stanley & Co. International PLC	Call	KRW	780,000.00	6/10/14	1,405	(38,596)
NH Hoteles SA	Goldman Sachs International	Call	EUR	5.07	6/10/14	113,500	(10,824)
Statoil ASA	Morgan Stanley & Co. International PLC	Call	NOK	169.48	6/10/14	128,400	(253,549)
Svenska Cellulosa AB SCA, Class B	Deutsche Bank AG	Call	SEK	185.88	6/10/14	133,800	(66,974)
Actelion Ltd.	UBS AG	Call	CHF	89.37	6/11/14	32,400	(92,638)
Nokia OYJ	Credit Suisse International	Call	EUR	5.69	6/11/14	170,000	(24,453)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	42.78	6/11/14	25,000	(5,917)
Rexel SA	Goldman Sachs International	Call	EUR	18.49	6/11/14	30,000	(16,137)
Societe Generale SA	Goldman Sachs International	Call	EUR	45.26	6/11/14	13,100	(16,855)
Sumitomo Mitsui Financial Group, Inc.	Morgan Stanley & Co. International PLC	Call	JPY	4,284.50	6/11/14	162,300	(89,184)
Tokyo Tatemono Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	849.74	6/11/14	200,000	(64,085)
Nabtesco Corp.	Citibank N.A.	Call	JPY	2,385.00	6/12/14	53,800	(13,940)
Ping An Insurance Group Co. of China Ltd., Class H	UBS AG	Call	HKD	61.76	6/12/14	443,500	(27,304)
Shinsei Bank Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	207.00	6/12/14	474,000	(38,674)
Aalberts Industries NV	Deutsche Bank AG	Call	EUR	24.60	6/13/14	21,000	(12,132)
BNP Paribas SA	Bank of America N.A.	Call	EUR	57.02	6/13/14	62,800	(40,584)
Novo Nordisk A/S, Class B	Goldman Sachs International	Call	DKK	246.64	6/13/14	62,000	(58,166)
Shire PLC	Deutsche Bank AG	Call	GBP	33.17	6/13/14	36,500	(149,793)
Aixtron SE	Morgan Stanley & Co. International PLC	Call	EUR	12.26	6/17/14	24,300	(8,216)
Crest Nicholson Holdings PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.56	6/17/14	50,000	(8,823)
CRH PLC	Goldman Sachs International	Call	GBP	17.45	6/17/14	161,000	(149,912)
Foxtons Group PLC	Bank of America N.A.	Call	GBP	3.25	6/17/14	25,000	(5,188)
Great Wall Motor Co. Ltd., Class H	Goldman Sachs International	Call	HKD	42.58	6/17/14	273,000	(7,446)
Halma PLC	Morgan Stanley & Co. International PLC	Call	GBP	6.00	6/17/14	35,000	(1,882)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Kingspan Group PLC	Goldman Sachs International	Call	EUR	14.15	6/17/14	10,000	\$ (4,231)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.76	6/17/14	100,000	(32,209)
NH Hoteles SA	Morgan Stanley & Co. International PLC	Call	EUR	5.23	6/17/14	100,000	(7,671)
Samsonite International SA	Deutsche Bank AG	Call	HKD	24.82	6/17/14	350,700	(55,148)
Suncor Energy, Inc.	UBS AG	Call	CAD	41.78	6/17/14	35,500	(38,515)
Anheuser-Busch InBev NV	Morgan Stanley & Co. International PLC	Call	EUR	79.13	6/18/14	47,400	(106,427)
Anhui Conch Cement Co. Ltd., Class H	UBS AG	Call	HKD	33.07	6/18/14	387,000	(14,180)
Hargreaves Lansdown PLC	Goldman Sachs International	Call	GBP	12.17	6/18/14	59,000	(26,688)
Monitise PLC	Morgan Stanley & Co. International PLC	Call	GBP	0.66	6/18/14	1,060,000	(104,250)
Credicorp Ltd.	Morgan Stanley & Co. International PLC	Call	USD	145.42	6/19/14	9,600	(63,489)
Vivendi SA	Morgan Stanley & Co. International PLC	Call	EUR	19.79	6/24/14	128,500	(65,266)
Actelion Ltd.	UBS AG	Call	CHF	89.37	6/25/14	32,400	(112,542)
Aixtron SE	Goldman Sachs International	Call	EUR	11.60	6/25/14	59,100	(44,470)
Imperial Tobacco Group PLC	Goldman Sachs International	Call	GBP	25.36	6/25/14	65,800	(102,069)
Tokyo Tatemono Co. Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	849.68	6/25/14	200,000	(78,134)
Aalberts Industries NV	Deutsche Bank AG	Call	EUR	24.60	6/26/14	21,000	(14,272)
Chr Hansen Holding A/S	Bank of America N.A.	Call	DKK	245.02	6/26/14	19,000	(28,012)
DS Smith PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.22	6/26/14	178,000	(32,686)
Halma PLC	Morgan Stanley & Co. International PLC	Call	GBP	6.00	6/26/14	35,000	(2,405)
NH Hoteles SA	Morgan Stanley & Co. International PLC	Call	EUR	5.01	6/26/14	180,000	(30,212)
Nokia OYJ	UBS AG	Call	EUR	5.41	6/26/14	127,000	(43,038)
OSRAM Licht AG	Goldman Sachs International	Call	EUR	42.28	6/26/14	25,000	(10,522)
Publicis Groupe SA	Morgan Stanley & Co. International PLC	Call	EUR	61.48	6/26/14	58,000	(119,143)
Shinsei Bank Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	205.92	6/26/14	556,000	(57,035)
Adecco SA	Deutsche Bank AG	Call	CHF	74.44	6/27/14	30,000	(90,630)
Shire PLC	Deutsche Bank AG	Call	GBP	33.17	6/27/14	36,500	(167,719)
Suncor Energy, Inc.	UBS AG	Call	CAD	41.78	6/30/14	35,500	(42,952)
Kingspan Group PLC	UBS AG	Call	EUR	13.16	7/01/14	12,000	(14,113)
Halma PLC	Morgan Stanley & Co. International PLC	Call	GBP	5.83	7/02/14	40,000	(5,931)
NH Hoteles SA	Goldman Sachs International	Call	EUR	4.55	7/08/14	80,000	(37,953)
Halma PLC	Credit Suisse International	Call	GBP	5.72	7/09/14	35,000	(7,868)
Shinsei Bank Ltd.	Morgan Stanley & Co. International PLC	Call	JPY	203.27	7/10/14	556,000	(71,252)
Halma PLC	UBS AG	Call	GBP	5.89	7/28/14	38,000	(6,411)
Total							\$ (10,713,900)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

85

Table of Contents**Schedule of Investments (continued)****BlackRock International Growth and Income Trust (BGY)**

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Austria		\$ 10,242,001		\$ 10,242,001
Belgium		16,855,747		16,855,747
Brazil	\$ 7,907,376			7,907,376
Canada	32,650,431			32,650,431
China	11,534,167	28,736,878		40,271,045
Denmark	4,978,664	24,320,707		29,299,371
Finland		14,760,999		14,760,999
France	11,114,322	61,251,174		72,365,496
Germany		72,692,217		72,692,217
Greece		7,409,495		7,409,495
Hong Kong	1,916,803	17,882,132		19,798,935
India	9,444,808			9,444,808
Indonesia		11,573,123		11,573,123
Ireland	34,879,088	21,804,189		56,683,277
Italy	8,156,776	20,704,839		28,861,615
Japan	24,441,569	97,918,321		122,359,890
Malaysia	1,724,055			1,724,055
Mexico	9,787,759			9,787,759
Netherlands		26,829,696		26,829,696
New Zealand		7,793,842		7,793,842
Norway		14,032,435		14,032,435
Panama	4,640,104			4,640,104
Peru	2,596,950			2,596,950
South Africa		4,696,614		4,696,614
South Korea	3,694,822	5,112,829		8,807,651
Spain		25,479,687		25,479,687
Sweden	6,959,137	23,987,977		30,947,114
Switzerland		97,910,984		97,910,984
Taiwan	2,796,583	7,956,861		10,753,444
Turkey	5,582,833			5,582,833
United Kingdom	51,871,286	90,864,242	\$ 5,070,808	147,806,336
United States	10,323,064			10,323,064
Investment Companies	7,395,620			7,395,620
Rights	1,379,800			1,379,800
Warrants	215,196			215,196
Short-Term Securities		10,177,930		10,177,930
Total	\$ 255,991,213	\$ 720,994,919	\$ 5,070,808	\$ 982,056,940
	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (1,365,973)	\$ (10,939,582)		\$ (12,305,555)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

¹ Derivative financial instruments are options written, which are shown at value.

See Notes to Financial Statements.

86

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (concluded)****BlackRock International Growth and Income Trust (BGY)**

The carrying amount for certain of the Trust's assets and/or liabilities approximates fair value for financial statement purposes. As of April 30, 2014, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Foreign currency at value	\$ 2,255,325			\$ 2,255,325
Cash pledged as collateral for OTC derivatives	7,744,504			7,744,504
Cash pledged as collateral for exchange-traded options written	4,050,000			4,050,000
Liabilities:				
Bank overdraft		\$ (3,767,000)		(3,767,000)
Collateral on securities loaned at value		(10,177,930)		(10,177,930)
Total	\$ 14,049,829	\$ (13,944,930)		\$ 104,899

The Trust's investments that are categorized as Level 3 were valued utilizing third party pricing information without adjustment. Such valuations are based on unobservable inputs. A significant change in third party information inputs could result in a significantly lower or higher value of such Level 3 investments.

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013, the Trust did not utilize the external pricing service model adjustments as significant market movements did not occur. As of April 30 2014, securities with a value of \$119,208,229 were systematically fair valued due to significant market movements. Therefore, these securities were transferred from Level 1 to Level 2 during the period October 31, 2013 to April 30, 2014.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock Real Asset Equity Trust (BCF)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Chemicals 15.7%		
Agrium, Inc.	67,900	\$ 6,523,153
Air Products & Chemicals, Inc. (a)	88,600	10,412,272
Celanese Corp., Series A (a)	89,300	5,485,699
The Dow Chemical Co.	154,325	7,700,818
EI du Pont de Nemours & Co. (a)	347,800	23,413,894
Monsanto Co. (a)	64,500	7,140,150
The Mosaic Co. (a)	19,000	950,760
Olin Corp.	162,200	4,557,820
Potash Corp. of Saskatchewan, Inc. (a)	179,400	6,487,104
Praxair, Inc. (a)	157,600	20,574,680
		93,246,350
Containers & Packaging 2.8%		
MeadWestvaco Corp.	419,800	16,401,586
Energy Equipment & Services 3.6%		
Cameron International Corp. (a)(b)	56,000	3,637,760
Halliburton Co. (a)	124,400	7,845,908
Schlumberger Ltd. (a)	99,983	10,153,274
		21,636,942
Machinery 4.7%		
Caterpillar, Inc. (a)	199,500	21,027,300
Deere & Co. (a)	71,400	6,664,476
		27,691,776
Metals & Mining 31.8%		
African Rainbow Minerals Ltd.	224,750	4,231,849
Agnico Eagle Mines Ltd.	48,400	1,430,704
Alcoa, Inc. (a)	250,650	3,376,256
Allegheny Technologies, Inc. (a)	35,000	1,442,000
Alumina Ltd. (b)	1,627,566	2,044,454
Anglo American Platinum Ltd. (b)	35,444	1,687,669
Anglo American PLC	77,945	2,083,702
AngloGold Ashanti Ltd. ADR (a)(b)	166,165	3,007,588
Barrick Gold Corp. (a)	87,000	1,519,890
BHP Billiton PLC	648,600	21,056,284
Carpenter Technology Corp. (a)	36,366	2,283,785
Cia de Minas Buenaventura SAA ADR	143,900	1,870,700
Detour Gold Corp. (a)(b)	129,200	1,286,047
Dominion Diamond Corp. (a)(b)	126,700	1,591,770
Eldorado Gold Corp.	409,900	2,498,182
First Quantum Minerals Ltd. (a)	484,600	9,651,766
Freeport-McMoRan Copper & Gold, Inc. (a)	108,400	3,725,708
Fresnillo PLC	475,000	6,849,448
Glencore Xstrata PLC	3,270,868	17,648,759
Goldcorp, Inc.	216,950	5,363,004
Goldcorp, Inc.	80,000	1,975,822
Iluka Resources Ltd.	812,686	6,751,615
Impala Platinum Holdings Ltd.	130,000	1,465,527
Industrias Penoles SAB de CV	292,531	6,810,649
Jiangxi Copper Co. Ltd., Class H	1,339,500	2,215,934
Kazakhmys PLC (b)	444,011	1,784,950
Kinross Gold Corp.	314,024	1,274,937
Lundin Mining Corp. (a)(b)	796,600	4,070,033
Minsur SA	3,846,986	2,439,051
MMC Norilsk Nickel OJSC ADR	68,120	1,231,553
Nevsun Resources Ltd.	978,250	3,543,317

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

New Gold, Inc. (b)	284,900	1,440,031
Newcrest Mining Ltd. (b)	314,085	3,063,317
OZ Minerals Ltd.	381,759	1,313,837
Platinum Group Metals Ltd. (b)(c)	888,518	916,040
Randgold Resources Ltd. ADR (a)	38,341	3,069,964
Rio Tinto PLC	381,629	20,748,195
Silver Wheaton Corp.	80,000	1,776,000
Common Stocks	Shares	Value
Metals & Mining (concluded)		
Southern Copper Corp. (a)	68,806	\$ 2,073,813
Teck Resources Ltd., Class B (a)	330,203	7,525,634
United States Steel Corp. (a)	38,200	993,964
Vale SA ADR (a)	493,983	6,530,455
Vedanta Resources PLC	390,288	6,249,741
Western Areas Ltd.	879,500	3,394,882
Zijin Mining Group Co Ltd., Class H	5,225,731	1,276,727
		188,585,553
Oil, Gas & Consumable Fuels 32.3%		
Anadarko Petroleum Corp. (a)	92,200	9,129,644
BG Group PLC	347,000	7,019,541
BP PLC	1,143,839	9,657,516
Cairn Energy PLC (b)	498,000	1,551,150
Canadian Natural Resources Ltd. (a)	107,000	4,359,856
Canadian Oil Sands Ltd. (a)	81,704	1,771,168
Caracal Energy, Inc. (b)	275,700	2,527,607
Chevron Corp. (a)(d)	177,800	22,317,456
Cimarex Energy Co. (a)	36,000	4,288,320
ConocoPhillips (a)	156,300	11,614,653
CONSOL Energy, Inc. (a)	63,579	2,829,901
Devon Energy Corp. (a)	42,000	2,940,000
Enbridge, Inc. (a)	59,800	2,885,655
Encana Corp. (a)	191,000	4,424,515
EOG Resources, Inc. (a)	70,000	6,860,000
Exxon Mobil Corp. (a)(d)	210,800	21,588,028
Imperial Oil Ltd. (a)	52,000	2,539,154
Kosmos Energy Ltd. (b)	216,570	2,364,944
Murphy Oil Corp.	33,500	2,124,905
Noble Energy, Inc. (a)	101,000	7,249,780
Oil Search Ltd.	585,197	4,848,349
Phillips 66 (a)	49,400	4,111,068
Pioneer Natural Resources Co. (a)	28,000	5,411,560
Range Resources Corp. (a)	36,000	3,256,200
Royal Dutch Shell PLC ADR	287,400	22,629,876
Southwestern Energy Co. (a)(b)	67,500	3,231,900
Statoil ASA	198,451	6,049,860
Total SA	94,700	6,775,224
TransCanada Corp. (a)	115,400	5,378,069
		191,735,899
Paper & Forest Products 3.8%		
Fibria Celulose SA ADR (b)	238,100	2,364,333
International Paper Co. (a)	341,900	15,949,635
Mondi PLC	237,512	3,948,360
		22,262,328
Real Estate Investment Trusts (REITs) 2.2%		
Weyerhaeuser Co. (a)	439,200	13,110,120
Total Long-Term Investments		
(Cost \$478,206,377) 96.9%		574,670,554

See Notes to Financial Statements.

Table of Contents**BlackRock Real Asset Equity Trust (BCF)****Schedule of Investments (continued)**

(Percentages shown are based on Net Assets)

	Shares	Value
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (e)(f)	24,861,572	\$ 24,861,572
	Beneficial Interest (000)	
BlackRock Liquidity Series, LLC Money Market Series, 0.18% (e)(f)(g)	\$ 71	70,955
Total Short-Term Securities		
(Cost \$ 24,932,527) 4.2%		24,932,527
Total Investments Before Options Written		
(Cost \$ 503,138,904) 101.1%		599,603,081
Options Written		Value
(Premiums Received \$4,432,487) (1.0)%		\$ (6,182,281)
Total Investments Net of Options Written 100.1%		593,420,800
Liabilities in Excess of Other Assets (0.1)%		(482,297)
Net Assets 100.0%		\$ 592,938,503

Notes to Schedule of Investments

(a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(b) Non-income producing security.

(c) Security, or a portion of security, is on loan.

(d) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(e) Represents the current yield as of report date.

(f) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares/Beneficial Interest Held at	Net	Shares/Beneficial Interest Held at	Income
------------------	---	------------	---	---------------

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	October 31, 2013	Activity	April 30, 2014	
BlackRock Liquidity Funds, TempFund, Institutional Class	21,163,179	3,698,393	24,861,572	\$ 4,174
BlackRock Liquidity Series, LLC, Money Market Series		\$ 70,955	\$ 70,955	\$ 161

(g) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series, LLC Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration Date	Contracts	Market
		Price				Value
El du Pont de Nemours & Co.	Call	USD	67.00	5/02/14	340	\$ (17,510)
EOG Resources, Inc.	Call	USD	100.00	5/02/14	76	(1,748)
Exxon Mobil Corp.	Call	USD	94.00	5/02/14	252	(204,120)
Schlumberger Ltd.	Call	USD	91.00	5/02/14	87	(88,522)
Chevron Corp.	Call	USD	120.00	5/05/14	82	(46,945)
ConocoPhillips	Call	USD	68.50	5/05/14	326	(197,230)
Deere & Co.	Call	USD	89.00	5/05/14	249	(108,905)
Schlumberger Ltd.	Call	USD	93.00	5/05/14	87	(73,732)
Caterpillar, Inc.	Call	USD	105.00	5/09/14	100	(13,750)
El du Pont de Nemours & Co.	Call	USD	67.00	5/09/14	340	(26,860)
EOG Resources, Inc.	Call	USD	100.00	5/09/14	111	(20,702)
EOG Resources, Inc.	Call	USD	102.00	5/09/14	58	(6,989)
The Mosaic Co.	Call	USD	50.00	5/09/14	17	(1,556)
Potash Corp. of Saskatchewan, Inc.	Call	USD	35.50	5/09/14	317	(27,104)
Air Products & Chemicals, Inc.	Call	USD	120.00	5/19/14	155	(18,600)
Alcoa, Inc.	Call	USD	12.00	5/19/14	439	(65,192)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Real Asset Equity Trust (BCF)**

Exchange-traded options written as of April 30, 2014 were as follows: (continued)

Description	Put/ Call	Strike Price	Expiration Date	Contracts	Market Value
Allegheny Technologies, Inc.	Call	USD 42.50	5/19/14	131	\$ (5,240)
Anadarko Petroleum Corp.	Call	USD 87.50	5/19/14	180	(207,450)
AngloGold Ashanti Ltd. ADR	Call	USD 19.00	5/19/14	290	(8,700)
Cameron International Corp.	Call	USD 65.00	5/19/14	196	(22,050)
Canadian Natural Resources Ltd.	Call	CAD 46.00	5/19/14	188	(6,175)
Canadian Oil Sands Ltd.	Call	CAD 23.00	5/19/14	240	(19,379)
Carpenter Technology Corp.	Call	USD 65.00	5/19/14	63	(2,835)
Caterpillar, Inc.	Call	USD 105.00	5/19/14	417	(70,682)
Cimarex Energy Co.	Call	USD 125.00	5/19/14	50	(7,625)
ConocoPhillips	Call	USD 75.00	5/19/14	326	(21,679)
CONSOL Energy, Inc.	Call	USD 43.00	5/19/14	111	(20,868)
Detour Gold Corp.	Call	CAD 11.50	5/19/14	220	(5,520)
Detour Gold Corp.	Call	CAD 12.00	5/19/14	230	(3,148)
Devon Energy Corp.	Call	USD 72.50	5/19/14	147	(8,820)
Dominion Diamond Corp.	Call	CAD 14.00	5/19/14	220	(3,613)
EI du Pont de Nemours & Co.	Call	USD 70.00	5/19/14	305	(1,830)
Enbridge, Inc.	Call	CAD 52.00	5/19/14	161	(16,966)
Encana Corp.	Call	CAD 26.00	5/19/14	334	(12,342)
Exxon Mobil Corp.	Call	USD 100.00	5/19/14	199	(54,426)
First Quantum Minerals Ltd.	Call	CAD 20.00	5/19/14	848	(147,774)
First Quantum Minerals Ltd.	Call	CAD 21.00	5/19/14	848	(82,785)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD 34.00	5/19/14	142	(12,212)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD 35.00	5/19/14	135	(5,062)
Halliburton Co.	Call	USD 62.50	5/19/14	310	(46,810)
Imperial Oil Ltd.	Call	CAD 50.00	5/19/14	91	(29,682)
Imperial Oil Ltd.	Call	CAD 52.00	5/19/14	91	(14,529)
Lundin Mining Corp.	Call	CAD 5.00	5/19/14	425	(23,265)
Noble Energy, Inc.	Call	USD 75.00	5/19/14	122	(3,660)
Phillips 66	Call	USD 80.00	5/19/14	172	(62,780)
Pioneer Natural Resources Co.	Call	USD 195.00	5/19/14	49	(24,745)
Potash Corp. of Saskatchewan, Inc.	Call	USD 36.00	5/19/14	310	(21,080)
Praxair, Inc.	Call	USD 132.00	5/19/14	551	(52,389)
Randgold Resources Ltd. ADR	Call	USD 82.50	5/19/14	70	(8,225)
Range Resources Corp.	Call	USD 92.50	5/19/14	63	(6,615)
Range Resources Corp.	Call	USD 95.00	5/19/14	63	(2,835)
Schlumberger Ltd.	Call	USD 92.50	5/19/14	175	(159,688)
Southern Copper Corp.	Call	USD 31.00	5/19/14	120	(3,300)
Southwestern Energy Co.	Call	USD 47.00	5/19/14	217	(38,192)
Teck Resources Ltd., Class B	Call	CAD 27.00	5/19/14	365	(1,499)
TransCanada Corp.	Call	CAD 52.00	5/19/14	470	(7,933)
United States Steel Corp.	Call	USD 28.00	5/19/14	133	(1,729)
Vale SA ADR	Call	USD 14.00	5/19/14	864	(9,936)
Monsanto Co.	Call	USD 112.00	5/22/14	112	(15,096)
Barrick Gold Corp.	Call	USD 19.50	5/23/14	304	(3,040)
Caterpillar, Inc.	Call	USD 103.00	5/23/14	980	(320,947)
Chevron Corp.	Call	USD 123.00	5/23/14	160	(53,200)
EI du Pont de Nemours & Co.	Call	USD 68.50	5/23/14	250	(8,125)
The Mosaic Co.	Call	USD 49.50	5/23/14	49	(7,056)
Chevron Corp.	Call	USD 123.00	5/30/14	160	(55,200)
Exxon Mobil Corp.	Call	USD 101.00	5/30/14	143	(30,459)
Anadarko Petroleum Corp.	Call	USD 100.00	6/04/14	143	(37,988)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Real Asset Equity Trust (BCF)**

Exchange-Traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market	
		Price				Value	
Chevron Corp.	Call	USD	125.00	6/06/14	110	\$	(24,750)
Exxon Mobil Corp.	Call	USD	101.00	6/06/14	143		(31,818)
Halliburton Co.	Call	USD	64.50	6/06/14	125		(13,875)
Monsanto Co.	Call	USD	115.00	6/10/14	113		(11,184)
Air Products & Chemicals, Inc.	Call	USD	125.00	6/23/14	155		(18,988)
Alcoa, Inc.	Call	USD	13.00	6/23/14	439		(35,120)
Allegheny Technologies, Inc.	Call	USD	40.00	6/23/14	131		(29,148)
Canadian Oil Sands Ltd.	Call	CAD	25.00	6/23/14	250		(2,737)
Carpenter Technology Corp.	Call	USD	65.00	6/23/14	63		(7,560)
Celanese Corp., Series A	Call	USD	61.00	6/23/14	312		(57,720)
Chevron Corp.	Call	USD	125.00	6/23/14	110		(27,555)
Cimarex Energy Co.	Call	USD	120.00	6/23/14	76		(41,420)
Encana Corp.	Call	CAD	26.00	6/23/14	334		(20,569)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD	34.00	6/23/14	100		(13,850)
International Paper Co.	Call	USD	46.00	6/23/14	601		(83,238)
Pioneer Natural Resources Co.	Call	USD	205.00	6/23/14	49		(21,560)
Randgold Resources Ltd. ADR	Call	USD	82.50	6/23/14	70		(18,025)
Teck Resources Ltd., Class B	Call	CAD	26.00	6/23/14	420		(17,819)
Vale SA ADR	Call	USD	14.00	6/23/14	864		(28,512)
Weyerhaeuser Co.	Call	USD	30.00	6/23/14	385		(21,175)
CONSOL Energy, Inc.	Call	USD	44.00	7/21/14	111		(26,529)
Total						\$	(3,269,801)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market	
			Price				Value	
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	74.28	5/02/14	6,300	\$	(28,082)
The Dow Chemical Co.	UBS AG	Call	USD	50.73	5/05/14	54,000		(9,013)
Kosmos Energy Ltd.	Morgan Stanley & Co. International PLC	Call	USD	11.15	5/05/14	20,700		(789)
MeadWestvaco Corp.	Citibank N.A.	Call	USD	36.42	5/05/14	63,500		(168,035)
African Rainbow Minerals Ltd.	Goldman Sachs International	Call	ZAR	204.27	5/06/14	36,000		(3,300)
BG Group PLC	Credit Suisse International	Call	GBP	11.22	5/06/14	57,500		(74,763)
BP PLC	Morgan Stanley & Co. International PLC	Call	GBP	4.79	5/06/14	160,000		(57,634)
Fresnillo PLC	Deutsche Bank AG	Call	GBP	9.46	5/06/14	125,598		(1,269)
Mining and Metallurgical Co. Norilsk								
Nickel OJSC	Goldman Sachs International	Call	USD	17.37	5/06/14	23,800		(17,011)
Rio Tinto PLC	Credit Suisse International	Call	GBP	33.24	5/06/14	51,000		(8,299)
Eldorado Gold Corp.	Morgan Stanley & Co. International PLC	Call	CAD	7.75	5/07/14	71,700		(24)
Kosmos Energy Ltd.	Morgan Stanley & Co. International PLC	Call	USD	11.09	5/07/14	21,500		(3,216)
Noble Energy, Inc.	Citibank N.A.	Call	USD	70.00	5/07/14	23,200		(44,756)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/07/14	15,600		(38,052)
Total SA	Goldman Sachs International	Call	EUR	48.11	5/07/14	16,500		(79,595)
BHP Billiton PLC	Morgan Stanley & Co. International PLC	Call	GBP	19.45	5/08/14	113,500		(27,491)
Caracal Energy, Inc.	Credit Suisse International	Call	GBP	3.74	5/08/14	10,000		(28,479)
Oil Search Ltd.	Goldman Sachs International	Call	AUD	8.41	5/08/14	114,600		(55,258)
Western Areas Ltd.	Deutsche Bank AG	Call	AUD	3.54	5/08/14	307,800		(177,062)
International Paper Co.	Credit Suisse International	Call	USD	45.73	5/12/14	59,500		(67,765)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Agrium, Inc.	Credit Suisse International	Call	USD	97.00	5/13/14	11,800	(13,179)
Impala Platinum Holdings Ltd.	Goldman Sachs International	Call	ZAR	121.10	5/13/14	130,000	(26,045)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/13/14	15,600	(38,968)
Total SA	Goldman Sachs International	Call	EUR	48.11	5/13/14	16,500	(80,895)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

91

Table of Contents**Schedule of Investments (continued)****BlackRock Real Asset Equity Trust (BCF)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Alumina Ltd.	Deutsche Bank AG	Call	AUD	1.17	5/14/14	569,600	\$ (101,049)
Jiangxi Copper Co. Ltd., Class H	Goldman Sachs International	Call	HKD	12.46	5/14/14	469,000	(32,524)
MeadWestvaco Corp.	Citibank N.A.	Call	USD	36.42	5/14/14	63,500	(168,021)
Weyerhaeuser Co.	Citibank N.A.	Call	USD	29.77	5/14/14	76,700	(22,343)
Zijin Mining Group Co Ltd., Class H	Morgan Stanley & Co. International PLC	Call	HKD	1.67	5/14/14	1,830,000	(54,214)
Murphy Oil Corp.	Citibank N.A.	Call	USD	63.35	5/15/14	6,000	(6,956)
Olin Corp.	Credit Suisse International	Call	USD	27.93	5/15/14	27,100	(14,985)
Minsur SA	Citibank N.A.	Call	PEN	1.60	5/20/14	320,000	(20,576)
Deere & Co.	Citibank N.A.	Call	USD	92.00	5/21/14	28,600	(72,019)
Eldorado Gold Corp.	Morgan Stanley & Co. International PLC	Call	CAD	7.75	5/21/14	71,700	(1,152)
Vedanta Resources PLC	Morgan Stanley & Co. International PLC	Call	GBP	9.17	5/21/14	63,600	(51,271)
Agrium, Inc.	Credit Suisse International	Call	USD	97.00	5/27/14	11,800	(21,083)
Canadian Natural Resources Ltd.	Citibank N.A.	Call	CAD	44.53	5/28/14	9,300	(10,344)
Minsur SA	UBS AG	Call	PEN	1.65	5/28/14	400,000	(20,700)
Statoil ASA	UBS AG	Call	NOK	169.92	5/28/14	40,350	(77,222)
Murphy Oil Corp.	Citibank N.A.	Call	USD	63.35	5/29/14	6,000	(9,914)
Kazakhmys PLC	Morgan Stanley & Co. International PLC	Call	GBP	2.80	5/30/14	108,000	(5,868)
BHP Billiton PLC	Morgan Stanley & Co. International PLC	Call	GBP	19.39	6/03/14	113,500	(76,675)
Glencore Xstrata PLC	Deutsche Bank AG	Call	GBP	3.20	6/03/14	615,000	(67,842)
Mondi PLC	Morgan Stanley & Co. International PLC	Call	GBP	10.16	6/03/14	83,000	(26,965)
Statoil ASA	UBS AG	Call	NOK	169.92	6/03/14	40,350	(77,527)
MeadWestvaco Corp.	Goldman Sachs International	Call	USD	38.50	6/04/14	19,900	(19,888)
Southwestern Energy Co.	Goldman Sachs International	Call	USD	49.38	6/04/14	2,000	(1,779)
Glencore Xstrata PLC	Deutsche Bank AG	Call	GBP	3.21	6/05/14	615,000	(65,769)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.24	6/05/14	56,800	(176,779)
Lundin Mining Corp.	UBS AG	Call	CAD	5.43	6/06/14	118,000	(35,895)
Rio Tinto PLC	Deutsche Bank AG	Call	GBP	33.85	6/06/14	82,600	(52,231)
Olin Corp.	Citibank N.A.	Call	USD	28.10	6/09/14	29,600	(24,966)
Anglo American PLC	Credit Suisse International	Call	GBP	15.67	6/10/14	27,200	(34,484)
Iluka Resources Ltd.	Morgan Stanley & Co. International PLC	Call	AUD	10.12	6/11/14	284,400	(13,032)
Kazakhmys PLC	Credit Suisse International	Call	GBP	2.47	6/12/14	47,000	(11,521)
Newcrest Mining Ltd.	UBS AG	Call	AUD	10.84	6/12/14	109,900	(51,457)
Oil Search Ltd.	UBS AG	Call	AUD	8.73	6/12/14	90,200	(30,235)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/12/14	18,700	(55,641)
BP PLC	Deutsche Bank AG	Call	GBP	5.10	6/13/14	240,000	(14,389)
BG Group PLC	Goldman Sachs International	Call	GBP	11.92	6/17/14	64,000	(53,533)
Canadian Natural Resources Ltd.	Citibank N.A.	Call	CAD	44.53	6/17/14	9,300	(12,672)
Fresnillo PLC	Bank of America N.A.	Call	GBP	8.71	6/17/14	41,200	(29,117)
OZ Minerals Ltd.	UBS AG	Call	AUD	3.94	6/17/14	133,600	(15,688)
Anglo American Platinum Ltd.	Bank of America N.A.	Call	ZAR	511.33	6/18/14	12,400	(23,511)
Kosmos Energy Ltd.	Morgan Stanley & Co. International PLC	Call	USD	11.00	6/18/14	33,500	(18,265)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/18/14	18,800	(57,828)
Vedanta Resources PLC	Bank of America N.A.	Call	GBP	9.58	6/18/14	73,000	(46,870)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	6/21/14	2,400	(1,708)
African Rainbow Minerals Ltd.	Deutsche Bank AG	Call	ZAR	198.34	6/26/14	42,000	(32,416)
Lundin Mining Corp.	UBS AG	Call	CAD	5.43	6/27/14	118,000	(42,408)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	7/09/14	2,400	(2,168)
Total							\$ (2,912,480)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Real Asset Equity Trust (BCF)**

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Chemicals	\$ 93,246,350			\$ 93,246,350
Containers & Packaging	16,401,586			16,401,586
Energy Equipment & Services	21,636,942			21,636,942
Machinery	27,691,776			27,691,776
Metals & Mining	85,272,060	\$ 103,313,493		188,585,553
Oil, Gas & Consumable Fuels	155,834,259	35,901,640		191,735,899
Paper & Forest Products	18,313,968	3,948,360		22,262,328
Real Estate Investment Trusts (REITs)	13,110,120			13,110,120
Short-Term Securities	24,861,572	70,955		24,932,527
Total	\$ 456,368,633	\$ 143,234,448		\$ 599,603,081
	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (2,986,519)	\$ (3,195,762)		\$ (6,182,281)

¹ Derivative financial instruments are options written, which are shown at value.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

93

Table of Contents**Schedule of Investments (concluded)****BlackRock Real Asset Equity Trust (BCF)**

The carrying amount for certain of the Trust's assets and/or liabilities approximates fair value for financial statement purposes. As of April 30, 2014, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 15,014			\$ 15,014
Foreign currency at value	94,421			94,421
Liabilities:				
Collateral on securities loaned at value		\$ (70,955)		(70,955)
Total	\$ 109,435	\$ (70,955)		\$ 38,480

There were no transfers between levels during the six months ended April 30, 2014.

See Notes to Financial Statements.

Table of Contents**Consolidated Schedule of Investments** April 30, 2014

(Unaudited)

BlackRock Resources & Commodities Strategy Trust (BCX)
(Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
Chemicals 11.3%		
Agrium, Inc.	73,800	\$ 7,089,966
CF Industries Holdings, Inc. (a)	16,000	3,922,720
Israel Chemicals Ltd.	35,000	310,634
Monsanto Co. (a)	240,300	26,601,210
The Mosaic Co. (a)	153,908	7,701,556
Potash Corp. of Saskatchewan, Inc. (a)	200,000	7,232,000
Syngenta AG	51,000	20,195,574
		73,053,660
Food Products 9.2%		
Archer-Daniels-Midland Co. (a)	287,700	12,581,121
BRF SA ADR	290,000	6,554,000
Bunge Ltd. (a)	175,300	13,962,645
First Resources Ltd.	1,700,000	3,484,885
Ingredion, Inc. (a)	143,195	10,088,088
Select Harvests Ltd.	120,000	703,789
Tyson Foods, Inc., Class A (a)	300,000	12,591,000
		59,965,528
Machinery 1.1%		
Deere & Co. (a)	72,420	6,759,683
Metals & Mining 22.2%		
BHP Billiton Ltd. ADR (a)	502,100	35,418,134
First Quantum Minerals Ltd. (a)	352,600	7,022,725
Freeport-McMoRan Copper & Gold, Inc. (a)	593,200	20,388,284
Fresnillo PLC	628,700	9,065,785
Glencore Xstrata PLC	1,531,500	8,263,579
Labrador Iron Ore Royalty Corp. (a)	200,353	5,489,349
Lundin Mining Corp. (a)(b)	1,357,700	6,936,837
MMC Norilsk Nickel OJSC ADR	738,200	13,346,043
Nevsun Resources Ltd.	2,204,650	7,985,457
Rio Tinto PLC ADR (a)	445,900	24,207,911
Vedanta Resources PLC	386,750	6,193,086
		144,317,190
Oil, Gas & Consumable Fuels 50.1%		
BP PLC ADR (a)(c)	452,500	22,905,550
Cairn Energy PLC (b)	2,715,000	8,456,573
Canadian Oil Sands Ltd. (a)	744,000	16,128,315
Chevron Corp. (a)(c)	382,300	47,986,296
Common Stocks		
Oil, Gas & Consumable Fuels (concluded)		
China Shenhua Energy Co. Ltd., Series H	5,209,000	\$ 14,146,193
ConocoPhillips (a)	418,500	31,098,735
Cosan Ltd., Class A	150,000	1,819,500
Enbridge, Inc. (a)	279,800	13,501,776
Eni SpA ADR	236,400	12,207,696
Exxon Mobil Corp. (a)(c)	512,399	52,474,782
Imperial Oil Ltd. (a)	197,300	9,634,137
Inpex Corp.	897,900	13,094,443
Royal Dutch Shell PLC ADR (a)(c)	397,900	31,330,646
Southwestern Energy Co. (a)(b)	133,500	6,391,980
Statoil ASA	671,100	20,458,760
Total SA ADR	148,900	10,607,636
Ultra Petroleum Corp. (a)(b)	441,100	13,144,780

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

		325,387,798
Paper & Forest Products 1.1%		
Canfor Corp. (a)(b)	160,000	3,629,032
International Forest Products Ltd., Class A (b)	240,000	3,639,250
		7,268,282
Real Estate Investment Trusts (REITs) 0.5%		
Plum Creek Timber Co., Inc.	30,000	1,308,000
Rayonier, Inc.	46,600	2,101,660
		3,409,660
Total Long-Term Investments		
(Cost \$567,646,783) 95.5%		620,161,801
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (d)(e)	36,702,308	36,702,308
Total Short-Term Securities		
(Cost \$36,702,308) 5.6%		36,702,308
Total Investments Before Options Written		
(Cost \$604,349,091) 101.1%		656,864,109
Options Written		
(Premiums Received \$3,956,279) (1.1)%		(7,214,666)
Total Investments Net of Options Written 100.0%		649,649,443
Liabilities in Excess of Other Assets 0.0%		(242,448)
Net Assets 100.0%		\$ 649,406,995

Notes to Schedule of Investments

(a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(b) Non-income producing security.

(c) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(d) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares Held at October 31, 2013	Net Activity	Shares Held at April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	29,416,955	7,285,353	36,702,308	\$ 4,729

(e) Represents the current yield as of report date.

See Notes to Financial Statements.

Table of Contents**Consolidated Schedule of Investments
(continued)****BlackRock Resources & Commodities Strategy Trust (BCX)**

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
BP PLC ADR	Call	USD	49.50	5/02/14	550	\$ (65,725)
Exxon Mobil Corp.	Call	USD	94.00	5/02/14	304	(246,240)
Chevron Corp.	Call	USD	120.00	5/05/14	179	(102,478)
ConocoPhillips	Call	USD	68.50	5/05/14	680	(411,400)
Deere & Co.	Call	USD	89.00	5/05/14	253	(110,655)
Ingredion, Inc.	Call	USD	69.00	5/05/14	27	(4,246)
Archer-Daniels-Midland Co.	Call	USD	43.50	5/09/14	188	(11,656)
CF Industries Holdings, Inc.	Call	USD	260.00	5/09/14	56	(5,880)
The Mosaic Co.	Call	USD	50.00	5/09/14	135	(12,352)
Potash Corp. of Saskatchewan, Inc.	Call	USD	35.50	5/09/14	214	(18,297)
Archer-Daniels-Midland Co.	Call	USD	44.00	5/19/14	409	(18,814)
BHP Billiton Ltd. ADR	Call	USD	67.50	5/19/14	340	(113,900)
BHP Billiton Ltd. ADR	Call	USD	70.00	5/19/14	315	(43,628)
BHP Billiton Ltd. ADR	Call	USD	72.50	5/19/14	644	(23,828)
BP PLC ADR	Call	USD	48.00	5/19/14	553	(142,674)
Bunge Ltd.	Call	USD	82.50	5/19/14	622	(68,420)
Canadian Oil Sands Ltd.	Call	CAD	23.00	5/19/14	860	(69,440)
Canfor Corp.	Call	CAD	28.00	5/19/14	185	(1,013)
ConocoPhillips	Call	USD	75.00	5/19/14	784	(52,136)
Enbridge, Inc.	Call	CAD	52.00	5/19/14	617	(65,018)
Exxon Mobil Corp.	Call	USD	100.00	5/19/14	1,111	(303,858)
First Quantum Minerals Ltd.	Call	CAD	20.00	5/19/14	617	(107,520)
First Quantum Minerals Ltd.	Call	CAD	21.00	5/19/14	617	(60,234)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD	34.00	5/19/14	779	(66,994)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD	35.00	5/19/14	775	(29,062)
Imperial Oil Ltd.	Call	CAD	50.00	5/19/14	345	(112,529)
Imperial Oil Ltd.	Call	CAD	52.00	5/19/14	345	(55,084)
Ingredion, Inc.	Call	USD	70.00	5/19/14	225	(29,812)
Labrador Iron Ore Royalty Corp.	Call	CAD	31.85	5/19/14	400	(3,285)
Lundin Mining Corp.	Call	CAD	5.00	5/19/14	425	(23,265)
The Mosaic Co.	Call	USD	47.50	5/19/14	403	(111,832)
Potash Corp. of Saskatchewan, Inc.	Call	USD	36.00	5/19/14	486	(33,048)
Rio Tinto PLC ADR	Call	USD	60.00	5/19/14	540	(2,700)
Southwestern Energy Co.	Call	USD	47.00	5/19/14	298	(52,448)
Tyson Foods, Inc., Class A	Call	USD	43.00	5/19/14	525	(35,438)
Tyson Foods, Inc., Class A	Call	USD	44.00	5/19/14	525	(18,375)
Ultra Petroleum Corp.	Call	USD	30.00	5/19/14	945	(92,138)
Ultra Petroleum Corp.	Call	USD	31.00	5/19/14	945	(56,700)
Monsanto Co.	Call	USD	112.00	5/22/14	420	(56,616)
Archer-Daniels-Midland Co.	Call	USD	44.00	5/23/14	409	(23,926)
BP PLC ADR	Call	USD	48.50	5/23/14	480	(100,080)
Chevron Corp.	Call	USD	123.00	5/23/14	390	(129,675)
Chevron Corp.	Call	USD	123.00	5/30/14	390	(134,550)
Exxon Mobil Corp.	Call	USD	101.00	5/30/14	189	(40,257)
Chevron Corp.	Call	USD	125.00	6/06/14	189	(42,525)
Exxon Mobil Corp.	Call	USD	101.00	6/06/14	189	(42,052)
Monsanto Co.	Call	USD	115.00	6/10/14	421	(41,666)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Canadian Oil Sands Ltd.

Call CAD 25.00 6/23/14 875 (9,580)

See Notes to Financial Statements.

96

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Consolidated Schedule of Investments
(continued)****BlackRock Resources & Commodities Strategy Trust (BCX)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Canfor Corp.	Call	CAD	27.00	6/23/14	250	\$ (9,124)
Chevron Corp.	Call	USD	125.00	6/23/14	190	(47,595)
Freeport-McMoRan Copper & Gold, Inc.	Call	USD	34.00	6/23/14	520	(72,020)
Labrador Iron Ore Royalty Corp.	Call	CAD	32.00	6/23/14	300	(8,211)
Total						\$ (3,539,999)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	73.90	5/02/14	16,300	\$ (78,883)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	74.28	5/02/14	6,900	(30,756)
Eni SpA ADR	Goldman Sachs International	Call	USD	48.35	5/05/14	32,700	(107,593)
Ingredion, Inc.	UBS AG	Call	USD	67.50	5/05/14	25,000	(74,971)
Total SA ADR	Morgan Stanley & Co. International PLC	Call	USD	64.50	5/05/14	6,300	(42,464)
Fresnillo PLC	Deutsche Bank AG	Call	GBP	9.46	5/06/14	115,550	(1,167)
Mining and Metallurgical Co. Norilsk Nickel OJSC	Goldman Sachs International	Call	USD	17.37	5/06/14	139,300	(99,565)
Vedanta Resources PLC	Morgan Stanley & Co. International PLC	Call	GBP	8.41	5/06/14	44,000	(80,193)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/07/14	60,900	(148,548)
First Resources Ltd.	Bank of America N.A.	Call	SGD	2.38	5/08/14	297,000	(47,409)
Inpex Corp.	Morgan Stanley & Co. International PLC	Call	JPY	1,341.80	5/08/14	314,200	(455,939)
Select Harvests Ltd.	Morgan Stanley & Co. International PLC	Call	AUD	6.78	5/08/14	42,000	(674)
Ultra Petroleum Corp.	UBS AG	Call	USD	26.25	5/12/14	95,000	(339,635)
Agrium, Inc.	Credit Suisse International	Call	USD	97.00	5/13/14	12,900	(14,407)
Statoil ASA	Deutsche Bank AG	Call	NOK	166.73	5/13/14	60,900	(152,126)
Syngenta AG	Goldman Sachs International	Call	CHF	340.78	5/13/14	17,900	(167,985)
Eni SpA ADR	UBS AG	Call	USD	49.11	5/14/14	25,000	(65,646)
Fresnillo PLC	Morgan Stanley & Co. International PLC	Call	GBP	9.08	5/14/14	53,253	(7,800)
Israel Chemicals Ltd.	Goldman Sachs International	Call	ILS	31.24	5/14/14	35,000	(3,933)
Total SA ADR	Deutsche Bank AG	Call	USD	64.85	5/14/14	39,500	(254,901)
Vedanta Resources PLC	Morgan Stanley & Co. International PLC	Call	GBP	9.17	5/21/14	69,700	(56,188)
China Shenhua Energy Co. Ltd., Series H	Deutsche Bank AG	Call	HKD	22.81	5/22/14	539,000	(6,101)
International Forest Products Ltd., Class A	Goldman Sachs International	Call	CAD	15.80	5/23/14	28,000	(28,648)
Agrium, Inc.	Credit Suisse International	Call	USD	97.00	5/27/14	12,900	(23,049)
BHP Billiton Ltd. ADR	Deutsche Bank AG	Call	USD	71.09	5/27/14	50,000	(56,483)
Eni SpA ADR	UBS AG	Call	USD	49.11	5/27/14	25,000	(63,250)
Mining and Metallurgical Co. Norilsk Nickel OJSC	Deutsche Bank AG	Call	USD	18.40	5/28/14	17,500	(4,351)
MMC Norilsk Nickel OJSC ADR	Morgan Stanley & Co. International PLC	Call	USD	17.65	5/28/14	101,000	(79,505)
Rio Tinto PLC ADR	UBS AG	Call	USD	56.50	5/28/14	55,000	(28,138)
BRF SA ADR	Morgan Stanley & Co. International PLC	Call	USD	22.19	6/02/14	101,500	(89,789)
Glencore Xstrata PLC	Deutsche Bank AG	Call	GBP	3.20	6/03/14	418,500	(46,165)
Rio Tinto PLC ADR	Deutsche Bank AG	Call	USD	55.86	6/04/14	50,000	(49,739)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Southwestern Energy Co.	Goldman Sachs International	Call	USD	49.38	6/04/14	62,500	(55,602)
China Shenhua Energy Co. Ltd., Series H	Deutsche Bank AG	Call	HKD	22.81	6/05/14	539,000	(12,842)
Enbridge, Inc.	Citibank N.A.	Call	CAD	51.10	6/05/14	18,000	(32,064)
Glencore Xstrata PLC	Deutsche Bank AG	Call	GBP	3.21	6/05/14	110,000	(11,764)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.24	6/05/14	58,000	(180,513)
Total SA ADR	Morgan Stanley & Co. International PLC	Call	USD	66.83	6/05/14	6,300	(27,997)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

97

Table of Contents**Consolidated Schedule of Investments
(continued)****BlackRock Resources & Commodities Strategy Trust (BCX)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Lundin Mining Corp.	UBS AG	Call	CAD	5.43	6/06/14	216,000	\$ (65,706)
Statoil ASA	Morgan Stanley & Co. International PLC	Call	NOK	169.48	6/10/14	113,000	(223,139)
First Resources Ltd.	Bank of America N.A.	Call	SGD	2.57	6/11/14	149,000	(11,708)
China Shenhua Energy Co. Ltd., Series H	Goldman Sachs International	Call	HKD	23.39	6/12/14	745,000	(13,730)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/12/14	29,000	(86,288)
Fresnillo PLC	Bank of America N.A.	Call	GBP	8.71	6/17/14	52,500	(37,103)
Royal Dutch Shell PLC ADR	Citibank N.A.	Call	USD	76.62	6/18/14	29,000	(89,203)
Vedanta Resources PLC	Bank of America N.A.	Call	GBP	9.58	6/18/14	22,000	(14,125)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	6/21/14	9,100	(6,476)
First Resources Ltd.	Bank of America N.A.	Call	SGD	2.56	6/26/14	149,000	(14,558)
Lundin Mining Corp.	UBS AG	Call	CAD	5.43	6/27/14	216,000	(77,628)
Enbridge, Inc.	Deutsche Bank AG	Call	CAD	53.00	7/09/14	9,100	(8,220)
Total							\$ (3,674,667)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, please refer to Note 2 of the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Chemicals	\$ 52,547,452	\$ 20,506,208		\$ 73,053,660
Food Products	59,261,739	703,789		59,965,528
Machinery	6,759,683			6,759,683
Metals & Mining	107,448,697	36,868,493		144,317,190
Oil, Gas & Consumable Fuels	269,231,829	56,155,969		325,387,798
Paper & Forest Products	7,268,282			7,268,282
Real Estate Investment Trusts (REITs)	3,409,660			3,409,660
Short-Term Securities	36,702,308			36,702,308
Total	\$ 542,629,650	\$ 114,234,459		\$ 656,864,109

See Notes to Financial Statements.

Table of Contents**Consolidated Schedule of Investments
(concluded)****BlackRock Resources & Commodities Strategy Trust (BCX)**

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (3,326,816)	\$ (3,887,850)		\$ (7,214,666)

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets and/or liabilities approximates fair value for financial statement purposes. As of April 30, 2014, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 25,495			\$ 25,495
Liabilities:				
Foreign bank overdraft		\$ (58,695)		(58,695)
Total	\$ 25,495	(58,695)		\$ (33,200)

There were no transfers between levels during the six months ended April 30, 2014.

See Notes to Financial Statements.

Table of Contents**Schedule of Investments** April 30, 2014 (Unaudited)**BlackRock Utility and Infrastructure Trust (BUI)**
(Percentages shown are based on Net Assets)

	Shares	Value
Common Stocks		
Construction & Engineering 4.0%		
Ferrovial SA	303,500	\$ 6,746,295
Vinci SA	110,200	8,320,791
		15,067,086
Diversified Telecommunication Services 4.9%		
BT Group PLC	426,800	2,664,348
Frontier Communications Corp.	389,800	2,319,310
Swisscom AG	2,010	1,222,843
Telenor ASA	139,100	3,268,436
Verizon Communications, Inc. (a)(b)	190,400	8,897,392
		18,372,329
Electric Utilities 17.5%		
American Electric Power Co., Inc. (a)	36,300	1,953,303
Cleco Corp. (a)	36,400	1,912,820
Duke Energy Corp. (a)	157,868	11,759,587
Edison International	127,600	7,217,056
ITC Holdings Corp.	144,600	5,345,862
NextEra Energy, Inc. (a)(b)	150,400	15,017,440
Northeast Utilities (a)	74,000	3,497,240
NRG Yield, Inc., Class A	154,500	6,618,780
OGE Energy Corp.	52,400	1,956,092
PPL Corp.	82,700	2,757,218
Spark Infrastructure Group	670,800	1,102,316
Terna Rete Elettrica Nazionale SpA	251,100	1,360,380
Westar Energy, Inc.	88,600	3,178,968
Xcel Energy, Inc.	59,900	1,909,013
		65,586,075
Gas Utilities 1.1%		
Snam SpA (a)	692,300	4,164,141
Independent Power and Renewable Electricity Producers 2.7%		
EDP Renovaveis SA (c)	313,900	2,152,610
Enel Green Power SpA (a)	822,500	2,353,995
NRG Energy, Inc. (a)	143,701	4,701,897
Pattern Energy Group, Inc.	38,800	1,039,840
		10,248,342
Machinery 0.8%		
Xylem, Inc.	79,500	2,988,405
Media 2.3%		
Comcast Corp., Special Class A (a)(b)	85,900	4,383,477
Time Warner Cable, Inc. (a)	28,700	4,059,902
		8,443,379
Multi-Utilities 20.2%		
CenterPoint Energy, Inc.	155,900	3,860,084
CMS Energy Corp. (a)(b)	397,600	12,051,256
Dominion Resources, Inc. (a)	152,400	11,055,096
DTE Energy Co. (a)	25,100	1,961,314
E.ON SE	39,300	752,785
MDU Resources Group, Inc.	138,500	4,905,670
National Grid PLC	1,020,500	14,504,558
NiSource, Inc. (a)	84,800	3,079,936
NorthWestern Corp.	67,000	3,241,460
Public Service Enterprise Group, Inc.	158,756	6,504,233

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Sempra Energy	75,300	7,425,333
Veolia Environnement SA	55,000	1,026,073
Wisconsin Energy Corp.	113,000	5,478,240
		75,846,038
Oil, Gas & Consumable Fuels 23.2%		
Access Midstream Partners LP (a)	33,576	1,992,736
AltaGas Ltd. (a)	56,900	2,424,369
Atlas Pipeline Partners LP	24,600	796,548
Delek Logistics Partners LP (a)	37,200	1,252,896
Common Stocks	Shares	Value
Oil, Gas & Consumable Fuels (concluded)		
Enable Midstream Partners LP (c)	45,800	\$ 1,133,092
Enbridge, Inc.	162,200	7,832,638
Energy Transfer Partners LP (a)	29,496	1,627,884
Enterprise Products Partners LP	115,977	8,481,398
EQT Midstream Partners LP	50,700	3,905,421
Genesis Energy LP	143,669	7,962,136
Magellan Midstream Partners LP (a)	74,100	5,498,961
MarkWest Energy Partners LP	77,453	4,905,873
MPLX LP (a)	60,500	3,274,865
ONEOK Partners LP (a)	78,245	4,459,183
Pembina Pipeline Corp.	84,200	3,308,694
Phillips 66 Partners LP	43,300	2,321,746
Plains All American Pipeline LP (a)(b)	109,670	6,119,586
QEP Midstream Partners LP	44,300	1,054,340
Rose Rock Midstream LP	18,300	763,110
Sunoco Logistics Partners LP	49,300	4,484,328
Tesoro Logistics LP	88,600	5,661,540
TransCanada Corp. (a)	74,800	3,485,958
Valero Energy Partners LP (a)	45,400	1,870,934
Western Gas Partners LP	23,514	1,598,952
Williams Partners LP	16,790	866,028
		87,083,216
Real Estate Investment Trusts (REITs) 3.4%		
American Tower Corp. (a)(b)	153,400	12,811,968
Transportation Infrastructure 13.4%		
Abertis Infraestructuras SA	390,900	8,798,975
Aeroports de Paris	29,300	3,643,623
Atlantia SpA (a)	488,884	12,734,894
CCR SA	223,900	1,755,252
Flughafen Zuerich AG	6,300	3,974,555
Fraport AG Frankfurt Airport Services Worldwide	69,400	5,132,617
Groupe Eurotunnel SA	348,800	4,682,570
Sydney Airport	597,666	2,348,508
Transurban Group	1,090,300	7,363,675
		50,434,669
Water Utilities 2.9%		
American Water Works Co., Inc. (a)	184,600	8,404,838
Aqua America, Inc.	58,050	1,456,475
Severn Trent PLC	26,400	822,381
		10,683,694
Wireless Telecommunication Services 0.6%		
SBA Communications Corp., Class A (a)(c)	22,800	2,046,528
Total Long-Term Investments		
(Cost \$285,230,957) 97.0%		363,775,870

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Utility and Infrastructure Trust (BUI)**
(Percentages shown are based on Net Assets)

Short-Term Securities	Shares	Value
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.03% (d)(e)	12,817,865	\$ 12,817,865
Total Short-Term Securities		
(Cost \$12,817,865) 3.4%		12,817,865
Total Investments Before Options Written		
(Cost \$298,048,822) 100.4%		376,593,735
Options Written		Value
(Premiums Received \$2,198,766) (0.9)%		\$ (3,420,626)
Total Investments Net of Options Written 99.5%		373,173,109
Other Assets Less Liabilities 0.5%		1,962,516
Net Assets 100.0%		\$ 375,135,625

Notes to Schedule of Investments

(a) All or a portion of security has been pledged/segregated as collateral in connection with outstanding options written.

(b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(c) Non-income producing security.

(d) Investments in issuers considered to be an affiliate of the Trust during the six months ended April 30, 2014, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares Held at October 31, 2013	Net Activity	Shares Held at April 30, 2014	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	15,720,002	(2,902,137)	12,817,865	\$ 1,958

(e) Represents the current yield as of report date.

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment advisor. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Exchange-traded options written as of April 30, 2014 were as follows:

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
NRG Energy, Inc.	Call	USD	30.75	5/13/14	250	\$ (52,174)
Atlantia SpA	Call	EUR	19.00	5/16/14	170	(29,884)
Snam SpA	Call	EUR	4.20	5/16/14	170	(31,980)
Access Midstream Partners LP	Call	USD	60.00	5/19/14	60	(2,550)
AltaGas Ltd.	Call	CAD	46.00	5/19/14	110	(9,534)
American Tower Corp.	Call	USD	82.50	5/19/14	268	(49,580)
Cleco Corp.	Call	USD	50.00	5/19/14	63	(18,428)
Comcast Corp., Special Class A	Call	USD	49.00	5/19/14	76	(16,910)
Duke Energy Corp.	Call	USD	72.50	5/19/14	525	(114,188)
Energy Transfer Partners LP	Call	USD	55.00	5/19/14	103	(4,120)
Magellan Midstream Partners LP	Call	USD	72.50	5/19/14	191	(35,335)
NiSource, Inc.	Call	USD	36.00	5/19/14	296	(19,240)
Northeast Utilities	Call	USD	45.00	5/19/14	196	(44,590)
NRG Energy, Inc.	Call	USD	33.00	5/19/14	252	(13,860)
ONEOK Partners LP	Call	USD	55.00	5/19/14	91	(21,158)
SBA Communications Corp., Class A	Call	USD	95.00	5/19/14	80	(3,000)
Time Warner Cable, Inc.	Call	USD	140.00	5/19/14	100	(26,000)
TransCanada Corp.	Call	CAD	52.00	5/19/14	261	(4,405)
Valero Energy Partners LP	Call	USD	40.00	5/19/14	88	(17,820)
Verizon Communications, Inc.	Call	USD	48.00	5/19/14	188	(1,974)
Verizon Communications, Inc.	Call	USD	48.00	5/23/14	188	(3,384)
Verizon Communications, Inc.	Call	USD	48.50	5/30/14	130	(1,820)
American Tower Corp.	Call	USD	84.00	6/06/14	268	(39,530)
DTE Energy Co.	Call	USD	78.00	6/06/14	87	(12,782)
Atlantia SpA	Call	EUR	19.50	6/20/14	170	(45,387)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

101

Table of Contents**Schedule of Investments (continued)****BlackRock Utility and Infrastructure Trust (BUI)**

Exchange-traded options written as of April 30, 2014 were as follows: (concluded)

Description	Put/ Call	Strike		Expiration Date	Contracts	Market Value
		Price				
Enel Green Power SpA	Call	EUR	2.10	6/20/14	290	\$ (30,092)
Delek Logistics Partners LP	Call	USD	35.00	6/23/14	120	(8,400)
Dominion Resources, Inc.	Call	USD	72.50	6/23/14	250	(33,750)
Duke Energy Corp.	Call	USD	72.50	6/23/14	30	(7,050)
MPLX LP	Call	USD	55.00	6/23/14	250	(36,250)
NextEra Energy, Inc.	Call	USD	97.50	6/23/14	183	(68,625)
Verizon Communications, Inc.	Call	USD	47.00	6/23/14	160	(13,520)
Total						\$ (817,320)

Over-the-counter options written as of April 30, 2014 were as follows:

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Sempra Energy	Goldman Sachs International	Call	USD	97.72	5/02/14	6,600	\$ (6,333)
Western Gas Partners LP	UBS AG	Call	USD	67.04	5/02/14	8,200	(8,038)
American Water Works Co., Inc.	Citibank N.A.	Call	USD	45.54	5/05/14	16,200	(9,306)
Edison International	Citibank N.A.	Call	USD	54.54	5/05/14	44,600	(90,967)
ITC Holdings Corp.	Morgan Stanley & Co. International PLC	Call	USD	36.59	5/05/14	25,400	(14,089)
Northeast Utilities	Deutsche Bank AG	Call	USD	43.95	5/05/14	6,300	(20,889)
ONEOK Partners LP	Morgan Stanley & Co. International PLC	Call	USD	53.97	5/05/14	13,800	(41,681)
CenterPoint Energy, Inc.	Deutsche Bank AG	Call	USD	24.37	5/06/14	30,600	(16,256)
CMS Energy Corp.	UBS AG	Call	USD	28.01	5/06/14	44,900	(103,270)
Fraport AG Frankfurt Airport Services Worldwide	Morgan Stanley & Co. International PLC	Call	EUR	54.68	5/06/14	4,800	(812)
MDU Resources Group, Inc.	Morgan Stanley & Co. International PLC	Call	USD	34.46	5/06/14	15,500	(15,497)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	45.94	5/07/14	16,000	(8,157)
Enbridge, Inc.	Deutsche Bank AG	Call	USD	45.69	5/07/14	56,700	(147,549)
Telenor ASA	Credit Suisse International	Call	NOK	131.53	5/07/14	48,600	(67,254)
Westar Energy, Inc.	Citibank N.A.	Call	USD	35.56	5/07/14	15,500	(7,763)
E.ON SE	Morgan Stanley & Co. International PLC	Call	EUR	14.35	5/08/14	13,700	(39)
Sempra Energy	UBS AG	Call	USD	97.00	5/08/14	19,700	(39,421)
Spark Infrastructure Group	Deutsche Bank AG	Call	AUD	1.74	5/08/14	234,800	(7,834)
Sydney Airport	UBS AG	Call	AUD	4.18	5/08/14	209,100	(14,894)
ITC Holdings Corp.	Citibank N.A.	Call	USD	37.48	5/09/14	25,200	(6,010)
Frontier Communications Corp.	JPMorgan Chase Bank N.A.	Call	USD	5.71	5/12/14	68,300	(21,775)
NextEra Energy, Inc.	Morgan Stanley & Co. International PLC	Call	USD	94.50	5/12/14	34,300	(191,522)
NorthWestern Corp.	UBS AG	Call	USD	45.95	5/12/14	21,300	(53,353)
Sunoco Logistics Partners LP	Goldman Sachs International	Call	USD	90.58	5/12/14	8,600	(8,032)
Tesoro Logistics LP	Citibank N.A.	Call	USD	64.00	5/12/14	10,500	(7,983)
Xcel Energy, Inc.	Bank of America N.A.	Call	USD	30.16	5/12/14	20,900	(35,750)
Cleco Corp.	Citibank N.A.	Call	USD	50.30	5/13/14	6,400	(14,413)
Comcast Corp., Special Class A	Citibank N.A.	Call	USD	50.75	5/13/14	5,600	(4,386)
Fraport AG Frankfurt Airport Services Worldwide	Goldman Sachs International	Call	EUR	54.64	5/13/14	4,800	(1,894)
Fraport AG Frankfurt Airport Services Worldwide	Morgan Stanley & Co. International PLC	Call	EUR	54.89	5/13/14	4,400	(1,494)
MarkWest Energy Partners LP	UBS AG	Call	USD	67.11	5/13/14	13,500	(1,196)
Plains All American Pipeline LP	Morgan Stanley & Co. International PLC	Call	USD	53.00	5/13/14	6,200	(18,549)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Westar Energy, Inc.	Citibank N.A.	Call	USD	35.56	5/13/14	15,500	(9,482)
Xylem, Inc.	Morgan Stanley & Co. International PLC	Call	USD	39.00	5/13/14	27,800	(10,480)
Phillips 66 Partners LP	UBS AG	Call	USD	43.46	5/14/14	5,000	(50,811)
Severn Trent PLC	Deutsche Bank AG	Call	GBP	18.13	5/14/14	4,600	(3,774)
Enterprise Products Partners LP	Deutsche Bank AG	Call	USD	71.00	5/15/14	35,500	(80,797)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Utility and Infrastructure Trust (BUI)**

Over-the-counter options written as of April 30, 2014 were as follows: (continued)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
Groupe Eurotunnel SA	Morgan Stanley & Co. International PLC	Call	EUR	9.18	5/15/14	88,700	\$ (66,997)
CCR SA	Deutsche Bank AG	Call	BRL	17.48	5/20/14	39,000	(9,147)
Transurban Group	Goldman Sachs International	Call	AUD	7.32	5/20/14	381,600	(41,084)
Fraport AG Frankfurt Airport Services Worldwide	Morgan Stanley & Co. International PLC	Call	EUR	54.03	5/21/14	2,200	(2,033)
National Grid PLC	Deutsche Bank AG	Call	GBP	8.25	5/21/14	164,200	(67,042)
Access Midstream Partners LP	UBS AG	Call	USD	57.94	5/22/14	5,900	(9,531)
Aeroports de Paris	Morgan Stanley & Co. International PLC	Call	EUR	93.80	5/22/14	2,600	(848)
American Electric Power Co., Inc.	UBS AG	Call	USD	52.27	5/22/14	12,700	(19,558)
CMS Energy Corp.	Goldman Sachs International	Call	USD	29.14	5/22/14	49,600	(58,032)
Ferrovial SA	Goldman Sachs International	Call	EUR	15.85	5/22/14	77,000	(54,193)
Comcast Corp., Special Class A	Citibank N.A.	Call	USD	49.25	5/27/14	11,200	(24,433)
Genesis Energy LP	Morgan Stanley & Co. International PLC	Call	USD	54.76	5/27/14	25,000	(40,385)
NRG Yield, Inc., Class A	Citibank N.A.	Call	USD	43.03	5/27/14	15,700	(16,913)
CCR SA	Goldman Sachs International	Call	BRL	17.64	5/28/14	20,000	(4,965)
CenterPoint Energy, Inc.	Citibank N.A.	Call	USD	24.50	5/28/14	23,900	(15,382)
EDP Renovaveis SA	Goldman Sachs International	Call	EUR	4.73	5/28/14	13,250	(4,645)
Frontier Communications Corp.	JPMorgan Chase Bank N.A.	Call	USD	5.71	5/28/14	68,300	(27,072)
Enterprise Products Partners LP	Morgan Stanley & Co. International PLC	Call	USD	73.42	5/29/14	5,000	(4,343)
MarkWest Energy Partners LP	UBS AG	Call	USD	67.11	5/29/14	13,500	(5,274)
Public Service Enterprise Group, Inc.	Deutsche Bank AG	Call	USD	38.70	5/29/14	24,800	(61,727)
Tesoro Logistics LP	Morgan Stanley & Co. International PLC	Call	USD	61.79	5/29/14	20,500	(53,217)
Aqua America, Inc.	Goldman Sachs International	Call	USD	25.95	5/30/14	20,300	(4,085)
MDU Resources Group, Inc.	Morgan Stanley & Co. International PLC	Call	USD	34.40	5/30/14	16,000	(20,509)
Sunoco Logistics Partners LP	Goldman Sachs International	Call	USD	90.58	5/30/14	8,600	(13,393)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	46.66	6/02/14	16,200	(14,388)
CMS Energy Corp.	Morgan Stanley & Co. International PLC	Call	USD	30.52	6/02/14	44,600	(23,498)
Dominion Resources, Inc.	Credit Suisse International	Call	USD	73.10	6/02/14	28,400	(28,063)
Pembina Pipeline Corp.	Goldman Sachs International	Call	CAD	41.93	6/02/14	29,400	(37,120)
Aeroports de Paris	UBS AG	Call	EUR	92.92	6/03/14	2,600	(1,070)
BT Group PLC	Morgan Stanley & Co. International PLC	Call	GBP	3.76	6/03/14	148,000	(19,579)
Ferrovial SA	Deutsche Bank AG	Call	EUR	16.15	6/03/14	29,000	(13,570)
Fraport AG Frankfurt Airport Services Worldwide	UBS AG	Call	EUR	54.05	6/03/14	2,200	(1,389)
National Grid PLC	Morgan Stanley & Co. International PLC	Call	GBP	8.31	6/03/14	193,000	(69,178)
Veolia Environnement SA	Deutsche Bank AG	Call	EUR	14.32	6/03/14	20,000	(116)
Vinci SA	Deutsche Bank AG	Call	EUR	54.54	6/03/14	39,000	(69,854)
EQT Midstream Partners LP	Citibank N.A.	Call	USD	71.00	6/05/14	8,900	(53,667)
MDU Resources Group, Inc.	UBS AG	Call	USD	34.49	6/05/14	8,500	(10,817)
OGE Energy Corp.	Credit Suisse International	Call	USD	37.39	6/05/14	9,100	(9,553)
Pattern Energy Group, Inc.	Deutsche Bank AG	Call	USD	29.13	6/05/14	13,500	(4,863)
Phillips 66 Partners LP	UBS AG	Call	USD	56.92	6/05/14	5,000	(3,281)
Public Service Enterprise Group, Inc.	Citibank N.A.	Call	USD	39.95	6/05/14	6,000	(7,216)
Swisscom AG	Goldman Sachs International	Call	CHF	537.83	6/05/14	700	(6,413)
Valero Energy Partners LP	Morgan Stanley & Co. International PLC	Call	USD	44.56	6/05/14	3,500	(2,152)
Wisconsin Energy Corp.	UBS AG	Call	USD	48.42	6/05/14	39,500	(22,380)
American Water Works Co., Inc.	Morgan Stanley & Co. International PLC	Call	USD	45.75	6/09/14	16,200	(12,023)
Comcast Corp., Special Class A	Citibank N.A.	Call	USD	51.59	6/09/14	5,600	(4,424)
Magellan Midstream Partners LP	Citibank N.A.	Call	USD	73.17	6/09/14	6,800	(11,495)

See Notes to Financial Statements.

Table of Contents**Schedule of Investments (continued)****BlackRock Utility and Infrastructure Trust (BUI)**

Over-the-counter options written as of April 30, 2014 were as follows: (concluded)

Description	Counterparty	Put/ Call	Strike		Expiration Date	Contracts	Market Value
			Price				
EDP Renovaveis SA	Goldman Sachs International	Call	EUR	4.73	6/10/14	13,250	\$ (5,018)
Genesis Energy LP	Morgan Stanley & Co. International PLC	Call	USD	54.76	6/10/14	25,000	(46,151)
OGE Energy Corp.	Credit Suisse International	Call	USD	37.58	6/10/14	9,200	(8,599)
Plains All American Pipeline LP	Morgan Stanley & Co. International PLC	Call	USD	57.00	6/10/14	26,000	(13,791)
Fraport AG Frankfurt Airport Services Worldwide	Morgan Stanley & Co. International PLC	Call	EUR	53.34	6/11/14	5,700	(4,845)
MDU Resources Group, Inc.	UBS AG	Call	USD	34.49	6/12/14	8,400	(10,094)
NorthWestern Corp.	UBS AG	Call	USD	48.00	6/12/14	2,100	(2,036)
Public Service Enterprise Group, Inc.	Deutsche Bank AG	Call	USD	38.70	6/12/14	24,800	(56,296)
Severn Trent PLC	Bank of America N.A.	Call	GBP	18.42	6/13/14	4,600	(4,113)
AltaGas Ltd.	Morgan Stanley & Co. International PLC	Call	CAD	46.02	6/16/14	8,900	(9,266)
EDP Renovaveis SA	Morgan Stanley & Co. International PLC	Call	EUR	4.72	6/17/14	13,250	(5,230)
Groupe Eurotunnel SA	Morgan Stanley & Co. International PLC	Call	EUR	9.73	6/17/14	32,700	(11,231)
Abertis Infraestructuras SA	Bank of America N.A.	Call	EUR	16.47	6/18/14	68,200	(33,177)
Valero Energy Partners LP	Morgan Stanley & Co. International PLC	Call	USD	44.56	6/18/14	3,500	(2,973)
Aeroports de Paris	Morgan Stanley & Co. International PLC	Call	EUR	89.29	6/25/14	5,000	(11,649)
Phillips 66 Partners LP	UBS AG	Call	USD	57.50	6/25/14	5,100	(4,583)
Plains All American Pipeline LP	Morgan Stanley & Co. International PLC	Call	USD	56.57	6/25/14	6,200	(5,238)
EDP Renovaveis SA	Morgan Stanley & Co. International PLC	Call	EUR	4.72	6/26/14	13,250	(5,441)
EQT Midstream Partners LP	UBS AG	Call	USD	76.25	6/26/14	8,800	(23,922)
NRG Yield, Inc., Class A	Citibank N.A.	Call	USD	42.25	6/26/14	38,300	(77,104)
Williams Partners LP	Morgan Stanley & Co. International PLC	Call	USD	51.81	6/30/14	5,800	(6,400)
Abertis Infraestructuras SA	Bank of America N.A.	Call	EUR	16.47	7/01/14	68,200	(38,703)
EDP Renovaveis SA	Goldman Sachs International	Call	EUR	4.75	7/09/14	28,800	(11,540)
EDP Renovaveis SA	UBS AG	Call	EUR	4.69	7/16/14	28,100	(13,239)
Total							\$ (2,603,306)

Fair Value Measurements Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a disclosure hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Changes in valuation techniques may result in transfers into or out of an assigned level within the disclosure hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value disclosure hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investment and derivative financial instrument and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instrument, please refer to Note 2 of the Notes to Financial Statements.

See Notes to Financial Statements.

104

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Schedule of Investments (concluded)****BlackRock Utility and Infrastructure Trust (BUI)**

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy as of April 30, 2014:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Construction & Engineering		\$ 15,067,086		\$ 15,067,086
Diversified Telecommunication Services	\$ 11,216,702	7,155,627		18,372,329
Electric Utilities	63,123,379	2,462,696		65,586,075
Gas Utilities		4,164,141		4,164,141
Independent Power and Renewable Electricity Producers	5,741,737	4,506,605		10,248,342
Machinery	2,988,405			2,988,405
Media	8,443,379			8,443,379
Multi-Utilities	59,562,622	16,283,416		75,846,038
Oil, Gas & Consumable Fuels	87,083,216			87,083,216
Real Estate Investment Trusts (REITs)	12,811,968			12,811,968
Transportation Infrastructure	1,755,252	48,679,417		50,434,669
Water Utilities	10,683,694			10,683,694
Wireless Telecommunication Services	2,046,528			2,046,528
Short-Term Securities	12,817,865			12,817,865
Total	\$ 278,274,747	\$ 98,318,988		\$ 376,593,735
	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹				
Liabilities:				
Equity contracts	\$ (615,020)	\$ (2,805,606)		\$ (3,420,626)

¹ Derivative financial instruments are options written, which are shown at value.

The carrying amount for certain of the Trust's assets approximates fair value for financial statement purposes. As of April 30, 2014, such assets are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3	Total
Assets:				
Cash	\$ 23,663			\$ 23,663
Foreign currency at value	190,232			190,232
Total	\$ 213,895			\$ 213,895

Certain foreign securities are fair valued utilizing an external pricing service to reflect any significant market movements between the time the Trust values such foreign securities and the earlier closing of foreign markets. Such fair valuations are categorized as Level 2 in the disclosure hierarchy. As of October 31, 2013 the Trust did not utilize the external pricing service model adjustments as significant market movements did not occur. As of April 30 2014, securities with a value of

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

\$7,807,764 were systematically fair valued due to significant market movements. Therefore, these securities were transferred from Level 1 to Level 2 during the period October 31, 2013 to April 30, 2014.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

105

Table of Contents**Statements of Assets and Liabilities**

April 30, 2014 (Unaudited)	BlackRock Dividend Income Trust (BQY)	BlackRock EcoSolutions Investment Trust (BQR)	BlackRock Energy and Resources Trust (BGR)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)	BlackRock Enhanced Equity Dividend Trust (BDJ)	BlackRock Global Opportunities Equity Trust (BOE)
Assets						
Investments at value unaffiliated ²	\$ 87,280,306	\$ 112,631,982	\$ 823,406,787	\$ 675,395,664	\$ 1,623,925,289	\$ 1,152,719,564
Investments at value affiliated ¹	3,038,407	4,186,554	31,463,547	3,204,081	38,251,313	18,266,327
Cash	23,966		6,930	2,113	74,629	24,330
Cash pledged as collateral for OTC derivatives		100,000		200,000	100,000	
Foreign currency at value ⁴	26,460	16,164	184,978	3,608	1,778	10,988,841
Investments sold receivable		215,108		18,299,325	1,705,015	5,377,999
Options written receivable	29,366	85,586	380,400	105,220	635,368	499,240
Dividends receivable affiliated	78	92	884	302	903	161
Dividends receivable	187,315	276,632	195,650	1,064,894	1,356,427	2,080,207
Securities lending income receivable affiliated		482				30,912
Other assets	4,114	10,690	29,349	22,092	79,122	53,509
Total assets	90,590,012	117,523,290	855,668,525	698,297,299	1,666,129,844	1,190,041,090
Liabilities						
Options written at value ⁵	875,586	1,174,848	11,333,766	9,841,545	18,043,340	13,786,827
Collateral on securities loaned at value						9,198,761
Investments purchased payable		52,915		2,310,770	718,620	21,648,897
Options written payable	75,517	178,787	796,858	36,682	1,253,227	175,848
Investment advisory fees payable	53,973	108,633	808,221	472,876	1,079,867	937,820
Officers and Trustees fees payable	14,875	595	369,160	81,077	672,598	531,628
Other accrued expenses payable	127,513	117,257	186,786	154,097	335,685	296,285
Total liabilities	1,147,464	1,633,035	13,494,791	12,897,047	22,103,337	46,576,066
Net Assets	\$ 89,442,548	\$ 115,890,255	\$ 842,173,734	\$ 685,400,252	\$ 1,644,026,507	\$ 1,143,465,024
Net Assets Consist of						
Paid-in capital	\$ 82,951,843	\$ 172,464,776	\$ 671,744,850	\$ 722,434,062	\$ 1,597,828,802	\$ 1,154,307,475
Distributions in excess of net investment income	(1,711,885)	(3,990,196)	(98,847,386)	(5,897,076)	(35,892,255)	(38,496,228)
Accumulated net realized gain (loss)	(618,754)	(66,835,306)	146,297,578	(103,620,770)	(188,152,688)	(85,465,250)
Net unrealized appreciation/depreciation	8,821,344	14,250,981	122,978,692	72,484,036	270,242,648	113,119,027
Net Assets	\$ 89,442,548	\$ 115,890,255	\$ 842,173,734	\$ 685,400,252	\$ 1,644,026,507	\$ 1,143,465,024
Net asset value ^{6,7}	\$ 14.83	\$ 9.22	\$ 28.29	\$ 15.53	\$ 9.16	\$ 16.46
¹ Investments at cost unaffiliated	\$ 78,114,427	\$ 98,187,781	\$ 694,491,167	\$ 602,097,260	\$ 1,349,391,681	\$ 1,038,567,107
² Securities loaned at value						\$ 8,679,198
³ Investments at cost affiliated	\$ 3,038,407	\$ 4,186,554	\$ 31,463,547	\$ 3,204,081	\$ 38,251,313	\$ 18,266,327
⁴ Foreign currency at cost	\$ 26,419	\$ 17,786	\$ 184,978	\$ 9,211	\$ 1,650	\$ 10,931,252
⁵ Premiums received	\$ 529,380	\$ 982,018	\$ 5,396,719	\$ 9,033,294	\$ 13,752,252	\$ 12,733,116
⁶ Shares outstanding, unlimited number of shares authorized, \$0.001 par value	6,033,028	12,564,457	29,766,217		179,482,756	69,483,161
⁷ Shares outstanding, 200 million shares authorized, \$0.10 par value				44,121,400		

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

106

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Statements of Assets and Liabilities (concluded)**

April 30, 2014 (Unaudited)	BlackRock Health Sciences Trust (BME)	BlackRock International Growth and Income Trust (BGY)	BlackRock Real Asset Equity Trust (BCF)	BlackRock Resources & Commodities Strategy Trust (BCX)¹	BlackRock Utility and Infrastructure Trust (BUI)
Assets					
Investments at value unaffiliated ²	\$ 263,336,474	\$ 971,879,010	\$ 574,670,554	\$ 620,161,801	\$ 363,775,870
Investments at value affiliated ³	9,167,290	10,177,930	24,932,527	36,702,308	12,817,865
Cash	22,182		15,014	25,495	23,663
Cash pledged as collateral for OTC derivatives		7,744,504			
Cash pledged as collateral for exchange-traded options written	1,892,100	4,050,000			
Foreign currency at value ⁵	120,537	2,255,325	94,421		190,232
Investments sold receivable	662,612	11,048,447		199,946	1,625,640
Options written receivable		712,334	290,764	164,737	178,681
Dividends receivable affiliated	207	94	560	568	169
Dividends receivable	279,947	2,944,250	705,491	663,546	813,870
Securities lending income receivable affiliated	221	21,987	161		
Other assets	16,233	60,515	31,387	21,891	12,372
Total assets	275,497,803	1,010,894,396	600,740,879	657,940,292	379,438,362
Liabilities					
Bank overdraft		3,767,000			
Foreign bank overdraft ⁵				58,695	
Options written at value ⁶	2,030,854	12,305,555	6,182,281	7,214,666	3,420,626
Collateral on securities loaned at value	287,000	10,177,930	70,955		
Investments purchased payable	632,622	8,441,015			38,413
Options written payable	26,600	243,308	507,058	506,916	381,572
Investment advisory fees payable	221,062	761,038	550,335	521,875	302,957
Officers and Trustees fees payable	17,380	470,283	297,141	2,774	1,216
Other accrued expenses payable	98,825	291,701	194,606	228,371	157,953
Total liabilities	3,314,343	36,457,830	7,802,376	8,533,297	4,302,737
Net Assets	\$ 272,183,460	\$ 974,436,566	\$ 592,938,503	\$ 649,406,995	\$ 375,135,625
Net Assets Consist of					
Paid-in capital	\$ 182,592,761	\$ 1,421,001,423	\$ 621,054,142	\$ 765,766,937	\$ 310,378,484
Distributions in excess of net investment income	(20,740,167)	(30,769,824)	(20,767,572)	(22,274,085)	(6,140,281)
Accumulated net realized gain (loss)	40,405,349	(510,849,455)	(102,062,676)	(143,347,095)	(6,427,432)
Net unrealized appreciation/depreciation	69,925,517	95,054,422	94,714,609	49,261,238	77,324,854
Net Assets	\$ 272,183,460	\$ 974,436,566	\$ 592,938,503	\$ 649,406,995	\$ 375,135,625
Net asset value ⁷	\$ 34.94	\$ 8.86	\$ 10.37	\$ 13.94	\$ 22.19
¹ Consolidated Statement of Assets and Liabilities.					
² Investments at cost unaffiliated					
	\$ 193,466,167	\$ 876,743,346	\$ 478,206,377	\$ 567,646,783	\$ 285,230,957
³ Securities loaned at value					
	\$ 260,586	\$ 9,690,661	\$ 64,168		
⁴ Investments at cost affiliated					
	\$ 9,167,290	\$ 10,177,930	\$ 24,932,527	\$ 36,702,308	\$ 12,817,865
⁵ Foreign currency/Foreign bank overdraft at cost					
	\$ 120,518	\$ 2,248,714	\$ 94,422	\$ (58,566)	\$ 190,218
⁶ Premiums received					
	\$ 2,086,319	\$ 12,221,364	\$ 4,432,487	\$ 3,956,279	\$ 2,198,766
⁷ Shares outstanding, unlimited number of shares authorized, \$0.001 par value					
	7,788,926	109,989,277	57,173,280	46,575,310	16,906,964

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

107

Table of Contents**Statements of Operations**

Six Months Ended April 30, 2014 (Unaudited)	BlackRock Dividend Income Trust (BQY)	BlackRock EcoSolutions Investment Trust (BQR)	BlackRock Energy and Resources Trust (BGR)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)	BlackRock Enhanced Equity Dividend Trust (BDJ)	BlackRock Global Opportunities Equity Trust (BOE)
Investment Income						
Dividends unaffiliated	\$ 1,415,805	\$ 1,358,111	\$ 7,980,228	\$ 23,945,550	\$ 22,157,689	\$ 13,976,515
Foreign taxes withheld	(34,604)	(74,049)	(402,713)	(220,621)	(255,723)	(582,311)
Dividends affiliated	856	1,326	10,556	3,966	9,059	5,179
Securities lending affiliated net		1,261				63,183
Other income affiliated	1,802	3,778	7,901	843	7,663	7,530
Total income	1,383,859	1,290,427	7,595,972	23,729,738	21,918,688	13,470,096
Expenses						
Investment advisory	322,082	677,889	4,885,618	2,873,903	6,495,798	5,745,700
Custodian	50,075	49,965	66,769	38,983	109,888	148,325
Professional	23,906	28,078	27,133	84,577	45,247	36,546
Transfer agent	14,540	16,821	57,546	45,475	103,241	78,354
Officer and Trustees	4,937	5,490	60,248	35,941	113,039	85,299
Printing	3,364	4,058	19,521	16,525	33,718	23,850
Insurance	2,075	3,289	19,517	9,972	27,362	19,522
Registration	1,321	4,609	4,506	7,467	30,422	11,759
Licensing	64,417					
Miscellaneous	19,056	16,508	11,273	10,767	13,903	38,226
Total expenses	505,773	806,707	5,152,131	3,123,610	6,972,618	6,187,581
Less fees waived by Manager	(1,454)	(30,442)	(17,438)	(6,892)	(17,620)	(9,395)
Total expenses after fees waived	504,319	776,265	5,134,693	3,116,718	6,954,998	6,178,186
Net investment income	879,540	514,162	2,461,279	20,613,020	14,963,690	7,291,910
Realized and Unrealized Gain (Loss)						
Net realized gain (loss) from:						
Investments unaffiliated	3,175,586	(5,322,643)	69,784,243	8,691,326	(6,477,750)	23,624,024
Options written	(662)	432,783	4,100,785	8,747,295	6,164,737	18,367,345
Foreign currency transactions	3,821	(21,381)	3,162	74,355	10,080	318,475
	3,178,745	(4,911,241)	73,888,190	17,512,976	(302,933)	42,309,844
Net change in unrealized appreciation/depreciation on:						
Investments unaffiliated	1,135,823	9,684,020	(23,890,662)	(5,181,531)	81,831,129	(24,951,630)
Options written	38,926	(31,903)	(8,393,919)	3,488,224	3,566,337	3,196,023
Foreign currency translations	1,358	1,935	154	(31,616)	80	(144,536)
	1,176,107	9,654,052	(32,284,427)	(1,724,923)	85,397,546	(21,900,143)
Total realized and unrealized gain	4,354,852	4,742,811	41,603,763	15,788,053	85,094,613	20,409,701
Net Increase in Net Assets Resulting from Operations	\$ 5,234,392	\$ 5,256,973	\$ 44,065,042	\$ 36,401,073	\$ 100,058,303	\$ 27,701,611

See Notes to Financial Statements.

108

SEMI-ANNUAL REPORT

APRIL 30, 2014

Table of Contents**Statements of Operations (concluded)**

Six Months Ended April 30, 2014 (Unaudited)	BlackRock Health Sciences Trust (BME)	BlackRock International Growth and Income Trust (BGY)	BlackRock Real Asset Equity Trust (BCF)	BlackRock Resources & Commodities Strategy Trust (BCX) ¹	BlackRock Utility and Infrastructure Trust (BUI)
Investment Income					
Dividends unaffiliated	\$ 1,838,471	\$ 14,234,983	\$ 6,585,898	\$ 7,379,451	\$ 6,730,875
Foreign taxes withheld	(86,615)	(868,004)	(208,860)	(427,440)	(244,001)
Dividends affiliated	1,515	4,500	4,174	4,729	1,958
Securities lending affiliated net	359	48,630	161		
Other income affiliated	2,267	7,166	3,498	21,128	3,288
Total income	1,755,997	13,427,275	6,384,871	6,977,868	6,492,120
Expenses					
Investment advisory	1,365,470	4,933,112	3,414,387	3,727,318	1,754,401
Custodian	62,860	166,603	81,618	60,929	72,141
Professional	27,271	37,590	28,832	36,520	32,645
Transfer agent	19,938	69,690	51,840	43,777	25,256
Officer and Trustees	13,247	75,310	44,401	29,891	16,590
Printing	6,937	21,220	11,962	7,750	8,874
Insurance	5,326	28,544	16,667	7,942	4,347
Registration	4,549	18,614	7,543	7,789	4,474
Miscellaneous	9,771	67,201	21,853	6,676	24,036
Total expenses	1,515,369	5,417,884	3,679,103	3,928,592	1,942,764
Less fees waived by Manager	(2,456)	(254,046)	(149,554)	(629,967)	(3,359)
Total expenses after fees waived	1,512,913	5,163,838	3,529,549	3,298,625	1,939,405
Net investment income	243,084	8,263,437	2,855,322	3,679,243	4,552,715
Realized and Unrealized Gain (Loss)					
Net realized gain (loss) from:					
Investments unaffiliated	25,722,248	42,377,055	1,654,903	(12,714,643)	344,015
Options written	1,421,480	7,501,228	3,073,991	1,802,049	(1,430,345)
Foreign currency transactions	50,101	574,414	512	(86,499)	9,923
	27,193,829	50,452,697	4,729,406	(10,999,093)	(1,076,407)
Net change in unrealized appreciation/depreciation on:					
Investments unaffiliated	(5,165,036)	(47,073,467)	21,488,285	50,653,830	31,945,791
Options written	(588,708)	4,017,024	(1,780,573)	(3,011,396)	626,003
Foreign currency translations	(4,163)	(35,289)	364	3,341	19,784
	(5,757,907)	(43,091,732)	19,708,076	47,645,775	32,591,578
Total realized and unrealized gain	21,435,922	7,360,965	24,437,482	36,646,682	31,515,171
Net Increase in Net Assets Resulting from Operations	\$ 21,679,006	\$ 15,624,402	\$ 27,292,804	\$ 40,325,925	\$ 36,067,886

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

¹ Consolidated Statement of Operations.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

109

Table of Contents

Statements of Changes in Net Assets

	BlackRock Dividend Income Trust (BQY)		BlackRock EcoSolutions Investment Trust (BQR)	
	Six Months Ended April 30, 2014 (Unaudited)	Year Ended October 31, 2013	Six Months Ended April 30, 2014 (Unaudited)	Year Ended October 31, 2013
Increase (Decrease) in Net Assets:				
Operations				
Net investment income	\$ 879,540	\$ 1,911,679	\$ 514,162	\$ 1,147,375
Net realized gain (loss)	3,178,745	4,615,388	(4,911,241)	1,515,988
Net change in unrealized appreciation/depreciation	1,176,107	4,941,159	9,654,052	6,617,063
Net increase in net assets resulting from operations	5,234,392	11,468,226	5,256,973	9,280,426
Dividends and Distributions to Shareholders				
Net investment income	(2,775,193) ¹	(1,708,290) ²	(4,504,358) ¹	(1,031,216) ²
Net realized gains		(3,962,756) ²		
Return of capital				(7,977,500) ²
Decrease in net assets resulting from dividends and distributions to shareholders	(2,775,193)	(5,671,046)	(4,504,358)	(9,008,716)
Net Assets				
Total increase in net assets	2,459,199	5,797,180	752,615	271,710
Beginning of period	86,983,349	81,186,169	115,137,640	114,865,930
End of period	\$ 89,442,548	\$ 86,983,349	\$ 115,890,255	\$ 115,137,640
Undistributed (distributions in excess of) net investment income, end of period	\$ (1,711,885)	\$ 183,768	\$ (3,990,196)	

¹ A portion of the dividends from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

Table of Contents

Statements of Changes in Net Assets (continued)

	BlackRock Energy and Resources Trust (BGR)		BlackRock Enhanced Capital and Income Fund, Inc. (CII)	
	Six Months Ended	Year Ended	Six Months Ended	Year Ended
Increase (Decrease) in Net Assets:	April 30, 2014 (Unaudited)	October 31, 2013	April 30, 2014 (Unaudited)	October 31, 2013
Operations				
Net investment income	\$ 2,461,279	\$ 3,487,794	\$ 20,613,020	\$ 13,662,033
Net realized gain	73,888,190	137,486,490	17,512,976	41,586,734
Net change in unrealized appreciation/depreciation	(32,284,427)	31,425,100	(1,724,923)	50,511,787
Net increase in net assets resulting from operations	44,065,042	172,399,384	36,401,073	105,760,554
Dividends and Distributions to Shareholders				
Net investment income	(98,526,178) ¹		(26,472,840) ¹	(13,908,365) ²
Net realized gains		(48,221,272) ²		
Return of capital				(39,037,315) ²
Decrease in net assets resulting from dividends and distributions to shareholders	(98,526,178)	(48,221,272)	(26,472,840)	(52,945,680)
Net Assets				
Total increase (decrease) in net assets	(54,461,136)	124,178,112	9,928,233	52,814,874
Beginning of period	896,634,870	772,456,758	675,472,019	622,657,145
End of period	\$ 842,173,734	\$ 896,634,870	\$ 685,400,252	\$ 675,472,019
Distributions in excess of net investment income, end of period	\$ (98,847,386)	\$ (2,782,487)	\$ (5,897,076)	\$ (37,256)

¹ A portion of the dividends from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

Table of Contents

Statements of Changes in Net Assets (continued)

	BlackRock Enhanced Equity Dividend Trust (BDJ) Six Months		BlackRock Global Opportunities Equity Trust (BOE) Six Months	
	Ended		Ended	
	April 30,		April 30,	
	2014	Year Ended October 31, 2013	2014	Year Ended October 31, 2013
Increase (Decrease) in Net Assets:	(Unaudited)	2013	(Unaudited)	2013
Operations				
Net investment income	\$ 14,963,690	\$ 32,816,080	\$ 7,291,910	\$ 8,382,978
Net realized gain (loss)	(302,933)	117,623,639	42,309,844	109,951,890
Net change in unrealized appreciation/depreciation	85,397,546	54,197,961	(21,900,143)	86,145,100
Net increase in net assets resulting from operations	100,058,303	204,637,680	27,701,611	204,479,968
Dividends and Distributions to Shareholders				
Net investment income	(50,255,172) ¹	(32,582,758) ²	(43,308,854) ¹	(11,468,669) ²
Distributions in excess of net investment income ³		(35,787,362) ²		(63,152,174) ²
Net realized gains		(32,140,223) ²		
Return of capital				(11,996,866) ²
Decrease in net assets resulting from dividends and distributions to shareholders	(50,255,172)	(100,510,343)	(43,308,854)	(86,617,709)
Net Assets				
Total increase (decrease) in net assets	49,803,131	104,127,337	(15,607,243)	117,862,259
Beginning of period	1,594,223,376	1,490,096,039	1,159,072,267	1,041,210,008
End of period	\$ 1,644,026,507	\$ 1,594,223,376	\$ 1,143,465,024	\$ 1,159,072,267
Distributions in excess of net investment income, end of period	\$ (35,892,255)	\$ (600,773)	\$ (38,496,228)	\$ (2,479,284)

¹ A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

² Determined in accordance with federal income tax regulations.

³ Taxable distribution.

See Notes to Financial Statements.

Table of Contents

Statements of Changes in Net Assets (continued)

	BlackRock Health Sciences Trust (BME)		BlackRock International Growth and Income Trust (BGY)	
	Six Months Ended		Six Months Ended	
	April 30, 2014 (Unaudited)	Year Ended October 31, 2013	April 30, 2014 (Unaudited)	Year Ended October 31, 2013
Increase (Decrease) in Net Assets:				
Operations				
Net investment income	\$ 243,084	\$ 923,733	\$ 8,263,437	\$ 14,055,907
Net realized gain	27,193,829	24,717,008	50,452,697	72,629,297
Net change in unrealized appreciation/depreciation	(5,757,907)	43,710,073	(43,091,732)	72,416,478
Net increase in net assets resulting from operations	21,679,006	69,350,814	15,624,402	159,101,682
Dividends and Distributions to Shareholders				
Net investment income	(21,450,045) ¹	(446,759) ²	(36,923,400) ¹	(18,226,947) ²
Net realized gains		(17,987,036) ²		
Return of capital				(55,619,854) ²
Decrease in net assets resulting from dividends and distributions to shareholders	(21,450,045)	(18,433,795)	(36,923,400)	(73,846,801)
Capital Share Transactions				
Reinvestment of dividends	1,793,000	867,486		
Net Assets				
Total increase (decrease) in net assets	2,021,961	51,784,505	(21,298,998)	85,254,881
Beginning of period	270,161,499	218,376,994	995,735,564	910,480,683
End of period	\$ 272,183,460	\$ 270,161,499	\$ 974,436,566	\$ 995,735,564
Undistributed (distributions in excess of) net investment income, end of period	\$ (20,740,167)	\$ 466,794	\$ (30,769,824)	\$ (2,109,861)

¹ A portion of the dividends from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

Table of Contents

Statements of Changes in Net Assets (continued)

	BlackRock Real Asset Equity Trust (BCF)		BlackRock Resources & Commodities Strategy Trust (BCX) ¹	
	Six Months Ended		Six Months Ended	
	April 30, 2014 (Unaudited)	Year Ended October 31, 2013	April 30, 2014 (Unaudited)	Year Ended October 31, 2013
Increase (Decrease) in Net Assets:				
Operations				
Net investment income	\$ 2,855,322	\$ 6,199,566	\$ 3,679,243	\$ 11,454,960
Net realized gain (loss)	4,729,406	(10,322,502)	(10,999,093)	(65,371,790)
Net change in unrealized appreciation/depreciation	19,708,076	9,610,522	47,645,775	20,545,737
Net increase (decrease) in net assets resulting from operations	27,292,804	5,487,586	40,325,925	(33,371,093)
Dividends and Distributions to Shareholders				
Net investment income	(19,987,779) ²	(6,692,838) ³	(21,536,423) ²	(6,452,839) ³
Return of capital		(43,962,688) ³		(47,574,521) ³
Decrease in net assets resulting from dividends and distributions to shareholders	(19,987,779)	(50,655,526)	(21,536,423)	(54,027,360)
Net Assets				
Total increase (decrease) in net assets	7,305,025	(45,167,940)	18,789,502	(87,398,453)
Beginning of period	585,633,478	630,801,418	630,617,493	718,015,946
End of period	\$ 592,938,503	\$ 585,633,478	\$ 649,406,995	\$ 630,617,493
Distributions in excess of net investment income, end of period	\$ (20,767,572)	\$ (3,635,115)	\$ (22,274,085)	\$ (4,416,905)

¹ Consolidated Statements of Changes in Net Assets.

² A portion of the dividends from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

³ Determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

Table of Contents

Statements of Changes in Net Assets (concluded)

	BlackRock Utility and Infrastructure Trust (BUI)	
	Six Months Ended	
	April 30,	Year Ended October 31,
Increase (Decrease) in Net Assets:	2014 (Unaudited)	2013
Operations		
Net investment income	\$ 4,552,715	\$ 9,640,424
Net realized gain (loss)	(1,076,407)	6,418,044
Net change in unrealized appreciation/depreciation	32,591,578	17,842,699
Net increase in net assets resulting from operations	36,067,886	33,901,167
Dividends and Distributions to Shareholders		
Net investment income	(12,257,549) ¹	(8,709,264) ²
Net realized gains		(7,173,603) ²
Return of capital		(8,632,231) ²
Decrease in net assets resulting from dividends and distributions to shareholders	(12,257,549)	(24,515,098)
Net Assets		
Total increase in net assets	23,810,337	9,386,069
Beginning of period	351,325,288	341,939,219
End of period	\$ 375,135,625	\$ 351,325,288
Undistributed (distributions in excess of) net investment income, end of period	\$ (6,140,281)	\$ 1,564,553

¹ A portion of the dividends from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

Table of Contents**Statements of Cash Flows**

Six Months Ended April 30, 2014 (Unaudited)	BlackRock Dividend Income Trust (BQY)	BlackRock EcoSolutions Investment Trust (BQR)	BlackRock Energy and Resources Trust (BGR)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)
Cash Provided by Operating Activities				
Net increase in net assets resulting from operations	\$ 5,234,392	\$ 5,256,973	\$ 44,065,042	\$ 36,401,073
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:				
Decrease in dividends receivable affiliated		160	860	172
Decrease (increase) in dividends receivable	(33,716)	(168,138)	342,525	(910,759)
Decrease in securities lending income receivable affiliated		(482)		
Increase in other assets	(1,645)	(4,652)	(11,156)	(16,315)
Decrease in cash pledged as collateral for OTC derivatives				500,000
Increase in investment advisory fees payable	(220)	(3,515)	(99,100)	(4,550)
Increase (decrease) in Officers and Trustees fees payable	706	(1)	38,531	17,501
Increase (decrease) in other accrued expenses payable	15,170	(2,964)	(6,828)	(117,398)
Net realized (gain) loss on investments, options written and foreign currency transactions	(3,174,924)	4,889,860	(73,885,028)	(17,438,621)
Net unrealized (gain) loss on investments, options written and foreign currency translations	(1,174,743)	(9,660,384)	32,284,582	1,694,131
Premiums received from options written	2,087,214	3,639,258	20,554,488	31,108,904
Premiums paid on closing options written	(1,532,693)	(2,858,334)	(16,613,014)	(13,121,850)
Proceeds from sales of long-term investments	34,930,712	49,101,199	654,477,272	437,125,453
Purchases of long-term investments	(34,215,616)	(48,560,148)	(591,888,025)	(467,989,087)
Net (purchases) sales of short-term securities	669,938	3,502,311	29,346,976	17,278,451
Cash provided by operating activities	2,804,575	5,131,143	98,607,125	24,527,105
Cash Used for Financing Activities				
Decrease in bank overdraft/foreign bank overdraft		(618,888)		(119,260)
Cash dividends paid to shareholders	(2,775,193)	(4,504,358)	(98,526,178)	(26,472,840)
Cash used for financing activities	(2,775,193)	(5,123,246)	(98,526,178)	(26,592,100)
Cash Impact from Foreign Exchange Fluctuations				
Cash impact from foreign exchange fluctuations	(25)	8,267	(1)	2,179
Cash and Foreign Currency				
Net increase (decrease) in cash and foreign currency	29,357	16,164	80,946	(2,062,816)
Cash and foreign currency at beginning of period	21,069		110,962	2,068,537
Cash and foreign currency at end of period	\$ 50,426	\$ 16,164	\$ 191,908	\$ 5,721

See Notes to Financial Statements.

Table of Contents**Statements of Cash Flows (continued)**

	BlackRock Enhanced Equity Dividend Trust (BDJ)	BlackRock Global Opportunities Equity Trust (BOE)	BlackRock Health Sciences Trust (BME)	BlackRock International Growth and Income Trust (BGY)
Six Months Ended April 30, 2014 (Unaudited)				
Cash Provided by Operating Activities				
Net increase in net assets resulting from operations	\$ 100,058,303	\$ 27,701,611	\$ 21,679,006	\$ 15,624,402
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:				
Decrease (increase) in dividends receivable affiliated	217	183	(114)	287
Decrease (increase) in dividends receivable	244,848	194,518	57,876	(514,010)
Increase in securities lending income receivable affiliated		(30,912)	(221)	(21,987)
Decrease (increase) in other assets	(48,259)	344,817	(10,035)	(18,275)
Increase in cash pledged as collateral for OTC derivatives				(2,020,504)
Increase in cash pledged as collateral for exchange-traded options written			(1,892,100)	(4,050,000)
Increase (decrease) in investment advisory fees payable	4,440	(34,841)	(6,371)	(31,760)
Increase in collateral on securities loaned at value		9,198,761	287,000	10,177,930
Increase in Officers and Trustees fees payable	69,090	53,654	155	48,339
Increase (decrease) in other accrued expenses payable	17,517	(39,920)	(16,933)	(43,599)
Net realized (gain) loss on investments, options written and foreign currency transactions	313,013	(41,991,369)	(27,143,728)	(49,878,283)
Net unrealized (gain) loss on investments, options written and foreign currency translations	(85,397,386)	21,652,656	5,753,753	43,030,820
Premiums received from options written	53,946,547	56,028,222	9,511,509	45,091,288
Premiums paid on closing options written	(32,733,155)	(28,448,251)	(7,378,000)	(31,760,242)
Proceeds from sales of long-term investments	923,695,444	1,210,168,669	185,371,492	965,092,331
Purchases of long-term investments	(920,517,103)	(1,222,749,306)	(158,393,386)	(970,539,804)
Net (purchases) sales of short-term securities	10,669,033	18,121,257	(8,022,628)	12,168,800
Cash provided by operating activities	50,322,549	50,169,749	19,797,275	32,355,733
Cash Used for Financing Activities				
Increase (decrease) in bank overdraft		(295)		3,765,642
Cash dividends paid to shareholders	(50,255,172)	(43,308,854)	(19,657,045)	(36,923,400)
Cash used for financing activities	(50,255,172)	(43,309,149)	(19,657,045)	(33,157,758)
Cash Impact from Foreign Exchange Fluctuations				
Cash impact from foreign exchange fluctuations	(80)	109,213	(9)	15,310
Cash and Foreign Currency				
Net increase (decrease) in cash and foreign currency	67,297	6,969,813	140,221	(786,715)
Cash and foreign currency at beginning of period	9,110	4,043,358	2,498	3,042,040
Cash and foreign currency at end of period	\$ 76,407	\$ 11,013,171	\$ 142,719	\$ 2,255,325

See Notes to Financial Statements.

Table of Contents**Statements of Cash Flows (concluded)**

	BlackRock Real Asset Equity Trust (BCF)	BlackRock Resources & Commodities Strategy Trust (BCX)¹	BlackRock Utility and Infrastructure Trust (BUI)
Six Months Ended April 30, 2014 (Unaudited)			
Cash Provided by Operating Activities			
Net increase in net assets resulting from operations	\$ 27,292,804	\$ 40,325,925	\$ 36,067,886
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:			
Decrease in dividends receivable – affiliated	157	68	339
Decrease in dividends receivable	189,207	326,504	350,618
Increase in securities lending income receivable – affiliated	(161)		
Increase in other assets	(11,892)	(17,934)	(10,089)
Increase (decrease) in investment advisory fees payable	(15,936)	(7,831)	10,907
Increase (decrease) in Officers and Trustees fees payable	29,237	(364)	(571)
Decrease in other accrued expenses payable	(12,357)	(37,141)	(25,451)
Net realized (gain) loss on investments, options written and foreign currency transactions	(4,728,894)	10,912,594	1,086,330
Net unrealized (gain) loss on investments, options written and foreign currency translations	(19,707,857)	(47,642,643)	(32,566,237)
Premiums received from options written	16,382,677	14,441,371	7,390,483
Premiums paid on closing options written	(10,954,206)	(9,990,499)	(6,900,487)
Proceeds from sales of long-term investments	266,860,818	284,116,395	109,998,954
Purchases of long-term investments	(251,689,813)	(263,884,050)	(106,332,709)
Net (purchases) sales of short-term securities	(3,698,393)	(7,285,353)	2,902,137
Cash provided by operating activities	19,935,391	21,257,042	11,972,110
Cash Used for Financing Activities			
Increase (decrease) in bank overdraft		58,695	(990,610)
Cash dividends paid to shareholders	(19,987,779)	(21,536,423)	(12,257,549)
Cash used for financing activities	(19,987,779)	(21,477,728)	(13,248,159)
Cash Impact from Foreign Exchange Fluctuations			
Cash impact from foreign exchange fluctuations	3		(5,557)
Cash and Foreign Currency			
Net decrease in cash and foreign currency	(52,385)	(220,686)	(1,281,606)
Cash and foreign currency at beginning of period	161,820	246,181	1,495,501
Cash and foreign currency at end of period	\$ 109,435	\$ 25,495	\$ 213,895

¹ Consolidated Statement of Cash Flows.

See Notes to Financial Statements.

Table of Contents**Financial Highlights****BlackRock Dividend Income Trust (BQY)**

	Six Months Ended April 30, 2014	Year Ended October 31,				
		(Unaudited)	2013	2012	2011	2010
Per Share Operating Performance						
Net asset value, beginning of period	\$ 14.42	\$ 13.46	\$ 13.61	\$ 14.26	\$ 13.38	\$ 12.38
Net investment income ¹	0.15	0.32	0.33	0.35	0.33	0.36
Net realized and unrealized gain (loss)	0.72	1.58	(0.79)	(0.00) ²	1.36	1.43
Net increase from investment operations	0.87	1.90	1.12	0.35	1.69	1.79
Dividends and distributions:						
Net investment income	(0.46) ³	(0.28) ⁴	(0.67) ⁴	(0.22) ⁴	(0.11) ⁴	(0.35) ^{4,5}
Distributions in excess of net investment income ⁶						(0.04) ^{4,5}
Net realized gain		(0.66) ⁴	(0.60) ⁴	(0.78) ⁴	(0.70) ⁴	(0.33) ⁴
Return of capital						(0.07) ⁴
Total dividends and distributions	(0.46)	(0.94)	(1.27)	(1.00)	(0.81)	(0.79)
Net asset value, end of period	\$ 14.83	\$ 14.42	\$ 13.46	\$ 13.61	\$ 14.26	\$ 13.38
Market price, end of period	\$ 13.34	\$ 12.84	\$ 12.34	\$ 12.43	\$ 13.44	\$ 11.54
Total Investment Return⁷						
Based on net asset value	6.58% ⁸	15.50%	9.48%	2.79%	14.08%	17.64%
Based on market price	7.67% ⁸	12.18%	9.90%	(0.40)%	24.67%	19.63%
Ratios to Average Net Assets						
Total expenses	1.18% ⁹	1.19%	1.18%	1.19%	1.23%	1.17%
Total expenses after fees waived	1.17% ⁹	1.18%	1.18%	1.19%	1.22%	1.16%
Net investment income	2.05% ⁹	2.29%	2.50%	2.45%	2.40%	3.39%
Supplemental Data						
Net assets, end of period (000)	\$ 89,443	\$ 86,893	\$ 81,186	\$ 82,096	\$ 86,047	\$ 80,716
Portfolio turnover	40%	103%	129%	97%	59%	64%

¹ Based on average shares outstanding.

² Amount is less than \$(0.005) per share.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁴ Determined in accordance with federal income tax regulations.
- ⁵ The amount of dividends and distributions to shareholders from net investment income reported in October 31, 2009 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.39.
- ⁶ Taxable distribution.
- ⁷ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁸ Aggregate total investment return.
- ⁹ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

119

Table of Contents**Financial Highlights****BlackRock EcoSolutions Investments Trust (BQR)**

	Six Months Ended April 30, 2014	Year Ended October 31,				
		(Unaudited)	2013	2012	2011	2010
Per Share Operating Performance						
Net asset value, beginning of period	\$ 9.16	\$ 9.14	\$ 9.38	\$ 10.65	\$ 10.56	\$ 10.23
Net investment income ¹	0.04	0.09	0.08	0.10	0.05	0.06
Net realized and unrealized gain (loss)	0.38	0.65	0.56	(0.30)	1.24	1.78
Net increase (decrease) from investment operations	0.42	0.74	0.64	(0.20)	1.29	1.84
Dividends and distributions:						
Net investment income	(0.36) ²	(0.08) ³	(0.07) ³	(0.11) ³	(0.05) ³	(0.07) ³
Net realized gain						(0.09) ³
Return of capital		(0.64) ³	(0.81) ³	(0.96) ³	(1.15) ³	(1.35) ³
Total dividends and distributions	(0.36)	(0.72)	(0.88)	(1.07)	(1.20)	(1.51)
Net asset value, end of period	\$ 9.22	\$ 9.16	\$ 9.14	\$ 9.38	\$ 10.65	\$ 10.56
Market price, end of period	\$ 8.15	\$ 7.93	\$ 8.66	\$ 8.58	\$ 11.69	\$ 10.23
Total Investment Return⁴						
Based on net asset value	5.24% ⁵	9.08%	7.77%	(2.13)%	13.04%	19.64%
Based on market price	7.46% ⁵	(0.34)%	11.63%	(18.45)%	28.08%	28.88%
Ratios to Average Net Assets						
Total expenses	1.43% ⁶	1.44%	1.44%	1.40%	1.45%	1.51%
Total expenses after fees waived	1.37% ⁶	1.41%	1.43%	1.40%	1.45%	1.50%
Net investment income	0.91% ⁶	0.98%	0.92%	0.98%	0.47%	0.65%
Supplemental Data						
Net assets, end of period (000)	\$ 115,890	\$ 115,138	\$ 114,866	\$ 117,497	\$ 131,002	\$ 127,025
Portfolio turnover	43%	94%	107%	86%	124%	62%

¹ Based on average shares outstanding.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ³ Determined in accordance with federal income tax regulations.
- ⁴ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁵ Aggregate total investment return.
- ⁶ Annualized.

See Notes to Financial Statements.

Table of Contents**Financial Highlights****BlackRock Energy and Resources Trust (BGR)**

	Six Months Ended April 30, 2014	Year Ended October 31,				
	(Unaudited)	2013	2012	2011	2010	2009
Per Share Operating Performance						
Net asset value, beginning of period	\$ 30.12	\$ 25.95	\$ 28.33	\$ 25.87	\$ 23.81	\$ 20.71
Net investment income ¹	0.08	0.12	0.13	0.06	0.26	0.41
Net realized and unrealized gain (loss)	1.40	5.67	(0.74)	4.02	3.42	4.32
Net increase (decrease) from investment operations	1.48	5.79	(0.61)	4.08	3.68	4.73
Dividends and distributions:						
Net investment income	(3.31) ²		(0.03) ³	(0.24) ³	(0.17) ³	(0.47) ³
Net realized gain		(1.62) ³	(1.44) ³	(1.38) ³	(1.45) ³	(0.19) ³
Return of capital			(0.30) ³			(0.97) ³
Total dividends and distributions	(3.31)	(1.62)	(1.77)	(1.62)	(1.62)	(1.63)
Net asset value, end of period	\$ 28.29	\$ 30.12	\$ 25.95	\$ 28.33	\$ 25.87	\$ 23.81
Market price, end of period	\$ 25.05	\$ 26.82	\$ 24.28	\$ 26.54	\$ 25.36	\$ 22.18
Total Investment Return⁴						
Based on net asset value	6.83% ⁵	23.68%	(1.76)%	16.09%	15.89%	25.54%
Based on market price	6.23% ⁵	17.70%	(1.88)%	10.95%	21.95%	34.63%
Ratios to Average Net Assets						
Total expenses	1.27% ⁶	1.26%	1.28%	1.26%	1.27%	1.30%
Total expenses after fees waived	1.26% ⁶	1.25%	1.22%	1.15%	1.11%	1.10%
Net investment income	0.60% ⁶	0.42%	0.50%	0.19%	1.04%	1.77%
Supplemental Data						
Net assets, end of period (000)	\$ 842,174	\$ 896,635	\$ 772,457	\$ 843,328	\$ 769,976	\$ 708,589
Portfolio turnover	69%	132%	86%	111%	80%	62%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Determined in accordance with federal income tax regulations.
- ⁴ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁵ Aggregate total investment return.
- ⁶ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

121

Table of Contents**Financial Highlights****BlackRock Enhanced Capital and Income Fund, Inc. (CII)**

	Six Months Ended April 30, 2014	Year Ended October 31,				
		(Unaudited)	2013	2012	2011	2010
Per Share Operating Performance						
Net asset value, beginning of period	\$ 15.31	\$ 14.11	\$ 13.87	\$ 14.53	\$ 14.40	\$ 13.78
Net investment income ¹	0.47	0.31	0.33	0.35	0.31	0.29
Net realized and unrealized gain	0.35	2.09	1.29	0.68	1.76	2.27
Net increase from investment operations	0.82	2.40	1.62	1.03	2.07	2.56
Dividends and distributions:						
Net investment income	(0.60) ²	(0.32) ³	(0.33) ^{3,4}	(0.35) ^{3,4}	(0.31) ³	(0.29) ³
Distributions in excess of net investment income ⁵			(0.20) ^{3,4}	(0.23) ^{3,4}		
Net realized gain			(0.13) ³	(1.11) ³	(1.33) ³	(1.19) ³
Return of capital		(0.88) ³	(0.72) ³		(0.30) ³	(0.46) ³
Total dividends and distributions	(0.60)	(1.20)	(1.38)	(1.69)	(1.94)	(1.94)
Net asset value, end of period	\$ 15.53	\$ 15.31	\$ 14.11	\$ 13.87	\$ 14.53	\$ 14.40
Market price, end of period	\$ 14.30	\$ 13.52	\$ 12.99	\$ 12.39	\$ 15.03	\$ 13.76
Total Investment Return⁶						
Based on net asset value	5.88% ⁷	18.97%	12.94%	7.56%	15.22%	22.01%
Based on market price	10.40% ⁷	14.11%	16.39%	(7.11)%	24.73%	29.88%
Ratios to Average Net Assets						
Total expenses	0.92% ⁸	0.93%	0.94%	0.94%	0.93%	0.95%
Total expenses after fees waived	0.92% ⁸	0.93%	0.94%	0.93%	0.93%	0.95%
Net investment income	6.10% ⁸	2.15%	2.34%	2.40%	2.14%	(2.16)%
Supplemental Data						
Net assets, end of period (000)	\$ 685,400	\$ 675,472	\$ 622,657	\$ 612,145	\$ 635,849	\$ 618,462
Portfolio turnover	66%	218%	205%	190%	210%	138%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Determined in accordance with federal income tax regulations.
- ⁴ The amount of dividends and distributions to shareholders from net investment income reported in October 31, 2012 and October 31, 2011 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.53 and \$0.58, respectively.
- ⁵ Taxable distribution.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Annualized.

See Notes to Financial Statements.

Table of Contents**Financial Highlights****BlackRock Enhanced Equity Dividend Trust (BDJ)**

	Six Months Ended April 30, 2014		Year Ended October 31,			
	(Unaudited)	2013	2012	2011	2010	2009
Per Share Operating Performance						
Net asset value, beginning of period	\$ 8.88	\$ 8.30	\$ 8.03	\$ 8.32	\$ 8.13	\$ 9.59
Net investment income ¹	0.08	0.18	0.18	0.16	0.17	0.25
Net realized and unrealized gain (loss)	0.48	0.96	0.77	0.38	1.00	(0.55)
Net increase (decrease) from investment operations	0.56	1.14	0.95	0.54	1.17	(0.30)
Dividends and distributions:						
Net investment income	(0.28) ²	(0.18) ³	(0.18) ^{3,4}	(0.16) ^{3,4}	(0.17) ³	(0.25) ³
Distributions in excess of net investment income ⁵		(0.20) ³	(0.22) ^{3,4}	(0.35) ^{3,4}		
Net realized gain		(0.18) ³				
Return of capital			(0.28) ³	(0.32) ³	(0.81) ³	(0.91) ³
Total dividends and distributions	(0.28)	(0.56)	(0.68)	(0.83)	(0.98)	(1.16)
Net asset value, end of period	\$ 9.16	\$ 8.88	\$ 8.30	\$ 8.03	\$ 8.32	\$ 8.13
Market price, end of period	\$ 8.10	\$ 7.72	\$ 7.41	\$ 7.29	\$ 8.99	\$ 7.89
Total Investment Return⁶						
Based on net asset value	6.81% ⁷	15.11%	13.22%	6.88%	15.23%	(1.63)%
Based on market price	8.64% ⁷	12.09%	11.34%	(10.20)%	28.30%	8.08%
Ratios to Average Net Assets						
Total expenses	0.87% ⁸	0.87%	0.95%	1.15%	1.16%	1.20%
Total expenses after fees waived	0.87% ⁸	0.87%	0.95%	1.14%	1.16%	1.20%
Net investment income	1.87% ⁸	2.13%	2.16%	1.92%	2.06%	3.11%
Supplemental Data						
Net assets, end of period (000)	\$ 1,644,027	\$ 1,594,223	\$ 1,490,096	\$ 575,712	\$ 592,328	\$ 572,066
Portfolio turnover	55%	180%	185%	231%	232%	117%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Determined in accordance with federal income tax regulations.
- ⁴ The amount of dividends and distributions to shareholders from net investment income reported in October 31, 2012 and October 31, 2011 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.40 and \$0.51, respectively.
- ⁵ Taxable distribution.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

123

Table of Contents**Financial Highlights****BlackRock Global Opportunities Equity Trust (BOE)**

	Six Months Ended April 30, 2014		Year Ended October 31,			
	(Unaudited)	2013	2012	2011	2010	2009
Per Share Operating Performance						
Net asset value, beginning of period	\$ 16.68	\$ 14.99	\$ 16.03	\$ 18.68	\$ 18.64	\$ 18.03
Net investment income ¹	0.10	0.12	0.20	0.17	0.19	0.19
Net realized and unrealized gain (loss)	0.30	2.82	0.72	(0.54)	2.13	2.70
Net increase (decrease) from investment operations	0.40	2.94	0.92	(0.37)	2.32	2.89
Dividends and distributions:						
Net investment income	(0.62) ²	(0.17) ³	(0.22) ³	(0.17) ^{3,4}	(0.18) ^{3,4}	(0.20) ³
Distributions in excess of net investment income ⁵		(0.91) ³		(0.68) ^{3,4}	(1.26) ^{3,4}	
Net realized gain				(0.61) ³	(0.25) ³	
Return of capital		(0.17) ³	(1.74) ³	(0.82) ³	(0.59) ³	(2.08) ³
Total dividends and distributions	(0.62)	(1.25)	(1.96)	(2.28)	(2.28)	(2.28)
Net asset value, end of period	\$ 16.46	\$ 16.68	\$ 14.99	\$ 16.03	\$ 18.68	\$ 18.64
Market price, end of period	\$ 14.78	\$ 14.74	\$ 13.24	\$ 14.95	\$ 19.06	\$ 18.40
Total Investment Return⁶						
Based on net asset value	2.91% ⁷	21.93%	7.36%	(2.55)%	13.76%	20.50%
Based on market price	4.57% ⁷	21.99%	1.68%	(10.93)%	17.58%	34.97%
Ratios to Average Net Assets						
Total expenses	1.08% ⁸	1.08%	1.10%	1.10%	1.11%	1.21%
Total expenses after fees waived	1.08% ⁸	1.08%	1.10%	1.09%	1.10%	1.20%
Net investment income	1.27% ⁸	0.77%	1.34%	0.96%	1.03%	1.05%
Supplemental Data						
Net assets, end of period (000)	\$ 1,143,465	\$ 1,159,072	\$ 1,041,210	\$ 1,113,920	\$ 1,290,105	\$ 1,278,170
Portfolio turnover	103%	279%	298%	253%	264%	300%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Determined in accordance with federal income tax regulations.
- ⁴ The amount of dividends and distributions to shareholders from net investment income reported in October 31, 2011 and October 31, 2010 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.85 and \$1.44, respectively.
- ⁵ Taxable distribution.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Annualized.

See Notes to Financial Statements.

Table of Contents**Financial Highlights****BlackRock Health Sciences Trust (BME)**

	Year Ended October 31,					
	Six Months Ended April 30 2014	2013	2012	2011	2010	2009
	(Unaudited)					
Per Share Operating Performance						
Net asset value, beginning of period	\$ 34.92	\$ 28.34	26.65	\$ 27.19	\$ 25.37	\$ 23.66
Net investment income (loss) ¹	0.03	0.12	0.08	(0.01)	0.02	0.10
Net realized and unrealized gain	2.76	8.85	4.11	1.71	3.34	3.32
Net increase from investment operations	2.79	8.97	4.19	1.70	3.36	3.42
Dividends and distributions:						
Net investment income	(2.77) ²	(0.06) ³	(0.09) ³		(0.02) ³	(0.13) ³
Net realized gain		(2.33) ³	(2.41) ³	(2.24) ³	(1.52) ³	(1.01) ³
Return of capital						(0.57) ³
Total dividends and distributions	(2.77)	(2.39)	(2.50)	(2.24)	(1.54)	(1.71)
Net asset value, end of period	\$ 34.94	\$ 34.92	\$ 28.34	\$ 26.65	\$ 27.19	\$ 25.37
Market price, end of period	\$ 35.66	\$ 33.56	\$ 27.86	\$ 25.81	\$ 27.14	\$ 22.61
Total Investment Return⁴						
Based on net asset value	8.17% ⁵	33.37%	16.42%	6.43%	13.69%	16.31%
Based on market price	14.88% ⁵	30.38%	18.17%	3.26%	27.33%	13.44%
Ratios to Average Net Assets						
Total expenses	1.11% ⁶	1.12%	1.13%	1.14%	1.15%	1.15%
Total expenses after fees waived	1.11% ⁶	1.12%	1.13%	1.13%	1.15%	1.15%
Net investment income (loss)	0.18% ⁶	0.38%	0.29%	(0.02)%	0.09%	0.37%
Supplemental Data						
Net assets, end of period (000)	\$ 272,183	\$ 270,161	\$ 218,377	\$ 202,675	\$ 206,392	\$ 192,602
Portfolio turnover	58%	155%	209%	226%	239%	167%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

³ Determined in accordance with federal income tax regulations.

⁴ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.

⁵ Aggregate total investment return.

⁶ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

125

Table of Contents**Financial Highlights****BlackRock International Growth and Income Trust (BGY)**

	Six Months Ended April 30, 2014	Year Ended October 31,				
		(Unaudited)	2013	2012	2011	2010
Per Share Operating Performance						
Net asset value, beginning of period	\$ 9.05	\$ 8.28	\$ 8.72	\$ 10.52	\$ 10.92	\$ 10.41
Net investment income ¹	0.08	0.13	0.16	0.14	0.14	0.29
Net realized and unrealized gain (loss)	0.07	1.31	0.35	(0.58)	1.05	2.04
Net increase (decrease) from investment operations	0.15	1.44	0.51	(0.44)	1.19	2.33
Dividends and distributions:						
Net investment income	(0.34) ²	(0.17) ³	(0.18) ³	(0.14) ^{3,4}	(0.12) ³	(0.30) ³
Distributions in excess of net investment income ⁵				(0.53) ^{3,4}		
Return of capital		(0.50) ³	(0.77) ³	(0.69) ³	(1.47) ³	(1.52) ³
Total dividends and distributions	(0.34)	(0.67)	(0.95)	(1.36)	(1.59)	(1.82)
Net asset value, end of period	\$ 8.86	\$ 9.05	\$ 8.28	\$ 8.72	\$ 10.52	\$ 10.92
Market price, end of period	\$ 8.08	\$ 8.14	\$ 7.41	\$ 7.88	\$ 10.56	\$ 10.92
Total Investment Return⁶						
Based on net asset value	1.99% ⁷	19.25%	7.65%	(4.55)%	12.06%	26.28%
Based on market price	3.41% ⁷	19.86%	6.61%	(14.07)%	12.49%	44.62%
Ratios to Average Net Assets						
Total expenses	1.10% ⁸	1.09%	1.11%	1.10%	1.13%	1.12%
Total expenses after fees waived	1.05% ⁸	1.07%	1.11%	1.10%	1.13%	1.12%
Net investment income	1.68% ⁸	1.49%	1.97%	1.37%	1.40%	2.68%
Supplemental Data						
Net assets, end of period (000)	\$ 974,437	\$ 995,736	\$ 910,481	\$ 959,153	\$ 1,156,583	\$ 1,178,647
Portfolio turnover	97%	266%	226%	217%	247%	198%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Determined in accordance with federal income tax regulations.
- ⁴ The amount of dividends and distributions to shareholders from net investment income reported in October 31, 2011 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.67.
- ⁵ Taxable distribution.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Annualized.

See Notes to Financial Statements.

Table of Contents**Financial Highlights****BlackRock Real Asset Equity Trust (BCF)**

	Six Months Ended April 30, 2014	Year Ended October 31,				
		(Unaudited)	2013	2012	2011	2010
Per Share Operating Performance						
Net asset value, beginning of period	\$ 10.24	\$ 11.03	\$ 12.45	\$ 13.42	\$ 11.73	\$ 9.44
Net investment income ¹	0.05	0.11	0.12	0.11	0.17	0.08
Net realized and unrealized gain (loss)	0.43	(0.01)	(0.50)	0.01	2.61	3.30
Net increase (decrease) from investment operations	0.48	0.10	(0.38)	0.12	2.78	3.38
Dividends and distributions:						
Net investment income	(0.35) ²	(0.12) ³	(0.13) ³	(0.07) ^{3,4}	(0.26) ^{3,4}	(0.11) ³
Distributions in excess of net investment income ⁵				(0.14) ^{3,4}	(0.48) ^{3,4}	
Net realized gain			(0.55) ³	(0.50) ³		
Return of capital		(0.77) ³	(0.36) ³	(0.38) ³	(0.35) ³	(0.98) ³
Total dividends and distributions	(0.35)	(0.89)	(1.04)	(1.09)	(1.09)	(1.09)
Net asset value, end of period	\$ 10.37	\$ 10.24	\$ 11.03	\$ 12.45	\$ 13.42	\$ 11.73
Market price, end of period	\$ 9.13	\$ 9.12	\$ 10.39	\$ 11.84	\$ 13.46	\$ 11.45
Total Investment Return⁶						
Based on net asset value	5.32% ⁷	1.81%	(2.79)%	0.58%	24.65%	40.96%
Based on market price	4.11% ⁷	(3.75)%	(3.71)%	(4.64)%	28.08%	67.81%
Ratios to Average Net Assets						
Total expenses	1.29% ⁸	1.29%	1.29%	1.29%	1.28%	1.32%
Total expenses after fees waived and paid indirectly	1.24% ⁸	1.19%	1.14%	1.09%	1.08%	1.12%
Net investment income	1.00% ⁸	1.04%	1.08%	0.77%	1.37%	0.68%
Supplemental Data						
Net assets, end of period (000)	\$ 592,939	\$ 585,633	\$ 630,801	\$ 711,917	\$ 765,463	\$ 664,928
Portfolio turnover	44%	89%	72%	79%	71%	58%

¹ Based on average shares outstanding.

² A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Determined in accordance with federal income tax regulations.
- ⁴ The amount of dividends and distributions to shareholders from net investment income reported in October 31, 2011 and October 31, 2010 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.21 and \$0.74, respectively.
- ⁵ Taxable distribution.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

127

Table of Contents**Consolidated Financial Highlights****BlackRock Resources & Commodities Strategy Trust (BCX)**

	Six Months Ended April 30, 2014	Year Ended October 31		Period March 30, 2011 ¹ through
	(Unaudited)	2013	2012	October 31, 2011
Per Share Operating Performance				
Net asset value, beginning of period	\$ 13.54	\$ 15.42	\$ 16.83	\$ 19.10 ²
Net investment income ³	0.08	0.25	0.18	0.03
Net realized and unrealized gain (loss)	0.78	(0.97)	(0.19)	(1.57)
Net increase (decrease) from investment operations	0.86	(0.72)	(0.01)	(1.54)
Dividends and distributions:				
Net investment income	(0.46) ⁴	(0.14) ⁵	(0.26) ⁵	
Net realized gain			(0.01) ⁵	(0.24) ⁵
Return of capital		(1.02) ⁵	(1.13) ⁵	(0.46) ⁵
Total dividends and distributions	(0.46)	(1.16)	(1.40)	(0.70)
Capital charges with respect to the issuance of shares				(0.03)
Net asset value, end of period	\$ 13.94	\$ 13.54	\$ 15.42	\$ 16.83
Market price, end of period	\$ 12.02	\$ 11.68	\$ 14.12	\$ 14.95
Total Investment Return⁶				
Based on net asset value	7.09% ⁷	(3.61)% ⁸	0.90%	(7.80)% ⁷
Based on market price	7.05% ⁷	(9.19)%	4.02%	(21.79)% ⁷
Ratios to Average Net Assets				
Total expenses	1.26% ⁹	1.27%	1.25%	1.35% ⁹
Total expenses after fees waived	1.06% ⁹	1.07%	1.05%	1.13% ⁹
Net investment income	1.18% ⁹	1.76%	1.14%	0.27% ⁹
Supplemental Data				
Net assets, end of period (000)	\$ 649,407	\$ 630,617	\$ 718,016	\$ 783,792
Portfolio turnover	40%	156%	100%	27%

¹ Commencement of investment operations. This information includes the initial investment by BlackRock HoldCo2, Inc.

² Net asset value, beginning of period, reflects a deduction of \$0.8975 per share sales charge from initial offering price of \$20.00 per share.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ³ Based on average shares outstanding.
- ⁴ A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁵ Determined in accordance with federal income tax regulations.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Includes a payment from an affiliate to compensate for foregone securities lending revenue which impacted the Trust's total investment return. Not including this payment the Trust's total return would have been (3.68)%.
- ⁹ Annualized.

See Notes to Financial Statements.

Table of Contents**Financial Highlights (concluded)****BlackRock Utility and Infrastructure Trust (BUI)**

	Six Months Ended April 30, 2014 (Unaudited)	Year Ended October 31, 2013	Period November 25, 2011 ¹ through October 31, 2012
Per Share Operating Performance			
Net asset value, beginning of period	\$ 20.78	\$ 20.22	\$ 19.10 ²
Net investment income ³	0.27	0.57	0.54
Net realized and unrealized gain	1.87	1.44	1.71
Net increase from investment operations	2.14	2.01	2.25
Dividends and distributions:			
Net investment income	(0.73) ⁴	(0.52) ⁵	(0.49) ⁵
Net realized gain		(0.42) ⁵	(0.41) ⁵
Return of capital		(0.51) ⁵	(0.19) ⁵
Total dividends and distributions	(0.73)	(1.45)	(1.09)
Capital charges with respect to the issuance of shares			(0.04)
Net asset value, end of period	\$ 22.19	\$ 20.78	\$ 20.22
Market price, end of period	\$ 19.35	\$ 18.36	\$ 19.03
Total Investment Return⁶			
Based on net asset value	11.10% ⁷	11.18%	12.05% ⁷
Based on market price	9.65% ⁷	4.37%	0.71% ⁷
Ratios to Average Net Assets			
Total expenses	1.11% ⁸	1.11%	1.12% ⁸
Total expenses after fees waived	1.11% ⁸	1.10%	1.11% ⁸
Total expenses after fees waived and excluding excise tax	1.11% ⁸	1.10%	1.10% ⁸
Net investment income	2.60% ⁸	2.83%	2.94% ⁸
Supplemental Data			
Net assets, end of period (000)	\$ 375,136	\$ 351,325	\$ 341,939
Portfolio turnover	28%	133%	90%

¹ Commencement of investment operations. This information includes the initial investment by BlackRock HoldCo2, Inc.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

- ² Net asset value, beginning of period, reflects a deduction of \$0.8975 per share sales charge from initial offering price of \$20.00 per share.
- ³ Based on average shares outstanding.
- ⁴ A portion of the dividends from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁵ Determined in accordance with federal income tax regulations.
- ⁶ Total investment returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of dividends and distributions.
- ⁷ Aggregate total investment return.
- ⁸ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

APRIL 30, 2014

129

Table of Contents**Notes to Financial Statements****1. Organization:**

BlackRock Dividend Income Trust (BQY), BlackRock EcoSolutions Investment Trust (BQR), BlackRock Energy and Resources Trust (BGR), BlackRock Enhanced Capital and Income Fund, Inc. (CII), BlackRock Enhanced Equity Dividend Trust (BDJ), BlackRock Global Opportunities Equity Trust (BOE), BlackRock Health Sciences Trust (BME), BlackRock International Growth and Income Trust (BGY), BlackRock Real Asset Equity Trust (BCF), BlackRock Resources & Commodities Strategy Trust (BCX), and BlackRock Utility and Infrastructure Trust (BUI) (each, a Trust and collectively, the Trusts) are organized as Delaware statutory trusts, except CII which is organized as a Maryland Corporation. BQY, CII, BDJ and BOE are registered as diversified, closed-end management investment companies under the Investment Company Act of 1940, as amended (the 1940 Act). BQR, BGR, BME, BGY, BCF, BCX and BUI are registered as non-diversified, closed-end management investment companies under the 1940 Act. The Board of Directors and Board of Trustees of the Trusts are collectively referred to throughout this report as the Board of Trustees or the Board , and the directors/trustees thereof are collectively referred to throughout this report as Trustees. The Trusts determine and make available for publication the NAVs of their shares on a daily basis.

Basis of Consolidation: The accompanying consolidated financial statements include the accounts of BlackRock Cayman Resources & Commodities Strategy Fund, Ltd. (the Subsidiary), which is a wholly owned subsidiary of BCX and primarily invests in commodity-related instruments. The Subsidiary enables BCX to hold these commodity-related instruments and satisfy regulated investment company tax requirements. BCX may invest up to 25% of its total assets in the Subsidiary. Intercompany accounts and transactions, if any, have been eliminated. The Subsidiary is subject to the same investment policies and restrictions that apply to BCX, except that the Subsidiary may invest without limitation in commodity-related instruments.

The Trusts, together with certain other registered investment companies advised by the Manager or its affiliates, are included in a complex of closed-end funds referred to as the Closed-End Complex.

2. Significant Accounting Policies:

The Trusts' financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates. The following is a summary of significant accounting policies followed by the Trusts.

Valuation: U.S. GAAP defines fair value as the price the Trusts would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. The Trusts determine the fair values of their financial instruments at market value using independent dealers or pricing services under policies approved by the Board. The BlackRock Global Valuation

Methodologies Committee (the Global Valuation Committee) is the committee formed by management to develop global pricing policies and procedures and to provide oversight of the pricing function for the Trusts for all financial instruments.

Equity investments traded on a recognized securities exchange or the NASDAQ Stock Market (NASDAQ) are valued at the last reported sale price that day or the NASDAQ official closing price, if applicable. For equity investments traded on more than one exchange, the last reported sale price on the exchange where the stock is primarily traded is used. Equity investments traded on a recognized exchange for which there were no sales on that day are valued at the last available bid. Investments in open-end registered investment companies are valued at the NAV each business day.

The Trusts value their bond investments on the basis of last available bid prices or current market quotations provided by dealers or pricing services. In determining the value of a particular investment, pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrixes, market transactions in comparable investments, various relationships observed in the market between investments and calculated yield measures. Investments in open-end registered investment companies are valued at NAV each business day.

The Trusts value their investments in BlackRock Liquidity Series, LLC Money Market Series (the Money Market Series) are valued at fair value, which is ordinarily based upon each Trust's pro rata ownership in the underlying fund's net assets. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments will follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act. The Trusts may

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

withdraw up to 25% of their investment daily, although the manager of the Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of business on the New York Stock Exchange (NYSE). Foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of business on the NYSE. Interpolated values are derived when the settlement date of the contract is an interim date for which quotations are not available.

Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day's price will be used, unless it is determined that the prior day's price no longer reflects the fair value of the option. Over-the-counter (OTC) options are valued by an independent pricing service using a mathematical model which

Table of Contents**Notes to Financial Statements (continued)**

incorporates a number of market data factors, such as the trades and prices of the underlying instruments.

In the event that the application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not available, the investment will be valued by the Global Valuation Committee, or its delegate, in accordance with a policy approved by the Board as reflecting fair value (Fair Value Assets). When determining the price for Fair Value Assets, the Global Valuation Committee, or its delegate, seeks to determine the price that each Trust might reasonably expect to receive from the current sale of that asset in an arm s-length transaction. Fair value determinations shall be based upon all available factors that the Global Valuation Committee, or its delegate, deems relevant consistent with the principles of fair value measurement, which include the market approach, income approach and/or in the case of recent investments, the cost approach, as appropriate. The market approach generally consists of using comparable market transactions. The income approach generally is used to discount future cash flows to present value and is adjusted for liquidity as appropriate. These factors include but are not limited to: (i) attributes specific to the investment or asset; (ii) the principal market for the investment or asset; (iii) the customary participants in the principal market for the investment or asset; (iv) data assumptions by market participants for the investment or asset, if reasonably available; (v) quoted prices for similar investments or assets in active markets; and (vi) other factors, such as future cash flows, interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates. Due to the inherent uncertainty of valuations of such investments, the fair values may differ from the values that would have been used had an active market existed. The Global Valuation Committee, or its delegate, employs various methods for calibrating valuation approaches for investments where an active market does not exist, including regular due diligence of the Trusts pricing vendors, regular reviews of key inputs and assumptions, transactional back-testing or disposition analysis to compare unrealized gains and losses to realized gains and losses, reviews of missing or stale prices and large movements in market values and reviews of any market related activity. The pricing of all Fair Value Assets is subsequently reported to the Board or a committee thereof on a quarterly basis.

Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of business on the NYSE. Occasionally, events affecting the values of such instruments may occur between the foreign market close and the close of business on the NYSE that may not be reflected in the computation of each Trust s net assets. If events (e.g., a company announcement, market volatility or a natural disaster) occur during such periods that are expected to materially affect the value of such instruments, those instruments may be Fair Value Assets and valued at their fair value, as determined in good faith by the Global Valuation Committee, or its delegate, using a pricing service and/or policies approved by the Board. Each business day, each Trust uses a pricing service to assist with the valuation of certain foreign exchange-traded equity securities and foreign exchange-traded

and OTC options (the Systematic Fair Value Price). Using current market factors, the Systematic Fair Value Price is designed to value such foreign securities and foreign options at fair value as of the close of business on the NYSE, which follows the close of the local markets.

Foreign Currency: The Trusts books and records are maintained in U.S. dollars. Purchases and sales of investment securities are recorded at the rates of exchange prevailing on the respective date of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the Trusts investments denominated in that currency will lose value because that currency is worth fewer U.S. dollars; the opposite effect occurs if the U.S. dollar falls in relative value.

The Trusts do not isolate the portion of the results of operations arising as a result of changes in the foreign exchange rates from the changes in the market prices of investments held or sold for financial reporting purposes. Accordingly, the effects of changes in foreign currency exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments but are included as a component of net realized and unrealized gain (loss) from investments. The Trusts report realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for federal income tax purposes.

Segregation and Collateralization: In cases where a Trust enters into certain investments (e.g., options written), that would be senior securities for 1940 Act purposes, such Trust may segregate or designate on its books and records cash or liquid securities having a market value at least equal to the amount of a Trust s future obligations under such investments or borrowings. Doing so allows the investment to be excluded from treatment as a senior security. Furthermore, if required by an exchange or counterparty agreement, each Trust may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments or obligations.

Investment Transactions and Investment Income: For financial reporting purposes, investment transactions are recorded on the dates the transactions are entered into (the trade dates). Realized gains and losses on investment transactions are determined on the identified cost basis. Dividend income is recorded on the ex-dividend dates. Dividends from foreign securities where the ex-dividend date may have passed are

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

subsequently recorded when a Trust is informed of the ex-dividend date. Under the applicable foreign tax laws, a withholding tax at various rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, some of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain. Interest income, including amortization and accretion of premiums and discounts on debt securities, is recognized on the accrual basis.

SEMI-ANNUAL REPORT

APRIL 30, 2014

131

Table of Contents**Notes to Financial Statements (continued)**

Dividends and Distributions: Dividends and distributions paid by the Trusts are recorded on the ex-dividend date. Subject to each Trust's level distribution plan, each Trust intends to make quarterly cash dividends and/or distributions to shareholders, which may consist of net investment income, net options premium, net realized and unrealized gains on investments, and/or return of capital.

Portions of return of capital distributions under U.S. GAAP may be taxed at ordinary income rates.

The character of dividends and distributions is determined in accordance with federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust's current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital. Realized net capital gains can be offset by capital losses carried forward from prior years. However, certain Trusts have capital loss carry-forwards from pre-2012 tax years that offset realized net capital gains but do not offset current earnings and profits. Consequently, if distributions in any tax year are less than a Trust's current earnings and profits but greater than net investment income and net realized capital gains (taxable income), distributions in excess of taxable income are not treated as non-taxable return of capital, but rather may be taxable to shareholders at ordinary income rates. Under certain circumstances, taxable excess distributions could be significant.

Net income and realized gains from investments held by the Subsidiary are treated as ordinary income for tax purposes. Accordingly, the net investment income (loss) and realized gains (losses) reported in the Trust's financial statements presented under U.S. GAAP for such investments held by the Subsidiary may differ significantly from income dividends and capital gain distributions. As such, any net gain will pass through to the Trust as ordinary income for federal income tax purposes. If a net loss is realized by the Subsidiary in any taxable year, the loss will generally not be available to offset the Trust's ordinary income and/or capital gains for that year.

Income Taxes: It is the Trusts' policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of their taxable income to their shareholders. Therefore, no federal income tax provision is required.

The Trusts file U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on the Trusts' U.S. federal tax returns remains open for each of the four years ended October 31, 2013 with the exception of BCX and BUI. The statute of limitations on BCX's U.S. federal tax returns remains open for the two years ended October 31, 2013 and the period ended October 31, 2011. The statute of limitations on BUI's U.S. federal tax returns remains open for the year ended October 31, 2013 and the period ended October 31, 2012. The statutes of limitations on each Trust's state and local tax returns may remain open for an additional year depending upon the jurisdiction.

Management has analyzed tax laws and regulations and their application to the Trusts' facts and circumstances and does not believe there are any uncertain tax positions that require recognition of a tax liability.

Deferred Compensation: Under the Deferred Compensation Plan (the Plan) approved by each Trust's Board, except CII, the independent Trustees (Independent Trustees) may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain other BlackRock Closed-End Funds selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain other BlackRock Closed-End Funds.

The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust. Deferred compensation liabilities are included in officer's and trustees fees payable in the Statement of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan.

S&P Quality Rankings: BQY had been granted a license by Standard & Poor's (S&P) to use the S&P Quality Rankings and the S&P International Quality Rankings. Effective September 17, 2013, BQY terminated its license to use either the S&P Quality Rankings or the S&P International Quality Rankings. Standard & Poor's, S&P, Standard & Poor's Earnings and Dividend Rankings, S&P Earnings and Dividend Rankings, Standard & Poor's Quality Rankings, Standard & Poor's International Quality Rankings, S&P International Quality Rankings and S&P Quality Rankings are trademarks of S&P and had been licensed for use by BQY. BQY was not sponsored, endorsed, managed, sold or promoted by S&P and S&P made no representation regarding the advisability of investing in BQY. BQY is required to pay a quarterly licensing fee, which is shown in the Statements of Operations as licensing, for a period of 1 year following the termination date.

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Other: Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds are pro rated among those funds on the basis of relative net assets or other appropriate methods.

The Trusts have an arrangement with the custodian whereby fees may be reduced by credits earned on uninvested cash balances, which, if applicable, are shown as fees paid indirectly in the Statements of Operations. The custodian imposes fees on overdrawn cash balances, which can be offset by accumulated credits earned or may result in additional custody charges.

3. Securities and Other Investments:

Preferred Stock: The Trusts may invest in preferred stock. Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well) but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred

Table of Contents**Notes to Financial Statements (continued)**

stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer's board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.

Securities Lending: Each Trust may lend its securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. government. The initial collateral received by the Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter, at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust on the next business day. During the term of the loan, the Trust earns dividend or interest income on the securities loaned but does not receive interest income on any securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.

The market value of securities on loan and the value of the related collateral are shown separately in the Statements of Assets and Liabilities as a component of investments at value, and collateral on securities loaned at value, respectively. As of April 30, 2014, any securities on loan were collateralized by cash. The cash collateral invested by the securities lending agent, BlackRock Investment Management, LLC ("BIM"), if any, is disclosed in the Schedules of Investments.

Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each an "MSLA") which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. The value of the collateral is typically greater than that of the market value of the securities loaned, leaving the lender with a

net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty's bankruptcy or insolvency. Under the MSLA, the borrower can resell or re-pledge the loaned securities, and the Trusts can reinvest cash collateral, or, upon an event of default, resell or re-pledge the collateral.

The following table is a summary of the Trusts' securities lending agreements by counterparty which are subject to offset under an MSLA as of April 30, 2014:

Counterparty	Securities Loaned at Value	Cash Collateral Received¹	Net Amount
Bank of America N.A.	\$ 329,487	\$ (329,487)	
Citigroup Global Markets, Inc.	3,970,774	(3,970,774)	
Credit Suisse Securities (USA) LLC	159,814	(159,814)	
Goldman Sachs & Co.	377,276	(377,276)	
Morgan Stanley & Co. LLC	2,732,819	(2,732,819)	
UBS Securities LLC	1,109,028	(1,109,028)	
Total	\$ 8,679,198	\$ (8,679,198)	

Counterparty	Securities Loaned at Value	Cash Collateral Received¹	Net Amount
---------------------	---	---	-----------------------

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Morgan Stanley & Co. LLC	\$	159,336	\$	(159,336)
National Financial Services LLC		101,250		(101,250)
Total	\$	260,586	\$	(260,586)

Counterparty		Securities Loaned at Value	Cash Collateral Received¹	Net Amount
Bank of America N.A.	\$	2,742	\$ (2,527)	\$ 215
Deutsche Bank Securities, Inc.		20,556	(20,556)	
Goldman Sachs & Co.		2,775,272	(2,775,272)	
Morgan Stanley & Co. LLC		5,034,733	(5,034,733)	
UBS Securities LLC		1,857,358	(1,857,358)	
Total	\$	9,690,661	\$ (9,690,446)	\$ 215

Counterparty		Securities Loaned at Value	Cash Collateral Received¹	Net Amount
Barclays Capital, Inc	\$	64,168	\$ (64,168)	

¹ Collateral with a value of \$9,198,761, \$287,000, \$10,177,930 and \$70,955 has been received in connection with securities lending agreements for BOE, BME, BGY and BCF, respectively. Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

Table of Contents**Notes to Financial Statements (continued)**

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM's indemnity allows for full replacement of the securities lent. The Trusts could suffer a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral received.

4. Derivative Financial Instruments:

The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to economically hedge, their exposure to certain risks such as equity risk. These contracts may be transacted on an exchange or OTC.

Options: The Trusts purchase and write call and put options to increase or decrease their exposure to underlying instruments (including equity risk and/or commodity price risk) and/or, in the case of options written, to generate gains from options premiums. A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised), the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument

at the exercise or strike price at any time or at a specified time during the option period. When the Trusts purchase (write) an option, an amount equal to the premium paid (received) by the Trusts is reflected as an asset (liability). The amount of the asset (liability) is subsequently marked-to-market to reflect the current market value of the option purchased (written). When an instrument is purchased or sold through an exercise of an option, the related premium paid (or received) is added to (or deducted from) the basis of the instrument acquired or deducted from (or added to) the proceeds of the instrument sold. When an option expires (or the Trusts enter into a closing transaction), the Trusts realize a gain or loss on the option to the extent of the premiums received or paid (or gain or loss to the extent the cost of the closing transaction exceeds the premiums received or paid). When the Trusts write a call option, such option is covered, meaning that the Trusts hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, such option is covered by cash in an amount sufficient to cover the obligation.

In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that the Trusts may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when it otherwise would not, or at a price different from the current market value.

The following is a summary of the Trusts' derivative financial instruments categorized by risk exposure:

Fair Values of Derivative Financial Instruments as of April 30, 2014

		Asset Derivatives					
		Statements of Assets and Liabilities Location				BDJ	BOE
						Value	
Equity contracts		Investments at value	unaffiliated			\$ 4,329	\$ 9,200
		Liability Derivatives					
		BQY	BQR	BGR	CH	BDJ	BOE

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Statements of Assets and Liabilities Location		Value					
Equity contracts	Options written at value	\$ 875,586	\$ 1,174,848	\$ 11,333,766	\$ 9,841,545	\$ 18,043,340	\$ 13,786,827

Statements of Assets and Liabilities Location		Liability Derivatives				
		BME	BGY	BCF	BCX	BUI
Statements of Assets and Liabilities Location		Value				
Equity contracts	Options written at value	\$ 2,030,854	\$ 12,305,555	\$ 6,182,281	\$ 7,214,666	\$ 3,420,626

¹ Includes options purchased at value as reported in the Schedules of Investments.

Table of Contents

Notes to Financial Statements (continued)

The Effect of Derivative Financial Instruments in the Statements of Operations**Six Months Ended April 30, 2014**

	Net Realized Gain (Loss) From					
	BQY	BQR	BGR	CII	BDJ	BOE
Equity contracts:						
Options ²	\$ (984)	\$ 432,394	\$ 4,099,327	\$ 8,747,295	\$ 6,152,789	\$ 18,363,488

	Net Realized Gain (Loss) From				
	BME	BGY	BCF	BCX	BUI
Equity contracts:					
Options ²	\$ 1,418,840	\$ 7,501,228	\$ 3,074,308	\$ 1,802,049	\$ (1,430,557)

² Options purchased are included in the net realized gain (loss) from investments - unaffiliated and net change in unrealized appreciation/depreciation on investments.

The Effect of Derivative Financial Instruments in the Statements of Operations**Six Months Ended April 30, 2014**

	Net Change in Unrealized Appreciation/Depreciation on					
	BQY	BQR	BGR	CII	BDJ	BOE
Equity contracts:						
Options ²	\$ 38,982	\$ (31,903)	\$ (8,393,919)	\$ 3,488,224	\$ 3,563,393	\$ 3,201,160

	Net Change in Unrealized Appreciation/Depreciation on				
	BME	BGY	BCF	BCX	BUI
Equity contracts:					
Options ²	\$ (587,714)	\$ 4,017,024	\$ (1,780,573)	\$ (3,011,396)	\$ 626,003

² Options purchased are included in the net realized gain (loss) from investments-unaffiliated and net change in unrealized appreciation/depreciation on investments.

For the six months ended April 30, 2014, the average quarterly balances of outstanding derivative financial instruments were as follows:

	BQY	BQR	BGR	CII	BDJ	BOE
Options:						
Average number of options contracts purchased	4,150	6,400	35,750		293,050	91,400
Average number of options contracts written	769,720	5,523,008	5,857,850	6,912,500	13,953,300	24,702,095
Average notional value of options contracts purchased	\$ 105,825	\$ 38,400	\$ 2,502,500		\$ 14,447,650	\$ 3,795,000
Average notional value of contracts written	\$ 32,348,868	\$ 43,910,886	\$ 272,997,344	\$ 349,687,647	\$ 800,298,837	\$ 522,582,103
	BME	BGY	BCF	BCX	BUI	

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Options:

Average number of options contracts purchased	3,150		46,350		3,500
Average number of options contracts written	1,412,875	35,508,065	11,237,799	7,908,502	4,518,700
Average notional value of options contracts purchased	\$ 283,500		\$ 3,382,125		\$ 175,000
Average notional value of options contracts written	\$ 90,155,068	\$ 446,456,633	\$ 197,828,688	\$ 207,362,955	\$ 111,754,207

Counterparty Credit Risk: A derivative contract may suffer a mark to market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.

A Trust's risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain netted against any collateral held by such Trust.

For OTC options purchased, each Trust bears the risk of loss of the amount of the premiums paid plus the positive change in market values net of any collateral held by such Trust should the counterparty fail to

Table of Contents**Notes to Financial Statements (continued)**

perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not, the counterparty to perform.

With exchange traded purchased options, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments, guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse. While clearing brokers are required to segregate customer margin from their own assets, in the event that a clearing broker becomes insolvent or goes into bankruptcy and at that time there is a shortfall in the aggregate amount of margin held by the clearing broker for all its clients, typically the shortfall would be on a pro rata basis across all the clearing broker's customers, potentially resulting in losses to the Trusts.

In order to better define its contractual rights and to secure rights that will help the Trusts mitigate its counterparty risk, the Trusts may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (ISDA Master Agreement) or similar agreement with its derivative contract counterparties. An ISDA Master Agreement is a bilateral agreement between each Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, each Trust may, under certain circumstances, offset with the counterparty certain derivative financial instruments payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. When the Trusts enters into an ISDA and an MRA and/or MSLA with the same counterparty, the agreements may contain a set-off provision allowing a trust to offset a net amount payable with amounts due to the Trust upon default of the counterparty. Bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against the right of offset in bankruptcy, insolvency or other events. For example, notwithstanding what contractual rights may be included in an ISDA Master Agreement, such laws may prohibit the Trust from setting off

amounts owed to a defaulting counterparty under an ISDA Master Agreement against amounts owed to the Trust by affiliates of the defaulting counterparty. The insolvency regimes of many jurisdictions do, however, generally permit set-off of simultaneous payables and receivables under certain types of financial contracts between the same legal entity upon a default of the entity, regardless of the existence of a contractual set-off right in those contracts. In addition, certain ISDA Master Agreements allow counterparties to OTC derivatives to terminate derivative contracts prior to maturity in the event the Trust's net assets decline by a stated percentage or the Trust fails to meet the terms of its ISDA Master Agreements, which would cause the Trust to accelerate payment of any net liability owed to the counterparty.

Collateral Requirements: For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by a Trust and the counterparty.

Cash collateral that has been pledged to cover obligations of a Trust and cash collateral received from the counterparty, if any, is reported separately on the Statement of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by a Trust, if any, is noted in the Schedule of Investments. Generally, the amount of collateral due from or to a party has to exceed a minimum transfer amount threshold (typically either \$250,000 or \$500,000) before a transfer is required, which is determined at the close of business of the Trusts and any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, the Trusts and counterparties are not permitted to sell, re-pledge or use the collateral they receive. To the extent amounts due to a Trust from its counterparties are not fully collateralized, contractually or otherwise, a Trust bears the risk of loss from counterparty non-performance.

For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.

At April 30, 2014, the Trusts' derivative assets and liabilities (by type) are as follows:

	BQY		BQR		BGR		CII	
	Assets	Liabilities	Assets	Liabilities	Assets	Liabilities	Assets	Liabilities
Derivative Financial Instruments:								
Options	\$ 875,586		\$ 1,174,848		\$ 11,333,766		\$ 9,841,545	
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(465,151)		(343,811)		(6,757,050)		(5,684,840)
Total derivative assets and liabilities subject to an MNA	\$ 410,435		\$ 831,037		\$ 4,576,716		\$ 4,156,705	

Table of Contents

Notes to Financial Statements (continued)

	BDJ		BOE		BME		BGY	
	Assets	Liabilities	Assets	Liabilities	Assets	Liabilities	Assets	Liabilities
Derivative Financial Instruments:								
Options ¹	\$ 4,329	\$ 18,043,340	\$ 9,200	\$ 13,786,827	\$ 2,030,854		\$ 12,305,555	
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(4,329)	(13,255,096)	(9,200)	(5,821,057)	(1,462,665)		(1,591,655)	
Total derivative assets and liabilities subject to an MNA		\$ 4,788,244		\$ 7,965,770	\$ 568,189		\$ 10,713,900	

	BCF		BCX		BUI	
	Assets	Liabilities	Assets	Liabilities	Assets	Liabilities
Derivative Financial Instruments:						
Options				\$ 6,182,281	\$ 7,214,666	\$ 3,420,626
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)				(3,269,801)	(3,539,999)	(817,320)
Total derivative assets and liabilities subject to an MNA				\$ 2,912,480	\$ 3,674,667	\$ 2,603,306

¹ Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

The following tables present the Trusts' derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trusts as of April 30, 2014:

Counterparty	Derivative Liabilities Subject to an MNA		Non-cash Collateral Pledged	Cash Collateral Pledged	Net Amount of Derivative Liabilities ¹	Net Options Written Receivable/ (Payable) ²
	by Counterparty	Derivatives Available for Offset				
Bank of America N.A.	\$ 15,718				\$ 15,718	\$ 7,226
Citibank N.A.	50,402				50,402	(2,421)
Credit Suisse International	29,897				29,897	(25,859)
Deutsche Bank AG	35,572				35,572	13,416
Goldman Sachs International	2,864				2,864	
JPMorgan Chase Bank N.A.	28,036				28,036	
Morgan Stanley & Co. International PLC	228,488				228,488	(23,463)
UBS AG	19,458				19,458	(13,976)
Total	\$ 410,435				\$ 410,435	\$ (45,077)

Counterparty	Derivative Liabilities Subject to an MNA		Non-cash Collateral Pledged ³	Cash Collateral Pledged	Net Amount of Derivative Liabilities ¹	Net Options Written Receivable/ (Payable) ²
	by Counterparty	Derivatives Available for Offset				
Bank of America N.A.	\$ 74,636				\$ 74,636	\$ 38,201

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Citibank N.A.	16,601			16,601	(8,533)
Credit Suisse International	21,915	\$ (21,915)			(3,544)
Deutsche Bank AG	100,079		\$ (100,000)	79	(10,792)
Goldman Sachs International	154,094			154,094	(22,544)
Morgan Stanley & Co. International PLC	154,778			154,778	(92,312)
UBS AG	308,934	(308,934)			6,323
Total	\$ 831,037	\$ (330,849)	\$ (100,000)	\$ 400,188	\$ (93,201)

¹ Net amount represents the net amount payable due to the counterparty in the event of default.

² Derivative contract can be offset with options written receivable/payable.

³ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

SEMI-ANNUAL REPORT

APRIL 30, 2014

137

Table of Contents

Notes to Financial Statements (continued)

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities²	Net Options Written Receivable/ (Payable)³
Citibank N.A.	\$ 1,952,941		\$ (1,952,941)			\$ (129,269)
Credit Suisse International	430,918				\$ 430,918	
Deutsche Bank AG	371,034		(371,034)			(435,160)
Goldman Sachs International	1,025,808		(1,025,808)			148,662
Morgan Stanley & Co. International PLC	69,453		(69,453)			
UBS AG	726,562		(261,965)		464,597	
Total	\$ 4,576,716		\$ (3,681,201)		\$ 895,515	\$ (415,767)

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged¹	Cash Collateral Pledged¹	Net Amount of Derivative Liabilities²	Net Options Written Receivable/ (Payable)³
Bank of America N.A.	\$ 16,147		\$ (16,147)			
Citibank N.A.	519,396		(519,396)			\$ 15,915
Credit Suisse International	14,712			\$ (14,712)		
Deutsche Bank AG	218,937			(100,000)	\$ 118,937	
Goldman Sachs International	21,390				21,390	
Morgan Stanley & Co. International PLC	3,111,299		(3,111,299)			52,623
UBS AG	254,824				254,824	
Total	\$ 4,156,705		\$ (3,646,842)	\$ (114,712)	395,151	\$ 68,538

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities²	Net Options Written Receivable/ (Payable)³
Citibank N.A.	\$ 1,092,554		\$ (1,092,554)			\$ (181,825)
Credit Suisse International	1,056,724		(1,056,724)			(232,328)
Deutsche Bank AG	655,496		(568,059)		\$ 87,437	93,986
Goldman Sachs International	86,826				86,826	50,725
Morgan Stanley & Co. International PLC	1,710,732		(1,710,732)			(325,771)
UBS AG	185,912				185,912	
Total	\$ 4,788,244		\$ (4,428,069)		\$ 360,175	\$ (595,213)

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities²	Net Options Written Receivable/ (Payable)³
Bank of America N.A.	\$ 230,596		\$ (230,596)			\$ 122,893

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Citibank N.A.	103,525	(103,525)			
Credit Suisse International	493,464	(493,464)			
Deutsche Bank AG	1,915,294	(1,915,294)			
Goldman Sachs International	1,257,396	(1,257,396)			55,011
JPMorgan Chase Bank N.A.	20,568		\$	20,568	
Morgan Stanley & Co. International PLC	3,066,227	(3,066,227)			38,656
UBS AG	878,700	(878,700)			106,832
Total	\$ 7,965,770	\$ (7,945,202)	\$	20,568	\$ 323,392

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default.

³ Derivative contract can be offset with options written receivable/payable.

Table of Contents

Notes to Financial Statements (continued)

Counterparty	Derivative Liabilities Subject to an MNA					Net	
	by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities	Option Written	
						Receivable/(Payable) ³	
Bank of America N.A.	\$ 13,331				\$ 13,331		
Barclays Bank PLC	2,980				2,980		
Citibank N.A.	4,358				4,358		
Credit Suisse International	300,306				300,306		
Goldman Sachs International	96,776				96,776		
Morgan Stanley & Co. International PLC	106,866		\$ (106,866)			\$	(26,600)
UBS AG	43,572				43,572		
Total	\$ 568,189		\$ (106,866)		\$ 461,323	\$	(26,600)

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty					Net	
	by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged ¹	Net Amount of Derivative Liabilities	Option Written	
						Receivable/(Payable) ³	
Bank of America N.A.	\$ 259,835			\$ (259,835)		\$	117,456
Citibank N.A.	72,740			(72,740)			
Credit Suisse International	1,683,953			(1,420,000)	\$ 263,953		
Deutsche Bank AG	2,368,217			(1,967,000)	401,217		
Goldman Sachs International	2,037,492		\$ (2,037,492)				(49,051)
JPMorgan Chase Bank N.A.	19,762				19,762		
Morgan Stanley & Co. International PLC	3,632,680			(2,759,504)	873,176		293,939
Société Générale	5,738				5,738		
UBS AG	633,483			(278,000)	355,483		48,243
Total	\$ 10,713,900		\$ (2,037,492)	\$ (6,757,079)	\$ 1,919,329	\$	410,587

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty					Net	
	by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities	Option Written	
						Receivable/(Payable) ³	
Bank of America N.A.	\$ 99,498				\$ 99,498	\$	101,330
Citibank N.A.	878,932		\$ (878,932)				(95,476)
Credit Suisse International	274,558		(274,558)				(128,682)
Deutsche Bank AG	592,923		(592,923)				(38,165)
Goldman Sachs International	369,828		(369,828)				55,685
Morgan Stanley & Co. International PLC	336,596		(336,596)				
UBS AG	360,145		(356,387)		3,758		(44,704)
Total	\$ 2,912,480		\$ (2,809,224)		\$ 103,256	\$	(150,012)

BCX
Counterparty Net

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

	Derivative Liabilities Subject to an MNA by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged ¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities ²	Options Written
						Receivable/(Payable) ³
Bank of America N.A.	\$ 124,903		\$ (73,053)		\$ 51,850	\$ 52,036
Citibank N.A.	497,707		(497,707)			(108,170)
Credit Suisse International	37,456		(37,456)			
Deutsche Bank AG	758,883		(593,978)		164,905	14,696
Goldman Sachs International	477,056		(477,056)			
Morgan Stanley & Co. International PLC	1,063,688		(1,063,688)			(279,567)
UBS AG	714,974		(714,974)			
Total	\$ 3,674,667		\$ (3,457,912)		\$ 216,755	\$ (321,005)

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default.

³ Derivative contract can be offset with options written receivable/payable.

Table of Contents

Notes to Financial Statements (continued)

BUI

Counterparty	Derivative Liabilities		Non-cash Collateral Pledged ¹	Cash Collateral Pledged	Net Amount of Derivative Liabilities ²	Net Option Written Receivable/(Payable) ³		
	Subject to an MNA b	Derivatives Available for Offset						
Bank of America N.A.	\$	111,743			\$	111,743	\$	68,252
Citibank N.A.		360,944	\$	(360,944)				(34,018)
Credit Suisse International		113,469		(113,469)				(66,179)
Deutsche Bank AG		559,714		(559,714)				
Goldman Sachs International		256,747		(256,747)				(13,278)
JPMorgan Chase Bank N.A.		48,847				48,847		
Morgan Stanley & Co. International PLC		753,685		(753,685)				(33,010)
UBS AG		398,157		(261,423)		136,734		(124,658)
Total	\$	2,603,306	\$	(2,305,982)	\$	297,324	\$	(202,891)

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default.

³ Derivative contract can be offset with options written receivable/payable.

5. Investment Advisory Agreement and Other Transactions with Affiliates:

The PNC Financial Services Group, Inc. is the largest stockholder and an affiliate, for 1940 Act purposes, of BlackRock.

Each Trust entered into an Investment Advisory Agreement with BlackRock Advisors, LLC (the Manager), the Trusts' investment advisor, an indirect, wholly owned subsidiary of BlackRock, to provide investment advisory and administration services. The Manager is responsible for the management of each Trust's portfolio and provides the necessary personnel, facilities, equipment and certain other services necessary to the operations of each Trust. For such services, each Trust pays the Manager a monthly fee at the following annual rates:

Average weekly value of each Trust's net assets:

BQY	0.75%
BGR	1.20%
BDJ	0.81%
BOE	1.00%
BME	1.00%
BCF	1.20%

Average daily value of each Trust's net assets:

BQR	1.20%
CII	0.85%

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

BGY	1.00%
BCX	1.20%
BUI	1.00%

The Manager has agreed to waive 0.05% of the investment advisory fees on BCF as a percentage of their average weekly net assets expiring on September 29, 2014.

The Manager has agreed to waive a portion of the investment advisory fees on BCX as a percentage of its average daily net assets as follows:

		Expiration Date
BCX	0.20%	October 31, 2015
	0.15%	October 31, 2016
	0.10%	October 31, 2017
	0.05%	October 31, 2018

Effective June 6, 2013, the Manager has voluntarily agreed to waive a portion of the investment advisory fees on BQR and BGY as a percentage of their average daily net assets as follows:

BQR	0.05%
BGY	0.05%

The Manager provides investment management and other services to the Subsidiary. The Manager does not receive separate compensation from the Subsidiary for providing investment management or administrative services. However, BCX pays the Manager based on the Trust's net assets which includes the assets of the Subsidiary.

The Manager voluntarily agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds. However, the Manager does not waive its investment advisory fees by the amount of investment advisory fees paid in connection with each Trust's investment in other affiliated investment companies, if any. These amounts are included in fees waived by Manager in the Statements of Operations. For the six months ended April 30, 2014, the amounts waived were as follows:

BQY	\$ 1,454
BQR	\$ 2,196
BGR	\$ 17,438
CII	\$ 6,892
BDJ	\$ 17,620
BOE	\$ 9,395
BME	\$ 2,456
BGY	\$ 7,384
BCF	\$ 7,284
BCX	\$ 8,742
BUI	\$ 3,359

The Manager, on behalf of each Trust, entered into a sub-advisory agreements with BlackRock Financial Management, Inc. (BFM) for BQY, BGR, CII, BDJ and BUI, BIM for BQR, CII, BCF and BUI, BlackRock Capital Management, Inc. for BGY, BCF and BCX and BlackRock International Ltd. for BQR, BGR, BCF and BCX, each an affiliate of the Manager. The Manager pays each sub-advisor for services

Table of Contents**Notes to Financial Statements (continued)**

they provide, a monthly fee that is a percentage of the investment advisory fee paid by each Trust to the Manager.

The U.S. Securities and Exchange Commission has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the collateral investment expenses). The cash collateral is invested in a private investment company managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the private investment company to an annual rate of 0.04%. The investment advisor to the private investment company will not charge any advisory fees with respect to shares purchased by the Trusts.

Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent. Pursuant to the securities lending agreement effective February 1, 2014, BIM may lend securities only when the difference between the borrower rebate rate and the risk free rate exceeds a certain level (such securities, the specials only securities).

Pursuant to such agreement, each Trust retains 80% of securities lending income. In addition, commencing the business day following the date that the aggregate securities lending income earned across the Closed-End Complex in a calendar year exceeds the breakpoint dollar threshold applicable in the given year as set forth in the securities lending agreement, each Trust, pursuant to the securities lending agreement, will retain for the remainder of the calendar year securities lending income in an amount equal to 85% of securities lending income. Prior to February 1, 2014, each Trust retained 65% of securities lending income and paid a fee to BIM equal to 35% of such income. The share of securities lending income earned by each Trust is shown as securities lending affiliated net in the Statements of Operations. For the six months ended April 30, 2014, each Trust paid BIM the following amounts for securities lending agent services:

BQR	\$ 282
BOE	\$ 14,858
BME	\$ 86
BGY	\$ 11,427
BCF	\$ 34

Certain Trusts recorded payments from an affiliate to compensate for foregone securities lending revenue which is included in other income -affiliated in the Statements of Operations as follows:

BQY	\$ 1,802
BQR	\$ 3,778
BGR	\$ 7,901
CII	\$ 843
BDJ	\$ 7,663
BOE	\$ 7,530
BME	\$ 2,267
BGY	\$ 7,166
BCF	\$ 3,498
BCX	\$ 21,128
BUI	\$ 3,288

Certain officers and/or trustees of the Trusts are officers and/or trustees of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts Chief Compliance Officer, which is included in officer and directors in the Statement of Operations.

The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the six months ended April 30, 2014, the purchase and sale transactions with an affiliated fund in compliance with Rule 17a-7 under the 1940 Act were as follows:

	Purchases	Sales
BQY	\$ 170,827	
BGR		\$ 9,890,273
BDJ	\$ 2,962,425	
BOE	\$ 396,740	\$ 106,334
BME	\$ 1,018,711	\$ 1,422,915
BGY	\$ 339,380	\$ 91,731

6. Purchases and Sales:

Purchases and sales of investment securities, excluding short-term securities, for the six months ended April 30, 2014, were as follows:

	Purchases	Sales
BQY	\$ 34,034,270	\$ 33,629,245
BQR	\$ 47,765,293	\$ 47,143,409
BGR	\$ 546,952,199	\$ 610,280,794
CII	\$ 457,573,416	\$ 445,161,677
BDJ	\$ 882,457,896	\$ 918,142,716
BOE	\$ 1,198,368,379	\$ 1,188,976,055
BME	\$ 158,181,205	\$ 184,107,485
BGY	\$ 953,069,922	\$ 954,414,779
BCF	\$ 247,564,224	\$ 259,223,564
BCX	\$ 246,816,948	\$ 277,906,685
BUI	\$ 97,972,663	\$ 108,813,486

Table of Contents**Notes to Financial Statements (continued)**

Transactions in options written for the six months ended April 30, 2014, were as follows:

	Contracts	Calls Premiums Received	Contracts	Puts Premiums Received
BQY				
Outstanding options at beginning of period	442,340	\$ 543,360		
Options written	1,576,822	2,115,813	31	\$ 767
Options expired	(680,690)	(601,669)	(24)	(543)
Options closed	(637,424)	(1,005,336)		
Options exercised	(305,572)	(522,788)	(7)	(224)
Outstanding options at end of period	395,476	\$ 529,380		
BQR				
Outstanding options at beginning of period	6,216,894	\$ 1,199,341		
Options written	17,431,293	3,724,844		
Options expired	(12,921,419)	(1,667,675)		
Options closed	(5,321,209)	(1,802,229)		
Options exercised	(878,942)	(472,263)		
Outstanding options at end of period	4,526,617	\$ 982,018		
BGR				
Outstanding options at beginning of period	3,588,237	\$ 8,474,085		
Options written	14,114,058	20,934,888		
Options expired	(7,478,797)	(8,863,716)		
Options closed	(6,358,421)	(12,646,941)		
Options exercised	(873,090)	(2,501,597)		
Outstanding options at end of period	2,991,987	\$ 5,396,719		
CII				
Outstanding options at beginning of period	2,714,615	\$ 6,091,953		
Options written	9,024,458	30,167,182	842,975	\$ 1,046,942
Options expired	(4,168,188)	(12,081,919)		
Options closed	(2,705,473)	(9,823,908)		
Options exercised	(2,862,596)	(6,330,596)	(375)	(36,360)
Outstanding options at end of period	2,002,816	\$ 8,022,712	842,600	\$ 1,010,582
BDJ				
Outstanding options at beginning of period	5,090,227	\$ 12,448,564		
Options written	17,966,668	54,391,477	122,040	\$ 190,438
Options expired	(5,654,118)	(15,456,441)	(611)	(14,207)

Edgar Filing: ADEONA PHARMACEUTICALS, INC. - Form 10-Q

Options closed	(8,577,653)	(24,680,471)		
Options exercised	(5,302,596)	(13,123,123)	(129)	(3,985)
Outstanding options at end of period	3,522,528	\$ 13,580,006	121,300	\$ 172,246

	Calls		Puts	
	Contracts	Premiums Received	Contracts	Premiums Received
BOE				
Outstanding options at beginning of period	25,066,642	\$ 15,614,350		
Options written	81,270,408	56,527,462		
Options expired	(34,976,800)	(22,659,801)		
Options closed	(33,978,657)	(24,331,643)		
Options exercised	(15,266,450)	(12,417,252)		
Outstanding options at end of period	22,115,143	\$ 12,733,116		

BME				
Outstanding options at beginning of period	599,254	\$ 3,147,245	36,800	\$ 105,616
Options written	1,573,659	9,329,700	379	181,809
Options expired	(817,186)	(3,979,144)	(144)	(56,123)
Options closed	(598,077)	(4,665,127)	(235)	(125,686)
Options exercised	(336,863)	(1,746,355)	(36,800)	(105,616)
Outstanding options at end of period	420,787	\$ 2,086,319		

BGY				
Outstanding options at beginning of period	57,843,462	\$ 13,626,299		
Options written	144,831,327	45,803,622		
Options expired	(61,362,838)	(18,363,623)		
Options closed	(74,272,737)	(21,141,155)		
Options exercised	(36,547,429)	(7,703,779)		
Outstanding options at end of period	30,491,785	\$ 12,221,364		

BCF				
Outstanding options at beginning of period	9,327,960	\$ 4,859,346		
Options written	31,282,373	16,673,441		
Options expired	(20,892,807)	(6,684,910)		
Options closed	(8,551,925)	(7,850,345)		
Options exercised	(2,373,463)	(2,565,045)		
Outstanding options at end of period	8,792,138	\$ 4,432,487		

BCX				
Outstanding options at beginning of period	5,065,799	\$ 4,250,223		
Options written	18,113,151	14,606,108		
Options expired	(8,646,155)	(5,439,980)		
Options closed	(6,372,359)	(6,859,484)		
Options exercised	(2,696,800)	(2,600,588)		
Outstanding options at end of period	5,463,636	\$ 3,956,279		

Table of Contents

Notes to Financial Statements (continued)

	Calls		Puts	
BUI	Contracts	Premiums Received	Contracts	Premiums Received
Outstanding options at beginning of period	3,799,037	\$ 2,144,575		
Options written	12,630,689	7,569,164		
Options expired	(3,653,546)	(2,063,139)		